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Presentation
Scientifi c information is more accessible than ever today, but however, the enormous volume 
of information requires the use of tools aimed at helping to take the correct, effective and safe 
clinical decisions, as well as practitioners with updated skills and knowledge. Clinical Practice 
Guidelines (CPG) provide answers to the most relevant questions that may be asked about pa-
tients with a specifi c pathology, and they present scientifi c evidence in the form of graded recom-
mendations according to the quality of the studies that support them.
The Quality Agency supports the drawing-up, dissemination and use of CPGs as it is aware 
that they provide daily support to clinical decision-making and that they are also a tool to improve 
health outcome. It also ensures that the CPGs drawn up in Spain reach a certain quality level.
In 2003, the Spanish National Health Service (SNS) International Council created the 
GuiaSalud Project whose ultimate aim is to improve clinical decision-making based on scientifi c 
evidence, through training activities and the confi guration of a library of CPGs in the SNS. Since 
then, the GuiaSalud project has assessed dozens of CPGs in agreement with explicit criteria gen-
erated by its scientifi c committee, and it has registered them and disseminated them online.
At the beginning of 2006, the Directorate General of the Quality Agency of the Spanish 
National Health Service (SNS) drew up the Quality Plan for the SNS, which was divided into 
12 strategies. The purpose of this plan is to increase the cohesion of the SNS and help guarantee 
maximum quality healthcare for all citizens regardless of their place of residence.
The purpose of the tenth strategy of the plan is the Improvement of Clinical Practice and one 
of its objectives is to reduce the variability of clinical practice and foster the drawing up and use 
of CPGs. With the creation of a library, training and advice, the CPG development programme 
and the creation of new guidelines, GuiaSalud is providing an answer to the objectives set out in 
the Quality Plan.
Since 2006, with the participation of the scientifi c associations involved, CPGs, such as this 
one have addressed the comprehensive care of people with Alzheimer’s disease and other demen-
tias, which is presented today.
Dementia as a clinical syndrome is characterised by an acquired impairment affecting more 
than one cognitive domain, which represents a decline from a previous level that is serious enough 
so as to affect personal and social functioning.
Given the increase in life expectancy and progressive population ageing in western coun-
tries, dementia represents an enormous challenge for the public health systems of those societies.
The impact of dementia is felt directly by the patient, but it also has a considerable impact on 
relevant aspects of the social environment, such as affection, emotion, organisation, role change, 
as well as on economic aspects. In this sense, dementia is a problem that affects everyone and that 
must be addressed as a real family disease, and in short, as a disease of society.
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Care of people with dementia and of their relatives requires a multidisciplinary approach, 
and each professional must purport the specifi c aspects, typical of their disciplines.
Recommendations are given in this guideline on the care of patients with Alzheimer’s dis-
ease and other dementias, such as, for example, vascular dementia, Parkinson’s disease dementia, 
dementia with Lewy bodies and frontotemporal lobar degeneration.
Important research studies are being carried out all over the world to study the different 
aspects that make up the clinical syndrome of dementia, as well as its multiple affectations and 
effects, so we must be attentive to potential advances in clinical care, genetics, diagnosis tech-
niques, as well as new drugs or other non-pharmacological interventions.
This CPG has been reviewed by Spanish experts in the care of patients with Alzheimer’s 
disease and other dementias, by association of patients and relatives, scientifi c societies and other 
entities involved in the care of these people.
CARMEN MOYA GARCÍA 
General Director of the Quality Agency of the SNS
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Questions to be answered
DEFINITIONS AND CLASSIFICATION OF DEMENTIAS
1. What is dementia?
2. What is the incidence and prevalence of dementia?
3. How is dementia classifi ed?
4. What are the clinical manifestations of dementia?
5. How does the natural course of dementia evolve?
6. What is understood by degenerative dementia?
7. What is Alzheimer’s disease?
8. What is dementia with Lewy bodies?
9. What is Parkinson’s disease dementia?
10. What is frontotemporal lobar degeneration?
11. What other neurodegenerative diseases are accompanied by dementia?
12. What are vascular dementias? 
13. What is and how is secondary dementia classifi ed?
14. What is understood by mild cognitive impairment (MCI)?
15. What types of MCI exist?
16. What is the incidence and prevalence of MCI?
17. What are the risk markers for conversion from MCI to dementia?
18. Is there any treatment that modifi es the progression of MCI?
PATHOPHYSIOLOGY AND RISKS FACTORS OF DEMENTIAS
19. What are the pathophysiological mechanisms of degenerative dementia?
20. What are the pathophysiological mechanisms of vascular dementia?
21. What are the risk factors of dementias?
TREATMENT
22. Is primary prevention of dementia possible?
GENETIC STUDY OF DEMENTIAS
23. When are genetic analyses indicated to identify pathogenic mutations in patients with 
dementia?
24. When is a predictive genetic analysis indicated in asymptomatic individuals?
DEMENTIA DIAGNOSIS
25. How is dementia diagnosed?
26. What is the differential diagnosis of dementia?
27. What are the advantages of neuropsychological testing assessment in cognitive impair-
ment and dementia?
28. What neuropsychological tests, questionnaires or functional evaluation scales must be 
performed on patients with dementia?
29. Which laboratory tests are essential in diagnosing dementia?
30. Must the determination of apolipoprotein E (apoE) be requested?
16 CLINICAL PRACTICE GUIDELINES IN THE SNS
31. What are the advantages of analysing cerebrospinal fl uid (CSF) in the diagnosis of de-
mentia?
32. Which is the structural neuroimaging technique of choice in the diagnostic process of 
dementia and its different types?
33. Which is the functional neuroimaging technique of choice in the diagnostic process of 
dementia and its different types?
34. What are the advantages of EEG/mapping in the diagnosis of dementia?
35. What are the indications for performing a cerebral biopsy in the etiologic diagnosis of 
dementia?
DIFFERENT CARE LEVEL ACTIONS
36. What are the care levels and how are they classifi ed?
37. What role does primary care play in the all-round care of dementia? Must dementia 
screening be carried out in the general population? What are the criteria for referring to 
Specialist Dementia Care Team (SDCT)? What monitoring must be carried out by pri-
mary care on patients with dementia?
38. Which specialised care teams are required to address dementia (SDCT) and what role do 
they play?
39. What role does the social-health network play in a comprehensive approach to dementia?
40. What role do the mental health services play in the care of dementia?
41. Which social services are involved and what role do they play in the care of people with 
dementia?
42. How must the care continuity between the different dementia healthcare levels be coor-
dinated and guaranteed?
TREATMENT OF DEMENTIA 
General measures:
43. When and how must patients and their families be informed of the dementia diagnosis?
44. What basic content must the information given to patients and family have?
Specifi c pharmacological treatment of dementia:
45. Is there a specifi c pharmacological treatment for dementia?
46. Is the specifi c pharmacological treatment equally effective in all people?
Alzheimer’s Disease
47. Which pharmacological treatment is effective in the treatment of mild, moderate and 
severe Alzheimer’s disease?
48. Which specifi c pharmacological treatment is effective in cognitive, behavioural, func-
tional manifestations and/or quality of life in Alzheimer’s disease?
49. What adverse effects and contraindications exist for the specifi c pharmacological treat-
ment in Alzheimer’s disease?
50. How effective and safe is the combination of two or more specifi c drugs in mild, moderate 
and severe Alzheimer’s disease?
51. When must specifi c treatment in Alzheimer’s disease end?
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Parkinson’s Disease Dementia 
52. Which specifi c pharmacological treatment is effective in Parkinson’s disease dementia?
53. What adverse effects and contraindications exist in the pharmacological treatment of 
Parkinson’s disease dementia?
54. How effective and safe is the combination of two or more specifi c drugs in Parkinson’s 
disease dementia?
Dementia with Lewy Bodies
55. Which specifi c pharmacological treatment is effective in dementia with Lewy bodies?
56. What adverse effects and contraindications exist in the specifi c pharmacological treat-
ment of dementia with Lewy bodies?
57. How effective and safe is the combination of two or more specifi c drugs in mild, moderate 
and severe dementia with Lewy bodies?
58. How useful are drugs with dopaminergic action in dementia with Lewy bodies?
Frontotemporal lobar degeneration
59. Which pharmacological treatment is effective in cognitive and behavioural manifesta-
tions of frontotemporal lobar degeneration?
Vascular Dementia
60. Which pharmacological treatment is effective in mild, moderate and severe vascular de-
mentia?
61. What infl uence does pharmacological treatment have on vascular dementia with respect 
to cognitive, behavioural, functional manifestations and/or quality of life?
62. What adverse effects and contraindications exist in the specifi c pharmacological treat-
ment of vascular dementia?
Other pharmacological treatments
63. Are any other types of drugs effective in cognitive and functional manifestations in peo-
ple affected by any type of dementia?
Non-pharmacological treatment of dementias:
Cognitive intervention or stimulation
64. What is cognitive intervention or stimulation?
65. What types of cognitive intervention exist?
66. Are cognitive intervention programmes effective in dementia?
67. Are computer-based cognitive intervention programmes effective in patients with 
Alzheimer’s disease?
68. Are cognitive intervention programmes indicated in illiterate individuals or in patients 
with severe sensory limitations?
69. Are individual cognitive interventions recommendable?
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Intervention programmes on activities of daily living
70. What do intervention programmes on activities of daily living consist of in patients with 
dementia?
71. Do intervention programmes on activities of daily living improve the functionality of 
people with dementia?
Physical activity programmes
72. Are physical activity programmes effective in improving or stabilising the functional 
capacity and cognitive functions of patients affected by dementia?
Other non-pharmacological treatments
73. Are there any other non-pharmacological treatments that are effective in cognitive, func-
tional, motor and/or quality of life manifestations in dementias?
Safety of non-pharmacological treatments:
74. Could non-pharmacological treatments used in dementia have harmful effects?
Treatment of behavioural and psychological symptoms of dementia
75. What do we understand by behavioural and psychological symptoms of dementia (BPSD)?
76. Why are behavioural and psychological symptoms of dementia important?
77. How can the intensity and frequency of behavioural and psychological symptoms of de-
mentia be quantifi ed?
78. At what moment in time do BPSD appear in the evolution of dementia?
79. Are there some BPSD that are characteristic of some types of dementia?
80. Which non-pharmacological measures are indicated in each behavioural and psychologi-
cal symptom in dementia?
81. What are the general recommendations for the pharmacological treatment of BPSD?
82. Which is the optimal pharmacological treatment for each behavioural and psychological 
symptom in dementia?
83. What adverse effects and contraindications do drugs used to control BPSD have?
84. How effective is it to combine pharmacological and non-pharmacological treatment to 
treat behavioural and psychological symptoms in mild, moderate and severe dementia?
85. Which are the most effective recommendations to avoid BPSD in patients with dementia?
86. How must BPSD, which are diffi cult to monitor in outpatients, be treated?
87. What attitudes must the caregiver satisfy to deal with patients with behavioural and psy-
chological symptoms?
Alternative treatments of dementias
88. Are there any plant-based medications or food supplements that have proved to be useful 
in the treatment of dementia?
Assessment of the treatment of dementias
89. How must the response to the treatment of dementia be assessed in clinical practice?
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CAREGIVERS OF PATIENTS WITH DEMENTIA
90. What is understood by primary caregiver of a patient with dementia?
91. Are the characteristics of caregivers the same for people with different types of dementia?
92. What repercussions does caring for a person with dementia have on the caregiver?
93. What scales are useful to assess caregiver burden?
94. Are there effective interventions to prevent caregiver burden?
95. Are there effective interventions to deal with caregiver burden?
96. What are mutual aid groups (MAG)?
97. What benefi ts are obtained from participating in MAG?
98. In what cases is psychological treatment of the caregiver necessary?
99. What are associations of families of people affected by dementia and what role do they 
play in a comprehensive approach to dementia?
100. What must the relationship between the associations and the public social and health 
network be like?
EARLY ONSET OR PRE-SENILE DEMENTIA
101. What is understood by early onset or pre-senile dementia?
102. What are the most frequent causes of early onset or pre-senile dementia?
103. Do patients with early onset dementia have different clinical manifestations to patients 
with later onset?
104. Must the diagnostic process in people with early onset dementia be different to the pro-
cess of a patient who is more than 65 years old when the disease starts?
105. Is the pharmacological treatment of a person with early onset dementia different to that of 
a person with late onset dementia?
106. Is the non-pharmacological treatment prescribed to a person with early onset dementia 
different to that of a person with late onset dementia?
107. Are there differences in impact and psychological, social, family, occupational and eco-
nomic repercussion between a group of people diagnosed with early onset dementia and 
a group of people with late onset dementia?
108. What health and social-health resources do people with early onset dementia require?
ETHICS AND LEGAL ASPECTS OF DEMENTIAS
Abuse of people with dementia
109. What is understood by abuse of people with dementia?
110. How frequent is abuse in dementia and what are the risk factors?
111. What intervention strategies exist to detect a case of abuse?
112. What must professionals do when a case of abuse is detected?
113. What social resources exist to address abuse?
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Advance directives
114. When must the possibility of drafting advance directive documents, living wills and/or 
granting powers of attorney be suggested to people with dementia?
Evaluation of competences
115. Are there instruments that have been strictly designed to assess the competence of pa-
tients with dementia?
116. How are the specifi c competences assessed: driving licence, fi rearms licence and partici-
pation in clinical trials?
117. Which are the indications to start the legal incapacitation process of a patient with de-
mentia?
Aspects relating to the patient’s legal protection
118. What does legal incapacitation consist of?
119. What type of legal protection exists for a patient with dementia?
120. What is guardianship?
Restraint of the patient
121. What are the indications for pharmacological and/or psychological restraint of a patient 
with dementia?
122. What are the indications for physical restraint of a patient with dementia?
123. What are the ethical and legal aspects of restraint?
124. What are the indications for involuntary admission and what process must be followed?
CARE OF PEOPLE WITH ADVANCED DEMENTIA AND
AT END-OF-LIFE STAGE 
125. Which criteria defi ne an advanced and terminal situation with prognosis of limited life 
in patients with dementia?
126. Is it possible to determine, in people with advanced dementia at end-of-life stage, if 
their survival is going to be less than 6 months?
127. When must palliative care be started on people with dementia?
128. Which are the most suitable health resources to care for people with dementia at end-
of-life stage?
129. How are the clinical manifestations and the needs of people with dementia and their 
caregivers identifi ed and managed in the advanced and terminal phase of the disease?
130. How can worsening due to the natural evolution of the illness be differentiated from 
worsening caused by a potentially reversible concomitant process?
131. What are the objectives of caring for people with dementia in terminal phase?
132. What extraordinary or greater measures should be questioned in the care of people with 
advanced dementia?
133. What therapeutic intermediate measures should be questioned in the care of people with 
advanced dementia?
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134. What information and aid must be provided to the families of people with terminal 
dementia?
135. What legal regulations and ethical principles exist relating to communication with peo-
ple with advanced dementia or with their families at the end-of-life stage?
136. In what cases is a post-mortem pathoneurological study recommended?
DIFFUSION, TRAINING AND RESEARCH INTO CARE 
OF PEOPLE WITH DEMENTIA 
Diffusion
137. How must the topic of dementias be dealt with in the media in order to suitably inform 
the public, and which are the most appropriate media?
Training
138. What undergraduate dementia training must be given to health sciences and social 
services professionals?
139. What dementia training must be given in health branches of vocational training?
140. What post-graduate dementia training must health professionals in general receive?
141. What post-graduate dementia training must health professionals engaged in the spe-
cifi c care of people with dementia receive?
Research
142. How important is research in the fi eld of dementia?
143. What role must the different healthcare levels play in research on dementia?
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High quality meta-analyses, systematic reviews of clinical trials or high-quality 
clinical trials with a very low risk of bias.
1+
Well-conducted meta-analyses, systematic reviews of clinical trials or well-
conducted clinical trials with a very low risk of bias.
1-
Meta-analyses, systematic reviews of clinical trials or clinical trials with a high 
risk of bias.
2++
High-quality systematic reviews of case control or cohort of studies. Well-conducted 
studies of case control or cohort studies with a very low risk of confounding or bias 
and a high probability that the relationship is causal.
2+
Well-conducted case control or cohort studies with a low risk of confounding or 
bias and a moderate probability that the relationship is causal
2-
Case control or cohort studies with a high risk of confounding or bias and a 
signifi cant risk that the relationship is not causal.




At least one meta-analysis, systematic review or clinical trial rated as 1++ and 
directly applicable to the target population of the guidelines; or a body of scientifi c 
evidence consisting principally of studies rated as 1+ and demonstrating overall 
consistency of results.
B
A body of evidence including studies rated as 2++, directly applicable to the target 
population of the guideline and demonstrating overall consistency of results; or 
extrapolated evidence from studies rated as 1++ or 1+.
C
A body of evidence including studies rated as 2+, directly applicable to the target 
population of the guideline and demonstrating overall consistency of results; or 
extrapolated evidence from studies rated as 2 ++
D Evidence level of 3 or 4; or extrapolated evidence from studies rated as 2+.
The studies rated as 1 and 2 must not be used in the recommendations preparation process due to their 
high possibility of bias.
Good clinical practice
1 Recommended practice based on the clinical experience and the guideline 
development group.
1 At times, the development group realised that there were some important practical aspects that they 
wished to stress but for which there was probably no scientifi c evidence to support them. In general 
these cases have to do with some aspects of the treatment considered as good clinical practice and that 
nobody would normally question. These aspects are evaluated as good practice points. These messages 
are not an alternative to the scientifi c evidence-based recommendations, but rather, they must only be 
considered when there is no other way to highlight this aspect.
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Recommendations of the CPG
Grade of recommendation: A, B, C or D, depending on whether the quality of the evidence is 
very good, good, moderate or low.
 Good clinical practice: Recommendation by consensus of the development group.
DEFINITIONS AND CLASSIFICATION OF DEMENTIAS
Mild cognitive impairment (MCI) and conversion to dementia
C
Different biological and neuroimaging markers can be used to help predict 
the progression of MCI to dementia in a research context, but they cannot be 
recommended for use yet in normal clinical practice.
A
The use of ACE inhibitors to avoid or delay the progression of MCI to dementia is 
not currently recommended.
A
The use of NSAID, replacement therapy with oestrogens, ginkgo biloba or 
vitamin E to avoid or delay the progression of MCI to dementia is not currently 
recommended.
C
There is not enough evidence to recommend cognitive stimulation or physical 
exercise to avoid or delay the progression of MCI to dementia.
PREVENTION OF DEMENTIAS
C
The control of vascular risk factors (HBP, DM, hypercholesterolemia) and healthy 
lifestyle habits (consumption of omega-3 fatty acids, physical and mental exercise) 
is recommended due to the clear evidence that exists about their benefi t on other 
aspects of health, although their possible benefi t on the reduction of the risk of 
dementia is not supported by appropriately designed studies.
C
Although moderate alcohol consumption or chronic consumption of NSAIDs has 
been associated with a lower risk of AD, it also has other risks for health and there 
is not enough evidence to recommend it in the prevention of dementia.
C
Neither the intake of vitamin C nor vitamin E nor hormonal replacement therapy is 
recommended to prevent dementia.
GENETIC STUDY OF DEMENTIAS
D
Patients with a likelihood of suffering dementia due to genetic causes should be 
referred to specialist genetic counselling units.
C
Performing genetic analyses to detect causal mutations is indicated in patients with 
AD and an autosomal, dominant family history of pre-senile onset.
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C
In patients with FTLD, genetic analyses would be indicated in cases with a 
family history of a similar disease.
B
In patients with prion diseases, genetic studies would be indicated in all cases, 
regardless of family history or age.
B
Genetic studies are recommended if Huntington’s disease is suspected, to 





The execution of genetic analyses in clinical practice must be authorised in 
writing by the actual individual or his/her legal representative after receiving 
genetic counselling.
C
Predictive genetic studies can be performed on people of legal age who are at 
risk of being carriers of a pathogenic mutation known to cause dementia and 
who wish to have them conducted, following informed written consent and 
multidisciplinary genetic counselling prior to the genetic analysis and subsequent 
monitoring.
D
The study of genetic risk factors of dementia, such as the APOE genotype, is not 
indicated for genetic counselling purposes in asymptomatic individuals.
DEMENTIA DIAGNOSIS
✔
The assessment of the impact of cognitive impairment on the activities of daily 
living is recommended, given their affectation, which forms a dementia diagnostic 
criterion and determines the subsequent management of these patients.
✔ Obtaining data from an independent and reliable informant is recommended, 
whenever possible.
✔ An assessment of the psychological and behavioural symptoms is recommended, 
due to their importance for the diagnosis.
✔
The execution of a general physical and neurological examination of patients 
with dementia is recommended to detect comorbidity and associated neurological 
signs that may help towards the differential diagnosis of some subtypes of 
dementia.
D
The use of DSM-IV-TR and ICD-10 clinical criteria is recommended to diagnose 
dementia.
B
The use of DSM-IV-TR or NINCDS/ADRDA criteria is recommended to 
diagnose EA.
B
The use of INDS/AIREN criteria or the Hachinski scale is recommended to 
facilitate the diagnosis of VD.
D
The use of Emre et al. (Movement Disorder Society) criteria to diagnose 
Parkinson’s disease dementia is recommended.
B The use of McKeith criteria is recommended to diagnose DLB.
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B
The use of Lund-Manchester or Neary criteria to help diagnose FTLD is 
recommended.
B
Patients with cognitive complaints must be assessed by means of global cognition 
screen tests, neuropsychological test batteries, short cognitive instruments focused 
on specifi c aspects of cognition and/or standardised structured questionnaires to 
quantify the degree of cognitive impairment.
A
The dementia diagnosis must include a formal objective cognitive assessment 
with validated instruments.
A
The use of the Spanish standardised version of the MMSE or the MEC is 
recommended to screen dementia in individuals with cognitive complaints or 
advanced age in our medium.
B
Other short screening tests, such as the Pfeiffer test, the MIS, the 7-minute test, 
the clock test, the Eurotest or the T@M can also be recommended to screen 
dementia in individuals who are suspected of having cognitive impairment.
B
The neuropsychological examination using general brief-intermediate type 
evaluation tests is recommended when the aim is to make an evaluation of the 
most important neuropsychological areas in a reasonable time.
D
The performance of a detailed neuropsychological assessment via specifi c tests 
is recommendable when there are differences between the clinical impression 
and the screening tests, diagnostic doubts or else when the complaints are limited 
to just one cognitive domain or evolve over a short period of time.
C
The use of specifi c scales is recommendable to quantify the degree of global 
functional impairment in individuals who are suspected of having cognitive 
impairment.
✔
The choice of a specifi c instrument must be made depending on the time 
available, on the clinical experience and on the availability of regulatory data in 
the language and in the environment where they will be applied.
D
The performance of the following laboratory tests is recommended in all patients 
assessed for possible dementia: Haemogram, TSH, electrolytes, calcium and 
glucose, to rule out potentially reversible causes of dementia and to screen 
comorbidities.
D
The determination of folate levels can also be added, especially in patients with 
limited cereal intake and c levels, above all in older adults.
D
Serologies are also recommended for syphilis or HIV only in patients in whom 
these infections are clinically suspected as a potential cause of dementia or as 
comorbidity.
D
The determination of homocystein as a risk factor associated with cognitive 
impairment or AD is not recommended.
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A
The determination of the apoE genotype is not recommended in healthcare 
practice to diagnose AD.
B
The determination of T-tau, Aß-42 and P-tau in CSF can be used an additional 
test in cases of doubtful differential diagnosis between AD and other dementias. 
Its routine use is not recommended to diagnose dementia.
B
The determination of T-tau, Aß-42 and P-tau in CSF can be used as an additional 
test in cases of mild cognitive impairment when the clinical, neuropsychological 
and evolutionary features lead to AD being suspected as an aetiology of such 
impairment.
A The 14-3-3 protein test in CSF is recommended when CJD is suspected.
✔ The CSF analysis must always be performed whenever dementia secondary to an 
infection or encephalitic process is suspected.
B
Structural neuroimaging (CT and MRI) is recommended as a supplementary tool 
in the initial diagnosis of dementia, above all to identify lesions that can be 
treated by surgery, and vascular diseases.
✔ The MRI is recommended to detect vascular changes with greater sensitivity 
than the CT.
B
The execution of an MRI with diffusion sequences is recommended if CJD is 
suspected.
B
SPECT and PET can be used as a complement to structural neuroimaging to 
support the diagnosis or to help differentiate between different types of dementia 
when the diagnosis is uncertain. Its routine use or its use as a sole diagnosis tool 
is not recommended.
B
The123 I-FP-CIT SPECT is recommended to support the diagnosis of DLB (as a 
suggestive diagnostic feature) and for the differential diagnosis between DLB/
PDD and AD.
B
The execution of an EEG is recommended if the presence of delirium, complex 
partial epileptic crises or non-convulsive status epilepticus is suspected.
A The use of EEG to diagnose CJD is recommended.
D
The execution of a cerebral biopsy for diagnostic purposes must only be 
considered in highly selected patients when a reversible cause is suspected that 
cannot be diagnosed in any other way.
DIFFERENT CARE LEVEL ACTIONS
D
The PCT professionals must suspect the existence of cognitive impairment 
and/or dementia if they observe memory complaints, behavioural changes and 
diffi culties to carry out advanced and instrumental ADL, carrying out screening 
tests and starting complementary examinations to be able to formulate a diagnosis 
and refer to the SDC depending on the results.
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C
There is not enough scientifi c evidence to permit the recommendation of 
population-based dementia screening in people over the age of 65.
C
The PCT must refer people to the SDCT who have: a) early, family or genetic 
onset dementia, b) doubts in the diagnosis of cognitive impairment, c) potentially 
severe secondary dementia, d) suspicion of neurodegenerative disease, e) 
unpredictable or diffi cult to manage complications in the course of already 
diagnosed dementia.
D
The referral of patients with MCI or secondary dementia that can be solved by 
the PCT, or pluripathological patients with bad functional basic status, is not 
recommended.
D
The PCT must assume responsibility for the management, care and monitoring 
of people with dementia and of their caregivers.
D
People with a predictable evolution must be periodically controlled by the PCT. 
If there is unexpected worsening, alarm signals, behavioural crises, etc. they 
must be quickly attended by PCT, and if it is diffi cult to control them, they must 
be referred to the SDCT.
D
Coordination and communication between PCT, SDCT, SHC and AFA must be 
established to guarantee seamless healthcare throughout the entire process.
D
It is recommendable for the multi-disciplinary team of the SDCT to include an 
expert specialist physician in dementias (neurologist, geriatrician or psychiatrist), 
a psychologist/neuropsychologist, a nursing professional, a social worker and 
administrative staff. The SDCT must have access to diagnosis means to be able 
to design treatment, monitor strategies and satisfy their healthcare, teaching, 
research and management objectives.
D
Patients and/or their families must be informed about the diagnosis, the prognosis 
and the strategy to be followed.
D
Patients and/or their families must receive a written report listing all the 
examinations carried out, the diagnostic guideline and treatment, and monitoring 
plan. This information must be given to the PCT and/or to the referring 
practitioner.
D
The existence of specifi c resources is recommendable to care for people with 
dementia, and the SHC network must have specifi c resources that adapt to each 
phase of the disease.
✔ To optimise the comprehensive treatment of dementia, it is recommendable for 
there to be referral, admission and discharge criteria for each healthcare resource.
D
Treatment in specifi c day hospitals for dementia is recommended in the mild and 
moderate phases of dementia.
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✔
It must be taken into account that the mental health services carry out an essential 
role in the care of people with dementia, as they contribute to the aetiological 
diagnosis, the treatment and hospitalised care if severe BPSD appear. They 
provide coordinated, comprehensive and multidisciplinary care.
D
It is recommendable for health and social services professionals to know about 
the problems that affect their dementia patients to be able to provide an answer 
to their demands and know what tasks caregivers must carry out, the time they 
spend, the environment where they live, and the cost it represents for the family.
D
The Administration, through its social services network, must adapt to the 
increase in demand for care and services for people with dementia.
D
Favouring access to social services is recommendable as well as providing the 
services to give adequate support to the task of caring of families that care for 
people with dementia.
D
It is recommendable to step up the support measures to make it easier for people 
with dementia to remain at home.
C
Psychological support and psychoeducational interventions geared towards 
families with people with dementia are recommendable, in order to favour their 
task of caring, reduce the care burden and improve the quality of life.
D
In each case and depending on the moment of evolution of the dementia, it is 
recommendable to dynamically select the best social service resource that must 
be provided to a family caring for a person with dementia.
D
To ensure seamless social and health care in the care of people with dementia and 
their families, it is recommendable, throughout the entire process, for there to be 
coordination between the different care levels, social services and community 
resources.
D
To favour the comprehensive care of the person/family with dementia, it is 
recommendable for the communication and coordination between the different 
levels (health, social and community) to be fast, effi cient, effective and 
multidirectional.
D
It is recommendable for all the care levels to collaborate in obtaining a fail-safe 
diagnosis, favouring the obtaining of biological and neurological tissue samples.
D
Coordination at the different healthcare levels is recommendable in order 
to favour respect for the rights and freedoms of patients in decision-making 
(advance directives).
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D
Coordination between the healthcare levels, the SDCT, universities, 
pharmaceutical industry, teaching and research institutions and the AFA is 
recommendable to favour an increase in knowledge (training and research) of 
dementias (health, social, community aspects).
D
It is recommendable for the different professionals who intervene in the care 
of dementia to collaborate in drawing up a record of dementias to have a better 




Informing patients and their families of the dementia diagnosis is recommended 
when there is reasonable suspicion of dementia. The SDCT physician and/or 
PCT is the person who must inform the patient and family.
C
Informing patients who request this and the family of the diagnosis is 
recommended, as it has been proven that the information received does not 
predispose or generate a disorder in the person affected.
D
The patients’ right to be informed or not must be respected, as well as their right, 
if they are capacitated to do so, to choose those people around them who must 
be informed of the process.
C
Offering information via understandable, sensible, respectful, empathetic, verbal 
communication, and an adequate environment and conditions is recommended, 
to facilitate two-way dialogue. To make it easier to understand the diagnosis 
and its consequences, further information can be provided via information 
leafl ets, booklets, videos, Internet and other audiovisual means, and associations 
of relatives of dementia patients. If there are language barriers, communication 
must be facilitated through an independent cultural mediator.
D
The individual evaluation of the possible impact that communicating the 
diagnosis may generate is recommended, as well as doing so in instalments 
if necessary, providing further information during successive visits and in 
information sessions (SDCT, PCT, AFA).
C
Giving information to patients and families about dementia is recommended, as 
well as about its evolution, clinical manifestations, comprehensive treatment and 
support to the caregiver, which will enable them to plan their future.
D
It is advisable for the group information sessions aimed at families to contemplate 
basic aspects of dementia; function of the different professionals and healthcare 
levels; comprehensive treatment and available resources; management of 
emerging problems; detection of burdens derived from the task of caring, and 
support to the caregiver.
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D
The execution of specifi c training programmes for families who live with people 
affected by DLB, FTLD or VD and in advanced or terminal dementia stages is 
recommended.
D
Training health practitioners, social services professionals and volunteers/
professionals is recommended so that they can manage a group of patients and/
or families affected by dementia.
D
It is recommendable to train caregivers (families or professionals) to empower 
them to manage non-pharmacological interventions of dementia.
Specifi c pharmacological treatment of dementia
A
ACE inhibitors are recommended for the specifi c and symptomatic treatment of 
mild to moderate AD.
A
Treatment with ACE inhibitors is recommended to manage mild to moderate 
VD.
B ACE inhibitors have proved to be benefi cial in DLB and PDD.
B
No differences have been shown regarding ACE inhibitors (donepezil, 
rivastigmine and galantamine) in respect of effi cacy and safety profi les.
A
Memantine is recommended as specifi c treatment for moderate to severe AD in 
mono-therapy or combined with ACE inhibitors.
-
We have little evidence about whether specifi c pharmacological treatment is 
equally effective in all people due to the lack of studies that assess the individual 
response to different drugs.
Alzheimer’s Disease
A
Treatment is recommended with ACE inhibitors (donepezil 5-10 mg/day, 
galantamine 16-24 mg/day or rivastigmine 6-12 mg/day oral/4.6-9.5 mg/day 
transdermal) in patients with mild or moderate AD.
B
An ACE inhibitor can be used (donepezil or galantamine) in severe AD, although 
there is less evidence of its benefi t.
A
Treatment with memantine is recommended, at a dose of 20 mg/day in patients 
with moderate to severe AD.
A
Treatment with ACE inhibitors is recommended in patients with mild to moderate 
AD, to manage the cognitive and functional symptoms.
A
Treatment with ACE inhibitors is recommended in patients with mild to moderate 
AD, to manage behavioural alterations (apathy, anxiety and depression), despite 
the benefi t being modest.
A
Treatment with memantine is recommended in patients with moderate to severe 
AD, to manage the cognitive and functional symptoms.
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B
There is no evidence to recommend treatment with ACE inhibitors to improve 
the quality of life of patients with AD.
✔
Following the indications of the technical data sheet of the drug is recommended 
to avoid adverse effects and contraindications of the ACE inhibitors and 
memantine.
D
The administration of a progressive dose of the drug is recommended to avoid 
or reduce the adverse effects of the ACE inhibitors, starting the treatment at low 
doses, to reach the optimal tolerated therapeutic dose.
D
ACE inhibitors must be used with caution in patients with a background of 
epilepsy, asthma or obstructive lung disease, arrhythmias, syncopes, low blood 
pressure, presence of bradycardia or long QT, active peptic ulcer, urinary 
retention, renal or hepatic insuffi ciency. Memantine must be used with caution in 
patients with a background of epilepsy, renal insuffi ciency and urinary retention.
D
Domperidone can be used to treat mild gastrointestinal effects secondary to ACE 
inhibitors.
B
The addition of memantine is recommended in patients with moderate to severe 
AD, treated with donepezil at stable doses in combined therapy.
B
The addition of memantine to donepezil is not recommended to treat patients 
with mild to moderate AD.
 The addition of memantine to donepezil is not recommended to treat patients 
with mild to moderate AD.
Parkinson’s disease dementia
B The use of rivastigmine or donepezil is recommended in PDD.
B
The use of donepezil may be considered to treat cognitive and functional 
symptoms in PDD.
C There is not enough evidence to recommend the use of memantine in PDD.
B
In patients affected by PDD, treatment with donepezil and memantine is 
associated with a rate of adverse effects similar to the placebo group, unlike with 
rivastigmine, which showed a higher rate of secondary effects, an increase in 
tremors and a lower rate of mortality than the placebo group.
Dementia with Lewy bodies
B The use of rivastigmine is recommended to treat BPSD in DLB.
C
The use of donepezil or galantamine may be considered to treat cognitive 
symptoms and BPSD in DLB.
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C There is no evidence to recommend the use of memantine in DLB.
✔
The most frequent adverse effects observed in treated patients with DLB are: 
nausea, vomiting, weight loss and drowsiness. These were more frequent in 
patients treated with rivastigmine than with placebo, and also in those treated 
with memantine than with placebo. The potential adverse effects of rivastigmine 
must be detected and monitored during treatment.
C Levodopa can be used in monotherapy to treat the motor symptoms of DLB.
D
It is advisable to avoid the use of dopaminergic and anticholinergic agonists 
in DLB due to their potential effect of worsening the cognitive and psychotic 
symptoms and producing sleep alterations and orthostatic hypotension.
Frontotemporal lobar degeneration
B
The use of ACE inhibitors or memantine to treat cognitive-behavioural symptoms 
of patients with FTLD is not recommended.
B
The use of selective serotonin reuptake inhibitors, trazodone or atypical neuroleptics 
is recommended to treat agitation, inappropriate behaviour, compulsions or 
stereotypes in patients with FTLD.
Vascular Dementia
A The use of ACE inhibitors is recommended in mild to moderate VD.
A
ACE inhibitors are recommended to improve the cognitive symptoms of mild to 
moderate VD.
A
Donepezil is recommended to improve the global clinical impression and 
functional defi ciencies (ADL) in VD.
A
The use of galantamine is recommended to treat cognitive symptoms, functional 
defi ciency and BPSD in patients with mild to moderate VD, mixed dementia and/
or AD with cerebrovascular disease.
C Rivastigmine may be used to improve cognition in VD.
A Memantine may be used to treat cognitive symptoms of moderate and severe VD.
B ACE inhibitors may be used to treat cognitive symptoms of VD.
B
ACE inhibitors and/or memantine are not recommended to manage behavioural 
symptoms in VD.

Bearing in mind that patients with VD usually suffer a high cardiovascular risk, 
treatment with ACE inhibitors should be assessed individually, paying special 
attention to how the treatment is managed.
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✔ It is advisable to follow the indications given in the product technical data sheet.
Other pharmacological treatments
A
Hormonal therapies (ACTH, prednisone, oestrogens, dehydroepiandrosterone) 
are not recommended as treatment of AD.
A
Neither ibuprofen, indometacine nor low doses of naproxen are recommended to 
treat AD.
A Piracetam is not recommended to treat AD.
A Propentofylline is not recommended to treat AD or VD.
B Nimodipine is not recommended to treat VD.
A Selegiline is not recommended to treat AD.
A Ibedenone is not recommended to treat AD.
B Dihydroergotoxine mesylate is not recommended to treat AD or VD.
B Neither citicoline nor oral CDP-choline are recommended to treat VD.
D
Neither citicoline nor CDP-choline via parenteral administration are recommended 
to treat vascular cognitive impairment.
NON-PHARMACOLOGICAL TREATMENT OF DEMENTIAS
Cognitive intervention or stimulation
B
The participation in cognitive intervention programmes is recommendable for 
patients with mild or moderate AD, to maintain their cognitive function, their 
functionality and quality of life, although the magnitude of the effect attributable 
to the actual cognitive intervention is not well established.
C
There is currently no evidence of the effi cacy of cognitive stimulation in individuals 
with VD to recommend its use in this dementia subtype.
-
A type of specifi c cognitive intervention cannot be recommended at the present 
time, based on the degree of effi cacy in patients with mild or moderate AD, 
although interventions that require a general type of processing seem to have a 
greater overall benefi t than those where cognitive training of specifi c functions is 
carried out.
C
The use of computer-based cognitive intervention programmes in initial AD or 
mild cognitive impairment cannot be recommended at the present time.
B
Individual cognitive interventions are recommendable to stabilise the cognitive 
function and functionality of individuals with AD.
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-
The use of individual interventions rather than group interventions or vice versa 
cannot be recommended.
Intervention programmes on activities of daily living
B
Intervention programmes on activities of daily living are recommended to improve 
the functionality of patients with dementia and decrease the strain of the caregiver 




Long-term physical activity programmes are recommended to maintain the 
functionality of institutionalised patients with dementia.
Other non-pharmacological treatments
C
The use of therapeutic massages or touches, transcutaneous electrical nervous 
stimulation, music therapy or multisensory therapy cannot be recommended at 
the present time to treat cognitive or functional manifestations in patients with 
dementia or specifi cally with AD.
B
Behavioural changes, programmed hygiene and induced urination are 
recommendable to reduce urinary incontinence in individuals with dementia.
Safety of non-pharmacological treatments
✔
Cognitive intervention programmes, especially those based on reality counselling 
therapies and cognitive training, must be adapted to the cognitive skills and to 
the emotional tolerance of each patient, in order to avoid adverse emotional 
consequences.
Treatment of behavioural and psychological symptoms of dementia
✔
The systematic assessment of the presence of BPSD is recommended as it is a 
fundamental component of the clinical picture, it appears very frequently, it is 
diffi cult to manage, it has an impact on the quality of life and is a frequent reason 
for urgent care, family claudication and institutionalisation.
✔ The use of specifi cally designed instruments is recommended to evaluate BPSD in 
dementia, independently from cognitive and functional alterations.
✔
NPI (Neuropsychiatric Inventory) is recommended as an instrument to assess the 
intensity and frequency of BPSD, the CSDD scale (Cornell Scale for Depression 
in Dementia) to assess depressive symptomatology and DMAI (Cohen Mansfi eld 
Agitation Inventory) to assess agitation.
B
It is advisable to bear in mind that BPSD may appear at any time during the 
evolution of dementia, whatever its aetiology, and it is not unusual for it to be the 
fi rst manifestation.
CLINICAL PRACTICE GUIDELINE ON THE COMPREHENSIVE CARE 
OF PEOPLE WITH ALZHEIMER’S DISEASE AND OTHER DEMENTIAS 37 
B
If delusions and hallucinations appear in a person with early stage dementia, 
FTLD or DLB must be suspected. If there are REM sleep behaviour disorders, the 
fi rst suspicion will be DLB.
B
BPSD must be detected as soon as possible, in mild dementia stages, or throughout 
its subsequent evolution; they must be quantifi ed and grouped into syndromes that 
facilitate differential diagnosis between the different dementias.
B
It is advisable to know and recognise the BPSDs that appear in AD, VD, FTLD, 
DLB and PDD.
B
When a BPSD appears, health practitioners should perform a systematic evaluation 
of this and of the other symptoms in order to be able to perform a differential 
diagnosis with idiopathic psychiatric diseases.
B
Health practitioners must bear in mind the importance of BPSD from the 
semiological, repercussion, prognosis and resource viewpoint. BPSD must be 
detected as soon as possible, in mild dementia stages, or throughout its subsequent 
evolution, quantifying them and grouping them into syndromes that will enable 
us to provide a differential diagnosis between the different neurodegenerative 
entities and treat them appropriately.
B
It is advisable to know and recognise the groups of BPSDs that appear in AD, VD, 
FTLD, DLB, PDD, PSP, DCB and HD.
✔ Starting treatment with non-pharmacological strategic measures to manage BPSD 
is recommended.
C
It is especially important for caregivers to receive information and training that 
capacitates them to prevent the appearance of BPSD and act as co-therapists when 
they are already present.
C
Stimulation-orientated treatment with recreational activities and pleasurable 
activities has proved to be effective to cope with depression.
✔ Non-pharmacological sleep management mainly consists of establishing 
guidelines and good sleep hygiene.
C
There is limited evidence that therapeutic massages may be effective to treat 
agitation.
D
The use of electronic identifi cation techniques on dementia patients who present 
erratic wandering is recommended.
D
It is advisable to start with the non-pharmacological management of BPSD and 
use drugs in severe or rebellious symptoms.
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D
The symptom that is going to be treated as well as its possible causes or triggers 
must be identifi ed.
D
The general recommendation regarding pharmacological treatment of BPSD is to 
start basic treatment (ACE inhibitors and/or memantine) and, if the response is not 
suffi cient, add a specifi c psychotropic drug.
✔
Bear in mind the special sensitivity of these patients to adverse effects, especially 
the risk of anticholinergic effects, orthostatic hypotension, falls, extrapyramidal 
effects, worsening of cognitive function, confusion and delirium. Review the dose 
and the actual treatment need at regular intervals, generally every 3 months.
✔ Start with low doses and slowly reach the minimum effective doses. Preferential 
use of oral route. If necessary, intramuscular is preferable to intravenous route.
B
The use of ACE inhibitors and/or memantine is recommended as treatment of 
dementia, not only for cognitive symptoms but also for non-cognitive ones.
B
The use of rivastigmine is recommended to treat BPSD in patients with DLB or 
PDD.
D
The use of psychotropic drugs is recommended to treat BPSD, although evidence 
about their effi cacy in patients with dementia is generally low and the risk of 
adverse effects is high.
B
The use of these drugs in patients, on whom the use of ACE inhibitors or memantine 
is indicated, is recommended to treat BPSD, too.
✔ If they do not improve, non-pharmacological measures or specifi c psychotropic 
drugs will be used for the symptom, considering their adverse effects.
A Risperidone may be used in patients with AD and psychotic symptoms.
B
Donepezil may be used in patients with AD and psychotic symptoms. Rivastigmine 
may be used to treat psychosis in DLB.
D
Atypical anti-psychotics may be used in patients with AD or VD and psychotic 
symptoms.
B
Antidepressants, preferably sertraline and citalopram may be used in patients with 
dementia and depression. Tricyclic antidepressants are not recommended due to 
their adverse effects, despite their similar effi cacy.
D
Psychostimulants, amantadine, bromocriptine or bupropion may be used in 
patients with dementia and severe apathy.
-
There is not enough evidence to make recommendations about the treatment of 
anxiety in dementia.
D Risperidone may be effective in erratic wandering in AD.
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D
Benzodiazepines, trazodone or hypnotics may be used to treat sleep disorders in 
dementia. Melatonine is not recommended.
B
The use of neuroleptics is recommended to treat agitation and aggressiveness. The 
evidence is greater for risperidone than for other drugs.
D
In the case of intolerance to antipsychotics, donepezil (if indicated), SSRI or 
carbamazepine may be used to treat agitation and aggressiveness.
D
Antidepressants, antipsychotics, mood stabilisers, hormonal agents, cimetidine or 
pindolol may be used to treat inappropriate sexual behaviours.
A
Antipsychotics must be used with caution in patients with dementia, due to the 
risk of adverse reactions, always considering the risks of treating compared with 
the risks of not treating.
B Antipsychotics are contraindicated in DLB due to the high risk of adverse effects.
C Treatments with benzodiazepines must be short-term due to the adverse effects.
✔ The association of non-pharmacological and pharmacological measures is 
recommended to manage behavioural and psychological symptoms of dementia.
✔ A meticulous assessment is recommended if BPSD appear, to rule out concomitant 
pathology and achieve optimal environmental surroundings.
✔
Sensory stimulation, behavioural therapy, structured activities and social contact 
may be used to reduce the incidence of BPSD, although there is no scientifi c 
evidence to support this.
A The use of atypical or typical antipsychotics is recommendable in agitation.
B
To control delirium in a person with dementia, atypical antipsychotics (risperidone, 
olanzapine, quetiapine) may be used.
D
If the behaviour crises do not respond to the normal pharmacological measures in 
the home/nursing home, admission into hospital or into specifi c units is advised to 
diagnose the symptoms and aetiology, treat comorbidities, optimise the treatment 
of BPSD and guarantee the safety of patients and of their environment.
✔
It is advisable to inform and train caregivers of dementia patients in strategies 
to address and manage the BPSD so that it is possible to adopt and promote an 
appropriate attitude towards patients and prevent the strain and claudication of 
caregivers.
Alternative treatments of dementias
B Vitamin E supplements are not recommended to treat AD.
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A
The use of B1, B6, B
12
 vitamin or folic acid supplements is not recommended in 
patients with cognitive impairment that do not present a clear defi ciency of these 
elements.
B The use of copper supplements is not recommended to treat patients with AD.
B
There is not enough evidence in literature about the effi cacy of ginkgo biloba to 
recommend its use in the treatment of AD or VD.
C
Existing evidence does not permit recommending the use of lecithin, alpha-lipoic 
acid, omega-3 fatty acids, ginseng or yokukansan (TJ-54) in the treatment of 
cognitive symptoms of AD.
Assessment of the treatment of dementias
D
The periodic assessment of cognitive, functional, motor and behavioural aspects is 
recommended, as well as of the degree of strain on the caregiver when monitoring 
patients with dementia.
D
The use of tests, scales or questionnaires is recommended to quantify the therapeutic 
response and the appearance of complications in patients with dementia.
✔ The choice of a test, scale or questionnaire will be based on the physician’s 
experience and on its applicability in the context.
C
The use of the MMSE is recommended to assess the response to dementia 
treatment in clinical practice.
CAREGIVERS OF PATIENTS AFFECTED BY DEMENTIA
C
During the care of every person with dementia, their individual characteristics and 
the actual characteristics of the disease must be evaluated to be able to assess the 
needs and prevent the burden of the caregiver, and act consequently to optimise 
their support network.
D
Dementia is a dynamic process, which, as it progresses, increases the commitment 
and obligations of the caregiver. It is recommendable to meticulously evaluate the 
burden supported by primary caregivers and the support they receive in their task 
of caring. If the burden is too much, it is advisable to establish the appropriate 
measures to prevent this from affecting their physical and psychological health, 
thus giving rise to the risk of claudication.
C
The use of the Zarit scale (long and short versions) is recommended to quantify 
the caregiver burden.
✔ The use of specifi c adapted and validated instruments is recommended to assess 
other aspects that may be affected by the caregiver burden.
D
A basal evaluation of caregivers of people with dementia is recommendable in 
order to identify the factors that affect the burden of caring, the diffi culties that 
might arise in the course of the disease and the degree of burden that caregivers 
already have at the time of the diagnosis.
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D
Caregivers should be informed well and progressively about the disease and its 
possible complications, offering them the available social resources, as well as the 
formal or informal support systems to prevent strain.
B
To improve the care of caregivers of people with dementia and reduce their 
burden in the task of caring, as well as anxiety and depression, a programme that 
combines educational support, emotional support and the provision of resources 
may be benefi cial.
B
Interventions carried out in the caregiver’s own home and in a personalised 
manner are recommendable.
D
Comprehensive care of caregivers must contemplate many different actions: 
Welcome programme, information sessions, theoretical and practical training, 
advisory services, emotional support, adaptation of resources, pharmacological 
treatment if required and accompaniment throughout the entire process.
D
There should be a professional in the MAGs to favour and foster the skills of the 
group members.
D
It is advisable and desirable for caregivers of people with dementia to participate 
in MAGs, as they provide many different benefi ts, which will enable them to cope 
better with the task of caring and improve their personal situation.
D
Participation in TAGs or EESG to improve the strategies to cope with dementia 
is recommendable, relieving the burden and improving the level of anxiety and 
depression that might affect the caregiver.
D
Professionals that run the TAG or EESG must personalise their interventions to 
be more effective.
✔
It is recommended for those caregivers who express a signifi cant degree of stress 
and/or depression to be referred to their primary care physician and/or mental 
health specialists for their assessment and treatment.
C
Psychotherapy, especially cognitive-behavioural therapy, would be recommended 
to treat stress or depression due to excess caregiver burden when they present 
clinically relevant symptomatology.
D
Health practitioners and social services professionals who care for people with 
dementia and their families should comment on the existence of the AFAs and the 
benefi ts that they can obtain from them, and insist on their experience in living 
with people with dementia.
D
To achieve optimisation in the approach and management of dementia 
throughout the entire process, from diagnosis until after death, the existence 
of good coordination between the different healthcare levels and the AFAs is 
recommendable.
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D
The Public Administration and the AFAs should continue to maintain and improve 
their collaboration, in order to improve the quality of life of people affected by 
dementia.
D
There must be a close relationship between the tertiary sector and the Public 
Administration with permanent dialogue, thus favouring the exchange of 
knowledge both on the needs and collaboration proposals (programmes, subsidies, 
agreements, etc.).
D
It is recommendable to continue improving the relationship between the Public 
Administration and the AFAs, drafting referral protocols, recognising the role of 
the AFAs in the training of caregivers and professionals; fostering the creation 
of TAG and/or EESG and therapeutic programmes (DH, DC, rehabilitation 
workshops) and aid to develop complementary activities.
EARLY ONSET OR PRE-SENILE DEMENTIA
D
The use of neuropsychological test batteries validated for this age group is 
recommended in the assessment and characterisation of cognitive impairment in 
people with pre-senile dementia.
D
The aetiological study of a patient with early onset dementia should include the 
study of low incident causes in later age groups and atypical presentations of 
frequent dementias.
✔
It is recommendable for patients with early onset dementia to be assessed by 
professionals with experience in this age group and at centres that have the 
appropriate complementary tests to carry out this study.
✔
Lacking specifi c evidence in this age group, the therapeutic guidelines 
recommended for other age groups should be followed, depending on the type of 
dementia suffered by the patient.
✔
It is advisable for people with presenile dementia to carry out the same non-
pharmacological therapies that have proved to be effective in people over the age 
of 65.
✔
If we wish to favour their adherence to individual or group non-pharmacological 
therapeutic programmes, they must be adapted to the specifi c needs of the person 
with early onset dementia.
✔ It is recommendable for people with early onset dementia to have access to social-
health and health resources that focus specifi cally on their care.
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ETHICS AND LEGAL ASPECTS OF DEMENTIAS
Abuse of people with dementia
D
It is necessary for health practitioners, the social services and society in general 
to be concerned and become aware of the abuse that many elderly people 
suffer, whether they are affected or not by dementia. It is a personal, family, 
intergenerational, health problem, as well as one of justice and human rights. Its 
detection permits the establishing of prevention strategies, changes in attitude and 
the promotion of solutions.
D
Health and social services professionals must be trained and made aware how to 
detect, declare, prevent and treat problems derived from the abuse of people with 
dementia.
D
It is important to identify the type of abuse (action or omission), and determine its 
characteristics (psychological, physical, sexual, economic).
D
If abuse is suspected, the person must be questioned in private and with delicacy, 
given their fragility, bearing in mind the state of mind and the fear of the 
consequences that discovery of abuse may entail, in their environment.
D
For a complete diagnosis of abuse, it is advisable to evaluate the risk factors, those 
that depend on the patient, on the abusing caregiver and the circumstances that 
surround it.
D
The possibility of the existence of abuse must be suspected, if the person with 
dementia is hostile, aggressive, provocative, dependent for ADL and there is a 
lack of an appropriate support network.
D
Caregivers must be suspected as abusers if we observe symptoms of anxiety, 
depression, strain in the task of caring, low cultural level and when the person 
they are looking after is very dependent for ADL and/or presents BPSD.
D
If the person has mild to moderate dementia, we must get them to give us 
information about their physical and psychic state of health through fl uent and 
true communication. In initial stages, this can be relatively easy to obtain; in 
fl uctuating dementia, the most appropriate and reliable moment must be sought; in 
advanced stages, it will be possible to obtain information at moments of lucidity.
D
A meticulous and thorough clinical examination is recommendable to detect signs 
that lead us to suspect the possibility of abuse, evaluating physical, psychological 
and behavioural aspects.
D
It is advisable to be mindful of the possibility of abuse, as this facilitates its 
detection and permits protection, prevention and correction measures.
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B
We must systematically question aspects related to the abuse of any elderly person, 
with or without dementia, and use standardised scales to detect it.
B
We must assess caregivers of people with dementia to detect a possible person 
responsible for abuse. Scales can be used to detect it.
D
Health and social services professionals must be trained to prevent, detect, care 
for, protect, declare and recuperate a person with dementia suffering from abuse.
✔ The fundamental rights of the person to dignity, participation, autonomy and self-
determination must be preserved.
✔ People suffering abuse must be informed, respecting their right to confi dentiality, 
in order to cover their basic needs, and to preserve their social relationships.
✔
The victim’s demands must be defi ned and identifi ed individually, without 
prejudices or value judgements, determining an action strategy and seeking the 
best possible solution for all involved in a situation of abuse.
✔
If there is probable suspicion of abuse, the health personnel must activate the 
judicial resources that permit the defence of the victim of abuse. If there are 
physical injuries, a judicial report of injuries will be drafted. If there are injuries 
or other acute contingencies, the Public Prosecutor will be informed.
D
When abuse is detected and diagnosed, it is recommendable to launch strategies 
that permit improving the situation of the victim and of the aggressor. The actions 
of the different professionals must be coordinated, recording all the data of the 
abuse in the clinical record.
D
To prevent and treat abuse, avoiding social isolation, optimising patient care, 
adapting their home and institutionalising them if the family cannot guarantee 
their care, is recommended.
D
It is advisable to attend to the abuser, who is often a stressed or sick relative, 
or with an excessive burden. The burden can be reduced by sharing the task of 
caring, removing the patient from the family environment, participating in support 
groups, guaranteeing rest and offering medical treatment if required.
Advance directives
D
Health and social services professionals, and relatives must try to discover the AD 
of sick people to be able to comply with their wishes and respect their medical, 
legal and fi nancial preferences.
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D
It is important to continue informing and raising the awareness of the population 
at large as well as of the health and social services professionals, about the need 
for able and free adult people to exercise their rights to draw up an AD document 
containing their wishes regarding the care and treatment they accept to receive, as 
well as the appointment of a valid representative that can decide on their behalf 
in each health circumstance, and after death, about the destination of their organs.
D
It is advisable to draw up the AD document in adult age and being of sound mind. 
In respect of people with dementia, this must be attempted as soon as possible to 
guarantee their cognitive integrity to the utmost.
D
Health professionals must recommend the AD document to their patients, and 
insist upon it especially if they detect emerging cognitive impairment.
D
It is recommendable for the AD document to include everything that is important 
for the person, bearing in mind that another person, to whom they delegate, will 
have to take decisions in their name, following their own indications.
D
To make it easier for a person to have access to the AD, the AD document must be 
registered in the autonomous community and at the National Registry Offi ce for 
advance directives or AD of the Ministry of Health and Consumer Affairs, and it 
must be attached to the clinical record and to the health card.
Evaluation of competences
D
The utmost efforts should be made to maintain the autonomy of people affected 
by dementia, respecting their decision-making capacity, whenever possible, even 
at the end of their days.
D
It is recommendable for health and social services professionals, as well as 
the legal institutions that attend to them, to use a common language and share 
knowledge.
D
The decision capacity of any person affected by dementia should be assessed, 
using the assessment instrument of the Sitges 2009 document.
D
It is advisable to involve the patient in decisions made about the treatment. The 
patient’s desire must prevail; however, differences in opinion between patient and 
caregiver must be evaluated.
D
Total or partial incapacitation must be used as a legal resource to protect people 
with dementia.
D
When carrying out a comprehensive and multidisciplinary assessment of people 
with dementia, the evaluation of their decision-making capacity must be included, 
as well, if there is appropriate legal protection or not.
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D
The ability of people with dementia to drive a vehicle should be assessed, even 
during the initial stages, as an increase in the risk of suffering accidents has been 
proven.
D
A full psychological evaluation should always be carried out at drivers' examination 
centres to detect people with cognitive impairment in mild dementia.
D
Health professionals must inform patients with dementia and their families about 
the risk that continuing to drive may entail.
D
If a person with mild dementia continues to hold a licence, their ability to drive 
must be reviewed every 6 to 12 months, or earlier if necessary, to evaluate their 
risk.
D
A driving limitation must be proposed when alterations, although mild, are detected 
in attention, orientation, executive functioning or in visuospatial perception.
D
It is advisable to keep fi rearms or elements that might be dangerous to them or to 
third parties, away from people with dementia, above all if there are behavioural 
disorders.
D
People with dementia and their relatives must be informed of the possibility of 
participating in clinical trials.
D
People participating in research studies must receive extensive, detailed and 
understandable information, and they must sign an informed consent.
D Good Clinical Practice Guidelines must be implemented in research studies.
D
The RCTs should satisfy a series of conditions: a) correct methodology and 
competent research team; b) acceptable risk-benefi t ratio; c) independent 
supervision; d) fair load distribution, random distribution, with equal probability 
of effi cacy and safety in all groups; e) informed consent and confi dentiality; f) 
safety guarantees, and g) appropriate payment.
D
Professionals taking part in research studies must know about the agreements 
relating to human rights and biomedicine as well as the standards established by 
international ethical guidelines.
D
It is very important to respect the autonomy and freedom of the people at the time 
of the diagnosis and throughout the entire evolution process, bearing in mind that, 
despite the existence of advance directives, people, with age, due to circumstances 
and/or due to the actual disease process, may change their way of seeing things, 
and thus change their decisions.
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D
Beginning the incapacitation process must be recommended when the dementia 
progresses and the cognitive and/or behavioural impairment determines the 
taking of inadequate decisions that might harm the person affected by dementia 
and their environment.
D
The incapacitation process must be the result of a multidisciplinary evaluation, 
and must contemplate multiple aspects such as diagnosis, clinical manifestations, 
degree of dependence, social aspects, use of services and evolution of the process.





To request the incapacitation or modifi cation of the capacity to act, the procedure 
laid down by the Spanish Procedural and Civil Registration Law must be 
followed, whereby, based on a demand, the case is studied, challenged and the 
judge gives judgement.
✔
People with mild cognitive impairment and mild dementia should be advised to 
protect themselves through decision-making powers, or giving special power or 
writing the advance directive document.
✔
Any person with dementia, who still has suffi cient capacity to act, should appoint 
a guardian, foreseeing the possibility of being declared incapable. What is more 
provision referring to their personal care or the administration of their assets, 
identifying any person who should not be appointed, under any circumstances 
should be adopted.
✔ People with dementia who have lost their self-management skills, should have a 
legal representative or guardian to protect them, and substitute them.
✔
People with dementia with a reduced decision capacity should name a 
representative who shall care for their conservatorship, accompanying them, 
advising them and helping them take decisions.
✔ People with dementia with a reduced decision capacity should name an 
administrator for their estate to administer their assets if these are considerable.
✔
A judicial defender of the person with dementia must be named, to cope with 
urgent situations if a tutor has not been named or when important differences 
arise between guardian and the ward.
Restraint of the patient
B
It is recommendable to prevent and detect psychomotor agitation and 
aggressiveness of people with dementia at an early stage and treat it. The 
measures to be followed may be pharmacological or non-pharmacological, 
using mechanical restraint if required.
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A
The use of atypical antipsychotic drugs is recommendable as a primary 
pharmacological treatment of psychomotor agitation and aggressiveness of people 
affected by dementia.
D
When it has not been possible to control a person with dementia with pronounced 
psychomotor agitation using verbal and/or pharmacological measures, and they 
continue to be dangerous or at risk of causing harm to themselves or to others, 
mechanical restraint (MR) must be proposed.
D
Approved fastening elements must be used in the MR, in agreement with the 
legislation in force, and they must be in perfect conditions to be effective and safe.
D
To achieve adequate and safe MR, a coordinated team is required, comprised of 
four or fi ve well-trained people, who secure patients properly, taking care not to 
harm them, and acting calmly and with serenity, but fi rmly and surely. Throughout 
the entire MR procedure, all those measures aimed at preventing direct or indirect 
complications must be maximised, guaranteeing the patient’s comfort, privacy and 
respect. The MR measure will be stopped as soon as possible, and progressively, 
when the symptoms are under control.
D
MR is a therapeutic physical restriction measure that must only be applied under 
medical prescription. It must only be used if other restraint methods are not 
applicable or have failed. Its objective is to protect the actual patient and other 
people, objects or surrounding environment. It cannot cause greater harm than the 
harm aimed to be avoided.
D
Excessive use of MR should be avoided in people with dementia, only using it when 
it is really justifi ed, either due to the intensity of the symptoms and the possibility 
of them harming themselves or others. It must be as brief as possible to preserve 
the dignity and freedom of the person and reduce the risk of complications.
D
It is advisable for the MR to be a shared decision, agreed upon by the other 
members of the interdisciplinary team. The parentage details, the type and date 
of application of the measure, the reason for the restriction, the care guideline 
to follow, the periodicity of the controls, as well as the information given to the 
patient and to the family, and the informed consent, must be described in the 
clinical record, and signed by the physician.
C
The MR must be used in the following cases: To prevent injuries to the actual 
patients and to other people around them. To avoid interferences in the treatment 
(routes, probes, etc.), and material damage to the patient’s surroundings. To 
avoid escapes and prevent falls, and maintain the correct position of the body. To 
achieve the centre’s organisational objectives. To maintain a comfortable social 
environment.
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C
The contraindications of MR must be respected and it must not be carried out 
if not explicitly indicated by the health professional responsible, or if there 
are medical orders not to apply it. It must not be used, either, if there are 
equally effective alternative measures or procedures that have not been tried. It 
must never be used as punishment or as a show of force, or as a substitute for 
surveillance, or for the exclusive convenience or comfort of the professionals 
caring for them.
C
It is advisable for the MR to be maintained for a short period of time (hours, 
days), monitoring the patient to guarantee adequate observation to avoid 
risks and complications. When appropriate control has been achieved, it must 
gradually be brought to an end.
D
As restraint measures affect people’s freedom of movement, and their 
freedom of decision, and they are not free from complications, before starting 
to apply them, the legal regulations that govern them must be carefully and 
strictly observed and enforced. The action must contemplate the principles of 
benefi cence, non-malefi cence and justice, and respecting the right to personal 
autonomy.
C
People with dementia with severe behavioural disorders that entail a risk 
for the actual patient and/or for the people around them, and which are not 
adequately controlled in outpatients (primary and specialised care), should be 
admitted into specialised units to control the crisis and enable the family to rest. 
Admission into these centres should satisfy the dual objective of diagnosis and 
treatment.
D
Admissions in order to control crisis situations must be as short as possible, 
guaranteeing, at the time of discharge, that the symptoms have been controlled, 
that the environment and the receiving family are adequate, the caregiver’s 
burden has been reduced and support measures for them to continue with their 




The legal regulation that protects people who are involuntarily submitted to 
admission into hospital must be respected. The opinion and consent of the 
family will be required as well as the judicial authorisation before carrying out 
the admission. The reasons must be suitably justifi ed, ensuring their benefi cence 
and respect for the dignity and freedom of the person affected.
D
If involuntary internment is urgently required, for a person with dementia and 
severe behavioural disorders, it will be the physician attending to that person 
who shall take the decision. In this case, the person responsible at the centre 
must inform the competent court as soon as possible.
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CARE OF PEOPLE WITH ADVANCED DEMENTIA AND AT END-OF-LIFE STAGE
D
The term SEAT can be used in advanced degenerative dementia in terminal phase, 
which corresponds to stage GDS 7.
B
Evaluate the stage of SEAT using the Gold Standards Framework (GSF) instrument. 
The GSF is recommendable to fi nd out the expectations of the caregivers regarding 
the death of the patient, the need to establish palliative measures, the limitation of 
the therapeutic effort, and about the consumption of resources, complications and 
crisis situations.
C
Advanced dementia must be considered as terminal dementia if cognitive 
impairment is severe and there is severe dependence for the BADL, there is no 
possibility of therapeutic benefi t with the specifi c treatment, there is multiple 
comorbidity and a suitable nutritional status cannot be maintained.
B
To establish a life prognosis of less than 6 months in a person with advanced 
dementia, parameters with predictive power must be identifi ed, such as degree 
of cognitive impairment, degree of functional disability, presence of malnutrition 
and presence of systemic complications and comorbidity.
D
Palliative care must be implemented in the management of people with dementia, 
and this must be introduced early on after carrying out the diagnosis and it must 
be prolonged and increased as the disease progresses.
D
The aim of palliative care is to relieve physical and psychological suffering, 
provide quality of life and consider death as a natural process. Psychosocial and 
spiritual aspects must be integrated, giving support to relatives.
D
Health and social service professionals must be prepared to offer palliative care to 
people affected by dementia.
D
All people with advanced dementia must be provided with PC, whatever the 
healthcare level that is being applied.
D
Healthcare continuity must be maintained in PC when there is a change in the 
healthcare level of the person with advanced dementia.
D
Health organisations should foster training of all professionals to provide basic 
PC.
D
Health organisations must guarantee accessibility to specialised PC when 
necessary.
D
Coordination between the different services and healthcare areas must be 
guaranteed, as well as continuity of palliative care.
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D
Initial management of delirium must include the identifi cation and treatment of the 
triggering causes, as well as appropriate information for relatives and caregivers, 
and an evaluation of the need to use pharmacological treatment.
B Haloperidol is the drug of choice for treating delirium in patients in terminal phase.
C
Benzodiazepines are effective in the management of delirium with marked 
agitation.
D
The use of haloperidol and atypical antipsychotics must be avoided in patients 
with PDD and DLB, due to the risk of extrapyramidal reactions.
D
In people with advanced dementia at end-of-life stage due to a concomitant 
process, the diagnosis of depression must be based on the clinical observation, 
the information provided by relatives and, if possible, the use of specifi c scales.
B
If necessary, antidepressant drugs, such as SSRI and tricyclics may be used, 
bearing in mind the possibility of central anticholinergic effects.
D
Psychostimulants such as methylphenidate, dextroamphetamine, modafi lin and 
pemoline may have a fast response and are well-tolerated.
D
Treatment of dysphagia requires individualised assessment of each case in order 
to identify and if possible, treat the cause.
D
The diet must be adapted to the clinical characteristics of the dysphagia. In the case 
of liquid dysphagia, thickeners may be effective. A soft diet that adapts as much 
as possible to the patient’s tastes is recommended. If the patient collaborates, the 
adoption of postures that facilitate swallowing with the supervision of the speech 
therapist is effective.
D Whenever possible, liquids must be administered orally.
D
The parenteral administration of liquids during the end-of-life stage must be 
carried out weighing up the advantages and disadvantages, and always after 
discussing it with relatives.
B
The use of a nasogastric probe or permanent percutaneous gastrostomy must be 
assessed individually and with caution in patients with advanced dementia, as 
there is evidence of a bad relationship between benefi t and risk.
C
The presence of pain must always be suspected in advanced dementia. This 
must be assessed through the patient’s behaviour, observation of relatives and 
appropriate scales such as PACSLAC and DOLOPLUS.
D
The use of the WHO analgesic ladder guideline is recommended for the 
pharmacological treatment of pain in advanced dementia, and, if necessary, 
adding adjuvants.
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B
It is recommendable not to treat pneumonia with antibiotics in a person with 
advanced dementia as it does not entail a benefi t.
B
Hospital admission is not recommendable to treat pneumonia in a person with 
advanced dementia.
B
Treatment with antibiotics is recommendable in people with advanced dementia 
who have breathing diffi culties due to over-infection of bronchial secretions.
C
To prevent the appearance of pressure ulcers, there must be frequent changes in 
posture, using mechanical protections and maintaining a good state of nutrition, 
hydration and hygiene of the skin.
D
The psychosocial well-being of patients with life-threatening chronic diseases 
must be evaluated on a regular basis.
D
The psychosocial assessment of patients in PC should include the following fi elds: 
Aspects related to the moment in life, the meaning and impact of the disease, 
coping style, impact on the perception of oneself, relationships, sources of stress, 
spiritual resources, economic circumstances, doctor-patient relationship and 
social resources network.
D
Health and social services professionals attending them should offer basic 
emotional support.
D
People with signifi cant levels of psychological suffering should receive specialised 
psychological help.
D
The team attending people with dementia must bear in mind their beliefs and 
spiritual needs.
D
In the absence of appropriate evidence about what is the best way to provide 
spiritual support, offering this support as an integral part of the care is 
recommended, whatever the care context, and with an approach based on the 
principles of effective communication.
D
It is important to consider cultural differences with respect to spirituality, but 
this does not justify a lack of attention to these aspects in people who belong to 
different cultural or religious groups to our own.
C
Caregivers must be offered the possibility to express their needs for support and 
information.
D
Identifying the most vulnerable or depressed caregivers is recommended in order 
to offer them intensive psychosocial support or specialised services.
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CARE OF PEOPLE WITH DEMENTIA
AND THEIR FAMILIES DURING THE FINAL DAYS OF THEIR LIVES
D
Appropriate care during the fi nal days of their lives should include:
• Informing the family and caregivers of the situation of approaching death 
and, in general, provide the necessary information that adapts to their needs.
• Explaining and agreeing to the care plan with the patient, and whenever pos-
sible, with their families.
• Evaluating the medication the patient takes, suspending non-essential drugs, 
after explaining the reasons for this.
• Treating symptoms that produce suffering. The necessary drugs must be 
available if the patient is at home.
• Interrupting unnecessary or futile interventions or tests, according to the pa-
tient’s desires.
• Evaluating psychological, religious and spiritual needs of the patient, family 
and caregivers.
• Providing care in a quiet atmosphere, respecting privacy and facilitating 
proximity with family and friends.
• Providing the channels and resources necessary both for hospitalisation and 
for home care.
B
Referral of patients with complicated grief to specialised services (psychology, 
psychiatry, etc.) is recommended for them to receive specifi c and structured care.
B
Regular monitoring is recommended in risk grief, with emotional support, 
individually evaluating the need for specifi c and structured psychotherapies.
B Formal or structured interventions are not recommended in normal grief.
D
In normal grief, providing information about the grief and about the available 
resources is recommended, as well as basic emotional support.
D
Professionals caring for patients at the end-of-life stage as well as their relatives, 
should have access to elementary training in grief, which will enable them to 
provide basic care to the grievers, understand and explore their needs, evaluate 
the risk factors, detect people with complicated grief and refer them to specialised 
service.
D
In a person with advanced dementia, the existence of a concomitant process must 
be suspected if the progression suddenly speeds up and above all if there are 
unpredictable changes.
D
When considerable worsening appears, regardless of the cause, a series of factors 
must be evaluated that may affect the therapeutic decision, always bearing in 
mind the values of the person and of the family.
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D
It is recommendable to evaluate the possibility of therapeutic limitation if the 
dementia has reached a very advanced stage: FAST of over 7c in AD; when the 
Barthel index is 0; if the progression is very fast from the onset; if the infections are 
serious, repeated and with no relevant benefi t with the treatment; if the dysphagia 
is problematic, with malnutrition and/or dehydration, and if there are refractory 
pressure ulcers.
D
Whatever their location, it is recommendable for patients with advanced or terminal 
dementia to receive palliative measures to improve their comfort, suffering and 
quality of life, insofar as this is possible.
B
Cardiopulmonary resuscitation is not indicated in people with advanced dementia, 
as it is an extraordinary therapeutic measure that does not provide any signifi cant 
benefi t.
B
Neither artifi cial respiration nor dialysis are recommendable, either, in advanced 
dementia, because they provide no benefi t.
B
At the end-of-life stage of patients with advanced dementia, the use of intermediate 
range therapeutic measures (intravenous infusions, administration of antibiotics, 
artifi cial feeding, hospitalisation and execution of unnecessary diagnostic tests) is 
not recommended.
C
The use of intermediate range therapeutic measures should only be considered 
on those occasions when they can reduce suffering or they are the only available 
resource.
D
It is recommendable to give information and support to caregivers of people with 
advanced dementia for them to continue assuming their work as caregivers, take 
decisions, adapt and engage more.
D
Informing and communicating bad news to the caregivers of people with dementia 
at the end-of-life stage requires adequate preparation of the professionals.
D
The participation of patients and caregivers in decision-making at the end-of-life 
stage must be fostered.
D
If patients are not able to decide at this end-of-life stage, the advance directives 
expressed by them or their wishes included in the clinical record, or else the 
opinion of their legal representative and/or closest family, must be contemplated.
D
Informing the team of the decisions adopted at this end-of-life stage is 
recommended, recording the process in the clinical record.
D
If there are doubts during the decision-making process, consulting other expert 
professionals or the healthcare ethics committee is indicated.
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D
It is recommended for the medical team attending to the patient at this end-of-
life phase to request the post-mortem neuropathological study to confi rm the 
diagnosis (above all in those cases where there is not an accurate diagnosis, or if 
a prion disease is suspected or any other disease of compulsory declaration) and 
foster the investigation.
DIFFUSION, TRAINING AND RESEARCH INTO
THE CARE OF PEOPLE WITH DEMENTIA
Diffusion
✔ Information about dementia through the media must be based on ethical principles 
and good practice.
✔
The existence of specialised journalism in health issues is recommendable. 
The media, competent professional associations and family associations must 
collaborate in fostering good information about dementia.
Training
✔
It is recommendable for health sciences university students to receive general 
training in dementia, in aspects such as epidemiology, pathophysiology, clinical 
manifestations, diagnosis techniques, pharmacological and non-pharmacological 
treatment, on the needs of the patients and relatives, and resources available, as 
well as on associated ethical and legal aspects.
✔
Health vocational training must guarantee the acquisition of theoretical and 
practical knowledge, as well as positive attitudes of respect and tolerance, to 
appropriately manage dementia.
✔
VT health personnel must be prepared to carry out continuous ecological 
stimulation aimed at maintaining the capacities of the individual affected by 
dementia at a maximum level, delaying the decline of the person affected and 
giving information about the management and resources in dementia.
✔
All health and social services professionals must update their knowledge to be 
competent in the comprehensive management of dementia. Dementia must be 
addressed in an interdisciplinary fashion, providing care seamlessly from the 
moment it is detected until the end of life.
✔
All health and social services professionals integrated into the specialised care of 
people with dementia must receive specifi c training that will cover aspects related 
to the diagnosis and treatment, needs and resources available, ethical and legal 
aspects, and the need for it to be managed in an interdisciplinary manner.
56 CLINICAL PRACTICE GUIDELINES IN THE SNS
Research
✔
The collaboration of everyone involved (health and social services professionals, 
patients and relatives) is important to make a joint effort in the study and research 
of dementia.
✔
Research in dementia must be promoted and fostered from the public administrations, 
the governing bodies of the State and of the autonomous communities; it must be 
coordinated with other countries and it must favour the exchange of knowledge 
between the different teams that work in the same research line in dementia.
✔
The three healthcare levels, PCT, SDCT and the social-health network should 
participate in research in dementia; to this end, training in research methodology 
is required.
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1. Introduction
Dementia as a clinical syndrome is characterised by an acquired impairment affecting more than 
one cognitive domain, which represents a decline from a previous level that is serious enough so 
as to affect personal and social functioning. In the majority of the cases, behavioural and psycho-
logical symptoms are added.
All the epidemiological studies have confi rmed that age is the main risk factor for the devel-
opment of dementia; in such a way that both the prevalence and the incidence practically double 
every 5 years as from the age of 65.1 Given the increase in life expectancy and the progressive 
ageing of the population in developed and developing countries, dementia is understood to repre-
sent an enormous challenge for the public health systems of these societies.
Different systematic reviews (SR) on epidemiological studies performed in Europe have 
concluded that the prevalence of dementia (percentage of sick people within the population at a 
given time) varies between 5-10% among the population of over 65 2,3,4 and that there are about 
5 million sick people.5 There is also coincidence in the fact that Alzheimer’s Disease is the most 
frequent dementia (60-70% of the cases, followed by vascular dementia, 12.5-25%).3 
In Spain, epidemiological studies on the population over the age of 65 have shown preva-
lence fi gures that vary between 5 and 14.9% and in the group of over 70s, between 9 and 17.2%. 
6,7 A recent SR coordinated by the National Epidemiology Centre concludes that the prevalence 
in the Spanish population over the age of 70 is 10%, a similar fi gure to that of other countries of 
our environment.8
These are relevant data for the Spanish society, as it is one of the societies in the world that 
has aged the most due to the increase in life expectancy that has caused the spectacular social, 
economic and health advance experienced over the last 50 years. The proportion of people aged 
65 and over in Spain was 16.5% in 20089 and it has doubled over the last 30 years; the Spanish 
population is the seventh most aged among European countries. Furthermore, the population seg-
ment of over 80, the most susceptible to dementia, is the segment that has most increased.10
If an average prevalence of 7% is calculated, it can be concluded that there are approximate-
ly 500,000 to 750,000 people with dementia in Spain.6,7 The case of pre-senile onset dementia 
would have to be added to these fi gures, but we have no epidemiological studies in Spain and they 
are very scarce in Europe. A study conducted in London found a prevalence of 52/100,000 and 
that the main causes of presenile dementia are Alzheimer’s disease, frontotemporal degeneration, 
post-trauma dementia, alcohol-related dementia and dementia associated with infection due to 
human immunodefi ciency virus (HIV).11
Dementia has a direct impact on patients but it also has an enormous repercussion on their 
social environment, causing considerable moral, physical and economic harm to the family unit. 
In this sense, dementia must be addressed as a true family disease, and as a disease of society. 
Caring for people with dementia and their relatives requires a multidisciplinary approach, with 
active participation of the professionals involved; it must be comprehensive and it must guarantee 
healthcare continuum so that the participation of each professional and resource adapts to the 
changing needs of the patient and of the caregivers at each stage in the evolution of the disease. 
The standard must be a coordinated, fl exible and effective exchange of knowledge and resources 
among professionals from the social-health area, placed at the disposal of sick people and of their 
caregivers.
58 CLINICAL PRACTICE GUIDELINES IN THE SNS
Having common consultation elements may help enormously towards this coordinated work. 
The main aim of this clinical practice guideline (CPG) on Alzheimer’s disease and other dementia 
is for it to be a consultation tool that will provide every one of the professionals involved in the 
care process of people with dementia and their caregivers with effective answers, in each situa-
tion and at every moment of the disease, from the mild cognitive impairment (MCI) stage to the 
terminal stages of the disease. It also aims to be a learning, training and dissemination tool.
Recommendations are given in this CPG on care of patients with Alzheimer’s disease and 
other dementias, such as, for example, vascular dementia, Parkinson’s disease dementia, demen-
tia with Lewy bodies and frontotemporal lobar degeneration. References to other dementias, such 
as Huntington’s disease, other degenerative dementias, post-trauma dementia, HIV-associated 
dementia or metabolic-defi ciency dementias are not so broad, but the majority of the recommen-
dations are also valid for them.
The ambition of this guideline is to cover a national fi eld and it has some characteristics that 
make it special: it has been demanded by the Spanish Federation of Associations of Families of 
Alzheimer’s and other Dementias (CEAFA), supported and fi nanced by the Ministry of Health 
and Social Affairs, and drafted by representatives of all the professionals that work on a day-to-
day basis in the fi eld of care of people with dementia, both on the health side and on the social 
side.
Recommendations are given in this guideline and the most frequent questions asked in regu-
lar clinical practice are answered: how must a fast and early diagnosis of MCI and of dementia be 
carried out, how to select the neuropsychological tests and the laboratory examinations that adapt 
best to each case, how must patients and their relatives be informed about the diagnosis, progno-
sis and resources, what pharmacological and non-pharmacological treatment options exist; how 
to prevent and treat behavioural and psychological symptoms of dementias (BPSD), how must 
the monitoring of the disease be carried out, how must the strain on the caregiver be prevented, 
what is the role of cognitive stimulation, what options are correct in the terminal stage of the dis-
ease. It also aims to give adequate information about the best coordination between the different 
healthcare levels and about the role of the social-health resources, especially in advanced stages. 
Finally, it responds to questions on genetic counselling and on multiple legal and ethical type 
aspects that usually arise throughout the disease.
The recommendations of this guideline have been drawn up based on the best available evi-
dence in medical literature and on the recommendations of experts when no conclusive evidence 
existed. Finally, the complete document has been reviewed by experts of acknowledged national 
prestige in the fi eld of dementias. The methodology of the guideline has been supervised by the 
Agencia d’Informacio, Avaluacio i Qualitat en Salut (AIAQS) of the Department of Health of the 
Generalitat of Catalonia.
As in any CPG, however good the methodology used in its preparation, its use must not 
prevail over the responsibility of the professionals when taking the decisions that adapt best to 
patients’ circumstances, 
always respecting their opinions, values and beliefs, and always or, whenever possible, con-
sulting their legal representatives.
Important advances have been made over the last few years in clinical genetics and diagnosis 
techniques, through studies in the cerebrospinal fl uid (CSF) and neuroimaging tests; publications 
on the effi cacy of new drugs are also being awaited. This tendency is undoubtedly going to con-
tinue in coming years, so this guideline will have to be revised and re-published within 5 years 
at the latest, if any signifi cant advance is made, although an earlier update of its online version is 
not ruled out.
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2. Scope and objectives
Target population
This CPG focuses on the comprehensive care of people affected by dementia, whatever the age of 
onset of the process, of their relatives and caregivers. People under the age of 65 are included as 
they have different clinical manifestations and considerable social repercussion.
The clinical entities that are addressed with greater detail are: Alzheimer’s disease (AD), 
vascular dementia (VD), Parkinson’s Disease Dementia (PDD), dementia with Lewy bodies 
(DLB) and frontotemporal lobar degeneration (FTLD).
Field of action
Spanish National Health System (SNHS).
Healthcare Levels
Primary care team (PCT), specialised dementia care team (SDCT) and health and social care 
(HSC).
Aspects included
Clinical areas: prevention, detection, diagnosis, genetic counselling, pharmacological and non-
pharmacological treatment, prognosis, health and social resources and aid, monitoring and care 
at end-of-life stage.
Family and professional caregivers: Information and training for caregivers. The co-therapist car-
egiver. Needs and burdens of the caregiver. Caring for the caregiver. Free time. Associationism.
Other areas: Legal and ethical aspects, and considerations related to teaching and research.
Interventions
This CPG includes the following treatments:
• Specifi c and symptomatic pharmacological treatment
• Non-pharmacological treatment
• Concomitant pathology treatment
• Palliative cures in dementia and accompaniment during the end-of-life stage.
• General measures
• Training of caregivers and self-help strategies.
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Aspects excluded from the CPG
The CPG does NOT include:
• Dementias secondary to vitamin B
12
 defi ciency and normotensive hydrocephalia
• Dementia associated with infectious diseases: HIV, viral or bacterial infections
• Dementias due to human spongiform encephalopathies (prionopathies)
Objective
To prepare an evidence-based CPG on the comprehensive care of people with Alzheimer's disease 
and other dementias, with national scope that offers "systematically developed recommendations 
to help professionals and patients take decisions about the most appropriate healthcare, and select 
the most adequate diagnostic or therapeutic options to address a specifi c clinical condition or 
health problem", integrating and coordinating the different SNHS health devices involved.
Secondary objectives
• Guarantee equity in health and social care of people affected by dementia and their fami-
lies, regardless of their age, sex, social status, education or culture.
• Reduce the variability of clinical practice in comprehensive care of dementias, both re-
garding its diagnostic aspects and its therapeutic management.
• Offer comprehensive and integral care to the people, relatives and their environment, with 
a multi-interdisciplinary vision, evaluating biological, psychological and social aspects 
(bio-psychosocial approach),
• Improve the clinical skills of the health and social professionals involved in the care of 
people with dementia and their relatives.
• Use the most up-to-date diagnosis and treatment options based on the best scientifi c evi-
dence and on the consensus of experts.
• Assess the effectiveness, safety and effi cacy of the different diagnosis techniques and 
of the pharmacological (specifi c and symptomatic) and non-pharmacological therapeutic 
proposals.
• Provide useful information to the population, people affected by mild cognitive impair-
ment or dementia, relatives of the people affected, caregivers, health and social services 
professionals, and other professionals related to any of the aspects involved in the care of 
dementia, to facilitate decision-making.
• Develop quality healthcare indicators that permit assessing the implementation of the 
recommendations established in the CPG.
• Establish recommendations to increase the knowledge of all the professionals involved at 
undergraduate, post-graduate and lifelong training level.
• Prepare general and specifi c information material for people affected by dementia and 
above all for their relatives and caregivers, which will give them a better idea of the 
dementia process as a whole and each one of the elements that affects the course of the 
disease.
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• Establish recommendations for the participation and development of research in demen-
tias, from the different healthcare levels, in collaboration with the University, and the 
institutes and organisations dedicated to research.
Main users
This CPG is aimed at:
• Health professionals who have direct contact and have to take decisions about the care of 
people affected by dementia (general practitioners, neurologists, geriatricians, psychia-
trists, neuropsychologists, psychologists, nurses, pharmacists, internists, physiothera-
pists, occupational therapists, social workers, etc.).
• Professionals from other areas that have direct contact with people affected by dementia 
(social services, media, justice).
• People affected by dementia.
• Caregivers (relatives or not) of people affected by dementia
The CPG provides information for patients with dementia (Appendix 2) that may also be used by 
their relatives and friends as well as by the general population.
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3. Methodology
The methodology used in this guideline is contained in detail in the Methodology Manual for the 
preparation of CPG in the SNS12.
The steps below have been followed:
 – Formation of the guideline development group, comprised of health professionals, spe-
cialists in neurology, geriatrics, psychiatry, family medicine, neuropsychology, psychol-
ogy, nursing, pharmacy, psychogeriatrics, preventive medicine and public health, foren-
sic medicine and social work, and non-health professionals (lawyers and economists) 
involved in the study and treatment of dementia. Some of them have experience in the 
legal and bioethics area, are linked to the Social and Health Steering Plan of the Catalan 
Departament de Salut (DS) or are specialised in methodology from the AIAQS. The de-
velopment group has been guided by a coordination team. To incorporate the perspective 
of relatives, representatives from associations of relatives and patients have participated 
in the development group and in the external view of the guideline.
 – Formulation of clinical questions following the format: patient / intervention / compari-
son / result.
 – Bibliographic search in: Pubmed/Medline, The Cochrane Library, Psycinfo, Scopus, 
Tripdatabase, CMA Infobase (Canada), CPG GuíaSalud Library of the SNS, International 
Guidelines Library (GIN), National Electronic Library for Health and U.S. National 
Guidelines Clearinghouse. Timeline: From January 2006 to February 2009. Languages: 
Spanish, Catalan, French, English and Italian. The fi rst phase involved a preliminary 
search for CPGs and systematic reviews in the aforementioned databases. CPGs were 
identifi ed and evaluated using the AGREE instrument13, after which it was decided 
whether to include them as a secondary source of evidence, apart from serving as an 
inspiration and example for some of the sections of this guideline, due to their rigour 
and clarity. This was carried out in agreement with the preparation-adaptation-updating 
methodology used in the CPG on asthma of the Basque Country.14 part from these CPGs, 
consensus documents and position papers (recommendations) of scientifi c societies have 
been considered, (Appendix 6). A second phase entailed an extended search for original 
studies (randomised control trial, RCT; cohort studies, case and control studies, etc.) until 
July 2009. Later, search alerts were created in Pubmed to identify relevant studies in high 
impact biomedical journals, and the entire development group was consulted until May 
2010, when the fi rst draft of the guideline was closed.
 – Assessment of the quality of the studies and summary of evidence for each question, fol-
lowing SIGN (Scottish Intercollegiate Guidelines Network) recommendations.
64 CLINICAL PRACTICE GUIDELINES IN THE SNS
 – Formulation of recommendations based on the “formal assessment” or “reasoned judge-
ment” of SIGN. - The classifi cation of the evidence and grading of the recommendations 
have been carried out using the SIGN system. The Oxford Centre for Evidence-Based 
Medicine system has been used for the diagnosis questions (grade A: Level of evidence 
Ia or Ib [in the guideline it appears as 2++]; grade B: level of evidence II [in the guideline 
it appears as 2+]; grade C: level of evidence III [in the guideline it appears as 2-]; grade 
D: level of evidence IV [in the guideline it appears as 3 or 4]) as suggested by the CPG 
preparation manual of the SNS for diagnostic test studies.12 Controversial recommenda-
tions or those where there was a lack of evidence have been solved by simple consensus 
of the development group.
 – External reviewers have participated in the review of the second draft. The different scien-
tifi c societies involved have been contacted (Sociedad Española de Neurología, Societat 
Catalana de Neuropsicologia, Societat Catalana de Medicina Familiar i Comunitària, 
Societat Catalana de Infermeria en Salut Mental, Sociedad Española de Psicogeriatría, 
Sociedad Española de Medicina Familiar y Comunitaria and Sociedad Española de 
Geriatría y Gerontología).
 – The material, with detailed information about the methodological process of the CPG, is 
available at www.guiasalud.es. 
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4. Defi nition and Classifi cation of 
dementias
Questions to be answered
4.1. What is dementia?
4.2. What is the incidence and prevalence of dementia?
4.3. How is dementia classifi ed?
4.4. What are the clinical manifestations of dementia?
4.5. How does the natural course of dementia evolve?
4.6. What is understood by degenerative dementia?
4.7. What is Alzheimer’s disease?
4.8.  What is dementia with Lewy bodies?
4.9. What is Parkinson’s disease dementia?
4.10. What is frontotemporal lobar degeneration?
4.11. What other neurodegenerative diseases are accompanied by dementia? 
4.12. What are vascular dementias? 
4.13. What is and how is secondary dementia classifi ed?
Mild cognitive impairment and conversion to dementia
4.14. What is understood by mild cognitive impairment (MCI)?
4.15.  What types of MCI exist?
4.16.  What is the incidence and prevalence of MCI?
4.17.  What are the risk markers for conversion from MCI to dementia? 
4.18. Is there any treatment that modifi es the progression of MCI?
4.1. What is dementia?
Dementia as a clinical syndrome is characterised by an acquired impairment affecting more than 
one cognitive domain, which represents a decline from a previous level and which signifi cantly 
reduces functional autonomy. Dementia frequently appears with behavioural and psychological 
symptoms (BPSD), also called behavioural and emotional symptoms or neuropsychiatric symp-
toms.6,15 
The dementia diagnostic criteria of the Diagnostic and Statistical Manual of Mental 
Disorders, 4th edition, text revision (DSM-IV-TR)16,17 and of the International Classifi cation of 
Diseases (ICD) 10th edition (ICD-10) of the World Health Organisation (WHO)18 (Appendices 
1.1 and 1.2) state that the presence of mnesic impairment is compulsory. However, certain forms 
of dementia, such as frontotemporal lobar degeneration (FTLD), dementia with Lewy bodies 
(DLB), Parkinson’s disease dementia (PDD) or vascular dementia (VC) may not entail severe 
memory impairment until advanced stages. This has led to amnesia being excluded as a com-
pulsory element to establish the diagnosis of dementia syndromes. Thus, this symptom does not 
appear as compulsory in the criteria of the Spanish Society of Neurology (SEN)19 (Appendix 1.3).
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Cognitive impairment must be prolonged; for example, the ICD-10 criteria arbitrarily estab-
lish a minimum duration of 6 months. Although this timeline is useful for the differential diagno-
sis of dementia with acute confusion syndrome, in regular clinical practice, it is excessive, as it 
prevents classifying as dementia, sub-acute evolution cases that reach intense impairment in a few 
weeks or months, as in the Creutzfeldt-Jacob disease (CJD).
4.2. What is the incidence and prevalence of dementia?
The dementia incidence and prevalence fi gures show very variable results due to the lack of a 
diagnostic biological marker in the great majority of the diseases that cause dementia, and to 
methodological differences of the studies.
Incidence of dementia
The global incidence of dementia in the world is estimated at around 7.5/1,000 people/year.20 The 
appearance of new cases remains more or less stable until 65-70 years of age (< 5/1,000 people/
year) and from then on the growth is exponential (around 15, 30, 50 and 70-75/1,000 people/
year towards 75, 80, 85 and 90 years of age, respectively).21 The annual incidence of dementia 
in a study performed in Spain was estimated at between 10-15 cases per 1,000 people/year in the 
over-65 population.22
Prevalence of dementia
A prevalence of dementia in the European population is estimated at around 5.9 and 9.4% in over-
65s, according to data of the Eurodem consortium and from subsequent studies.6,7The prevalence 
doubles approximately every 5 years; for example, in Eurodem it was 1% between people aged 
60 to 65, 13% in people aged 80 to 85, and 32% in the 90 to 95 age group. 23A systematic review 
of the EuroCoDe group, published in 2009, showed that the prevalence of dementia in Europe has 
not changed signifi cantly with respect to the data of Eurodem, except for a greater prevalence in 
very elderly women (http:// ec.europa.eu/health/archive/ph_information/dissemination/diseases/
docs/eurocode.pdf).
Prevalence Studies in Spain have shown fi gures that vary between 5 and 14.9% for over 
65s,6,7and between 6.6 and 17.2% for over 70s, according to a recent review of the National 
Centre of Epidemiology of population-based surveys conducted in Spain. 8In the under-65 popu-
lation, there are few studies; the prevalence of dementia in people aged between 30 and 64 years 
living in an area of London was estimated at around 54/100,000. 11In general, the prevalence is 
higher in women and it increases with age. 8,24
Incidence and prevalence according to type of
Dementia Alzheimer's Disease (AD)
The incidence of AD increases with age, from 1-3/1,000 people/year between 65 and 70 years of 
age, up to 14-30/1,000 between 80-85,25 and it appears to be greater in women. In very elderly 
people it is even greater, up to 38.6/1,000 between 85 and 89 years of age and more than 65/1,000 
people per year in people over 95 years of age, according to date from the Framingham study.26
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The prevalence of AD is around 0.6-0.7% in Europe at the age of 65-69 years according to 
the Eurodem study, and it also increases with age (1.8% in men and 4.3% in women in the 75-79 
age group; 6.3 and 8.4% respectively in the 80 to 84 age group; 8.8 and 14.2% in the 85 to 89 age 
group, and 17.6 and 23.6%% in the over 89 age group).1 The prevalence of AD in our country is 
around 6% in the over 70s age group and it represents 70% of the dementias.27 
Vascular Dementia (VD)
VD represents 12.5-27% of the dementias. 6,7,27Whilst it is estimated that in AD the prevalence 
doubles every 5.3 years, in VD, it does so every 4.5 years. The prevalence of VD is less in women 
than in men in the population under the age of 80, and after that the proportion is inverted (0.1% 
in women and 0.5% in men in the age range between 65 and 69 years; 0.9 and 1.9% respectively 
between 75 and 79; 3.5 and 3.6% between 85 and 89; and 5.8 and 3.6% in the over 90s).25
Dementia with Lewy bodies (DLB)
DLB represents 10-15% of the cases of dementia in the clinical-pathological series originating 
from specialised units. 28The prevalence of DLB in epidemiological studies varies from 0.1% in 
a Japanese study of people over the age of 6529 to 5% in a Finnish study of people over the age of 
75. 30Two independent studies in Spain showed a prevalence of 1%, 27,31that is, around 8.9% of the 
dementias. 27There are not enough studies to estimate the incidence of DLB. 
Frontotemporal lobar degeneration (FTLD)
The prevalence of FTLD varies between 0% in a Japanese study29 and 3% in a Swedish study on 
patients aged 85 years. 32A study performed in El Prat de Llobregat (Barcelona)27 on people over 
70 showed a prevalence of 0.3%, the same as the study in Islington (London)33. There are not 
enough data to estimate the incidence of FTLD.
4.3. How is dementia classifi ed?
Currently, we do not have a specifi c methodology that enables us to address the classifi cation of 
dementia according to “evidence-based medicine".34 The most wide-spread classifi cation crite-
rion is the aetiological one. Three main aetiological categories can be considered: primary degen-
erative dementias (AD, FTLD, DLB, PDD and others), secondary dementias and combined or 
mixed dementias (with multiple aetiology). 6,35
Other forms of classifying dementia are based on the presence of other neurological symp-
toms, onset age or topographic distribution. It can also be classifi ed according to non-clinical 
criteria: neuropathological, molecular, genetic.36 A possible classifi cation would be that shown 
in Appendix 1.4 adapted from the SEN CPG (2009). 6,35
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4.4. What are the clinical manifestations of dementia?
Cognitive alterations
The clinical manifestations of dementia are heterogeneous due to the existence of multiple aeti-
ologies, different lesion patterns and variability in the course of evolution.25,37
Initially, in the typical presentation form of AD, an episodic memory disorder appears, be-
cause the limbic circuits of the memory are altered at a very early stage. When the lesions extend 
to posterior temporal parietal associative areas, apraxic, aphasic and agnostic disorders become 
evident.
In FTLD and at the onset of the disease, an alteration of the personality and of the social 
behaviour may prevail, due to the impairment of prefrontal regions, or progressive non-fl uent 
aphasia may stand out, due to affectation of the perisylvian frontal portion of the dominant hemi-
sphere, or an outstanding language impairment in the form of progressive fl uent aphasia (seman-
tic dementia) due to greater initial affectation of the temporal lobe of the dominant hemisphere.
The impairment of the so-called executive function or series of cognitive skills is frequent in 
the different types of dementia. These permit anticipating and establishing goals, designing plans 
and programmes, the start of activities and of mental operations, self-regulation and monitoring 
of tasks, the exact choice of behaviours, cognitive fl exibility and their organisation in time and 
space.
Mnesic impairment may appear in any type of dementia at any time of its evolution. 
Generally speaking, when the cortical regions are more affected, it is normal to fi nd, in different 
combinations, aphasia, apraxia, agnosia, amnesia and affectation of executive functioning. This 
occurs in degenerative cortical dementias such as AD and DLB, in lobar atrophies that occur with 
progressive aphasia or progressive apraxia, in corticobasal degeneration (CBD) or posterior corti-
cal atrophy and in any other dementia whose lesions are preferably located on the surface of the 
brain (many cases of multi-infarct dementia and other processes due to non-degenerative cortical 
focal brain lesions). When the alteration prevails in subcortical structures, such as, for example, 
in subcortical VD or in progressive supranuclear palsy (PSP), the mental processing slows down 
more (bradypsychia), there is a gradual reduction of sustained attention and verbal fl uency, mne-
sic evocation diffi culties, impairment of executive functioning and, because of the affectation of 
projection fi bres originating from motor and premotor cortex areas, hypokinesia and pseudobul-
bar symptoms appear.
Behavioural and psychological symptoms of dementia (BPSD)
Approximately 80% of patients with dementia present BPSD at some moment of its evolu-
tion. 38In some cases, their presence makes diagnosis diffi cult, but in others they help differenti-
ate the type of dementia (question 10.4.1). For example, disinhibited social behaviour, eating or 
sexual behaviour disorders, compulsions, stereotyped behaviour and apathy are more common in 
FTLD. 39Psychotic symptoms are frequent in DLB, especially visual hallucinations. In DLB and 
PDD,
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behavioural disorder associated with the REM sleep phase is typical. In subcortical pre-
dominant dementias (PSP, CBD, some forms of VD), apathy or pseudobulbar symptoms such as 
spasmodic crying or laughter are frequent. 
People with dementia are vulnerable to changes in their environment, which may cause a 
worsening of both the cognitive defi ciencies and the BPSD.42
Other symptoms
Some diseases that occur with dementia present other accompanying symptoms that help diag-
nose the type of dementia, such as parkinsonism (DLB, PDD, PSP, CBD), motor neuron signs (in 
some cases of FTLD), involuntary movements (such as in HD), cerebellar syndrome (spinocer-
ebellar ataxias), autonomic disorders (DLB, PDD) or release of primitive refl exes (AD). In the 
case of AD, motor manifestations are scarce.6,35
4.5. How does the natural course of dementia evolve?
Neurodegenerative origin dementias have in common a normally insidious start and progressive 
evolution.
In initial stages and in the majority of the cases, AD is characterised by an affectation of 
the memory for recent events, and later on defi ciencies in other cognitive functions appear, as 
well as a progressive impairment in advanced, instrumental and, fi nally, basic activities of daily 
living. This is followed by an impairment of motor functions, with the appearance of gait disor-
ders, tremors, myoclonia, sphincter incontinence, dysphagia and, fi nally, immobilisation of the 
patient and death due to an intercurrent complication such as thromboembolism or infections. The 
spontaneous evolution of the disease varies between some patients and others, although it does 
not usually last for more than 15 years. The presence of plateaux has been described through the 
course of evolution and mood fl uctuations, although these are more frequent and marked in DLB, 
so they have even been incorporated into the diagnostic criteria for this disease.40
FTLD, DLB and Parkinson dementias (PDD, DCB, PSP) also naturally evolve towards pro-
gressive worsening, often aggravated by the presence of the extrapyramidal syndrome, of other 
motor alterations (dysphagia, dysarthria) and of autonomic dysfunction. The evolution of FTLD 
is often accelerated by the co-existence of a motor neuron disease.43
BPSD complicate the evolution and are the frequent cause of early institutionalisation and 
the need for pharmacological treatment which sometimes worsens the cognitive defi ciency. BPSD 
may already occur in initial stages, above all in FTLD, although they are also frequent in AD 
(apathy, irritability, affective disorders), when they tend to become more frequent and severe as 
the disease progresses.6,44,45
The evolution of VD is less predictable. Certain stability is often observed for longer or 
shorter periods of time, although a new vascular event may cause a sudden decline of the cog-
nitive function, like a step. These stability periods have been objectifi ed in some clinical trials, 
probably due to the better management of the cardiovascular risk factors. On other occasions, the 
evolution pattern of VD, especially subcortical type, is a progressive impairment similar to that 
ofdegenerative dementia. 6,46Strategic infarct dementia usually has acute onset. Some symptoms 
may improve over the fi rst few months and the residual picture tends to remain stable.
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The natural cognitive evolution of the three main types of dementia (AD, VD and DLB), 
measured with a simple screen test such as MMSE, shows a similar impairment rate of close to 
3-4 points a year. 25
The evolution of secondary dementias will depend on the cause and how quickly the treat-
ment, if any, is established.
There are different scales to measure the evolution of dementias and that are used for the 
clinical monitoring and assessment of the therapeutic response in clinical trials (question 8.4).
4.6. What is understood by degenerative dementia?
Degenerative dementias are diseases characterised by neuronal and synaptic loss and by the ac-
cumulation on the brain of intra and/or extracellular insoluble protein aggregates (question 5.1). 
Each type of protein deposit tends to follow a topographic pattern that is correlated to the clini-
cal characteristics that defi ne each type of dementia. Dementia may be the predominant clini-
cal manifestation, as in AD, or form part of the clinical picture without being the predominant 
manifestation, as in Parkinson’s disease. The majority of degenerative dementias are diseases that 
appear at older ages, from 65 years onwards, and sporadically, although there are hereditary and 
early onset forms in almost all of them. They start insidiously, and continue to evolve progres-
sively and irreversibly.6,35 
4.7. What is Alzheimer’s disease?
AD is a degenerative type clinical-pathological entity that evolves progressively, which is clini-
cally characterised by cognitive impairment and dementia, and neuropathologically by the pres-
ence of neurofi brillary tangles and neuritic plaques. It is the most frequent type of dementia, 
representing up to 70% of the dementia cases. In the majority of cases, the presentation is spo-
radic, but there are familial cases, some of which are associated with known autosomal dominant 
transmission mutations.6,44
The main symptom of AD is the loss of episodic memory, which is initially expressed by 
greater diffi culty to register new information. Later on, aspects of speech, visuospatial skills, con-
structive capacities, motor praxis and executive functioning are affected. Although AD typically 
occurs as a loss of memory, there are infrequent atypical onset forms that occur with a frontal 
syndrome, a picture of progressive aphasia, progressive apraxia or a visual agnostic syndrome 
due to posterior cortex atrophy. As the disease evolves, there is a progressive loss of autonomy 
in the normal activities of daily living. The majority of patients also present behavioural and psy-
chological symptoms. These may already appear in mild stages although they are usually more 
obvious in moderate and advanced stages. These symptoms are important due to their frequency 
and their impact on the patients’ quality of life of the patients and on the burden of caregivers. The 
clinical criteria for the diagnosis of AD are described in Appendices 1.5-1.7.
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4.8. What is dementia with Lewy bodies?
DLB is clinically characterised by the association of fl uctuating dementia-cognitive impairment, 
parkinsonism and psychotic symptoms, and pathologically by the presence of Lewy bodies and 
neurites in the brain cortex, and normally, too, in subcortical nuclei. 6,47Dementia usually oc-
curs with fl uctuations of cognitive defi ciency and level of awareness. Parkinsonism is typically 
predominantly akinetic and usually symmetric with early alteration of gait although this may be 
absent in up to 25% of patients with pathologically confi rmed diagnosis, thus making diagnosis 
diffi cult. Typical psychotic symptoms are detailed visual hallucinations and structured delusions. 
Signs of autonomic dysfunction, behavioural disorder of REM sleep, hypersomnia, falls and hy-
persensitivity to neuroleptics are also frequent.
Typical pathological lesions are Lewy bodies and neuritis, which consist of pathological 
alpha-synuclein aggregates which extend over the limbic area, the cortex and brain stem. Similar 
plaques to the typical AD plaques are also observed.
The diagnostic criteria of DLB were formulated in 1996 by McKeith et al and they showed 
low sensitivity but specifi city of around 85-90%. These criteria were revised in 2005 (Appendix 
1.l8)40 and their sensitivity and specifi city still have not been determined.
4.9. What is Parkinson’s disease dementia?
Parkinson’s disease dementia (PDD) is dementia that appears in the context of a typical estab-
lished Parkinson’s disease, and which affects more than one cognitive domain, mainly attention 
a well a executive and visuospatial functioning.l6,48 By convention it is different to DLB in that in 
this disease the dementia appears prior to or at the same time as the Parkinson symptoms. For the 
operational diagnosis of PDD, it is considered that at least one year must have elapsed from the 
onset of parkinsonism and the appearance of dementia. 40The neuropathology is similar to DLB 
(question 4.8).
A longitudinal study observed that around 60-80% of patients with Parkinson's disease (PD) 
ended up developing dementia in the 8-year control period, depending on the patient's age.49
Much like VD, the anatomopathological lesions of PD and of DLB are often found, too, in 
autopsies on patients with AD, and vice versa, so there are controversies about the independence 
of both entities. Cases of disease with pure Lewy pathology without Alzheimer type pathology 
are rare.
Some diagnostic criteria were established in 2007 to diagnose PDD as probable or possible41 
(Appendix 1.9).
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4.10. What is frontotemporal lobar degeneration?
FTLD are a group of neurodegenerative diseases that are clinically characterised by prominent 
behaviour and/or language alterations, and pathologically by focal brain atrophy, normally of the 
frontal and/or temporal lobes, which may be symmetric or asymmetric. Although it is not very 
frequent, it is the second cause of dementia in people under the age of 65, after AD. It does not 
usually have a predominant effect on the memory or spatial skill.6,45 
Three major symptoms are distinguished in clinical practice: The frontal variant (FTLD) 
when frontal type behavioural disorder prevails, and semantic dementia (SD) and progressive 
non-fl uent aphasia (PNFA) when language disorder prevails. There are some less frequent forms 
where a progressive apraxia syndrome prevails. The most frequent presentation form is FTLD 
(50-60% of the cases), followed by PNFA and SD.50
The main characteristics of FTLD are:
 – Changes in early onset behaviour such as a behavioural alteration that affects the social 
sphere, lack of judgement, infl exibility, disinhibition, perseverance, gluttony, hyperpha-
gia, hyperorality, emotional incontinence, loss of empathy and anosognosia, which pre-
vail over memory alteration.
 – Progressive prominent alteration of expressive language with hypofl uent speech, logo-
penia, anomia, agrammatism and repetition disorder (progressive non-fl uent aphasia). 
Language alteration usually occurs at early stages, too, although frontal behavioural 
symptoms or apraxia may be associated later on.
 – Progressive alteration of the understanding of words, with hyperfl uent speech, anomia and 
progressive loss of the semantic contents of words, objects and concepts (semantic de-
mentia). Associated prosopagnosia may appear if the affectation is right-hand. Semantic 
alteration initially prevails, although frontal behavioural symptoms or apraxia may be 
associated later on.
Initially, there is not usually memory affectation or apraxia (except in the forms of progressive 
apraxia). In any of the three major symptoms, parkinsonism and motor neuron affectation may 
also be associated.51
The predominant and early symptoms of behaviour and of speech, and less affectation of 
the memory until advanced stages, together with progressive impairment that is usually faster, 
differentiate FTLD from AD, although the clinical evolution of both may be very heterogeneous.
In this type of dementia around 20-40% of the patients have a family history, although only 
10-15% of the cases have an autosomal, dominant inheritance pattern (Section 7).
Different diagnostic criteria have been published. The most commonly used are the criteria 
of Neary51 (Appendix 1.10).
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Atrophy of the frontal and/or temporal lobes is observed in the anatomopathological exami-
nation, which is usually asymmetric, and sometimes degeneration of black matter and atrophy of 
the basal ganglia. Different diseases with histological features have been defi ned, depending on 
the presence of certain protein inclusions (tau, progranulin, TDP-43). 6,52
Atrophy of the frontal and/or temporal lobes is observed in the macroscopic anatomopatho-
logical examination, which is usually asymmetric. The majority of the cases of FTLD are char-
acterised by the presence of certain intracellular inclusions and current nosology classifi es the 
cases of FTLD into neuropathological subtypes, based on the most characteristic molecular and 
histochemical fi ndings.6,53,52 85-90% of the cases present tau protein or TDP-43 protein deposits. 
The rest normally present FUS (fused in sarcoma) protein deposits, although there is a small 
percentage of cases where the identifi cation of typical protein deposits is not possible according 
to current knowledge. Any of the different neuropathological entities may be expressed with any 
of the clinical syndromes described and vice-versa. The only exception that can be made is that 
when motor neuron disease is associated, it can be anticipated that the neuropathological correlate 
will not be a taupathy.
4.11. What other neurodegenerative diseases are 
accompanied by dementia?
Other neurodegenerative diseases that may be accompanied by dementia are:
Huntington’s Disease: a hereditary neurodegenerative autosomal dominant transmission disease 
(Section 7). The mutation is found in the Huntingtin gene (HTT) in chromosome 4, a protein with 
an unknown function, and it gives rise to a variable expansion of CAG triplets. The most affected 
cells are the spinal neurons of the striate. It occurs with motor (korea, dystonia, tremors, stiffness), 
cognitive (memory, executive functioning and visual-motor skills) and psychiatric (irritability, 
mania, depression, psychosis or obsessive-compulsive disorder) alterations. Cognitive disorders 
usually appear in advanced stages, although they may also appear in initial stages, especially in 
juvenile forms (Westphal variant). The most important defi ciencies are disexecutive and visual-
perceptive.6,54
Prion diseases or transmissible spongiform encephalopathies: Neurodegenerative processes 
characterised by the accumulation of pathological isoforms of prion protein, neuronal loss, gliosis 
and spongiosis. The most frequent is Creutzfeldt-Jakob disease (CJD). They are not very preva-
lent, and are accompanied by a variable combination of dementia, ataxia, myoclonus, pyramidal 
and extrapyramidal signs and behaviour alterations. It has a rapidly progressive picture and death 
usually occurs in less than 1 year. Prion diseases may occur sporadically, genetically or they may 
have been acquired iatrogenically.6,55
Progressive supranuclear palsy: a neurogenerative disease that is characterised by gait disorder, 
falls, postural alterations, akinetic rigid parkinsonism with axial prevalence, eye-motor altera-
tions, pseudobulbar palsy and frontosubcortical cognitive alterations such as apathy and execu-
tive dysfunction. The pathology is characterised by tau protein deposits (4R isoforms) on neurons 
and glial cells in certain areas of the basal ganglia and brain stem. Due to its neuropathological 
characteristics, progressive supranuclear palsy is included within the frontotemporal lobar degen-
erations.56
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Corticobasal degeneration: neurodegenerative disease characterised by an asymmetric apraxia 
syndrome and frontal parietal dysfunction, feeling of foreign limb, loss of cortical sensitivity, 
myoclonus, focal dystonia, and signs of progressive supranuclear palsy. It is frequently associ-
ated with progressive aphasia or speech apraxia. It is an infrequent disease. The typical pathology 
consists of neuronal loss in frontal parietal cortex and black matter with astrocytic plaques, ach-
romatic convex cells, and tau protein inclusions (4R isoforms) in neurons and glial cells. Due to 
its neuropathological characteristics, corticobasal degeneration is included within the frontotem-
poral lobar degenerations. Lacking histological confi rmation it is called “corticobasal syndrome”, 
as the same clinical syndrome can be produced by another pathological substrate; in addition, the 
pathology of CBD may give rise to other clinical syndromes. The term “corticobasal degenera-
tion” is reserved for cases with histological confi rmation.52
Other infrequent degenerative diseases: dementia with argyrophilic granules, spinocerebel-
lar degenerations, leukodystrophies, Hallervorden-Spatz disease, familial encephalopathy with 
neuroserpin bodies, familial British and Danish familial amyloidosis, dementia with intranuclear 
inclusion bodies, etc.
Mixed dementias: overlapping of different neuropathological processes, although one type usu-
ally prevails over the rest. One of the most frequent is the combination of VD and AD. It is normal 
for both types of lesion to co-exist, with interaction between them. In each case, the clinical data 
and the neuroimaging fi ndings must dictate which of the two pathologies is the most important in 
the patient’s clinical picture. In this sense, it would be desirable to use terms such as “Alzheimer’s 
disease with cerebrovascular pathology” or “vascular dementia with possible AD” instead of the 
mixed dementia diagnosis. The fi nding of mixed pathology is normal in neuropathological stud-
ies (Alzheimer’s, vascular pathology, argyrophilic granules, synucleinopathy), which represented 
53% of the cases in a review by the BrainNet consortium, of 3304 brains of patients with dementia 
originating from European centres.57
4.12. What are vascular dementias? 
VDs are dementias secondary to one or several vascular brain lesions, of whatever aetiology. 
They include the following entities:6,46
• Multi-infarct dementia: dementia secondary to the repetition of cortical infarcts in the 
medium or large calibre artery territory. It is the form of VD that most adapts to the clas-
sical pattern of acute onset dementia and stepwise evolution with worsening related to 
new vascular events. The cognitive and focal defi ciencies depend on the location of the 
infarcts.
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• Strategic infarct dementia: dementia due to an infarct in a location that affects several 
cognitive functions. They include dementias due to infarcts in paramedian thalamus, an-
gular gyrus, knee of the internal capsule, bilateral caudate or deep territory of the anterior 
brain artery.
• Subcortical vascular dementia: Accumulation of lacunar infarct or vascular lesions of the 
periventricular deep white matter due to disease of the small vessels, normally hyperten-
sive (arteriolosclerosis); it may also be diabetic, due to amyloid angiopathy, hereditary 
angiopathies such as cerebral autosomal dominant arteriopathy with subcortical infarcts 
and leukoencephalopathy (CADASIL), hypercoagulability states or hypoxia. The course 
is usually progressive with frontosubcortical type mental impairment, focal signs, slow-
ness, gait alteration and incontinence. The term “subcortical vascular dementia” elimi-
nates the use of the former diagnosis of Binswanger’s disease.
• Post-stroke dementia: any type of dementia that develops after a stroke.
• Mixed dementia: The most frequent anatomopathological fi nding in population-based 
studies of dementia is the combination of different alterations (amyloidopathy, synucle-
inopathy, tauopathy and vascular disease). The term, mixed dementia, is normally applied 
to the combination of AD and vascular disease.
• Dementia due to haemorrhagic lesions.
There are different diagnostic criteria that are based on the presence of dementia, focal signs and 
evidence of cerebrovascular disease. All of them have high specifi city but very low sensitivity. 
The most commonly used criteria, NINDS/AIREN58 (Appendix 1.11) permit the diagnosis of 
possible VD when there are focal signs, in the absence of neuroimaging, or when there is relevant 
cerebrovascular disease with no clear temporal relationship between dementia and stroke. The 
Hachinski ischaemia scale helps distinguish between VD and AD59 (Appendix 1.12). It is used to 
identify and grade vascular disease in general and it has high sensitivity and low specifi city. Both 
patients with AD with cerebrovascular disease and those with multi-infarct dementia may have a 
high score.
There is not enough evidence to specify a vascular load threshold or to specify a necessary 
location of the lesions that defi ne VD in neuroimage, and the diagnosis of VD must be based on 
the correlationship between the degree of vascular load and the clinical and neuropsychological 
data.6,46
The term “Alzheimer’s disease with cerebrovascular disease” corresponds to patients who 
satisfy criteria of possible AD and who in turn have evidence of relevant cerebrovascular disease.
4.13. What is and how is secondary dementia classifi ed?
Secondary dementias are those caused by a non-degenerative neurological disorder or that do 
not originate in the nervous system. The cause may be vascular, infectious, defi cient, endocrine-
metabolic, toxicological or due to other medical pathologies which, during the clinical evolution, 
may end up developing dementia.
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The processes that might cause dementia include structural lesions of the CNS (tumours, 
subdural haematomas, normotensive hydrocephalia), traumatic brain injuries, endocrinological 
alterations (hypothyroidism, hypercalcaemia, hypoglycaemia), nutritional alterations (defi cien-
cy of vitamin B
12
, thiamin or niacin), infections (HIV, neurolues, Cryptococcus), hepatic and/or 
renal insuffi ciency, neurological diseases (multiple sclerosis), adverse pharmacological effects 
(benzodiazepines, beta blockers, anticholinergics), systemic autoimmune diseases (systemic lu-
pus erythematosus, Hashimoto encephalopathy, neurosarcoidoisis), environmental toxins (heavy 
metals, organic hydrocarbides), as well as the effects of long exposures to toxics such as the case 
of alcohol.42,6,60,35
As a general rule, they are not very frequent, but as they usually accompany isolated de-
mentia they are diagnosed by clinical context. The clinical record and execution of certain ad-
ditional tests (neuroimage, analytics) help us distinguish primary degenerative dementias from 
secondary dementias, whose aetiology, in some cases, could be potentially treatable. However, 
it must be taken into account that potentially reversible causes are infrequent and that there is no 
clinical test-based evidence vis-à-vis its treatment being able to reverse dementia. 25Furthermore, 
the presence of a process that is able to cause dementia does not mean that it is responsible for it. 
According to the NINCDS-ADRDA criteria of AD possible AD can be diagnosed when there is 
another brain disorder or another systemic process that is suffi cient to cause a dementia, but which 
is not considered to be the real cause of it (Appendix 1.6).
4.14. What is understood by mild cognitive impairment?
Different cognitive impairment syndromes with respect to a previous state are included within the 
concept of mild cognitive impairment, also called light cognitive impairment, but which is not 
suffi ciently intense to be considered dementia.42
MCI is an attempt to identify AD in its earliest stage. 61,62To this end, special consideration 
was given to memory defi cit. Its criteria to defi ne MCI included the fact that the patient expressed 
memory problems, had low performance in memory tests (the point of a standard and average 
deviation below expected with respect to a population of the same age and education level was 
generalised as reference), whose global cognitive function was normal, had an autonomous life 
without the memory defi cit having an infl uence on activities of daily living and did not satisfy 
dementia criteria.
The development and clinical use of the MCI concept demanded its classifi cation to include 
the non-amnestic subtype, where there would be no memory alteration but other cognitive func-
tions would be affected.63
For the European Alzheimer’s Disease Consortium,64 the MCI diagnostic criteria would be:
• Subjective complaint of loss of memory by patient or by a valid informant (family or 
person living with them).
• Objective evidence of cognitive disorders: impairment of memory or of another domain.
• There must be a change respect to previous levels and for change must last for at least 6 
months.
• No major repercussions on activities of daily living.
• Pathologies that might explain memory impairment, such as acute confusion syndrome, 
depression or mental retardation are excluded.
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• The dementia diagnostic criteria are not satisfi ed. This latter part is the most complicated 
to determine. It is necessary to defi ne well what is understood by signifi cant reduction of 
functional autonomy to talk about dementia, and there is no objective criterion to defi ne it.
These criteria could be modifi ed, especially in respect of the former, due to the fact that a non-
amnestic MCI can be defi ned, that is, with no memory alteration.63 
The SEN Behavioural Neurology and Dementia study group defends a broad concept of 
MCI that includes alteration in any cognitive area, of whatever aetiology, but, in turn it defi nes 
MCI as being attributable to AD when there is a combination of certain clinical features and diag-
nostic markers. The criteria proposed by the SEN are described in Appendix 1.1.36,65
Diagnosing MCI as early as possible is a key factor, due to the high probability of it being 
the fi rst manifestation of a degenerative disease and entailing, therefore, a high risk of progression 
to dementia.
The diagnostic criteria of MCI are largely clinical, and perhaps they are not suffi ciently opera-
tionalised, but they are useful to draw the clinician’ attention to identifying a clinical situation that 
might get worse.
Some anatomopathological studies have shown that more than half the patients with MCI 
have senile plaques and neurofi brillary tangles in their brains, which are typical of AD. In vivo 
studies with amyloid marker radiopharmaceuticals (PIB-PET) or with amyloid determination and 
TAU in cerebrospinal fl uid (CSF) have shown similar fi ndings in the sense that approximately 
60% of patients with amnestic MCI have PIB-PET and CSF patterns that are very similar to those 
of AD.
4.15. What types of MCI exist?
MCI is classifi ed as amnestic or non-amnestic depending on whether it affects the memory or not. 
Depending on the number of cognitive functions affected, it is classifi ed into MCI- single domain 
or MCI-multiple domains. 25Petersen et al. 63defend a classifi cation into four groups: Amnestic 
with one single cognitive alteration, amnestic with multiple cognitive alterations, non-amnestic 
with one single cognitive alteration, and non-amnestic with multiple cognitive alterations.
4.16. What is the incidence and prevalence of MCI?
Given the absence of a unanimous defi nition, MCI does not have an exact epidemiology. Its 
incidence and prevalence depend, to a great extent, on the diagnostic criteria used in the studies 
performed and on their interpretation. The prevalence varies, according to data of a large-scale 
cross-cutting population-based study in the United Kingdom, between 2.5 and 41%.66
In the LEILA75+ study, the prevalence varied between 3 and 20% depending on the criteria 
used. 67The incidence of amnestic MCI varies between 9.9 and 40.6 per 1000 people-year accord-
ing to a recent SR of studies on incidence of MCI, 68and that of non-amnestic MCI between 28 
and 3.63 per 1000 people-year. These fi ndings indicate the need for there to be commonly-agreed 
and operational criteria.
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4.17. What are the risk markers of conversion of MCI
to dementia?
The main use of the diagnosis of MCI is to identify population with a greater risk of suffering 
Alzheimer’s disease in pre-dementia stage (prodromic AD). This population group will be con-
verted into dementia in 10 to 15 % of the cases every year.37
In the Canadian consensus conference of 200669 they offer a list of possible 
markers that are currently under study, which have shown differences at group 
level between patients with MCI who have progressed to dementia and those 
that have not. Some variables that suggest a greater risk are: Age, number 
of neuropsychological areas altered, defi cit in memory encoding and stor-
age, incipient alteration of activities of daily living, hippocampus atrophy in 
magnetic resonance, cortical hypometabolism in PET or focal hypoperfusion 
in SPECT, accumulation of amyloid markers in SPECT, decrease of protein 
Aβ-42 and/or increase of tau protein in cerebrospinal fl uid or the presence of 
APOE allele ε4. 6,70
The PIB PET has proved to be very reliable as a marker of the accumulation 
of amyloid in pathological anatomy. It happens that patients with MCI and 
positive PIB progress to probable Alzheimer’s disease whilst the negative PIB 
do not do so.71,72,73,74
PET with glucose (FDG) has shown sensitivity and specifi city fi gures of over 
80% to predict progression and diagnose probable AD in a recent meta-anal-
ysis. 75,76
The CSF data begin to be convincing, too. Patients (up to 100% according to 
the ADNI study) with MCI who develop probable Alzheimer’s disease have 









There is evidence based on case and control, and cohort studies, the majority 
of which are not masked and with no neuropathological confi rmation, that some 
biological markers (age, encoding and storage defi ciency, incipient alteration of 
the ADL, hippocampus atrophy, hypometabolism or focal hypoperfusion in PET/
SPECT, accumulation of amyloid markers, decrease of Aβ-42 or increase of tau in 
CSF, presence of APOE allele ε4) are associated with a higher risk of progression 
to dementia in patients with MCI at group level, not being validated for use in 
clinical practice.69,37,6
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Recommendations
C
Different biological and neuroimaging markers can be used to help predict the pro-
gression of MCI to dementia in a research context, but they cannot be recommended 
for use yet in normal clinical practice.
4.18. Is there any treatment that modifi es the progression 
of MCI?
RCT have been performed with acetylcholinesterase inhibitors (ACE inhibi-
tors) [donepezil, rivastigmine and galantamine, NSAID (rofecoxib), replace-
ment therapy with oestrogens, ginkgo biloba and vitamin E, which have not 
shown any symptomatic benefi t or reduction of the risk of progression to de-
mentia in patients with MCI.69,81
At times, MCI is a clinical manifestation of a potentially reversible process. 
The results of RCT and cohort, variable quality, studies on the effect of cogni-
tive stimulation activities or physical training programmes have not provided 









The treatment with ACE indicators and with other drugs such as NSAID, oestrogens, 
ginkgo biloba or vitamin E have not shown any symptomatic benefi t or modifi cation 
of risk of progression to dementia in patients with MCI in quality RCT.69
1+/1–/
2+/2–
The cognitive stimulation or physical exercise programmes have not provided con-
sistent evidence that they can prevent progression to dementia in variable quality 
studies and with methodological limitations.69
Recommendations
A
The use of ACE inhibitors to avoid or delay the progression of MCI to dementia is 
not currently recommended.
A
The use of NSAID, replacement therapy with oestrogens, ginkgo biloba or vitamin E 
to avoid or delay the progression of MCI to dementia is not currently recommended.
C
There is not enough evidence to recommend cognitive stimulation or physical exer-
cise to avoid or delay the progression of MCI to dementia.
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5. Pathophysiology and risk factors of 
dementias
Questions to be answered
5.1. What are the pathophysiological mechanisms of degenerative dementia? 
5.2.  What are the pathophysiological mechanisms of vascular dementia? 
5.3.  What are the risks factors of dementias?
5.1. What are the pathophysiological mechanisms of 
degenerative dementias?
The term, neurodegeneration, is applied to name a progressive and inexorable phenomenon of 
loss of activity, of tropism and of nervous tissue functions, whose cause is not due to a known ex-
ternal agent or to a severe accident with brain injury. Thus, the term neurodegeneration excludes 
brain injury caused by vascular accidents, trauma, infectious diseases, infl ammatory diseases, 
neo-formative processes and congenital malformation diseases. Some ailments known previously 
as neurodegenerative diseases are currently considered to be included in other areas. For example: 
Mitochondrial cytopathies, peroxisomal diseases, amino acid metabolism diseases or lysosomal 
lipid and carbohydrate metabolic diseases.
A common fact of neurodegenerative diseases is the selective loss of certain populations 
of neurons, and this selective neuronal loss is the morphological substrate of the main clinical 
manifestations of each disease. Thus, the affectation of the entorhinal cortex, hippocampus and 
deep regions of the temporal lobe is the neuropathological substrate of the loss of recent memory 
in AD and in argyrophilic granule dementia, whilst the greater vulnerability of the frontal and 
temporal lobes explains the syndrome of frontotemporal dementia in different diseases, regard-
less of the molecular defect of each one of them. Other typical examples are the affectation of 
the black matter in PD and other parkinsonisms, the degeneration of the cerebellum in dominant 
spinocerebellar ataxias, the degeneration of striate nuclei and of the brain cortex in HD and the 
selective affectation of the upper and lower motor neurons in amyotrophic lateral sclerosis. This 
relationship between the clinical symptoms and the neuropathological lesions, together with the 
name of the author who discovered the disease, has been used for many years to classify the dif-
ferent neurodegenerative diseases.
Environmental factors and genetic factors of risk that intervene in the sporadic forms are 
known in practically all degenerative diseases. The percentage of family cases due to mutations of 
individual genes amounts to 5-10% in the majority of the neurodegenerative diseases. Curiously, 
mutations of different genes may give rise to what is known today as one same disease. Thus, 
familial early onset AD is associated with mutations of APP, PS1 and PS2, whilst familial PD with 
dominant or recessive autosomal inheritance has been proved to be linked to mutations of such 
different genes as those that encode α-synuclein, parkina, PINK1, DJ1 ad LRRK2, among others. 
Other diseases only appear in the context of dominant or recessive autosomal inheritance, and the 
appearance of new cases is due to the appearance of a new mutation. That is the case in HD, in 
spinocerebellar ataxias with dominant autosomal inheritance and in dentatorubropallidoluysian 
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atrophy or in Friedreich’s ataxia, respectively. The prion diseases, where there are sporadic, fa-
milial and transmissible forms, are an exception. A curious fact also occurs in the case of prion 
diseases: the disease seems different depending on the mutation in PRNP. Thus, pictures of famil-
ial CJD or of lethal familial insomnia associated with the D178N mutation in PRNP are known, 
the former with methionine at codon 129 of the mutated allele and the latter with valine at the 
same codon. Different diseases emerge from the PRNP mutation in other locations that give rise 
to the Gerstmann-Straüssler-Scheinker disease and to other hereditary prion diseases with clinical 
pictures of multisystemic degeneration.
Genetic studies have led to the discovery of the causal agents of the different diseases, but 
they have produced certain categorisation confusions, as the apparently same disease is caused 
by mutations in different genes. In this sense, there is no doubt that Huntington's disease is a 
huntingtinopathy as the cause of the disease is an increase in the number of CAG triplets in the 
Huntingtin gene in chromosome 4p16.3, or that Friedreich’s disease is a frataxinopathy resulting 
from a mutation in the gene of the frataxin mitochondrial protein in chromosome 9q13-21.1 and 
that it entails a very reduced protein expression. However, PD, from a genetic viewpoint, may be 
an α-synucleinopathy, a parkinopathy, a PINK1pathy or a DJ1pathy, among others, depending on 
the mutated gene causing the familial PD.
The majority of the neurodegenerative diseases are associated with the accumulation of ab-
normal protein aggregates. This fact has given rise to a classifi cation of the neurodegenerative dis-
eases that depends on the predominant abnormal protein accumulated in the brain. Taupathies are 
known where there is an accumulation of hyperphosphorylated tau in the neurons, and at times, in 
the glial cells; the α-synucleinopathies where there are deposits of phosphorylated, nitrated, oxi-
dised α-synuclein and with aggregability and solubility modifi cations; prionopathies, where the 
normal prion protein has been transformed into a protein with aberrant folding in beta laminae, or 
the amyloidopathies (amyloidosis) where there is an accumulation of amyloid and between which 
there are β-amyloidopathies, gelsolinopathies, cystatinopathies or amyloidosis linked to muta-
tions in the ITM2B gene (BRI2) caused by the ABri and ADan amyloidogenic peptides.
Taupathies include Pick’s disease, corticobasal degeneration, progressive supranuclear 
palsy, dementia with argyrophil granules, and frontotemproal dementias linked with mutations 
of the tau gene (MAPT) among others. PD, DLB and multisystemic atrophy are included in 
β-synucleinopathies, among others. AD and Down syndrome are expressed as a taupathy and a 
β-amyloidosis, and as a predominantly amigdalar α-synucleinopathy in many cases.
In a small proportion of cases, the molecular data coincide with specifi c genetic defects and 
the genetic and protein alteration nomenclatures coincide. For example, frontotemporal degenera-
tions linked to MAPT mutations are taupathies from a genetic and molecular viewpoint, but not 
all taupathies are the result of mutations of the tau gene.
Although the pathogeny is not totally known, there are different alterations that are common 
to the majority of the neurodegenerative diseases. One of them is the presence and accumulation 
of abnormal proteins. This aggregation is due to the production of abnormal protein, either due to 
genetic causes (mutations) or to post-translational changes of the protein, such as phosphoryla-
tion, oxidative lesion or structure modifi cations; but also to the loss of cellular capacity to destroy 
the abnormal proteins through the autophagic pathways or the ubiquitin proteasome system. The 
altered proteins accumulate on the inside of the neurons and glial cells, and give rise to typical 
inclusions: Neurofi brillar degeneration in AD and taupathies, Lewy bodies in PD and DLB, in-
tranuclear and cytoplasmic inclusions in expanded CAG triplet diseases, immunoreactive inclu-
sions for TDP-43 in amyotrophic lateral sclerosis and in the majority of non-tau frontotemporal 
degenerations. Such inclusions are currently interpreted as residual structures of the disease, not 
as causal agents of the degeneration. There is also a deposit of proteins in the extracellular space, 
as occurs with the amyloid deposits in AD and other cerebral amyloidoses, and with deposits of 
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protease resistant PrP in prion diseases.
Other common changes in the majority of neurodegenerative diseases are mitochondrial 
alterations, oxidative damage to DNA, RNA, to lipids and to proteins, secondary alteration of 
energy pathways and the modifi cation of the lipid composition of the cellular membranes. All 
of this entails a reduction of energy production and an excess demand which leads to neuronal 
energy fatigue.
The energy defect, the diffi culty in the exchange of cellular components, the reduction of 
trophic signals by neighbouring cells and the “primary” defect of each disease lead to neuron 
death caused by different mechanisms, including apoptosis, necrosis, autophagy or intermediate 
or complex forms.
The classifi cation of neurodegenerative diseases is currently a convention with instrumental 
implications. It is a classifi cation that is useful to understand and classify the different diseases, 
but it is not a dogma. New diseases or new mechanisms of better known diseases appear frequent-
ly. A progressive change in the classifi cation and categorisation of the current neurodegenerative 
diseases is likely to occur in the next few years.
5.2. What are the pathophysiological mechanisms of 
vascular dementias?
VD is a very heterogeneous entity and dementia may occur due to multiple mechanisms (ques-
tion 4.13). Mixed dementia is also frequent. This term is normally applied to the combination of 
AD and vascular disease and for which there are no clinical or neuropathological criteria.6
VD occurs due to the accumulation of ischaemic or haemorrhagic origin brain lesions. In 
multi-infarct dementia, infarcts may have atherothrombotic, cardioembolic origin in the territory 
of medium or large calibre arteries and they affect more or less extensive cortical or cortico-
subcortical areas.
Subcortical vascular dementia occurs in the majority of the cases because of a disease of a 
small vessel that gives rise to the accumulation of lacunar infarcts and/or changes in white matter 
(leukoaraiosis). The most frequent aetiology is hypertensive arteriolosclerosis. It may also be due 
to diabetic angiopathy, hereditary angiopathies (CADASIL), amyloid angiopathy and, in rarer 
cases, it may be related to states of hypercoagulability. The etiopathogeny of changes in white 
matter is not altogether clear. Not all the changes in white matter have a clinical effect in the form 
of cognitive impairment. Punctiform lesions or non-confl uent patch lesions with limited exten-
sion are often asymptomatic. Lesions that are associated with cognitive impairment, subcortical 
dementia and motor disorder are periventricular lesions that spread to the deep white matter, 
extensive confl uent patch lesions and diffuse lesions. In these cases there is a clear association 
with arteriolosclerotic changes in the vessels of the white matter and the ischaemic mechanism 
has been demonstrated. Punctiform lesions are the refl ection of the dilation of the Virchow-Robin 
perivascular spaces and they may be associated with global atrophy. An anatomopathological cor-
relation of patch lesions may be perivascular spongiosis and the extravasation of plasma proteins 
into brain parenchyma. In any case, these mechanisms would also have a relationship with pathol-
ogy of the wall of small deep vessels. The role of venous stasis due to venous colagenosis in the 
etiopathogeny of leukoaraiosis has also been postulated. The pathology of the small brain vessels 
may also give rise to cortical micro-infarcts. This pathological fi nding, which is not detectable 
with normal neuroimaging techniques, is frequent in patients with VD and also in patients with 
AD and associated amyloid angiopathy.
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The etiopathogenic mechanisms of VD due to strategic infarct correspond to the mecha-
nisms that produce capricious location infarcts.
The existence of a form of VD related to hypoperfusion or hypoxia mechanisms has been 
defended rather than classical atherothrombotic, cardioembolic or lacunar infarct mechanisms. 
There would be an acute form related to episodes of intense global cerebral anoxia (due to car-
diorespiratory arrest, for example) and another more “chronic” form secondary to the repetition 
of less important hypoperfusion-hypoxia episodes (bradyarrhythmias, syncopes, sleep apnoea, 
repeated pneumonias, epileptic crises, anaemia, etc.). The existence of situations of symptomatic 
misery perfusion from the cognitive viewpoint, which are reversible beyond the confusion states 
that are related to hypotension, hypoxhaemia or hypercapnia, has not been demonstrated. The 
proven effi cacy of carotideal surgery as treatment of VD has not been demonstrated. In any case, 
this form of VD due to hypoperfusion-hypoxia, would be the result of the presence of structural 
brain damage: border zone infarcts, changes in white matter or selective hippocampus or cortical 
vulnerability phenomena. Hippocampus sclerosis could be due to hypoxic mechanisms in some 
cases, but whether its origin is vascular or degenerative has still not been defi nitely clarifi ed. 
The accumulation of brain haemorrhages may give rise to dementia (haemorrhagic VD). 
The origin may be hypertensive angiopathy, but amyloid angiopathy must be suspected in the 
case of lobar haemorrhages. The importance of the role of microhaemorrhages detected via mag-
netic resonance is becoming more and more consolidated, if gradient echo sequences are applied. 
Secondary microhaemorrhages to amyloid angiopathy are usually located in the posterior (parie-
to-occipital) region and are juxtacortical whilst those related to hypertensive angiopathy tend to 
be located in deep regions.
Some rare forms of VD may respond to infl ammatory (vasculitis), infectious or metabolopa-
thy (Fabry’s disease) mechanisms.
The etiopathogeny of many cases of dementia related to vascular cerebral pathology de-
pends on the concomitant presence of AD. The presence of a brain infarct in the modifi cation and 
precipitation of the expression of a latent AD has been extensively proven. The interaction be-
tween vascular disease and AD relating to the occurrence of cognitive impairment and dementia 
may vary considerably. It could be a simple accumulation of brain damage due to the coincidence 
of both pathologies but a specifi c etiopathogenic interaction cannot be ruled out. AD may be the 
cause of ischaemic and haemorrhagic vascular pathology due to the accumulation of β-amyloid 
on the vascular wall and vice-versa, the pathology of the vascular wall could be a factor that 
favours the accumulation of β-amyloid if its elimination mechanisms were altered through the 
blood-brain barrier. 82
5.3. What are the risks factors of dementia?
The risk factors of dementia may be divided into non-modifi able and potentially modifi -
able. There are also protective factors. However, it must be taken into account that there are no 
prospective RCTs with prolonged follow-up period that prove that the modifi cation of certain risk 
factors may reduce the incidence of dementia. It is also important to remember that the fi nding of 
an epidemiological association between a clinical or social-demographic variable and a greater or 
lesser risk of dementia does not entail a causal relationship and that lacking well-designed RCT, 
we cannot state that an action on this variable would modify the risk of dementia.
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1. Non-modifi able risk factors
Age
Age may be a risk factor per se or it may refl ect the effect of the time when 
other factors have an infl uence. Age is the greatest risk factor for AD, VD 
and DLB, but other less frequent dementias (FTLD, CJD, HD) are more 
common in midlife. 25In general, the prevalence of AD and of VD doubles 
every 5 years, approximately.
The incidence of dementia remains more or less stable up to 65-70 years 
of age (around fi ve cases per 1000 people-year) and from the age of 70 
onwards, the growth is exponential (up to 65-75 cases per 100 people-year 
at the age of 90).21,24
Population-




Several studies associate the female sex with a greater risk of suffering 
dementia, especially AD, although others do not observe this association until 
very advanced ages. 83With reference to VD, the risk is greater in men in all 
age groups, and there are also less differences in older age groups. 84However, 
these differences could be due to other risk factors classifi ed as modifi able.
Population-
based case and 
control study,
2++
Family history of dementia
First-degree relatives of patients with AD have between 10 and 30% more 
probabilities of developing the disease. 85It is possible that if the onset of 
dementia in relatives takes place after the age of 75-80, this family history 
may not entail a greater risk.
Population-
based case and 
control study,
2++
Genetic factors related to AD
Genetic origin Alzheimer’s disease represents just 0.5-1% of the cases 
(Section 7). Only 10% of the cases of presenile onset AD (< 60 years) are 
due to rare high-penetrance mutations (dominant autosomal). 86The most 
frequent are those of PSEN1 (30-70%), followed by APP (10-15%) and 
PSEN2 (< 5%) (www.genetests.org). No mutation has been identifi ed for 
the others, to date.
No simple causal mutation has been identifi ed until now for late onset AD. 
It is believed that the majority of the cases are complex and infl uenced by 
a mixture of genetic and acquired risk factors. 87Many genes have been 
involved but only the APOE α4 allele has been confi rmed as a risk factor in 
large population-based studies.
Population-
based case and 
control study,
2++
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The association between APOE ε4 and AD is greater in women than in men, 
and between the ages of 55 and 65, and it is weaker in older ages. 87The risk 
of late onset AD is greater in homozygote’s APOE ε4 (8x) than in single 
copy carriers (3x), whilst having an ε2 allele has been associated with a 
lower risk of AD and a somewhat higher onset age89 Apo ε4 is also probably 
a risk factor for VD and DLB. 25An MA on the possible relationship between 
APOE ε4 and PDD did not show conclusive results due to the heterogeneity 
of the studies.90
Population-
based case and 
control study,
2++
Multiple polymorphisms have been studied and some have been associated 
with AD, but their real impact on the disease as well as their interaction 
with other factors and genes is unknown, so they currently have no clinical 
utility.91,87
Population-
based case and 
control study,
2++
2. Potentially modifi able factors
The majority of the studies that associate non-genetic risk factors with AD or dementia are usu-
ally cohort studies, but there are no RCT that permit establishing solid recommendations.
Vascular risk factors
Having suffered a cerebral vascular accident (CVA) prior to dementia is 
a diagnostic criterion for VD. However, a CVA also increases the risk of 
suffering AD (RR ~1.8) and dementia in general. Likewise, the presence of 
silent infarcts in imaging tests has been associated with a greater risk of VD 





In a SR that included longitudinal population-based studies that evaluated 
the incidence of dementia in connection with diabetes mellitus (DM) (n = 
14), high blood pressure (HBP) (n = 13), dyslipemia (n = 8) and obesity (n = 
9), the four factors were associated with a greater risk of dementia; the most 
consistent are DM and obesity. The magnitude of the effect was similar (OR 
of around 1.5 for “any dementia”). The risk of dementia was greater in stud-
ies that evaluated HBP, obesity and dyslipemia in midlife than in the elderly, 
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HBP
The relationship between HBP and dementia is complex. Data from the 
Kungsholmen project, a Swedish population-based cohort study, showed 
that both a high systolic BP (> 180 mmHg) and a systolic BP < 140 mmHg 
are associated with a greater risk of AD and dementia, in general, in the 
same population. 92This association could vary depending on the age. 
Longitudinal studies have shown a more marked consistent relationship 
between HBP in midlife (40-64 years) and cognitive impairment in the 
elderly (>65 years), in untreated patients. Some of these studies also 
indicate an association between HBP in midlife and the incidence of AD 
and dementia in general in the elderly, and in one of these studies, this 
association was only present in untreated patients. With respect to HBP 
in the elderly, the data are inconsistent, as some studies have found an 
association with cognitive impairment or dementia whilst others have not. 
On the other hand, a consistent association has been found between low 






Longitudinal studies have shown that the increase of total cholesterol in 
midlife is associated with a greater risk of dementia and AD. However, a 
SR of 18 prospective studies with a control period of between 3 and 29 
years did not fi nd any association between total cholesterol and AD or 
dementia in general during the end stage of life. 96
A MA of two studies did not fi nd any signifi cant association between total 
cholesterol (in middle age or in the elderly) and VD. 96




These results suggest that high cholesterol is a risk factor in midlife but not in the elderly, and 
that the cardiovascular risk factors may be different for AD and VD.
Diabetes Mellitus
In several SR, the incidence of dementia, AD and VD was higher in 






A prospective study on nurses found that the duration of DM was associated 
with a lower basal cognitive performance and with an increase in the 
risk of cognitive impairment after 2 years, and that the treatment of DM 
reduced this risk. Furthermore, hyperinsulinaemia seems to increase the 
risk of AD.99 However, the possible effect of the control of glycaemia and 
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In the Cardiovascular Health Study,100 patients with DM type 2 and APOE 
ε4 had a greater risk of AD (RR 4.99) than those who did not have either of 
the two risk factors, and greater than those that only had DM (RR 1.623) or 
only APOE ε4 (RR 2.50) separately. The joint risk is greater than expected 
due to a simple additive effect. No increase in risk of VD was found for 
either of the two risk factors. This study suggests that the presence of 





A prospective study has associated hyperhomocysteinaemia with an 
increase in the incidence of dementia due to any cause and AD. 92,84However, 
no cognitive improvement has been observed when the homocystein levels 





Obesity. Body weight in lifestyles.
Anaemia
A MA of two longitudinal studies that associated low haemoglobin and 
dementia showed signifi cant results (HR 1.94). A retrospective study of 
cases and controls presented similar results but only signifi cant in women, 
and a study on women did not obtain signifi cant data. There is little 













Levels of sex hormones in blood
There are few studies. Data from the Rotterdam study, a population-
based study monitoring chronic diseases, including dementia, associate 
high levels of total estradiol with a 43% increase of suffering dementia in 
women, whilst another longitudinal study on a male population associated 
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Depression
A MA of case and control, and cohort studies, carried out in 2006, concluded 
that depression is not only a prodromic symptom but also a risk factor of 
suffering AD, and the interval between the diagnosis of depression and 
the diagnosis of AD is correlated with a greater risk of AD (OR 2.03; 1.53 








Although the initial case and control studies suggested that smoking reduced 
the risk of dementia, more recent longitudinal cohort studies have identifi ed 
a greater risk of AD (RR 1.99) in smokers.92




An analysis of four European population-based studies concluded that 
current smokers, but not ex-smokers, had a greater risk of AD.87
Population study, 
2++/2+
In a MA of 19 prospective studies, smokers had a greater risk of dementia 
than non-smokers (RR 1.79 of AD, 1.78 of VD, 1.27 of dementia) than 






Another more recent MA found a greater risk of AD in current smokers 
(OR 1.59), a non-signifi cant risk of VD or non-specifi c dementia and that 
there was a clear relationship in ex-smokers. 104This MA concludes that 
being a smoker increases the risk of AD, and perhaps of other dementias, 
although it must be taken into account that very different studies have been 





Diet rich in fat and poor in omega-3
Biological and epidemiological studies suggest that a reduced intake of 
omega-3 polyunsaturated fatty acids is associated with a higher risk of 
dementia due to any cause (RR 2.4). Likewise, another longitudinal study 
puts forward that the Mediterranean diet and the consumption of fi sh are 
associated with a decrease in the risk of AD (RR 0.3) and of dementia 
in general (RR 0.4-0.8). The consumption of crustaceans has also been 
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A cohort study found no effect of the consumption of fi sh and omega-3 
fatty acids on the cognitive function in normal ageing, whilst in some 
studies, its consumption showed a tendency to reduce the risk of dementia 
and improve cognitive functioning.105
Cohort study,
2+/2–
According to a SR of 2005, which included four cohort studies and a low 






It has been associated with a decline in the incidence of dementia. In a 
Canadian study, the answer “yes” to a question on regular exercise was 
associated with an RR of 0.69 of developing AD in those who did more 
exercise than walking three or more times a week. This association was 
also observed in the Cardiovascular Health Study when it compared the 
quartile of people who consumed most energy every day doing exercise, 
with the quartile of those that consumed the least, both for dementia due to 




A relationship between physical activity and less risk of developing 





Carrying out regular intellectual activity has also been associated with a 
decrease in the risk of suffering dementia in longitudinal studies, especially 
in individuals who carry out new tasks or tasks they are not familiar with. 
There also seems to be a relationship with the type of work: The most 





The moderate consumption of wine (250-500 mL/d) has been associated 
with a lower risk of dementia (RR 0.6) and of AD (RR 0.53) compared 
with a higher or lower consumption. 92A study on nuns also showed that the 
consumption of < 15g/d reduced the risk of dementia but the consumption 
of 15-30 g/d did not produce any benefi t. Another study 99showed that 
the consumption of 1-6 drinks/week was associated with a lower risk of 
dementia and of AD (OR 0.46) and that the benefi t was lost at a higher 
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A recent MA on 23 longitudinal studies suggested that the moderate 
consumption of alcohol may protect from dementia (RR 0.63) and from 
AD (RR 0.57), but not from VD (RR 0.82) or cognitive impairment (RR 
0.89), but the studies are very heterogeneous vis-à-vis the duration of 
the control period, measurement of the alcohol intake, inclusion of real 





In a SR that included two case and control studies, and two cohort studies, 
the consumption of coffee was associated with a signifi cant reduction of 
the risk of suffering AD (weighted RR 0.7), although the authors warn that 






It was observed in a longitudinal population-based study on women that a 





A SR and a MA of prospective cohort studies showed a U-shaped association 
between BMI and dementia, with an increase in risk for obesity and also 
for underweight. In the case of obesity, the overall OR was 1.8 for AD and 
1.73 (non-signifi cant) for VD,108 and it was greater in studies with a longer 





In another SR that focuses on the risk of dementia due to any cause 
and BMI, eight studies were selected, four of which found signifi cant 
differences and the other four none, above all analysing overweight and 
obesity. The articles that published statistically signifi cant differences had 
a large sample size, so the authors suggest that the non-signifi cance could 
be due to a lack of statistical power, or that the association is complex, due 
to different cardiovascular risk factors that could act as a confusion factor 
in the relationship between BMI and dementia. 







In studies performed on soldiers, who were hospitalised due to trauma 
with loss of consciousness, a RR was observed of between 2.3 and 4.5 
of AD or dementia in general, depending on the severity of the trauma. 
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Social-demographic factors:
Schooling level
A low or intermediate schooling level is associated with a higher risk of 
dementia and AD compared with a high level. 110,111,21 A lower risk of AD 
has also been observed in people who participate in cognitive activities 
and a lower risk of AD and VD in people who participate in cognitively 





In a MA of cohort studies, and case and control studies, a signifi cantly 
higher risk of AD is estimated (OR of around 1.8) in people with low 
schooling level, compared with those with a high level, which is not 





A SR of cohort studies concluded that a high schooling level delays the 
onset of dementia in AD, but does not shorten survival after diagnosis.112
RS of cohort 
studies, 2+
Social media, civil status
There are few studies. Divorced people or people who have never married 
could have a greater risk of suffering dementia. In the Kungsholmen 
project, an index was drawn up with different social components (marital 
status, friendships, having been a mother or a father, living with others), 
and a decreasing curve of the risk of suffering dementia was observed the 





Community epidemiological studies, with variable methodology, suggest 
an association between low socioeconomic level and a greater incidence of 
dementia, but the data are not consistent in all the studies; the association 
may depend on other variables such as age, sex or education level, and 
the results are diffi cult to interpret. The existing evidence is not enough to 






Environmental exposure to pesticides and fertilisers has been associated 
with a greater risk of suffering VD (RR 2.05) and the exposure to fumigants 
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In one SR that included 24 studies (21 case and control studies, and 3 cohort 
studies) on the association between occupational exposure to toxics and 
AD, a relationship between exposure to pesticides and AD was observed, 
consistent among the different studies, whilst, due to the inconsistency of 
the results and to the low quality of the studies, no relationship was found 





Exposure to low frequency electromagnetic fi elds
One MA suggested an increased risk of AD in men who were occupationally 






In another review, the authors consider that the relationship between the 








Non-Steroid Anti-Infl ammatory drugs (NSAID)
Although one SR did not fi nd statistically signifi cant differences between 
the chronic consumption of NSAIDs and a lower risk of suffering AD 
or dementia in general, a more extensive and recent SR estimates that 
exposure to NSAIDs is associated with a decrease in the risk of dementia 
due to any cause in prospective (RR 0.74) and non-prospective (OR 0.51) 
studies. The risk is similar in ibuprofen, which reduces peptide Aβ-42, and 






The results of the studies are inconsistent. Some prospective studies 
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Vaccines
Data from the Canadian Study of Health and Ageing showed that 
individuals who had been vaccinated in the past for diphtheria, tetanus, 
poliomyelitis or fl ue had a lower risk of developing AD than those who 




Vitamins for hyperhomocysteinaemia. Hyperhomocysteinaemia.
Hormone replacement therapy (HRT)
A Cochrane SR and a MA of observational studies and of RCT116 did not 
observe a consistent benefi t of HRT on cognition and the risk of dementia 
in cognitively intact post-menopause women over 65.




Furthermore, the largest RCT performed (WHIMS: Women’s Health 
Initiative Memory Study) showed that HRT almost doubled the risk of 
dementia of any cause and of cognitive impairment.84
RCT, 
1+
Some authors suggest that the discrepancy between the protective effect found in some observa-
tional studies and the higher risk of dementia shown in this RCT could be due to a bias, due to 
the greater tendency of women with a healthier lifestyle to use HRT, or to the fact that the results 
of the WHIMS are not applicable to the population of under 65s, which was excluded from the 
study, whilst in observational studies, HRT began during menopause and ended before the age of 
65. There could be a perimenopause window where oestrogens would be protective, whilst from 
the age of 65 onwards, they would increase the risk.117,118
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Summary of evidence
Age, sex, fi rst-degree family background and APOE ε4 allele
2++
The main risks factors of non-modifi able dementia are: age (main risk factor 
for AD, VD and DLB),25,21,24 sex (AD is somewhat more frequent in women and 
VD in men),83,84 family background (10-30% more risk of AD in fi rst degree 
relatives affected)85 and APOE ε4 allele (greater risk of AD)87,91,90,88,86 according to 
population-based studies, and case and control studies.
Vascular risk factors
2+/2–
Vascular risk factors infl uence the risk of dementia according to cohort studies. 
This relationship is complex and the results are diffi cult to interpret due to their 
variability and the many different confusion factors.92,93
HBP
2+/2–
HBP in midlife, especially if not treated, has been associated with a greater risk 
of developing AD or dementia in general, in longitudinal cohort studies. In the 




High total cholesterol in midlife has been associated with a greater risk of 
developing AD or dementia in general, but not VD in cohort studies.96
Diabetes Mellitus (DM)
2-
Diabetes mellitus has been associated with a higher risk of dementia in the majority 
of the studies but not all of them. The presence of APOE ε4 allele increases the 
risk of AD in patients with DM type 2.100,99,93,97,98
Hyperhomocysteinaemia
2+
Hyperhomocysteinaemia was associated with a higher risk of AD and dementia in 
general in one prospective study.92,84
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Anaemia, TSH or sex hormone levels.
2-
Anaemia101 and alterations of the TSH92 or sex hormone92 levels have been 
associated with a higher risk of dementia in some studies.
Depression
2++
Depression increases the risk of AD (OR of around 2) and the interval between 
the depression diagnosis and the AD diagnosis correlates with the risk of AD, 




Being an active smoker (not being an ex-smoker) is associated with almost twice 
the risk of suffering AD according to at least two MA of prospective studies.103,104
Diet rich in fat and poor in omega-3
2+/
2–/1–
The consumption of omega-3 fatty acids (fi sh, Mediterranean diet) could 
reduce the risk of dementia according to data from observational and biological 
studies.87,92  However, one SR that included four cohort studies and one low 
quality RCT did not fi nd enough evidence to draw conclusions.105
Physical and intellectual activity
2+/2–
The execution of physical and intellectual activity is associated with a lower risk 
of AD or dementia in the majority of longitudinal studies,92,87,21 but it has not 
been possible to determine what type and how much activity is necessary or the 
mechanisms whereby this association occurs.
Consumption of alcohol
2+
The moderate consumption of alcohol, but not excessive consumption or 
abstinence, is associated with a lower risk of AD and dementia, according to a 
MA of 23 longitudinal studies.106
Consumption of coffee
2+
The moderate consumption of alcohol, but not excessive consumption or 
abstinence, is associated with a lower risk of AD and dementia, according to a 




Obesity and underweight have been associated with a higher risk of dementia 
according to a meta-analysis of prospective cohort studies (for obesity, OR of 
1.8 for AD). Some studies did not fi nd signifi cant differences, probably due to 
the small sample size and because the association is complex due to different, 
possibly confusing, cardiovascular risk factors of the association between BMI 
and dementia.108,109
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Traumatic brain injury
2–
A past history of severe traumatic brain injury was associated with a greater risk 
of AD in some studies but not in others.92
Schooling level
2+
A low schooling level is consistently associated with a greater risk of AD in 
different studies.110,111,21,25,87,112
Social media, civil status
2–
Married people or people with more social relations showed a lower incidence of 
dementia in one longitudinal study of a Swedish population.21
Socioeconomic level
2–
A greater incidence of dementia has been observed in patients with a low 
socioeconomic level in some cohort studies. The association may depend on other 
variables and there is not enough evidence to establish a relationship. 21
Exposure to toxins
2++
One SR consistently found a greater risk of AD in patients with a history of 
occupational exposure to pesticides.113
Exposure to low frequency electromagnetic fi elds
2-
No consistent association has been observed between exposure to electromagnetic 
fi elds and the risk of AD.114,113
NSAID
2++
In a recent study a lower risk of dementia was observed in individuals exposed to 
chronic consumption of NSAID.92
Benzodiazepines
2–




Individuals vaccinated for diphtheria, tetanus, poliomyelitis or fl u had a lower risk 
of dementia than those not vaccinated according to the Canadian Study of Health 
and Ageing. 92
Hormone replacement therapy (HRT)
1+/
1++
HRT has not demonstrated a consistent benefi t on the risk of dementia in 
post-menopause women over the age of 65 in a Cochrane SR115 and a MA. 
116Observational study data suggest that there could be a peri-menopause window 
where HRT would have a protective role.84,117,118
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6. Dementia prevention
Questions to be answered
6.1. Is primary prevention of dementia possible?
6.1. Is primary prevention of dementia possible?
To perform primary prevention, it is necessary to know the risk factors of dementia, the degree to 
which these are modifi able and there must be evidence that modifying these factors gives rise to a 
reduction in the incidence. 25Following the same outline as in the previous section, in this chapter 
we analyse evidence from studies that assess whether certain preventive actions on the possible 
risk factor can modify the risk of dementia.
HBP
There are no prospective RCT designed to evaluate if blood pressure treatment in midlife 
reduces the risk of dementia in the elderly.
The few prospective studies that exist only evaluated the cognitive function 
as a secondary variable, and they had a much shorter control period, less 
patients and more elderly than in the observational studies.
Cohort study,
2+/2–
A Cochrane SR (2009)94 did not fi nd convincing evidence based on 
a RCT that a decrease in blood pressure prevents the development of 
cognitive disorders and dementia in patients with no previous and manifest 
cerebrovascular disease. The combined analysis of SHEP 1991, Syst-Eur 
1997, SCOPE 2003 and HYVET 2008 studies did not show signifi cant 
differences between anti-hypotensive treatment and placebo in the incidence 
of dementia (secondary variable) after an average control period of about 
3 years on a total of 15,936 hypertensive patients aged between 60 and 89 
years (OR 0.89. CI 0.74-1.07). Only the Syst-Eur 1997 study showed a 
reduction of the incidence of dementia with the use of nitrendipine, but, 
lacking individual data, it is not possible to evaluate if the effect of the 
treatment depends on other basal risk variables such as sex, age or blood 
pressure level.
SR and MA 
of RCT,
1–
Unfortunately, due to the considerable heterogeneity between the RCT, to the presence of 
adverse events that caused the drop-out of many patients, and to the fact that some control 
individuals received antihypertensive drugs to recover the pre-established values, it was not 
possible to use the available data to assess the effi cacy of antihypertensive treatment in the 
prevention of cognitive disorders and dementia.
100 CLINICAL PRACTICE GUIDELINES IN THE SNS
Hypercholesterolaemia
There is no large-scale RCT aimed at studying the effect of hypolipemiant treatment on the 
cognitive function or the risk of dementia.94,99
A MA of cohort studies, and case and control studies (2005) designed to 
assess the effect of statins on the development of dementia and AD did not 
show any benefi t of these drugs.119




In two large RCTs that evaluated the effect of statins on the risk of vascular 
disease, no reduction of the incidence of dementia was observed after 3-5 
years in the group treated with pravastatin or simvastatin,87 and observational, 
and case and control studies have shown variable results. Some statins seem 







In the Nurses’ Health Study, on diabetic women over the age of 70 and a 
2-year control period, the sub-group treated with oral antidiabetic medication 
had an OR of 1.06 of bad basal cognitive performance with respect to 
the non-diabetes, whilst the untreated subgroup had an OR of 1.71.99 On 
the contrary, hyperinsulinaemia or treatment with insulin could increase 
the risk of dementia. Non-diabetic women with peptide C levels (insulin 
secretion marker) in the upper quartile, had a greater risk of dementia after 
10 years than women with levels in the lower quartile (OR 3.2); likewise, 
in the WHICAP study, patients with insulin levels in the upper quartile had 
a greater risk of AD than patients in the lower quartile (HR 1.7); the greater 
association was in non-diabetes, and they calculated that hyperinsulinaemia 





The normalisation of homocystein levels by the intake of complex 
B vitamins in healthy elderly people with high levels did not show any 
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Diet rich in fat and poor in omega-3
A Cochrane SR (2005) found that available epidemiological clinical studies 
that compare the presence of AD among elderly people with different 
dietetic intake levels of omega-3 polyunsaturated fatty acids suggest a 
signifi cant reduction of the risk of this disease among those with higher 
consumption levels of fi sh and omega-3 polyunsaturated fatty acids. There 
are no RCT that permit confi rming or refuting the usefulness of omega-3 







One SR concludes that the RR of cognitive impairment could decrease with 
age in physically active people. The majority of the studies have found 
an association between physical exercise and a lower risk of dementia, 
although others have not. The cause-effect ratio is not clear; in other words, 
if participating in physical activities improves cognition or if those that have 
a better cognitive function participate more. Furthermore, there could be 
other variables such as possible endogenous substance levels that stimulate 
both physical activity and the cognitive function. We do not know what type 
of exercise is more benefi cial (the study results vary depending on the type 
of exercise) nor the recommended duration or intensity. There is no RCT 
that investigates if exercise by previously sedentary people would reduce 






One SR that included seven RCT that have evaluated the effect of mental 
exercise on cognitive performance for at least 3 months in healthy elderly 
people, showed a favourable effect compared with non-training (weighted 
average difference = 1.07, CI: 0.32-1.83, z = 2.78, N = 7, p = 0.06, N = 3.94). 
Studies of more than 2 years did not produce a greater effect. The quality of 
the studies is low, and the incidence of dementia is not specifi cally evaluated. 
We still do not have any appropriately designed trials that demonstrate that 
cognitive exercise prevents the incidence of dementia.124
SR of RCT, 
1-
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Consumption of alcohol
In the Nurses’ Health Study it was observed that women over 70 years of 
age that consumed less than 15 g/d of alcohol had a lower risk (RR 0.81) of 
cognitive impairment after 2 years than non-consumers. The benefi t was not 
observed in higher consumptions. Likewise, in the Cardiovascular Health 
Study, individuals over the age of 65 who consumed 1-6 drinks per week 
had a lower risk of dementia (OR 0.46) than teetotallers, whilst the benefi t 
was lost in consumptions of 7-13 drinks, and the risk increased in more 
than 14 drinks (OR 1.22); the results were similar for AD, and with no 




There is no RCT on the consumption of alcohol, and observational studies 
support the moderate consumption of alcohol (< = 1 drink per day in women 
and < = 2 in men) to reduce the risk of cardiovascular disease and cognitive 




Use of statins (hypercholesterolaemia)
Use of NSAID
MA of observational and prospective studies have shown a lower risk 
of dementia in users of NSAIDs (ibuprofen or naproxen), but not when 
cognitive impairment was used as a major clinical variable. No effect was 
observed in studies with aspirin. There are no prospective RCT that confi rm 






Observational studies with vitamin C or E have shown variable results, and 
there are no RCT or consistent data of effi cacy that support their use to 




Hormone replacement therapy (HRT)
Some studies suggest that HRT may delay the onset of AD if started in a peri-
menopause “opportunity window” where oestrogens would be protective, 
whilst from the age of 65 onwards, they would increase the risk (question 
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Other risk factors
There are no prospective RCT aimed at assessing if the modifi cation of other possible risk 
factors (hyperthyroidism, sex hormone levels in blood, depression, nicotine addiction, 
consumption of coffee, obesity and low weight, social-demographic factors, exposure to 
toxins and electromagnetic fi elds, use of benzodiazepines, use of vaccines) may reduce the 
risk of dementia.
Despite the absence of RCT, the available data of observational studies 
suggest that action on these risk factors could be associated with a lower 




Overall, there is still no clear evidence of the risk factors to develop dementia and how to 
prevent it. The majority of the recommendations of documents are based on scientifi c evidence, 
but they are not specifi cally focused on the prevention of dementia but on the prevention of 
the risk factors that may be accompanied by dementia.
Summary of evidence
Vascular risk factors (HBP, DM and hypercholesterolaemia)
1–/2+/
2–
The available data of cohort studies or RCT designed to assess other variables do 
not permit demonstrating that the treatment of vascular risk factors (HBP,94 DM,99 
hypercholesterolaemia99,119,87,120) reduces the risk of developing dementia. No RCT 
have been appropriately designed to assess it.
Hyperhomocysteinaemia
2–
The correction of hyperhomocysteinaemia via vitamin B in healthy elderly 
individuals did not show a cognitive improvement in an inappropriate design 
study.121
Diet rich in fat and poor in omega-3
2++
A higher consumption of omega-3 fatty acids was associated with a lower risk 
of AD in one Cochrane SR of case and control studies, but there is no RCT that 
permits confi rming or refuting its usefulnesss.122
Physical or mental activity
2+/2–
There are no RCTs that assess if the execution of physical123 or mental124 exercise 
reduces the risk of developing dementia.
Consumption of alcohol or chronic consumption of NSAID
2++/
2+
The moderate consumption of alcohol99 or the chronic consumption of NSAID25 
has been associated with a lower risk of AD in cohort studies, and case and control 
studies, but there are no RCT that confi rm this benefi t.
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Vitamins
2–
There are no RCT or consistent data from observational studies that support a 
benefi t of taking vitamins C or E over the risk of dementia. 25
Hormone replacement therapy (HRT)
2++
Observational studies suggest that HRT could reduce the risk of dementia in a 
peri-menopause window and increase it from 65 years onwards,117,118 but there are 
no RCT that confi rm this.
Other risk factors
2+/2–
There are no RCT that assess the effect of the intervention on other possible 
risk factors (hyperthyroidism, sex hormone levels in blood, depression, nicotine 
addiction, consumption of coffee, obesity and low weight, social-demographic 
factors, exposure to toxins and electromagnetic fi elds, use of benzodiazepines, use 
of vaccines) on the risk of developing dementia (question 5.3).
Recommendations
C
The control of vascular risk factors (HBP, DM, hypercholesterolemia) and 
healthy lifestyle habits (consumption of omega-3 fatty acids, physical and mental 
exercise) is recommended due to the clear evidence that exists about its benefi t on 
other aspects of health, although its possible benefi t on the reduction of the risk of 
dementia is not supported by appropriately designed studies.
C
Although moderate alcohol consumption or chronic consumption of NSAIDs ha 
been associated with a lower risk of AD, they also have other risks for health and 
there is not enough evidence to recommend them in the prevention of dementia.
C
Neither the intake of vitamin C nor vitamin E nor hormonal replacement therapy 
are recommended to prevent dementia.
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7. Genetic study in dementias
Questions to be answered
7.1.  When are genetic analyses indicated to identify pathogenic mutations in patients with 
dementia?
7.2.  When is a predictive genetic analysis indicated in asymptomatic individuals?
Less than 1% of the cases of neurodegenerative dementias are genetically determined, that is, a 
specifi c genetic alteration is the cause of the disease.6,126 These cases often present a phenotype 
that is diffi cult to distinguish from the non-genetic forms, with the exception of the onset age, 
which is normally earlier in genetic cases.
The genetic alterations causing primary neurodegenerative dementia that have been identi-
fi ed to date are transmitted with an autosomal dominant inheritance pattern with high penetrance, 
although the age range for the onset of the disease varies depending on the gene involved.6,126
In genetic origin AD, which represents between 0.5 and 1% of the cases according to the 
series,25,6,126 causal mutations have been identifi ed in three different genes: the amyloid precursor 
protein (APP), presenilin 1 (PSEN1) and presenilin 2 (PSEN2).
Causal mutations in fi ve genes have been identifi ed to date in FTLD, representing between 
10 and 15% of the cases, but they do not explain all the familial cases. These genes are the gene of 
the microtubule-associated protein tau (MAPT), progranulin (PGRN), the gene of the Chromatin 
modifying protein 2B (CHMP2B), the valosin-containing protein gene (VCP) and the gene of the 
TAR DNA binding protein (TARDBP); mutations in MAPT and PGRN are the most frequent.
Genetic prion diseases (between 10 and 15% of the cases) are produced by mutations in the 
prion protein gene (PRNP).6,126
Genetic origin DLB is currently considered to be an exception, as is its familial presentation.
Huntington’s disease is produced by the alteration of exon 1 of gene IT15, a gene that en-
codes the huntingtin protein. The genetic alteration of HD consists in an expansion of cytosine-
adenine-guanine (CAG) triplets, which normally presents around 16 repetitions, but its expansion 
over 35 repetitions may cause symptomatology. Huntington’s disease is the paradigm of genetic 
dementias and, unlike the other types of dementias, mentioned above, it has an exclusively ge-
netic origin.
The detection of a genetic change in one of the genes involved in the pathogeny of the 
disease in a patient with dementia does not mean that this is the cause of the disease (existence 
of polymorphisms or non-pathogenic mutations).  For a change in the genome to be considered 
as causal, the segregation of this change with the disease in the family must be demonstrated, as 
well as its absence in normal population, and this change must cause an alteration at biological 
functioning level that justifi es its involvement in the pathogeny of the disease. However, in the 
majority of the cases, pathogenic mutations are recurrent in different families, so the existing 
bibliography is enough to support the pathogenic role of a mutation, without it having to be dem-
onstrated in each case.
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The majority of the cases of dementia, therefore, are not determined by a specifi c genetic 
defect, although the genetic component may exercise a predisposing factor in the development of 
a dementia. Thus, in AD, the presence of allele ε4 of the APOE gene has proved to be a risk factor 
for the development of the disease in many association studies; in sporadic Creutzfeldt-Jakob's 
disease there is an overrepresentation of the methionine-methionine homozygosis at codon 129 of 
the PRNP gene and in some of the frontotemporal lobar degeneration forms, an overrepresenta-
tion of haplotypes H1 of gene MAPT6 is objectifi ed. None of these genetic risk factors is, how-
ever, necessary or suffi cient, for the development of these diseases, so their usefulness in clinical 
practice is controversial (Section 5.2).
The detection of a genetic alteration as the cause of dementia not only has implications for 
the patient, but it also places direct relatives at a risk of having inherited that same alteration and 
therefore of suffering the same disease in the future. To date there are no preventive or curative 
therapies. In this sense, the genetic analyses have a legal and practical consideration in daily clini-
cal practice that differs from other diagnostic tests.
7.1. When are genetic analyses indicated to identify 
pathogenic mutations in patients with dementia?
The NICE guideline25 recommends that patients with a likelihood of 





The CPG of the EFNS,5 as a point of good clinical practice, recommends 
genetic analysis in patients with certain phenotypes or autosomal dominant 
familial history. This study should only be carried out at specialised centres 




The great majority of the cases of genetic caused AD appear as presenile 
onset AD and autosomal dominant history. The cases of genetic FTLD 
normally appear with a family history. Genetic cases of prion diseases 
may appear without family history. The CPG of the SEN,6,126 based on case 
and control studies, recommends performing genetic analyses on patients 
with AD and an autosomal, dominant family history of pre-senile onset. In 
patients with FTLD, the execution of genetic studies would be indicated 
in patients with autosomal dominant family history. In patients with prion 
diseases, the prion protein genetic study would be indicated in all cases, 
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The majority of patients with Huntington’s disease have a high number 
of CAG repetitions in the Huntingtin gene, so the diagnostic reliability of 
genetic studies in cases where Huntington's disease is suspected is high.6 
Given that Huntington’s disease is a purely genetic disease, in the event 








The Spanish Law on Biomedical Research (Law 14/2007)127 explains 
that prior written consent from the person affected or from their legal 
representative is necessary to perform genetic analyses. On the other hand, 
“when a genetic analysis is performed for health purposes, appropriate 
genetic counselling will have to be guaranteed for the interested party. 
The professional giving or coordinating the genetic counselling must offer 
adequate information and advice, related both to the importance of the 
resulting genetic diagnosis and to possible alternatives that the individual 






Patients with likelihood of suffering genetic origin dementia and their relatives 
require genetic counselling.
2+
The great majority of the cases of genetic cause AD appear as presenile onset 
AD and autosomal dominant history.6,126
2+ The great majority of the cases of FTLD appear as familial FTLD.6,
2++/
2+
The genetic cases of prion diseases may appear with or without family history. 
The genetic study of all patients with prion diseases has been proved necessary 
to detect genetic cases, even in the absence of family history.6,126
2++/
2+
Huntington’s disease is a purely genetic disease and the diagnostic reliability 




The prior written consent from the affected person or from his or her legal 
representative must be obtained to perform genetic studies, and appropriate 
genetic counselling must also be guaranteed for the interested party.127
Recommendations
D
Patients with a likelihood of suffering dementia due to genetic causes should 
be referred to specialist genetic counselling units.
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C
Performing genetic analyses to detect causal mutations is indicated in patients 
with AD and an autosomal, dominant family history of pre-senile onset.
C
In patients with FTLD, genetic analyses would be indicated in cases with a 
family history of a similar disease.
B
In patients with prion diseases, the genetic study would be indicated in all 
cases, regardless of family history or age.
B
The genetic study is recommended if Huntington’s disease is suspected, to 
confi rm the diagnosis.
According 
to applicable
The execution of genetic analyses in clinical practice must be authorised in 
writing by the actual individual or his/her legal representative after receiving 
genetic counselling
7.2. When is a predictive genetic analysis indicated in 
asymptomatic individuals?
The NICE guideline25 recommends that non-affected relatives at risk of 





Predictive genetic analysis on asymptomatic individuals at risk of developing 
genetic origin dementia has proved to be safe in the short to medium term 





Based on case and control studies, the CPG of the SEN6,126 proposes that 
presymptomatic or predictive genetic studies could be conducted on 
individuals of full legal age with a clear family history of dementia and known 
pathogenic mutation in patients of their family, following multidisciplinary 
assessment and genetic counselling before and after the genetic analysis, 
following the predictive study model for Huntington's disease, given that 




One RCT128 showed that relevant psychological alterations were not 
objectifi ed in the short term in a group of individuals on whom it was carried 
out and who were informed about their APOE genotype.
RCT,
1-
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However, the guidelines of the EFNS5 and of the SEN6 consider that studying 
non-determining genetic risk factors, such as the APOE genotype in AD or 
others, would not be indicated with genetic counselling purposes given that 






Presymptomatic predictive genetic studies have has proved safe in a 
multidisciplinary genetic counselling context.6,126
1–
The APOE genetic study has proved safe in asymptomatic individuals in a 
multidisciplinary genetic counselling context.128
2++
The study of the APOE genotype has not proved to be valid as a predictive test 
of AD in non-selected individuals.5,6,126
Recommendations
C
The predictive genetic study can be performed on people of full legal age 
who are at a risk of being carriers of a pathogenic mutation known to cause 
dementia and who wish to have it conducted, following informed written 
consent and multidisciplinary genetic counselling prior to the genetic analysis 
and subsequent monitoring.
D
The study of genetic risk factors of dementia, such as the APOE genotype, is 
not indicated for genetic counselling purposes in asymptomatic individuals.
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8. Dementia diagnosis
Questions to be answered
8.1. How is dementia diagnosed?
8.2.  What is the differential diagnosis of dementia?
8.3.  What are the advantages of neuropsychological testing assessment in cognitive impair-
ment and dementia?
8.4.  What neuropsychological tests, questionnaires or functional evaluation scales must be 
performed on patients with dementia?
8.5.  Which laboratory tests are essential in diagnosing dementia?
8.6.  Must the determination of apolipoprotein E (apoE) be requested?
8.7.  What are the advantages of analysing cerebrospinal fl uid (CSF) in the diagnosis of de-
mentia?
8.8.  Which is the structural neuroimaging technique of choice in the diagnostic process of 
dementia and its different types?
8.9.  Which is the functional neuroimaging technique of choice in the diagnostic process of 
dementia and its different types?
8.10. What are the advantages of EEG/mapping in the diagnosis of dementia?
8.11. What are the indications for performing a cerebral biopsy in the etiologic diagnosis of 
dementia?
8.1. How is dementia diagnosed?
Diagnostic assessment of dementia
The diagnosis of dementia is largely clinical and is based on DSM-IV-TR or 
ICD-10 criteria (Appendices 1.1 and 1.2).
Expert 
opinion, 4
The diagnostic process is usually based on a suspicion of cognitive 
impairment, either by the actual person affected, by a relative or the primary 
care team. Other possible causes of cognitive impairment must be ruled out 
before making a diagnosis of dementia (question 8.2.). All the information 
required to know if the patient satisfi es the clinical criteria of dementia and 
of its subtypes must be collected in the case history and examination.129
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A possible family background of dementia, previous diseases, vascular 
risk factors, the patient’s schooling level and social-family context must 
be studied in depth. The symptoms of cognitive dysfunction, its form of 
onset and evolution must then be evaluated. A functional assessment must 
be carried out on the patient, as the loss of capacity to undertake basic and 
instrumental activities is one of the main criteria for diagnosing dementia 




It is important to have a source of information that is close to the patient, 
for the case history, given the frequent presence of anosognosia. Several 
questionnaires have thus been designed for informants, such as the Blessed 
scale or the IQCODE (Informant Questionnaire on Cognitive Decline in 
the Elderly) (question 8.3). The BPSD as well as functional and social 
problems must be assessed, as these are the main causes of strain and stress 
in the caregiver (question 11.4).
Neurological examinations in early phases of dementia are usually normal, 
although alterations may be evident that guide towards a specifi c aetiology 
(extrapyramidal signs, oculomotor alterations, gait apraxia, etc.).5
Formal neuropsychological examinations permit the detection of mild cases 
and help make a differential diagnosis, and determine subtypes of dementia 
(question 8.2).
The data obtained via the case history, clinical and neuropsychological 
examinations will enable us to make a syndrome-based diagnosis (cortical vs. 
subcortical impairment, parietotemporal, frontal syndrome, etc.) and based 
on this, we will continue the study with the relevant complementary tests.
The aetiological diagnosis of certainty of degenerative dementias is based 
on neuropathological examinations, so, in the majority of the cases, we will 
only reach an aetiological diagnosis of probability, with the exception of 





The definition of dementia is based on diagnostic criteria. There are also different 
clinical criteria of consensus for the diagnosis of the different types of dementia 
(Appendices 1.3-1.11).
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The most commonly used for AD are the criteria of the National Institute 
of Neurological and Communicative Disorders and Stroke and of the 
Alzheimer’s Disease and Related Disorders Association (NINCDS/
ADRDA),131 which stratify the diagnostic precision with the degree of 
possible, probable or defi nite, or those of the DSM-IV-TR.17 The DSM-IIR 
criteria for Alzheimer’s type dementia and those of the NINCDS/ADRDA 
for probable AD have been validated in clinical-pathological studies and 





The NINCDS-ADRDA131 criteria have been recently reviewed by Dubois et al.133 for a 
research context and they have still not been validated for clinical application.
Each new version of criteria shows greater specifi city than the previous ones, above all because 
they incorporate new diagnosis markers (neuropsychological, neuroimaging, biochemical, 
genetic). The new criteria proposed by Dubois et al. in 2007 are of interest, as they permit 
the establishment of the clinical diagnosis of “probable AD” in patients who only present a 
prolonged disorder of episodic memory (more than 6 months), providing that an AD marker 
(support criteria) appears in the complementary test, and there are no data that identify any 
other cause of dementia (exclusion criteria). This diagnosis, in a patient who does not satisfy 
the dementia syndrome-based criterion (which requires an alteration of multiple cognitive 
domains), represents an advance in the early aetiological diagnosis of patients with cognitive 
function impairment, and a change in the concept shared by all criteria valid until 2007, which 
demanded the presence of dementia to be able to diagnose AD.
Currently, the fi nal determination of the existence of AD requires the person to have satisfi ed 
the clinical criteria of AD, also, the anatomopathological criteria of AD must have been 
confi rmed in brain studies or the presence of any of the mutations that cause familial AD must 
have been detected.
The most commonly used criteria for VD are those of the National Institute 
of Neurological Disorders and Stroke/Association Internationale pour la 
Recherche et l’Enseingement en Neurosciences (NINDS/AIREN), of great 
specifi city (around 95%) but very low sensitivity (less than 43%).6,46
The Hachinski ischaemia scale has high sensitivity to distinguish AD 
(score < 4) and VD (score < 7), but it is not reliable for mixed cases. 59The 
Hachinski scale was not designed as a diagnostic criterion for VD but to 
detect vascular brain lesions in patients with dementia. A meta-analysis 
of the Hachinski scale on patients with dementia and neuropathological 
confi rmation, showed that it was effective to differentiate Alzheimer’s type 
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There are no clinical or neuropathological criteria for the diagnosis of 
mixed dementia (if there are signs of both VD and AD, the NINDS / AIREN 
classifi es it as AD dementia associated with cerebrovascular disease).58
The diagnostic criteria for DLB were formulated by McKeith28 and reviewed 
in 2005 by the DLB International Workshop. 40The 1996 criteria have shown 





The diagnostic criteria for probable or possible dementia associated with 
Parkinson’s disease was defi ned by consensus by the group of experts from 




The Lund-Manchester criteria can be applied (The Lund and Manchester 
Groups, 1994) for FTLD, as well as the criteria of the NINDS Work Group 
on Frontotemporal Dementia135 or those of Neary,51 that are more operative 
and have shown 85% sensitivity and 99% specifi city when applied together 






The diagnosis of dementia is largely clinical. The information required to know if 
the clinical criteria of dementia and of its subtypes are satisfi ed, must be compiled 
in the case history and examination.
The case history includes: Family background of dementia, previous diseases, 
vascular risk factors, patient’s schooling level, social-familial context, cognitive 
dysfunction symptoms, form of onset and evolution, assessment of the capacity 
of activities of daily living, BPSD and social problems.
The neurological examination is usually normal with the exception of advanced 
stages or in diseases with associated neurological signs.5
The neuropsychological examination helps to detect mild cases and the differential 
diagnosis.
The aetiological diagnosis of certainty of degenerative dementias is based 




To diagnose AD, the NINCDS / ADRDA criteria for probable AD and the DSM-
IIR criteria for Alzheimer type dementia have shown an average sensitivity of 
81% and average specifi city of 70% in clinical-pathological studies.132
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2+
To diagnose VD, the NINDS/AIREN criteria have shown 43% sensitivity and 
95% specifi city in a clinico-pathological study. 6,46The Hachinski scale helps to 
detect brain infarcts in patients with dementia and may distinguish between EA 
(< 4) and VD (> 7), but it is not useful in mixed dementia.
2+
To diagnose DLB, the McKeith criteria have shown variable sensitivity (31-
83%) and 95-100% specifi city in prospective clinico-pathological studies.6,47
4
To diagnose probable or possible dementia associated with Parkinson’s disease, 
a group of experts from the Movement Disorder Society (Emre et al.) established 
some consensus criteria in 2007.41
2+
To diagnose FTLD, the Lund-Manchester or Neary criteria have shown 85% 




The assessment of the impact of cognitive impairment on the activities of 
daily living is recommended, given their affectation, which forms a dementia 
diagnostic criterion and determines the subsequent management of these patients.
✓ Obtaining data from an independent and reliable informant is recommended, 
whenever possible.
✓ An assessment of the psychological and behavioural symptoms is recommended, 
due to their importance for the diagnosis.
✓
The execution of a general physical and neurological examination of patients 
with dementia is recommended to detect comorbidity and associated neurological 
signs that may help towards the differential diagnosis of some subtypes of 
dementia.
D
The use of DSM-IV-TR and ICD-10 clinical criteria is recommended to diagnose 
dementia.
B
The use of DSM-IV-TR or NINCDS/ADRDA criteria is recommended to 
diagnose AD.
B
The use of INDS/AIREN criteria or the Hachinski scale is recommended to 
facilitate the diagnosis of VD.
D
The use of Emre et al. (Movement Disorder Society) criteria is recommended to 
diagnosis Parkinson’s disease dementia.
B The use of McKeith criteria is recommended to diagnose DLB.
B
The use of Lund-Manchester or Neary criteria to help diagnose FTLD is 
recommended.
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8.2. What is the differential diagnosis of dementia?
Before establishing the diagnosis of dementia, we must basically rule out all those processes that 
might simulate it.
Acute confusion syndrome (delirium)
Acute confusion syndrome or delirium is a severe, normally reversible, disorder that is associated 
with high morbidity and mortality. It is a real medical urgency, and is usually due to systemic 
causes. Advanced ages and neurodegenerative diseases are risk factors for this entity. Patients 
with dementia have a high risk of presenting acute confusion syndrome, but an initial diagnosis 
of dementia must not be made in the context of a confusion picture.136
It is clinically characterised by the disturbance of the level of consciousness, a reduction 
in capacity to direct and sustain attention, and fl uctuating cognitive evolution defi cits. The onset 
may be acute and the disturbances are usually reversible if the cause is detected and appropriately 
treated. The DSM-IV_TR criteria for diagnosing delirium are described in Table 1. Some charac-
teristics that help differentiate delirium from dementia are given in Table 2.
Table 1. DMS-IV-TR criteria for the diagnosis of delirium (translated from APA, 2000)16
A. Disturbance of consciousness (reduced clarity of awareness of the environment), with reduced ability 
to focus, sustain or shift attention.
B. A change in cognition (such as memory defi cit, disorientation or speech disorder) or the development 
of a perceptual disturbance that is not better accounted for by a pre-existing, established or evolving 
dementia.
C. The disturbance develops over a short period of time (usually hours to days) and tends to fl uctuate 
during the course of the day.
D. There is evidence from the history, physical examination or complementary examinations that the 
disturbance is caused by the direct pathophysiological consequences of a systemic disease, intoxi-
cation, effect of drugs or by more than one cause.
Table 2. Differential diagnosis between delirium and dementia137
DELIRIUM DEMENTIA
• Precise, sudden onset with identifi able date
• Gradual onset but impossible to give precise 
date
• Acute disease, generally lasting from days to 
weeks, rarely more than 1 month
• Chronic disease that typically progresses for 
years
• Generally reversible, often completely.
• Generally irreversible, often chronically pro-
gressive.
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• Early disorientation
• Disorientation in late phase of disease, often 
after months or years.
• Variability from one moment to the next, from 
one hour to the next, for the whole day.
• Much more stable from one day to another (un-
less delirium appears)
• Outstanding physiological impairments • Less striking physiological changes
• Cloudy, altered and variable level of conscious-
ness
• Consciousness is not obfuscated until terminal 
phase.
• Duration of attention strikingly short • Duration of attention is not typically reduced.
• Disturbance of sleep-wake cycle, with varia-
tions from one to another
• Disturbance of sleep-wake cycle, with day-
night inversion, with no hourly variations
• Marked psychomotor changes (hyperactive or 
hypoactive)
• Typically late psychomotor disturbances (un-
less depression appears).
The main risk factors of delirium are old age, the coexistence of neurological and psychiatric dis-
eases and sensory deprivation. Many precipitating factors have been described, including drugs 
(mainly hypnotic, narcotic, alcohol or poly-drug use), different neurological diseases (such as 
ictus, intracranial haemorrhage or meningitis), systemic disturbances (infections, surgeries, hy-
droelectrolytic disturbances), fecalomas, acute urine retention, pain and changes in normal envi-
ronment surrounding the patient (emotional stress, widow(er)hood, use of tethers and physical 
constraints, urine probes, change in place of residence or admissions into hospital). At times, an 
acute confusion syndrome may conceal prior cognitive disturbance.
Major depression and other psychiatric disorders
Major depression is another important element in the differential diagnosis of memory alterations. 
Frequently, people with depressive disorders present memory complaints, concentration diffi cul-
ties or reduction of intellectual performance, which may even have an effect on the patient’s 
global functioning. Thus, a comprehensive interrogation must be carried out, aimed at detecting 
depression syndromes such as sadness, anhedonia, anxiety, anorexia or sleep disorders. Patients 
usually highlight and insist on cognitive diffi culties. It may become necessary to start anti-de-
pression treatment and observe the evolution of anaemic and cognitive symptoms. Depression is 
often an early symptom in dementia, so the coexistence of both must be investigated. So much 
so that even when the onset of depression symptoms precedes or coincides in time with the ap-
pearance of cognitive symptoms and both are solved with antidepression treatment, up to 50% of 
the patients will develop mild cognitive impairment or dementia during the years following the 
depression episode. Likewise, patients with mild cognitive impairment who present depression 
episodes, may have a greater risk of developing AD. 42Dementia must also be distinguished from 
dissociative or conversive disorder, which is usually expressed with patterns of cognitive defi cit 
that are inconsistent in time and that are not the ones that are typically observed in dementia.42
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Mild cognitive impairment
Mild cognitive impairment (MCI), also called light cognitive impairment, is defi ned as an altera-
tion of one of more cognitive domains, which must be acquired, reported by the informant and 
objectifi ed in the neuropsychological assessment and which does not interfere or only does so 
minimally, with the patient’s ability to carry out activities of daily living (ADL). The variable 
evolution of MCI depends on the underlying cause. In general, these patients have an increased 
risk of developing dementia, so the clinical evolution must be monitored every 6-12 months. 
Subjective complaints about memory, where the neuropsychological tests do not show a signifi -
cant reduction in cognitive performance with respect to the normal values, may precede MCI by 
even 15 years, and they are often associated with mood disorders (anxiety and depression).138 
8.3. What are the advantages of neuropsychological testing 
assessment in cognitive impairment and dementia?
The American Neurology Academy (ANA), in its 2001 recommendations, concludes that there 
is not enough evidence in literature to postulate about the advantages of dementia screening 
in asymptomatic population. Individuals with cognitive complaints, expressed by themselves 
or by people close to them, present an increased risk of presenting or developing dementia, 
so the ANA does recommend assessment and clinical monitoring of this type of individual.139
On the other hand, different quality CPG recommend that the diagnosis of 
dementia be carried out after a global evaluation of the patient including a 




The tests can assess the cognitive function either globally or by cognitive domains, so they 
may also give indications about the clinical form or nosology of dementia. In addition, given 
that they are quantitative tests, they may determine the degree and evolution of the impairment.
Cognitive tests can be classifi ed into short screening tests, short-intermediate general 
assessment tests and specifi c tests. The short screening tests are simple tests that assess one or 
several cognitive fi elds and are designed to make a fast clinical assessment by non-specialised 
staff. The intermediate or specifi c neuropsychological assessment tests are sensitive to detect 
and characterise subtle cognitive disturbances, but they must be administered by specialised 
staff. They usually facilitate the differentiation between typical disturbances of age, mild 
cognitive dysfunctions and typical cognitive dysfunctions of dementia, so they are especially 
advantageous in stages of incipient cognitive impairment. They can indicate the risk of these 
dysfunctions leading to dementia in general, or into a subtype of dementia in particular.6,141
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In this sense, different CPG recommend performing complete neuropsycho-
logical studies via standardised and validated tests for the population under 




The SEN6 guideline recommends performing general brief-intermediate 
type evaluation tests when the aim is to make an assessment of the most 
important neuropsychological areas in a reasonable time. This guide also 
recommends performing detailed neuropsychological assessment via 
specifi c tests when there are differences between the clinical impression 
and the screening tests, diagnostic doubts or else when the complaints are 




Despite the great advantage of neuropsychological tests, as a tool they 
are not suffi cient to diagnose dementias and they must be interpreted as a 
complement to other diagnosis strategies. When these tests are administered 
to patients, it is advisable to bear in mind that the results may be dependent 
upon the age, the level of schooling, previous skills, attention levels, sensory 
diffi culty, mental diseases, physical or neurological problems, and drugs, 




8.4. What neuropsychological tests, questionnaires or 
functional evaluation scales must be performed on patients 
with dementia?
In individuals with cognitive complaints the ANA guideline139 recommends 
applying, in order to monitor the degree of cognitive impairment, global 
cognition screen tests, neuropsychological test batteries, short cognitive 






The ANA guideline139 considers global cognitive screen tests to be useful to 
detect dementia in populations with a high cognitive impairment prevalence 
(due to old age or the presence of memory complaints):
• The mini-mental state examination (level of evidence: 2++)
• Short test of mental state (level of evidence: 2–)
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Among the informant-based questionnaires, according to the ANA, the 
Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) 
is useful (level of evidence: 2++), the Clinical Dementia Rating (level 
of evidence: 2–) and the Blessed Roth scale (level of evidence: 2+). 139 
Other guidelines recommend the use of the Global Dementia Scale (GDS) 
(dementia) or the Functional Assessment Staging (FAST) (Alzheimer’s 




Not all these tests have been validated in Spain. The following have been 
validated and recommended in our medium as global or focalised cognition 
screen tests: the MMSE (level of evidence: 2++), test of which there are 
several versions in our country: standardised version,142 Lobo or MEC 
version;143,144 the MIS (level of evidence: 2++); the 7-minute test (level of 





Other short screen tests, developed in Spain, have proved useful to detect 
dementia and/or cognitive impairment, such as the Phototest (level of 





Likewise, the SEN6 guideline recommends the neuropsychological 
examination via general brief-intermediate type evaluation tests such 
as the Alzheimer’s Disease Assessment Scale (ADAS), the Cambridge 
Examination for Mental Disorders of the Elderly (CAMDEX) or the 
abridged Barcelona test (TBA) when the aim is to make an assessment that 





When specifi c tests are resorted to, they can be selected using a syndrome-
based or modal approach, that is, within a specifi c neuropsychological fi eld. 
The selection must be based on the psychometric characteristics of the 
instrument and on the existence of regulatory data in the medium where it is 
aimed to be used. In this sense, in the Spanish scenario, noteworthy are the 
NORMACODEM projects, and more recently NEURONORMA.ES, which 





The SEN guideline also recommends the systematic functional assessment 
of the individual with a reliable observer, either using standardised 
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The following functional assessment questionnaires are quoted as being 
useful: the Functional Activities Questionnaire (FAQ), Instrumental 
Activities of Daily living scale (IADL), Interview for the deterioration of 
Daily Living in dementia (IDDD), Bayer Activities of Daily Living scale 
(BAYER ADL), Informant Questionnaire on Cognitive Decline in the 
Elderly (informant’s test) (IQCODE), Barthel’s index, Katz’ index, Rapid 
Disability Rating Scale (RDRS-2) and the Blessed Dementia Rating scale 
(BDRS), with no priority of any one over the others.
The Global Deterioration Scale (GDS), the Functional Assessment Scale 
(FAST) and the Clinical Dementia Rating (CDR) are among the most 
outstanding global assessment scales.
In addition, the systematic assessment of neuropsychiatric symptoms is also 
recommended, either through a semi-structured history or via standardised 
scales such as the Neuropsychiatric Inventory (NPI), the Behavioural 
Symptoms in Alzheimer’s disease, geriatric depression scale or the Hamilton 
depression scale, etc
The GDS and FAST scales are described in Appendix 1.14
Summary of evidence (questions 8.3 and 8.4).
2++
/2-
Global cognition screen tests, neuropsychological test batteries, short focused 
cognitive instruments and/or standardised structured questionnaires are valid 
to quantify the degree of cognitive impairment in patients with suspicion of 
dementia.139
1+
Formal cognitive assessment via validated instruments is necessary to establish 
a diagnosis of dementia6,140,25,5,136
2++
The standardised Spanish version of the MMSE142 and the versions of Lobo or 
MEC,143,144 are global cognitive screen tests that have proved to be useful in our 
medium to detect dementia in individuals with cognitive complaints.
2++/
2+/2–
Other short screen tests such as the MIS,139 the Pfeiffer test,6 the 7-minute test,6 
the clock test,139 the Eurotest6 or the T@M146 may also be useful in screening 
dementia.
2+
The neuropsychological examination using general short-intermediate type 
assessment tests is useful to make an evaluation of the most important 
neuropsychological areas in a reasonable time.6
4
The performance of a detailed neuropsychological assessment via specifi c tests 
is useful when there are differences between the clinical impression and the 
screen tests, diagnostic doubts or else when the complaints are limited to just 
one cognitive domain or evolve over a short period of time.6
2++/
2–
When an individual with cognitive impairment is evaluated, it is useful to 
establish the degree of global functional impairment through specifi c scales.6,139
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Recommendations (questions 8.3 and 8.4)
B
Patients with cognitive complaints must be assessed by means of global cognition 
screen tests, neuropsychological test batteries, short cognitive instruments 
focused on specifi c aspects of cognition and/or standardised structured 
questionnaires to quantify the degree of cognitive impairment.
A
The dementia diagnosis must include a formal objective cognitive assessment 
with validated instruments.
A
The use of the Spanish standardised version of the MMSE or the MEC is 
recommended to screen dementia in individuals with cognitive complaints or 
advanced age in our medium.
B
Other short screening tests, such as the Pfeiffer test, the MIS, the 7-minute test, 
the clock test, the Eurotest or the T@M can also be recommended to screen 
dementia in individuals who are suspected of having cognitive impairment.
B
The neuropsychological examination using general brief-intermediate type 
evaluation tests is recommended when the aim is to make an evaluation of the 
most important neuropsychological areas in a reasonable time.
D
The performance of a detailed neuropsychological assessment via specifi c tests 
is recommendable when there are differences between the clinical impression 
and the screening tests, diagnostic doubts or else when the complaints are limited 
to just one cognitive domain or evolve over a short period of time.
C
The use of specifi c scales is recommendable to quantify the degree of global 
functional impairment in individuals who are suspected of having cognitive 
impairment.
✔
The choice of a specifi c instrument must be made depending on the time 
available, on the clinical experience and on the availability of regulatory data in 
the language and in the medium where they will be applied.
8.5. Which laboratory tests are essential in diagnosing 
dementia?
The main objective of laboratory tests is to rule out potentially reversible 
causes of dementia, comorbidities that may contribute to cognitive 
alterations and rule out other diagnosis such as delirium, for example. 
Potentially reversible causes are rare. In a SR that included 39 prospective 
and retrospective observational studies and a total of 7042 patients, only 
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There is no universal consensus about the appropriate test battery that must 
be carried out. However, the recommendations of the CPGs and consensus 
conferences are similar: Haemogram to rule out anaemia, TSH to rule out 
hypothyroidism, ionogram to rule out hyponatraemia or hypocalcaemia, 
glycaemia to rule out diabetes and serum levels of B
12
 to rule out defi cit. 
5,25,140,148,136Folate defi cit is rare and in the Canadian guideline they 
recommend determining levels only in cases of celiac disease or limited 
intake of cereals. 136Depending on the syndromes, it is advisable to request 
folate levels, hepatic and renal function, GSV, luetic serology or HIV 







For metabolic, infectious and toxic alterations that might be associated 
with dementia, there is no specifi c evidence based on controlled RCT that 
their treatment reverts the cognitive symptoms.5 Thyroid dysfunctions may 
cause cognitive and psychiatric symptoms and be confused with dementias, 
although the treatment of thyroid alterations does not always revert cognitive 
defi cits.149 There is no evidence that treatment with B
12
 or folate will improve 
cognitive functioning in patients with cognitive impairment with low levels 
of B
12
 or folate or high homocystein levels.149 Luetic serology is a problem 
due to the diffi culty in interpreting results. In the largest retrospective study 
with 672 patients referred due to dementia, 3% had positive serology for 
syphilis but only one patient had neurosyphilis. There are no prospective 
studies, and there was an improvement in cognitive symptoms in the cases 
treated. There are no quality studies that permit the recommendation of 







Biomarker analyses such as APOE genotype or tau and beta amyloid levels in CSF for AD, 
or 14-3-3 and specifi c neuronal enolase for CJD are not carried out on a routine basis, and the 
genetic study is only justifi ed in those cases where there is a family history of dementia with 
an autosomal, dominant inheritance pattern (question 7.1).
Summary of evidence
3/4
The CPGs5,25,140,148,136 recommend including: Haemogram, TSH, electrolytes, 
calcium and glucose as recommendable tests in general to rule out potentially 
reversible causes of dementia and to screen comorbidities, and determine folates, 
B
12
, luetic or HIV serology when it is suspected that these may have been altered 
due to the clinical context.
3/4
There is RCT-based evidence that the treatment of metabolic, infections and toxic 
alterations associated with some patients with dementia reverts the cognitive 
defi cits.5,149
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Recommendations
D
The performance of the following laboratory tests is recommended in all 
patients assessed for possible dementia: Haemogram, TSH, electrolytes, calcium 
and glucose, to rule out potentially reversible causes of dementia and to screen 
comorbidities.
D
The determination of folate levels can also be added, especially in patients with 
limited intake of cereals, and levels of B
12
, above all in older adults.
D
Serologies are also recommended for syphilis or HIV only in patients with 
clinical suspicion of these infections as a potential cause of dementia or as 
comorbidity.
D
The determination of homocystein as a risk factor associated with cognitive 
impairment or AD is not recommended.
8.6. Must the determination of apolipoprotein E (apoE)
be requested?
The apoE genotype is the only genotype that is clearly involved in late onset 
AD. The presence of the apoE allele ε4 is strongly associated with AD,150 
whilst the allele ε2 may have a protective effect.151
Case and 
control study,  
2++
The Singapore guidelines,140 of the EFNS5 and of the SEN,6 as well as SR 
of genetic association studies,149 do not recommend the determination of the 
apoE genotype at a diagnostic or predictive level in healthcare practice, as it 
is not sensitive or specifi c enough.
In a large series with neuropathological confi rmation, the sensitivity and 
specifi city of the presence of the apoE allele ε4 for the diagnosis of AD was 
65% and 68%. 153It is not a good tool, either, to distinguish the different 
types of dementia.
With respect to other susceptibility genes, no clear conclusion is reached, 
and more studies would be required to establish their role in AD and be able 
to have enough scientifi c evidence to make recommendations.
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Summary of evidence
2++
The presence of the apoE allele ε4 is consistently associated with AD in case 




The determination of the APOE genotype is not recommended in healthcare 
practice to diagnose AD.
8.7 What are the advantages of analysing cerebrospinal 
fl uid (CSF) in the diagnosis of dementia?
Tau and amyloid
Numerous studies have consistently found an increase in total tau (T-tau) and 
of phosphorylated tau (P-tau) and a reduction of amyloid Aβ-42 in the CSF of 
patients with AD respect to controls.149 These markers have high sensitivity 
and specifi city (> 80%) to differentiate AD from controls, depression and 
alcohol dementia, but they are not very specifi c to differentiate AD from 
other dementias.154,25,5
Case and 
control study,  
2++/2+
Combining Aβ-42 and T-tau helps increase the specifi city to distinguish AD 
from FTLD (85%), DLB (67%) or VD (48%). 5P-tau has greater specifi city 
to differentiate AD from other dementias and other neurological disorders. 
The sensitivity and specifi city values are highly variable between studies 
and depending on the technique.149
There is usually an increase of T-tau and P-tau in FTLD as well, and a 
decrease of Aβ-42, of less magnitude than in AD. In DLB and in VD there 
may be an increase of T-tau and P-tau in some patients and a reduction 
of Aβ-42 in the majority of the cases, which is probably due to the usual 
presence of concomitant AD pathology in these diseases.
Case and 
control study,  
2++/2+
In other neurological diseases, such as cerebrovascular disease without 
dementia, amyotrophic lateral sclerosis, PD without dementia, PSP, DCB, 
depression and alcohol dementia, the T-tau levels are normal or slightly 
high.149
Case and 
control study,  
2++/2+
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With respect to CJD, the tau levels are much higher than in AD and there is 
a considerable increase of the T-tau/P-tau ratio in CSF, which discriminates 
CJD from AD and other dementias with almost 100% reliability.149
Some studies on patients with MCI have shown sensitivity to predict 
progression to AD of 80% for T-tau, 71% for Aβ-42, 79% for P-tau and 
78% for the combination of T-tau and Aβ-42.155,149
Other biomarkers in CSF
Another possible biomarker in CSF are the heavy and light neurofi laments, 
which are augmented in AD, FTLD and VD, but their clinical utility is not 
established.156 Protein 14-3-3 is associated with a rapid neuronal loss and is 




The determination of 14-3-3 has 90-100% sensitivity and 84-96% specifi city 
in the diagnosis of CJD, with false positives in cerebral infarction, 
encephalitis, tumours and rapidly progressive AD. If the suspicion of CJD 








All of these case and control, or cohort studies, come from specialised centres and it is 
diffi cult to extrapolate the results. Furthermore, the reliability and standardisation of the tests 
is still not clear, and the absolute values and cut-off points to discriminate between normal 
and pathological values vary a great deal between studies and between laboratories. Other 
important limitations are that the execution of a lumbar puncture is troublesome and would 
not be widely accepted as a routine test among patients with dementia.25
The CSF analysis is obviously indicated whenever dementia secondary to an infection or 




The increase of T-tau and P-tau and the reduction of Aβ-42 in CSF have 
consistently shown high sensitivity and specifi city to distinguish AD from 




Some studies on patients with MCI have shown sensitivity to predict progression 
to AD of 80% for T-tau, 71% for Aβ-42, 79% for P-tau and 78% for the 
combination of T-tau and Aβ-42.155,149
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2++/
2+
An increase in the T-tau/P-tau ration in CSF is highly reliable to distinguish CJD 
from AD and other dementias.149
2++/
2+
The determination of protein 14-3-3 in CSF is highly sensitive to detect CJD, but 
there is around 10% false positives.5
Recommendations
B
The determination of T-tau, Aβ-42 and P-tau in CSF can be used as an additional 
test in cases of doubtful differential diagnosis between AD and other dementias. 
Its routine use is not recommended to diagnose dementia.
B
The determination of T-tau, Aβ42 and P-tau in CSF can be used as an additional 
test in cases of mild cognitive impairment when the clinical, neuropsychological 
and evolving features lead to AD being suspected as an aetiology of such 
impairment.
A The 14-3-3 protein test in CSF is recommended when CJD is suspected.
✔ The CSF analysis must always be performed whenever dementia secondary to 
an infection or encephalitic process is suspected.
8.8. Which is the structural neuroimaging technique 
of choice in the diagnostic process of dementia and its 
different types?
The study of structural neuroimaging has two aims: to rule out secondary 
causes of dementia (tumours, chronic hydrocephalia in adults, subdural 
haematoma) and136 to provide useful information for the differential 
diagnosis of dementias, showing, for example, hippocampus atrophy in AD 
and vascular lesions in VD. 149Neuroimaging is more useful in the initial 








The choice of one or the other depends on the clinical suspicion: Magnetic 
resonance (MRI) is, more sensitive to detect subcortical location vascular 




Studies with volumetric MRI have also helped detect volume loss patterns 
in AD and other degenerative dementias, but its applicability in clinical 
practice has still not been established.6 The coronal cuts in the MRI enable 
us to visualise and quantify the volume of medial temporal lobe, a reduction 
of which supports the diagnosis of AD.158
The SEN guideline6,70 and the EFNS5 recommend performing at least one 
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Summary of evidence
2+/4
Structural neuroimaging (CT or MRI) permit the diagnosis of some secondary 
causes of dementia and help towards the differential diagnosis between the 
dementia subtypes.136,149
2+/4




Structural neuroimaging (CT and MRI) is recommended as a supplementary 
tool in the initial diagnosis of dementia, above all to identify lesions that can be 
treated by surgery and vascular diseases.
 The MRI is recommended to detect vascular changes with greater sensitivity 
than the CT.
B
The execution of an MRI with diffusion sequences is recommended if CJD is 
suspected.
8.9. Which is the functional neuroimaging technique 
of choice in the diagnostic process of dementia and its 
different types?
Perfusion SPECT with 99mTc-HMPAO or 133Xe and PET with 18F-FDG are useful to measure 
cerebral blood fl ow or glucose metabolism, respectively. They are used in specialised centres 
as a complement to structural imaging to increase specifi city in cases of diffi cult different 
diagnosis.5
In AD, the observation of a pattern of hypoperfusion or tempoparietal hypo-
metabolism is typical. SPECT has 71% sensitivity and 90% specifi city 
to distinguish AD from controls and 76% specifi city for other dementias 
such as VD or FTLD. The diagnostic value of the PET is greater. These 
techniques provide greater specifi city to the clinical criteria to distinguish 
AD from other dementias, but they do not provide advantages when the 





The PET with amyloid markers shows an augmented capture in AD, variable in DLB and 
absent in FTLD; in MCI it can be augmented or normal. 159Its role in clinical practice still has 
to be determined, as well as that of other tau markers.
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The most useful technique for the differential diagnosis between AD 
and DLB is the 123I-FP-CIT SPECT, which uses a dopamine transporter 
as a marker (DAT). The striatum dopaminergic loss in DLB is similar to 
that of PD with or without dementia. According to a stage II study, an 
abnormal result has 77.7% sensitivity to detect clinically probable DLB; 
with 90.4% specifi city to rule out dementia of another cause, mainly AD. 
Hypocapture was also found in 38.2% of the patients with possible DLB; 
13.3% of possible AD and 6.9% of probable AD. 160False positives have 
been described (pathological SPECT) in 5% of major controls and false 
negatives (normal SPECT) in patients with typical DLB. The reliability of 
SPECT with dopamine transporter has been confi rmed with autopsy data. 
DAT capture reduction was incorporated into the reviewed criteria of DLB 




Other neuroimaging examinations can help diagnose DLB but with less 
sensitivity and specifi city: The presence of occipital hypoperfusion or 
hypometabolism has sensitivity and specifi city of 60-65%, so its utility 
is limited in individual cases; the PET with 11C-DTBZ (presynaptic 
striatum monoaminergic marker) and the cardiac SPECT with 123I-MIBG 
(sympathetic denervation) help discriminate DLB from AD, but they have 
not been applied yet in large-scale large multi-centre tests;160 the union of123 
I-IBZM with the striatal D2 dopaminergic receivers may be reduced in 




Frontal and/or temporal hypoperfusion is typical in FTLD, in SPECT or 







The sensitivity of the presence of temporoparietal hypoperfusion/hypometabolism 
in SPECT/PET is around 71% to detect AD and 90% specifi city to distinguish 
AD from controls and 76% to distinguish AD from VD and FTLD.25,5
2+
The presence of occipital hypoperfusion/hypometabolism in SPECT/PET only 
has 60-65% sensitivity and specifi city, to diagnose DLB.159
2+
The presence of frontal and/or temporal hypoperfusion/hypometabolism in 
SPECT or PET, has 80% sensitivity and 65% specifi city to distinguish FTLD 
from AD.159
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2+
The role of the PET with amyloid markers has been well-proven but its technical 
peculiarities mean that its application in routine clinical practice has still not 
been well studied.160
2++
The SPECT with dopamine transporter has 77.7% sensitivity to detect clinically 




SPECT and PET can be used as a complement to structural neuroimaging to 
support the diagnosis or to help differentiate between different types of dementia 
when the diagnosis is uncertain. Its routine use or its use as a sole diagnosis tool 
is not recommended.
B
The 123I-FP-CIT SPECT is recommended to support the diagnosis of DLB (as a 
suggestive diagnostic feature) and for the differential diagnosis between DLB/
PDD and AD.
8.10. What are the advantages of EEG/mapping in the 
diagnosis of dementia?
The electroencephalogram (EEG) and its quantitative analysis (mapping) 
are able to detect changes in the majority of patients with AD or DLB; but 
these are unspecifi c. On the other hand, a normal EEG may be perfectly 
compatible with some types of dementia (for example, FTLD). Therefore, 
neither the presence nor the absence of changes in the EEG permit diagnosing 
a dementia.5,25
The EEG is only useful when the dementia is suspected to be due to a CJD 
and it may be helpful to exclude other processes such as delirium, complex 
partial epileptic crises or state of non-convulsive status epilepticus, which 
can rarely simulate a dementia. Beyond these situations, the EEG has not 




The periodic sharp wave complexes are part of the clinical criteria to 
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Summary of evidence
2+
The EEG can show unspecifi c changes in patients with AD or DLB. It is not 
useful to diagnose dementia. 5,25It is useful to distinguish it from delirium or 
epilepsy.5,129.
2++
The presence of periodic sharp waves in the EEG has 44% sensitivity and 92% 
specifi city to diagnose CJD. 157
Recommendations
B
The execution of an EEG is recommended if the presence of delirium, complex 
partial epileptic crises or non-convulsive status epilepticus is suspected.
A The use of EEG to diagnose CJD is recommended.
8.11. What are the indications for performinga cerebral 
biopsy in the aetiological diagnosis of dementia?
Cerebral biopsies can provide a specifi c histological diagnosis when the 
presence of a potentially treatable origin is considered, such as certain 
metabolic, infectious or infl ammatory causes. As it is an aggressive 
technique with a high risk, its execution is only considered when a treatable 




During one retrospective study, the execution of a biopsy on selected patients 
provided the diagnosis in 57% of the cases. A potentially reversible aetiology 
(chronic meningoencephalitis, vasculitis, Behçet, neurosarcoidosis, 
granulomatose encephalopathy, Whipple), was detected in only 10%. 
Complications were recorded such as haemorrhages or comitial crises in 





In general, it is advisable to approach the frontal lobe or the temporal pole 
of the non-dominant hemisphere and extract a suffi ciently large sample 
(including leptomeninges and cerebral white matter) to increase the 
diagnostic effi cacy. It must be performed in very specialised centres.25
In situations where prion disease is suspected, special care must be taken, 
using disposable material or keeping the instruments in quarantine until the 
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Biopsies of other tissues can be useful in certain conditions, for example, to 
analyse tonsillar tissue in the CJD variant or a skin biopsy in the CADASIL.
Summary of evidence
3/4
Cerebral biopsies have a high risk of complications and their use is limited to 
the suspicion of treatable diseases that cannot be diagnosed in any other way, 
such as chronic meningoencephalitis, vasculitis, Behçet, neurosarcoidosis, 
granulomatose encephalopathy or Whipple.162
Recommendations
D
The execution of a cerebral biopsy for diagnostic purposes must only be 
considered in highly selected patients when a reversible cause is suspected that 
cannot be diagnosed in any other way.
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9. Different healthcare level actions
Questions to be answered
9.1.  What are the healthcare levels and how are they classifi ed?
9.2.  What role does primary care play in the all-round care of dementia? 
9.2.1.  Must dementia screening be carried out in the general population?
9.2.2.  What are the criteria for referring to Specialist Dementia Care Team (SDCT)?
9.2.3.  What monitoring must be carried out by primary care on patients with demen-
tia?
9.3.  Which specialised Dementia care teams are required to address dementia (SDCT) and 
what role do they play?
9.4.  What is the role of the social-health network in a comprehensive approach to demen-
tia? 
9.5.  What role do the mental health services play in the care of dementia? 
9.6. Which social services are involved and what role do they play in the care of people 
with dementia?
9.7.  How must the care continuity between the different dementia healthcare levels be 
coordinated and guaranteed?
9.1. What are the healthcare levels and how are they 
classifi ed?
Healthcare levels are understood as the different health care modalities that are offered to the 
population, ensuring optimal care in each specifi c situation, guaranteeing holistic and multidisci-
plinary care. The coordination and consensus between the different levels provide optimal health-
care quality and avoid competence-related problems.
The National Health System (Spanish Acronym, SNHS) is comprised of a series of Health 
Services pertaining the State Administration and Health Services pertaining to the Autonomous 
Communities (A.C) under the terms established in the General Law on Health. 163It recog-
nise two basic healthcare levels, primary care team (PCT) and specialised dementia care team 
(SDCT) Social Health Care (SHC) must also be mentioned, whose creation dates back to 1986, 
in Catalonia,164 as it was the fi rst autonomous community to plan and develop this healthcare 
modality. From the conceptual viewpoint, the SHC is included within specialised dementia care 
team (SDCT) although it has suffi cient entity and specifi c characteristics for it to be considered as 
a third healthcare level. The SHC has already been developed in the entire national territory165 
with different degrees of implementation and with the specifi cities typical of each autonomous 
community.166,167,168,169,170,171,172,173,174,175,176,177,178,179,180
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1. Primary Care Team (PCT)
PC is the fi rst health care level that citizens access, as individuals and members of the community. 
This is essential health care based on methods and practical technologies, that are scientifi cally 
based and socially acceptable, placed within the reach of all individuals and families of the com-
munity. PC forms an integral part of both the National Health System, where it plays a central role 
and of which it is the main core, and of the overall social and economic development of the com-
munity. This defi nition includes a series of health-related actions, such as prevention, diagnosis, 
treatment or rehabilitation, which must be carried out from a primary and local level in benefi t of 
the community and at an acceptable cost, to be able to respond to the people’s needs during each 
one of the stages of the disease.181
PC must guarantee the comprehensiveness and continuity of the care throughout the entire 
lives of the users, acting as a manager, coordinator of cases and regulator of fl ows.182
PC must be able to solve the majority of the health problems of people in the community, 
both related to diagnosis, treatment or adaptation of resources.
2. Specialised Dementia Care Team (SDCT)
SC is the second access level of citizens to healthcare. SC offers the population technical and 
human resources for diagnosis, treatment and rehabilitation that, due to their specialisation or 
nature, cannot be solved at PC level.183
Hospitals and their relative speciality centres comprise the health structure responsible for 
programmed and urgent SC, both in hospital and outpatients as well as at home, also developing 
health promotion functions, disease prevention, treatment and rehabilitation as well as teaching 
and research, in coordination with the PC level.
SC will guarantee the continuity of the comprehensive care for patients until they can con-
tinue to be cared for in PC.184
3. Social Health Care (SHC)
SHC follows a multi-disciplinary and comprehensive care model that guarantees care for the 
elderly, chronic dependent patients and people at end-of-life stage. SHC is mainly aimed at de-
pendent, non self-suffi cient people who require help, surveillance or special care,185 as is the case 
of dementia.
The principles that this model is based upon are healthcare continuity, evaluation and com-
prehensive treatment, bearing in mind the biopsychosocial aspects, multidisciplinary interven-
tion, attention to the family and caregiver, as well as coordination between healthcare levels. 
Both institutional and non-institutional resource connection and optimisation operating systems 
are established186
SHC is provided in different fi elds187 and in those territories where this care is deployed, it is 
possible to fi nd: In out-patients: a) specialised comprehensive evaluation teams for the diagnosis, 
treatment and monitoring of patients with cognitive disorders and dementia, fragile and geriatric 
patients; b) home palliative care (PC) teams; c) day hospitals (DH). In internment regime, we 
can fi nd: a) long-stay units that offer medical care and nursing care, which cannot be provided at 
home or at other healthcare levels, due to their complexity and the characteristics of the patient; 
b) medium-stay units whose main purpose is for rehabilitation, and PC units.
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In short, the healthcare levels are different coordinated health care modalities that provide 
multidisciplinary and comprehensive care that adapts to the needs of people with health prob-
lems. The National Health System (SNHS) recognises two basic healthcare levels: primary care 
(PC) and specialised care (SC). There is also a third social health care (SHC) level, with unequal 
implementation in the different autonomous communities, which covers the home, hospital and 
outpatients care resources that permit offering continued and comprehensive care until the end-
of-life stage.
Primary Care (PC): This is the fi rst health care level that citizens have access to and where a 
team of professionals carry out disease prevention, detection and diagnosis work, followed by 
treatment, monitoring, management of resources and accompaniment until end of life.181 
Specialised Care (SC): This is the second healthcare level and it offers specifi c and specialised 
care in the diagnosis, treatment and rehabilitation of health problems, which, due to their charac-
teristics or technology needs, cannot be solved at PC level.183 
Social-Health Care (SHC): Third level, based on a multidisciplinary and comprehensive care 
model that guarantees care for the elderly, chronic dependent patients and people at end-of-life 
stage.185
9.2. What role does primary care play in the all-round care 
of dementia?
The role of the PCT and SDCT is essential throughout the entire dementia process. Due to their 
proximity and contact with patients and families, they have the opportunity to detect cases of cog-
nitive impairment at early stages. However, dementia is still under-diagnosed, with fi gures that 
vary between 25 and 80%,188, 189,190,25 especially when dementia is in its mild-moderate stage. This 
is due to the diagnostic diffi culty often derived from a defi ciency in specifi c training in dementia 
and the reduced time to carry out the diagnosis.189
Early diagnosis reduces anxiety in patients and relatives and helps cope better with situa-
tions and problems that, in more advanced stages, will be more diffi cult to solve (decisions about 
guardianship, about assets, advance directive document, etc.).
The PCT must suspect the existence of cognitive impairment in the following situations: 
memory complaints corroborated by a reliable informant; observation of cognitive or behavioural 
changes; disorientation in time and space; persistent changes in mood, behaviour or personality; 
appearance of diffi culties to carry out the advanced and instrumental activities of daily living, 
etc.191,192,193,25 
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Summary of evidence
4
Alert signals for the suspicion of MCI or dementia are the appearance of 
memory complaints or other cognitive defi cits; non-justifi ed and persistent 
changes in mood, behaviour or personality; or diffi culties to carry out advanced 
or instrumental activities of daily living. 191,192,193,25 It is essential for these signals 
to be corroborated by a reliable informant.
4
If good, fl uent and two-directional communication is maintained between the 
PCT and their specialised care references, coordination between levels and 
healthcare continuity is guaranteed.
Recommendations
D
The PCT professionals must suspect the existence of cognitive impairment 
and/or dementia if they observe memory complaints, behavioural changes and 
diffi culties to carry out advanced and instrumental ADL, carrying out screening 
tests and starting complementary examinations to be able to formulate a diagnosis 
and refer to the SDCT depending on the results.
9.2.1. Must dementia screening be carried out in the general 
population?
The aim of the screening strategies is to detect diseases in their initial stages, treat them early on 
and establish control and monitoring that will help improve the health results. The screening has 
a population approach. A screening strategy of a certain pathology is justifi ed if a series of condi-
tions are satisfi ed.194
1. It is a frequent and relevant health problem.
2. With suffi ciently long clinical period to be able to be detected.
3. Availability of a sensitive, specifi c screen test at a reasonable price and with no side effects.
4. Have effective, safe and effi cient treatment.
The fi rst three conditions are satisfi ed in MCI and dementia: (1) high prevalence and major prob-
lem which, when it progresses, generates an important social and family burden; (2) prolonged 
clinical course; and (3) there are different screening tests with acceptable sensitivity and specifi c-
ity, that are relatively economical, easy to apply and require little time and non-specifi c staff, but 
the fourth condition is not satisfi ed.
The cognitive assessment tests used have a low positive predictive value and the disadvantage of 
not being able to many patients due to the limitations of these tests, which may be infl uenced by 
the patient’s age, sex, culture and education. The MMSE and the MEC are the most commonly 
used tests in PCT, and the score must be adapted according to age and study level194 (questions 
8.3 and 8.4).
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The result of a positive screening test does not necessarily entail the 
diagnosis of dementia. If cognitive or functional impairment is detected, the 
assessment must be extended with a detailed case history, which must also 




We do not have biochemical, genetic markers of neuroimaging tests 







Nowadays, and if the dementia does not satisfy all the requirements that would 
justify a population screen, this must not be carried out on people over the age 
of 65, as there are not treatments that effectively modify the evolution and 
prognosis of the more frequent dementias.194,199,25,139
Recommendations
C
There is not enough scientifi c evidence to permit the recommendation of 
population-based dementia screening in people over the age of 65.
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9.2.2. What are the criteria for referring to Specialist Dementia Care 
(SDC)?
The PCT must carry out the dementia orientation/diagnosis. The dementia subtype and its 
aetiology can be suspected in PCT but it will be confi rmed in SDCT.25,200,201 The criteria for 
referral to the SDCT are:
Early onset, familial of genetically determined dementias:
• Over the age of 65, with cognitive impairment in MCI degree or de-
mentia.200,202,203 
• Suspicion of familial dementia.203









Diffi culty to diagnose cognitive impairment, or defi ne its degree:
• When there is a reasonable diagnostic doubt in a person who has cog-
nitive impairment or dementia.200,203
• For assessment and early detection of degenerative dementias in peo-
ple with MCI, when secondary causes have been ruled out.25
When severe secondary dementia is suspected:
• Cognitive and/or behavioural impairment in a person with recent past 
history of traumatic brain injury, neoplasia, treatment with oral anti-
coagulants or haemostasia disorder, when it is not possible to quickly 
rule out a pathology that requires rapid intervention with a neuroimag-
ing test. 202
• Fast evolving cognitive impairment associated with focal neurological 







Suspicion of neurodegenerative disease:
• Which is accompanied by cognitive impairment and a diagnostic con-
fi rmation is required.200,202,203
• When the PCT requires the opinion of expert professionals; or addi-
tional examinations, services or treatments that are not available or not 
accessible through PCT.25,200,203
• Prescription of specifi c pharmacological for dementia.
• Participation in clinical trials with new experimental drugs. 
• When a neuropsychological assessment is required that will help quan-
tify and typify cognitive impairment, cognitive intervention, assess-
ment of the premorbid intellectual level, assessment of behavioural 
symptomatology (above all from 50 years up and if there is depression 
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Diffi cult to manage complications in dementia:
• Appearance of uncommon behavioural, cognitive and physical symp-
toms that appear in the evolving course of a person diagnosed with 
dementia.200 
• Presence of severe BPSD, which do not respond adequately or as ex-
pected to the treatment.25,200
• For clinical monitoring of a dementia that is therapeutically diffi cult 







The following should not be referred to SDCT:
• People with MCI or reversible secondary dementias with medical 
treatment or psychiatric approach, who can be diagnosed and treated 
by the PCT. Pluripathological patients with bad basic functional sta-
tus, where the benefi t that can be provided by the SDCT does not ex-










The approach of early onset, familial, genetically determined dementia (early 
AD, HD, FTLD) must be carried out in SDCT.200,202,203
3/4
When there are doubts in the diagnosis of MCI or dementia, patients must 
be referred to the SDCT for a specifi c and multidisciplinary approach for 
neuropsychological assessments or specifi c additional and neuroimaging 
examinations to be carried out that can confi rm the diagnosis 200,203,25
2+/3
Secondary dementias that require urgent action via fast additional examinations 
and specialised therapeutic decisions must be referred for assessment to 
SDCT.202,200
4
The diagnostic confi rmation of a neurodegenerative cause dementia (AD, DLB, 
FTLD) requires specialised, multidisciplinary assessment, which will include 
additional examinations and specifi c treatment, indicated and prescribed by 
specialists in dementia or the participation in clinical trials.200,202,203,25
3/4
People with already known dementia who present unusual, diffi cult to control 
behavioural, cognitive and physical symptoms are referred to SDCT;200,25,200 or 
for clinical monitoring of cases that are therapeutically diffi cult to manage and/
or when a new diagnosis confi rmation is required.202,201
3/4
It is not useful to refer people to SDCT who have MCI or secondary dementias 
that are reversible with medical treatment or psychiatric approach, who can be 
diagnosed and treated by the PCT. It is not useful either to refer patients to 
SDCT who have a lot of pathology, a bad functional base status, in whom the 
disadvantages of the referral exceed the possible benefi ts.
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Recommendations
C
The PCT is advised to refer people to the SDCT who have: a) early, family 
or genetic onset dementia, b) doubts in the diagnosis of cognitive impairment, 
c) potentially severe secondary dementia, d) suspicion of neurodegenerative 
disease, e) unpredictable or diffi cult to manage complications in the course of 
already diagnosed dementia.
D
The referral of patients with MCI or secondary dementia that can be solved by 
the PCT, or pluripathological patients with bad functional basic status, is not 
recommended.
9.2.3. What monitoring must be carried out by primary care on 
patients with dementia?
The PCT must assume responsibility for the care and monitoring of the 
majority of people with dementia and for the management of the resources 
they require, continuously adapting to the changes in the disease as it 
evolves, the complexity of its treatment and the concomitant processes that 




Coordination between the different levels, PCT, SDCT, SHC is required, and 
also with the AFAs. This coordination of the different social-health, social 
and community levels ensures healthcare continuity and integration into 
society. Given the chronic nature of dementia and its high level of healthcare 




Effective monitoring of dementia must consider actions that address the 
person affected and the care-giving family, carrying out a comprehensive 
approach that contemplates prevention measures of the vascular risk factors 
and progression of the dementia risk prevention, basic neurological and 
systemic assessment, assessment of the cognitive, behavioural, affective and 
functional functions, as well as the execution of any additional examinations 
required.202,196 Changes in the evolution of the dementia, complications and 
the possible existence of abuse towards the patient must also be detected. 
The work load and the needs of the family must be assessed, as well as the 




A control must be carried out to ensure that the benefi t, tolerability 
and adverse effects of the treatments used in dementia are specifi c or 
symptomatic, as well as a follow-up of other concomitant pathologies. The 
most representative symptoms will be specifi ed, as well as the actions and 
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The comprehensive care of dementia entails respect for dignity and defence 





If unexpected changes, alarm signals or behavioural crises occur, or other 
manifestations appear, fast attention must be provided in agreement with the 
requirements, guidelines and circuits established. Under normal conditions, 
if the process remains relatively stable or worsens in agreement with the 





The PCT must offer a care plan and support to the caregiver of the person 
affected by dementia, contemplating information and training aspects, 
accessibility and support to provide the patient with care and attention. PCT 
must manage the indication and access to health resources, such as home 
care programmes, day hospital (DH) and/or social programmes, such as the 






The PCT must assume responsibility for the care and monitoring of the majority 
of people with dementia and for the management of the resources they require 
(Appendix 1.14).193,196
4
Coordination and communication between PCT, SDCT, SHC and AFA guarantees 
healthcare continuity throughout the entire process.129,193,204,196
2++
Actions aimed at the person affected and the caregiving family must be carried 
out; via a comprehensive approach, pharmacological and non-pharmacological 
treatment, psychological and social support, detecting changes, alarm signals, 
complications, concomitant diseases, analysis of the suspicion of abuse, 
evaluation of the burden of caregivers, of their needs, and their physical, 
psychological and mental state of health.25,205,202,196
3
If unexpected changes, alarm signals or behavioural crises occur, or other 
manifestations, fast attention must be provided in agreement with the guidelines 
and circuits established. If the process remains relatively stable or predictable, 
the normal controls will be carried out.129,193
4
The PCT must provide caregivers with information, offering them support in 
their care work and managing the appropriate health and social resources.193
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Recommendations
D
The PCT must assume responsibility for the management, care and monitoring 
of people with dementia and of their caregivers.
D
People with predictable evolution must be periodically controlled by the PCT. 
If there is unexpected worsening, alarm signals, behavioural crises, etc. they 
must be quickly attended by PCT, and they are diffi cult to control, they must be 
referred to the SDCT.
D
Coordination and communication between PCT, SDCT, SHC and AFA must be 
established to guarantee healthcare continuity throughout the entire process.
9.3. Which specialised care teams are required to address 
dementia (SDCT) and what role do they play?
The SDCT are multidisciplinary teams of reference who carry out a comprehensive and special-
ised evaluation of AD and other dementias.
Each team must be made up of an expert physician in the management of dementia (neu-
rologist, geriatrician or psychiatrist), a psychologist/neuropsychologist, a nursing professional, a 
social worker and administrative staff. The SDCT can be located inside or outside the hospital 
and must have access to all the necessary technical means to make a diagnostic assessment of 
syndrome, familial and social dementia. They provide healthcare, teaching, research and manage-
ment functions.6,207
After carrying out the individual assessment, establishing the diagnosis and treatment strat-
egy to follow, the person affected and the family must be informed about the diagnostic guide-
line, therapeutic possibilities, probable evolution, monitoring and social-health and community 
resources available (questions 10.1.1 and 10.1.2). All of this information will be summed up and 
compiled in a healthcare report addressed to the patient and/or family and to the referring practi-
tioner from the PCT.
Summary of evidence
4
The SDCT is a multidisciplinary team of reference for a specifi c territorial area, 
which carries out a comprehensive and specialised approach for people affected 
by dementia.
4
The SDCT must be comprised of: an expert physician in the management 
of dementias (neurologist, geriatrician or psychiatrist), a psychologist/
neuropsychologist, a nurse, a social worker and administrative staff. This SDCT 
must have access to technical means to be able to confi rm the diagnostic guideline 
and with healthcare, teaching, research and management objectives.6,207
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4
The patient and his/her family must be informed about the diagnosis and strategy 
to be followed (questions 10.1.1 and 10.1.2).
4
The patient and/or family must be given a written report listing all the 
examinations carried out, the diagnosis and treatment, and monitoring plan. This 
information must be given to the referring practitioner so that they can carry out 
the most appropriate control. Shared control between the PCT and the SDCT 
will be carried out in complicated patients.
Recommendations
D
It is recommendable for the multidisciplinary team of the SDCT to include an 
expert specialist physician in dementia (neurologist, geriatrician or psychiatrist), 
a psychologist/neuropsychologist, a nursing professional, a social worker and 
administrative staff. The SDCT must have access to diagnosis means to be able 
to design treatment, monitor strategies and satisfy their healthcare, teaching, 
research and management objectives.
D
Patients and/or their families must be informed about the diagnosis, the prognosis 
and the strategy to be followed.
D
Patients and/or their families must receive a written report listing all the 
examinations carried out, the diagnostic guideline and treatment, and monitoring 
plan. This information must be given to the PCT and/or to the referring 
practitioner.
9.4. What is the role of the social-health network in a 
comprehensive approach to dementia?
Dementia is a progressive impairment of all the functions, with different characteristics and needs 
depending on the stages of evolution of the disease, which include progressive dependence for 
ADL, behavioural alterations, added comorbidity and strain in the caregiver. To respond to these 
needs and guarantee healthcare continuity, a healthcare network with well-developed and planned 
expert professionals is essential, to provide a comprehensive, multidisciplinary and coordinated 
approach to dementia.208,192,209
Some autonomous communities have a social-health network that has different types of re-
sources to care for people with dementia.
Dementia diagnosis and treatment units (question 9.3). They may or may not be framed within 
the SHC, but they are characterised by a work methodology based on comprehensive evaluation, 
the existence of a specialised multidisciplinary team, the integration of health care and social care, 
coordination with the different healthcare resources and healthcare continuity.
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Outpatient Services of Centres: They attend to in people with cognitive impairment without 
having to admit them. Access and registration in this type of resource must be agreed upon in 
each territory:185,186
• Day Hospital (DH): Its objectives are to apply non-pharmacological therapeutic meas-
ures, maintain autonomy and functional capacity with respect to the activities of daily 
living, physical rehabilitation, prevention and treatment of added comorbidity, health 
education, information, training and s to patients and to their relatives, as well a to reduce 
the caregiver’s burden. Patients attended in DH are people with MCI or mild or moderate 
degree of dementia. 167There is a multidisciplinary team at these DH that is usually com-
prised of an expert physician, psychologist/neuropsychologist, occupational therapist, 
physiotherapist, nursing staff, etc.
• Day Centres (DC): The aim of this type of resource, which often depends on the social 
area, is to maintain the ADL, behaviour control, cognition, physical functionality and at-
tention to other social aspects of dementia patients, as well as to decrease the burden of 
usual caregivers. It is the most adequate resource for advanced stages of the disease. They 
must have expert professionals in non-pharmacological, cognitive intervention treatments 
and other therapeutic type activities, adapted to the more advanced stages of dementia.
• Night care centres (NCC): These are not very common in Spain. This is a resource 
whose aim is to control and treat sleep disorders and remove the burden from the car-
egiver during this time period.
Internment care services:
• Medium-stay psychogeriatric units
Limited duration internment, whose main aim is to treat BPSD that are diffi cult to control 
out of hospital and which cause stress and strain on the caregiver. They are also used to 
adapt the pharmacological treatment, which cannot be done outside the hospital, to solve 
serious family crises, rest or convalescence of the caregiver. The care team i multidisci-
plinary, with expert professionals in the comprehensive approach to dementias. This type 
of unit is a resource that exists in the Autonomous Community of Catalonia.181,184,182,183
• Long-stay psychogeriatric units
They offer care to patients with dementia with different levels of dependence and degrees 
of clinical complexity, who require continuous health care and which cannot be provided 
at the home or at other healthcare levels.184 
Other resources:
There are other types of resources to care for people with dementia, the ones that merit special 
attention being residential centres, which are normally centres managed by the social services.
There are other resources available, which the health professionals must be aware of; these 
are telecare, home support teams of the social services, etc.185
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Summary of evidence
4
Dementia generates a series of needs that require a social health resources 
network with expert professionals who can respond to these needs, and 
guarantee healthcare continuity, ensuring a comprehensive, multidisciplinary 
and coordinated approach of each case.208,192,209
4
The social health resources in those territories that have this type of care can 
include: dementia diagnosis and treatment units (question 9.3); outpatient 
services: Day Hospital (DH); Night care centres (NCC); internment services: 
Medium-stay psychogeriatric units; Long-stay psychogeriatric units. Other 
resources: Telecare, home support social teams.185,181,184,182,183
Recommendations
D
The existence of specifi c resources is recommendable to care for people with 
dementia, and the SHC network must have specifi c resources that adapt to each 
stage of the disease.
✔ To optimise the comprehensive treatment of dementia, it is recommendable for 
there to be referral, admission and discharge criteria for each healthcare resource.
D
Treatment in specifi c day hospitals for dementia is recommended in mild and 
moderate phases of dementia.
9.5. What role do the mental health services play in the 
care of dementia?
There are no documents that provide scientifi c evidence to defi ne the role of the mental health 
services in the care of dementia.
The Mental Health Strategy of the SNHS (2007),210 published by the Ministry of Health and 
Consumer Affairs, indicates that the development of specifi c care systems for mental disorders 
in elderly people present a diversity that is linked to the territorial organisation of the State, and 
underlines as a critical point, the scarcity of specifi c multidisciplinary programmes to provide 
mental health care for elderly people, and includes dementia among these mental disorders
Today, the majority of autonomous communities have incorporated healthcare objectives 
into their mental health or gerontological health plans, aimed at elderly people with mental health 
problems in general and with dementia in particular.
The Spanish Consensus on Dementia, whose second edition was published in 2005,167 dedi-
cates a chapter to the management of patients with dementia, including several considerations 
about care for people with dementia made by the different mental health systems.
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Mental health care evolves around a central axis: The multidisciplinary and comprehen-
sive evaluation mental health teams that have a clear community vocation. These are teams that 
are closely related to PCT, from whom they receive demands to evaluate cases where cognitive 
impairment is suspected, above all when these are accompanied by psychological and/or behav-
ioural disorders (depression, psychotic symptoms, premorbid personality changes) or atypical 
disorders (in the case of young people who start with psychological and/or behavioural disorders 
prior to the manifestation of cognitive impairment), and in the assessment and differential diag-
nosis with psychiatric diseases.
The SDCT should have the systematic collaboration of psychiatry professionals. These play 
an outstanding role in the evaluation of behavioural and psychological manifestations of demen-
tia, as well as in the pharmacological treatment of the associated pathopsychology and in drawing 
up, together with the rest of the team, the non-pharmacological intervention plan. Community and 
comprehensive guidance is very important to evaluate the caregiver’s situation of strain and to 
plan interventions aimed at treating and preventing it.
Another area of care is hospitalisation in psychiatric units of general hospitals. The main 
admission criteria in these units are defi ned as: Risk of suicide, severe disruptive behaviour that 
cannot be controlled in community environments, the appearance of an acute/sub-acute cognitive 
impairment with no apparent cause and the need to carry out additional and complicated examina-
tions, The aim of the admission is to stabilise the acute symptoms and control the psychological 
and behavioural symptoms.192
The length of the stay, which may be necessary due to different circumstances, justifi es the 
existence of convalescence or medium-stay units, whose aim is to provide care in a hospitalisa-
tion regime for people who are suffering from crisis situations such as those described above, but 




There are no documents that provide scientifi c evidence to defi ne the role of the 
mental health services in the care of dementia.
4
The Mental Health Strategy of the SNS (2007) indicates that there are limited 
specifi c multidisciplinary programmes to provide mental health care for people 
with dementia.210
4
The majority of autonomous communities have published mental health plans 
that have healthcare objectives aimed at people with dementia.
4
The mental health teams carry out a comprehensive and multidisciplinary 
evaluation of people with dementia that present BPSD, as well as the differential 
diagnosis with psychiatric diseases.167
4
Hospitalisation in psychiatric units of general hospitals permits the admission 
of people with dementia when the BPSD are severe and diffi cult to control.192
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4
The convalescence or medium-stage unit permit a better and more prolonged 
control, if necessary, of the crisis situations that require specifi c care, that are 
diffi cult to solve in the community.192
Recommendations

It must be taken into account that the mental health services carry out an essential 
role in the care of people with dementia, as they contribute to the aetiological 
diagnosis, the treatment and hospitalised care if severe BPSD appear. They 
provide coordinated, comprehensive and multi-disciplinary care.
9.6. Which social services are involved and what role do 
they play in the care of people with dementia?
Social services are a series of resources, benefi ts, activities, programmes, material and amenities 
that are aimed at providing the population with social care. Their aim is to respond to the social 
needs of families, to complement the economic benefi ts and at the same time strive to achieve an 
improvement in the living conditions of the benefi ciaries, reducing, insofar as possible, the per-
sonal limitations caused by age or disability.211
The Public Care Social Services Network is comprised of public and private social services that 
are accredited and approved by the Administration. It is governed by the principles of universal-
ity, equality, public responsibility, solidarity, civic participation, globality, subsidiarity, prevention 
and community dimension, promotion of social cohesion, standardisation, coordination, person-
alised and comprehensive care, respect for the rights of people, promotion of personal autonomy, 
economy, effi cacy and effectiveness, quality of the services and continuity of services.212,213
The demand for social services is progressively increasing in agreement with the increasing num-
ber of people affected by dementia; this fact is favoured by changes that occur in the family struc-
ture, especially due to the majority participation of women in the labour world and the respective 
reduction of their caregiving activity.
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People affected by dementia are usually cared for by the family. The 
prevalence of family caregivers increases with age; it is 15% when the sick 
person is between 65 and 69 years old; it increases to 27% between the ages 
of 75 and 79 and reaches 47% when the patient is over 84 years old. 60% of 
dependent elderly people live in their own homes; 19% of them live in the 
homes of their closest relatives and 77% of them live in the same home in a 




Relatives, friends and neighbours share 85% of home care and carry out 
administrative formalities (93.2%), help in hygiene and showering (75.6%), 
in using the toilet (65.1%), bathing (46.4%), changing nappies due to 
urinary incontinence (35.4%) or faecal incontinence (31.1%), or else they 




More than half the caregivers spend an average of 4 to 5 hours a day, seven 
days a week. The average time dedicated to patients with dementia amounts 




The annual cost of the care of a person with AD in Spain may vary, 
depending on the stage of evolution, between 12,000 and 22,000 Euros.216 In 
a prospective multicentre cohort study, with one year control, with a sample 
of 560 patients with possible/probable AD, the monthly cost was 1425.73 
Euro. Of this amount, 74.3% (1059 Euro) were earmarked for overall costs 
and 88% (1,244.22 Euro) were assumed by the family. A SR that included 
16 studies on the cost of AD in Europe showed an average expenditure of 
28,000 Euro, with a marked variability between countries, varying between 




Spanish families express their preferences of caring for their relatives with 
dementia themselves; however, there are more and more caregivers (13.6 




The relatives of patients with dementia can access the public social care services network 
through the district, municipality, region, PCT, SDCT, hospitals or else other social health 
resources. Information, guidance and counselling are offered at any of these points of the 
network, and social diagnoses are carried out that permit access to the different basic and 
specialised social benefi ts.
All people diagnosed with dementia who are registered in a municipality are entitled to 
access the public social services network. Those who do not satisfy this requirement but are 
in precarious situations, may have access to them, in agreement with that established in the 
applicable legislation on aliens.
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The social services portfolio is organised differently with different characteristics in each 
territory or autonomous community so it will not be described in this guideline. By way of 
example:
Grassroots social services: These are the gateway to the network and accessible for the entire 
population. The professionals who provide them and manage them hold diplomas in social work 
and social education, and they are responsible for informing, counselling, making diagnoses 
and evaluations, prescribing services, detecting risk situations that require preventive action, 
and carrying out community projects for the social integration of risk groups and people.
Specialised social services: They respond to situations or needs that require technical 
specialisation or the availability of special resources. They provide technical support and 
collaboration to the grassroots social services in matters of their competence.
Provision of services: Activities aimed at prevention, diagnosis, evaluation, protection, 
promotion, care and social insertion. These can be grassroots or specialised social services.
Information and social support: to prevent and improve the burden related 
to the action of caring.
Cohort study,
2+/2++
• Psycho-educational interventions: They inform the family about exist-
ing resources that will enable them to plan the strategy to be followed dur-
ing each stage of evolution of dementia. These programmes can be applied 
to a family individually or to a group of them, as they provide them with 
tools and skills to cope better with the problems, enabling them to take 
care of themselves and care better.215,219
• Psychological interventions: They help improve the burden of the car-
egiver and facilitate their adaptation to it. There are therapeutic aid pro-
grammes for one single family or for several families at the same time. 
The most effective interventions are those that adapt to the needs of each 
case, and combine information, learning skills and emotional support in 
several sessions.220,221
Social resources: These can be outpatient or part-time (a few hours and days of the week), 
residential or permanent, and short holiday periods.
• Outpatient: Day Centres (DC); Night care centres (NCC) (question 9.4).
• Residential centres: Establishments designed as permanent residences, where comprehen-
sive and continuing health care is provided to those people affected by dementia that cannot 
be adequately cared for in their homes, either because they live alone or because their car-
egivers have not got the skills to care for them in a satisfactory manner.
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• Therapeutic holidays for people with dementia: This resource is limited; it provides peo-
ple with dementia and their relatives with the possibility of enjoying holidays with therapeu-
tic, training, respite, socialisation and free time activities. They can be carried out at spas, at 
hotels, country holiday houses, etc. There is always a multidisciplinary team of profession-
als, who act as a therapeutic, animation and care team.
Economic benefi ts: Monetary aid provided by the Administration to help people who are 
specifi cally in a situation of social need, including retirement, disability pension, grant related 
to the Law of Dependence, contract for the caregiver and other economic subsidies.
They can be granted by way of subjective right, right of attendance or social emergency and 
they are governed by Law 13/2006, 27 July, on economic social benefi ts.222
Home aid: They may or may not be instrumental. Their aim is to favour and prolong the time 
people with dementia can remain in their homes. It contemplates family worker measures 
for personal hygiene, eating or controlling medication, accompaniment, volunteerism, 
physiotherapy, speech therapy, cognitive intervention, nursing, meals on wheels service, 
home care service (HCS), adaptation of the home, telecare, intervention and communication 
techniques (ICT), etc.
The social services resources or helpful aids for people with dementia and their families are 
summed up in Table 3.223,224
Table 3. Social-health resources in the care of dementia223,224
Resources Person with dementia Relatives



















• Therapeutic aid groups (TAG)
• Mutual aid groups (MAG)
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Services such associal 
resources
• Day Centres














Economic benefi ts or aid • Disability pension
• Retirement
• Law of Dependence
• Caregiver contract-dependence 
law
• Economic aid











• Adaptation of the home
• Accompaniment
• Care to grief
Summary of evidence
4
The demand for social services increases as the number of people affected by 
dementia increases.
2+
The family usually cares for people with dementia. The number of caregivers 
increases with the age of the people: 15% (65 to 69 years), 27% (75 to 79 years), 
47% (over 84 years). 60% of dependent elderly people live in their own homes, 19% 
in the homes of relatives and 77% live in the same home as the family caregiver.214
2+
The most common tasks of the caregivers of people with dementia include: 
Carrying out administrative formalities, helping in hygiene, cleanliness, showering 
and use of the bathroom, changing nappies and helping them eat (30%).214
2+
More than half the caregivers of people with dementia spend an average of 4 to 




The annual cost of a person with AD in Spain may vary, depending on the stage 
of evolution, between 12,700 and 22,000 Euro. 216In a prospective cohort study, 
with one year control, on 560 patients with AD, the monthly cost was 1425.73 
Euro; 74.3% (1059 Euro) earmarked for overall costs. 88% of the total cost 
(1,244.22 Euro) was assumed by the family.217
2+
A SR that included 16 studies on the cost of AD in Europe showed an average 
expenditure of 28,000 Euro, with marked variability between countries, varying 
varied between a minimum of 6,614 Euro up to a maximum of 64,426 Euro.218
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2+
Spanish families prefer to care for their relatives with dementia themselves; 
however, there are more and more caregivers (13.6 to 24.6%) who request 
external aid from professionals and institutions.214
4
All families affected by dementia may access the social services network. There 
they are offered information, counselling, advice and social diagnosis, and 
access is provided to social benefi ts.
4
The Social Services Network of the Public Administration (Spanish acronym 
RSSAP) includes a services portfolio that may vary from one territory to another.
Recommendations
D
It is recommendable for health and social services professionals to have a 
knowledge of the problems that affect their dementia patients to be able to 
provide an answer to their demands and know what tasks caregivers must 
carry out, the time they spend, the environment where they live, and the cost it 
represents for the family.
D
The Administration, through its social services network, must adapt to the 
increase in demand for care and services for people with dementia.
D
Favouring access to social services is recommendable as well as providing the 
services to give adequate support to the task of caring of families that care for 
people with dementia.
D
It is recommendable to step up the support measures to make it easier for people 
with dementia to remain at home.
C
Psychological support and psychoeducational interventions geared towards 
families with people with dementia are recommendable, in order to favour their 
task of caring, reduce the care burden and improve the quality of life.
D
In each case and depending on the moment of evolution of the dementia, it is 
recommendable to dynamically select the best social service resource that must 
be provided to a family caring for a person with dementia.
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9.7. How must the care continuity between the different 
dementia healthcare levels be coordinated and guaranteed?
The PCT will make the referral to the SDCT when the referral criteria 
established are fulfi lled (question 9.2.2). Communications between 
both levels must be quick and effective, avoiding continuity solutions 
or unnecessary repetitions that may cause problems in those affected or 
additional costs.25,6,207
The multidisciplinary assessment by the SDCT must be carried out as soon 
as possible and in a coordinated manner. Once the diagnosis has been carried 
out and after establishing the therapeutic proposal it must be transmitted, 
with a detailed report, to the referring PCT, for them to put into motion the 
decisions and strategies established.25,6,207
There must be coordination in the use of the resources, avoiding unjustifi ed 
delays that might alter the effi cacy of early use, optimising times and 
contents, satisfying the admission and discharge criteria of each resource 




The continuity of care for patients and their families must be crosscutting 
and longitudinal, ensuring that there are no losses when the resources are 
changed and that the family never feels neglected. These measures must be 
stepped up in the most advanced stages of dementia, at the actual home and 







It is important for all the professionals, of the different healthcare and social 
services levels, to continue collaborating in the post mortem stage, to collect 
biological samples and neurological tissues to be able to carry out a fail-safe 




Coordinated and multidirectional action must contemplate the comprehensive 
nature of resources available at social health level and of the community, 
including the AFA and other institutions/foundations that work to improve 
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This coordination between healthcare levels must be adapted individually 
to each person and family and must be extended to joint coordination or 
work among the different SDCT.
This must also be extended to collaboration in teaching and research 
between the different levels, and the University, the pharmaceutical industry 
and other institutions that earmark resources for research in basic, clinical 
and social aspects in the fi eld of dementia.25
One element that may favour coordination is the supply, storage and 
exploitation of the data of a common and shared record of data available 
on prevalent cases of dementia. All the professionals from the different 
levels can collaborate in compiling information, maximising the personal 







The PCT must refer to the SDCT when the referral criteria established are fulfi lled 
(question 9.2.2). The coordination between both levels permits healthcare 
continuity and avoids repeating examinations and thus reduces problems or 
additional costs.25,6,207
4
The SDCT carries out a multidisciplinary assessment to reach the diagnosis, 
designs treatment and monitoring strategies, and transmits a detailed report to 
the PCT, for them to put the established strategies into motion.25
4
In the care of people with dementia, there must be coordination in the use of the 
resources, according to admission and discharge criteria, and avoid delays that 
might alter the effi cacy, optimising the duration and the interventions, facilitating 
formalities and access.25
4
The continuity in care of people with dementia and their families is longitudinal 
to guarantee that the family never feels neglected. These measures must be 
stepped up in the more advanced stages of dementia.25
4
To guarantee the diagnosis of people with dementia, there should be collaboration 
between the health professionals from the different levels and those of the social 
services who intervene in the process. This collaboration must continue in 
the post-mortem phases to facilitate the collection of biological samples and 
neurological tissues.25
4
The desirable coordination between the different SDCTs must be related to 
care (common criteria, action protocols), in teaching and research, and it will 
be reinforced by establishing links with the university, pharmaceutical industry 
and institutions that earmark resources to basic clinical and social research in 
dementia.25
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4
The selection and storage, by the professionals who intervene in the process, 
of minimum quality data of the people affected by dementia and their relatives 
in a common centralised record favours coordination between the three levels 
(PCT, SDCT, SHC). The exploitation and analysis of the data available in the 
record permits improving knowledge of dementia and planning health and social 
improvement strategies and policies.225
Recommendations
D
To ensure seamless social and health care in the care of people with dementia and 
their families, it is recommendable, throughout the entire process, for there to be 
coordination between the different care levels, social services and community 
resources.
D
To favour the comprehensive care of the person/family with dementia, it is 
recommendable for the communication and coordination between the different 
levels (health, social and community) to be fast, effi cient, effective and 
multidirectional.
D
It is recommendable for all the care levels to collaborate in obtaining a fail-safe 
diagnosis, favouring the obtaining of biological and neurological tissue samples.
D
Coordination at the different healthcare levels is recommendable in order 
to favour respect for the rights and freedoms of patients in decision-making 
(advance directives).
D
Coordination between the healthcare levels, the SDCT, universities, 
pharmaceutical industry, teaching and research institutions and the AFA is 
recommendable to favour an increase in knowledge (training and research) of 
dementias (health, social, community aspects).
D
It is recommendable for the different professionals who intervene in the care 
of dementia to collaborate in drawing up a record of dementias to have a better 
knowledge of reality and rationally plan new intervention strategies.
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10. Dementia treatment
10.1. General measures
Questions to be answered
10.1.1. When and how must patients and their families be informed of the dementia diag-
nosis?
10.1.2. What basic content must the information given to patients and family have?
10.1.1. When and how must patients and their families be informed 
of the dementia diagnosis?
98% of families want the patient to be informed.226 92% of the patients want 
to know the diagnosis. There are families that hide information from the 
patients arguing that they want to protect them and minimise the impact that 
the information about the disease may generate. It has been demonstrated 
that the information received does not predispose or generate an affective 




Patients and their families must be informed about the dementia diagnosis 
when we have a reasonable suspicion of the diagnosis. Normally it is 
the family of the person affected that fosters the consultation with the 
practitioner, alarmed by the uncertainty generated by detecting the changes 
observed in the relative affected. In these cases, the families and people 
affected need information that will enable them to understand the current 
problem and be able to cope with future problems. Patients and/or families 




There are patients who wish to be informed and others that do not wish to 
receive information, on their own volition or because they are unable to 
assume it, due to the actual disease. This right must be respected whenever 
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Patients and/or their families must be informed of the diagnosis with caution, 
without haste, and in appropriately intimate and comfortable conditions and 
environment. A professional/patient/family relationship must be created 
based on a commitment of respect and trust. The dialogue will be aimed at 
helping them understand the diagnosis and favour decision-making, and it 
must be empathic, simple and two-way, listening to the patients' and their 
families' opinions, and facilitating an exchange of questions and answers. 
Individually adapt the information offered to patients and families so that it 
is understood, bearing in mind the patient’s cognitive impairment, age, sex, 
race, education level, culture and religion. If there are language barriers, 





It is advisable to give the information progressively, devoting the necessary 
time. The information offered must be true and non-alarmist, not allowing 







Notifying the diagnosis may cause a great impact on patients and their 
families, to the extent that the session has to be interrupted and offering time 
for thought. In these cases, the information must be extended during control 
visits and/or with the subsequent participation in information sessions 
carried out by the SDCT and/or PCT and complemented in the associations 




Further information or verbal communication may be provided through 
explanatory leafl ets, videos and other audiovisual means aimed at helping 
understand the diagnosis. Further information can also be provided through 






The majority of patients and families wish to be informed.226 However, there are 
families that hide information from the patients to protect them and minimise 
the impact of the process. It has been shown that receiving information does not 
generate affective disorders or depression.227,228,229
4
To favour the comprehensive care of the person/family with dementia, it is 
recommendable for the communication and coordination between the different 
levels (health, social and community) to be fast, effi cient, effective and 
multidirectional.
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4
The patient’s right to be informed must be respected, especially in the onset 
stage of dementia, when they can maintain their memory, capacity to understand, 
assimilate information, be aware of the scope and impacts, and be able to decide 
on who they wish to inform about the process (family, friends). The right to not 
want to be informed must be respected.140,206
4
The information about dementia to be transmitted to patients and their families 
must be reasonable, individualised, respectful, empathic, simple, understandable 
and two-way. It must be transmitted in appropriately private and comfortable 
conditions and environment, aimed at helping understand the disease and 
decision-making. This will facilitate the exchange of questions and answers. If 
there are language barriers, the intervention of an independent cultural mediator 
will be provided.193
4
It is advisable to give the information progressively, if necessary, devoting the 
necessary time, with true, non-alarmist content and not leaving any doubts or 
creating false expectations.140
4
Communicating the diagnosis of dementia may produce a great impact on 
patients and their families. It may be necessary to interrupt the information 
session and offer time for thought. The information must be updated and/or 
further information provided during successive visits, with information sessions 
organised by the SDCT and/or PCT and complemented at the AFA.193
3
Further verbal information may be provided through explanatory leafl ets, 
videos, DVD and other audiovisual means, if necessary, to help understand 




Informing patients and their families of the dementia diagnosis is recommended 
when there is reasonable suspicion of dementia. The SDCT physician and/or 
PCT are the people who must inform.
C
Informing patients who request this and their families of the diagnosis is 
recommended; as it has been proven that the information received does not 
predispose or generate a disorder in the person affected.
D
The patients’ right to be informed or not must be respected, as well as their right, 
if they are capacitated to do so, to choose those people around them who must 
be informed of the process.
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C
Offering information via understandable, sensible, respectful, empathic, verbal 
communication, and an adequate environment and conditions is recommended, 
to facilitate two-way dialogue. To make it easy to understand the diagnosis and 
its consequences, further information can be provided via information leafl ets, 
booklets, videos, Internet and other audiovisual means and associations of families 
of dementia patients (AFA). If there are language barriers, communication must 
be facilitated through an independent cultural mediator.
D
The individual evaluation of the possible impact that communicating the 
diagnosis may generate is recommended, as well as doing so in instalments 
if necessary, providing further information during successive visits and in 
information sessions (SDCT, PCT, AFA).
10.1.2. What basic content must the information given to patients 
and family have?
The basic information received by patients and their families must be 
comprised of:129
• Diagnosis of the disease
• Type of dementia
• Stage in the evolution of dementia that the patient is in.
• Probable prognosis
• Treatment to follow
 – Drugs: Benefi ts and adverse effects
 – Non-pharmacological interventions
 – Guidelines and recommendations
• Guidance about successive controls and emerging alarm signals that re-
quire urgent attention.
• Information about available resources and their accessibility.
The information given must enable patients and their families to:
• Plan their future
• Decide on the guardian to take decisions
• Reorganise and take decisions about economic and legal questions.
• Accept the treatment proposed or not, weighing up risks and benefi ts.
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Information can be offered to patients with mild dementia who can 
understand the explanations, express their concerns and comment on the 
diffi culties to plan the future with the aid of relatives and professionals.
Knowing the prognosis of the disease will give them the chance to be able 
to plan their future, exercising their right to decide (advance directive 




The group information sessions aimed at the families must contemplate the 
following aspects:
• Inform about basic aspects of the disease and its evolution stages.
• Differentiate cognitive, behavioural and functional symptoms.
• Impact of the loss of autonomy.
• Involvement of the different professionals (PCT, SDCT, SHC).
• Foster comprehensive and multidisciplinary treatment
• Foster help to the caregiver and to the family.
• Advise about the prognosis and future prospects.
• Inform about the social health and social resources available.
• Advise about basic legal aspects.
• Management and attitudes to be adopted to cope with emerging problems.
• Evaluate the needs, burdens, demands, risks or repercussion of the car-
egiver.
• Help implement a solid family support network.
• Inform the caregiver about support resources.
The basic information about dementia must be complemented with more 
specifi c contributions, for those families with patients in very advanced 
stages of dementia, whatever the aetiology, or when they live with people 
affected by DLB, FTLD or VD, and they pose different problems to the 




Training health practitioners, social services professionals and professional 
volunteers is necessary so that they can manage a group of MAG or TAG. 
This training programme can be carried out at any of the healthcare levels, 
or at the AFA.140 it is advisable for the primary caregivers (relatives or 
professionals) to receive training that will empower them to manage dementia 
and carry out non-pharmacological interventions. Training provides useful 
competence to carry out the non-pharmacological interventions indicated 
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Summary of evidence
4
Patients with mild or moderate dementia can be informed. This information can 
be benefi cial as it will enable patients to express their concerns, doubts and be 
able to cope better with daily diffi culties. Knowing the prognosis of their disease 
may help them take decisions and plan their future.233,42
4
The basic information for patients and their families must be comprised 
of: Diagnosis of the disease, type of dementia, evolution stage, prognosis, 
pharmacological treatment, non-pharmacological treatment, monitoring and 
available resources.129
4
The information will enable patients and their families to plan for the future, 
decide on the guardian, reorganise fi nancial and legal questions, evaluate 
pharmacological and non-pharmacological treatment, and decide upon their 
participation in research programmes.129
4
Information sessions aimed at families must contemplate basic aspects of the 
disease, dementia stages, diagnosis, involvement of different professionals 
and healthcare levels (PCT, SDCT, SHC), comprehensive multidisciplinary 
treatment, social health and social resources available, legal advice and economic 
aid.193
4
The information sessions to relatives offer instruments to manage emerging 
problems during the evolution of the disease. They inform about the burden and 
support measures for the caregiver, risks and repercussions, and the usefulness 
of creating a solid family support network to help the caregiver.193
4
In very advanced stages of dementia or in DLB, FTLD and VC more specifi c aid 
and information programmes must be offered to the family.193
4
Health practitioners, social services and professional volunteers can collaborate 
as MAG or TAG group leaders, after having received suffi cient training in this 
regard. These programmes may be carried out in SPD, PC or else in the AFA.140
4
The primary caregivers can receive training that enables them to collaborate as 
co-therapists in non-pharmacological interventions of dementia.193
Recommendations
C
Giving information to patients and families about dementia is recommended, 
as well as about its evolution, clinical manifestations, comprehensive treatment 
and support to the caregiver, which will enable them to plan their future.
D
It is advisable for the group information sessions aimed at families to contemplate 
basic aspects of dementia; function of the different professionals and healthcare 
levels; comprehensive treatment and available resources; management of 
emerging problems; detection of burdens derived from the task of caring, and 
support to the caregiver.
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D
The execution of specifi c training programmes for families who live with people 
affected by DLB, FTLD or VC and in advanced or terminal dementia stages is 
recommended.
D
Training health practitioners, social services professionals and volunteers/
professionals is recommended so that they can manage a group of patients and/
or families affected by dementia.
D
It is recommendable to train caregivers (families or professionals) to empower 
them to manage non-pharmacological interventions of dementia.
10.2. Specifi c pharmacological treatment of dementia
Questions to be answered
10.2.1. When and how must patients and their families be informed of the dementia diagno-
sis?
10.2.2.  Is there a specifi c pharmacological treatment for dementia? 
10.2.3.  Is the specifi c pharmacological treatment equally effective in all people?
Alzheimer’s Disease
10.2.3.  Which pharmacological treatment is effective in the treatment of mild, moderate and 
severe Alzheimer’s disease?
10.2.4.  Which specifi c pharmacological treatment is effective in cognitive, behavioural, 
functional manifestations and/or quality of life in AD? 
10.2.5.  What adverse effects and contraindications exist for the specifi c pharmacological 
treatment in Alzheimer’s disease?
10.2.6.  How effective and safe is the combination of two or more specifi c drugs in mild, 
moderate and severe Alzheimer’s disease? 
10.2.7.  When must specifi c treatment in Alzheimer’s disease end?
Parkinson’s disease dementia 
10.2.8.  Which specifi c pharmacological treatment is effective in Parkinson’s disease dementia?
10.2.9.  What adverse effects and contraindications exist in the pharmacological treatment of 
Parkinson’s disease dementia?
10.2.10.  How effective and safe is the combination of two or more specifi c drugs in Parkinson’s 
disease dementia?
Dementia with Lewy bodies
10.2.11.  Which specifi c pharmacological treatment is effective in dementia with Lewy bod-
ies?
10.2.12.  What adverse effects and contraindications exist in the specifi c pharmacological 
treatment of dementia with Lewy bodies?
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10.2.13.  How effective and safe is the combination of two or more specifi c drugs in mild, 
moderate and severe dementia with Lewy bodies?
10.2.14.  How useful are drugs with dopaminergic action in dementia with Lewy bodies?
Frontotemporal lobar degeneration
10.2.15.  Which pharmacological treatment is effective in cognitive and behavioural mani-
festations of frontotemporal lobar degeneration?
Vascular Dementia
10.2.16.  Which pharmacological treatment is effective in mild, moderate and severe vascu-
lar dementia?
10.2.17.  What infl uence does pharmacological treatment have on vascular dementia with 
respect to cognitive, behavioural, functional manifestations and/or quality of life? 
10.2.18.  What adverse effects and contraindications exist in the pharmacological treatment 
of vascular dementia
Other pharmacological treatments
10.2.19. Are any other types of drugs effective in cognitive and functional manifestations in 
people affected by any type of dementia?
10.2.1. Is there a specifi c pharmacological treatment for dementia?
There are currently two types of specifi c drugs for the symptomatic treatment of Alzheimer’s 
disease (AD): a) acetylcholinerasterase enzyme inhibitors (ACE inhibitors): donepezil, 
rivastigmine and galantamine; b) a non-competitive N-methyl D-Aspartic receptor antagonist 
(NMDA): Memantine.
ACE inhibitors have been recommended for the treatment of patients 
diagnosed with mild to moderate AD.5,234,140,42,235
RCT,
1++/ 1+
ACE inhibitors have also proved benefi cial to manage mild to moderate VD 
and in DLB and PDD.140,42,5
RCT, 
1+
In RCT, patients who have been treated with ACE inhibitors have shown 




The effi cacy and safety profi les for the three ACE inhibitors are similar. RCT,
1++/ 1+
Memantine has proved to be effective in the treatment of moderate to severe 
AD, administered in mono-therapy or combined with ACE inhibitors.5,140,42
RCT,
1++/ 1+
There are no specifi c treatments for FTLD.5,6,52
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ACE inhibitors have proved benefi cial compared to placebo in the treatment of 
mild to moderate AD.5,234,140,42,235
1+




The effi cacy and safety profi les for the three ACE inhibitors are similar.140
1++/
1+
Memantine has proved benefi cial compared to placebo in the treatment of 
moderate to severe AD, in mono-therapy or combined with ACE inhibitors.5,140,42
- There is no specifi c pharmacological treatment for FTLD.5,6,52
Recommendations
A
ACE inhibitors are recommended for the specifi c and symptomatic treatment of 
mild to moderate AD.
A
Treatment with ACE inhibitors is recommended to manage mild to moderate 
VD.
B ACE inhibitors have proved to be benefi cial in dementia by DLB and PDD.
B
No differences have been shown regarding different ACE inhibitors (donepezil, 
rivastigmine and galantamine) in respect of effi cacy and safety
A
Memantine is recommended as specifi c treatment for moderate to severe AD in 
mono-therapy or combined with ACE inhibitors.
10.2.2. Is the specifi c pharmacological treatment equally effective 
in all people?
Some RCT have shown differing effi cacy of pharmacological treatment in 
people treated.
In one RCT,236 which included 240 patients with mild-to-moderate AD 
treated with galantamine, during a 48-month control, different degrees of 
cognitive decline were observed according to scores obtained in the ADAS-
Cog scale, and it was possible to identify three subgroups: In the fi rst group 
(82 patients) with less decline, the average score on the ADAS-Cog scale 
was 15+/-8, with respect to the basal, whilst in the other group (75 patients) 
with persistent progression, the score was 30+/-9, and in the third group 
(82 patients) with intermediate evolution, from 20+/-9. In general, patients 
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The other group of patients experienced considerable impairment and the 
other subgroup showed an intermediate degree of impairment, between 
the other two. The authors of this study conclude that they do not provide 
any indicative data that certain epidemiological, cognitive or genetic 
characteristics are correlated to greater effi cacy of the treatment, so it is not 
possible to identify patients who will respond to the treatment a priori.
In the case of VD, slight differences in response to the treatment have 
been found, depending on the type of vascular lesion (cortical, subcortical 
or small vessel)237 and depending on age (older people have a greater 





In an extension study of two RCTs with galantamine, the decline in the score on 
the ADAS-Cog scale after 2 years with respect to the basal was 15+/-8 points on 
average in one third of the patients, 20+/-9 points in another third and 30+/-10 
points in the remain third of the patients.236
1++/
1+
Modest response differences to the treatment have been observed in VD 
depending on the type of vascular lesion and on the age.237,238
Recommendations
-
We have little evidence about whether specifi c pharmacological treatment is just 
as effective in all people due to the lack of studies that assess the individual 
response to different drugs.
Alzheimer’s Disease
10.2.3. Which specifi c pharmacological treatment is effective in the 
treatment of mild, moderate and severe Alzheimer’s disease?
ACE inhibitors
ACE inhibitors are approved in Spain for mild or moderate AD. Memantine is approved for 
moderate and severe AD.
A Cochrane SR239 performed a MA of 13 multi-centre, double blind RCT, 
on parallel groups, with 7,298 participants (2,228 receiving treatment with 
donepezil, 2,267 receiving treatment with galantamine and 2,803 receiving 
treatment with rivastigmine) to assess the effi cacy (cognitive, functional 
and global) and safety of the ACE inhibitors in AD.
MA of RCT,
1++
CLINICAL PRACTICE GUIDELINE ON THE COMPREHENSIVE CARE 
OF PEOPLE WITH ALZHEIMER’S DISEASE AND OTHER DEMENTIAS 167 
The MA revealed benefi ts associated with ACE inhibitors compared with 
placebo in cognitive function, according to the improvement observed in 
the scores of the ADAS-Cog (-2.7 points) and MMSE scales, a benefi cial 
effect on ADL, according to scores on the PDS scale, and modest effi cacy 
on behavioural disorder (apathy, anxiety and depression), according to score 
of the NPI-total scale. With respect to quality of life, there is no evidence 
of a benefi t, assessed using quality of life scales after 12 and 24 weeks.240,241
There are very few comparative studies between the different ACE 
inhibitors. One Cochrane SR239 identifi ed four comparative studies. Two 
of them, simple blind, compared donepezil and galantamine: One of them 
showed a greater benefi t in cognitive function after 12 weeks (-2.5 points 
on average on the ADAS-Cog scale, with no differences in MMSE) and in 
ADL (2.10 points in DAD) in patients treated with donepezil, which was 
not corroborated by the other more prolonged study, lasting for 52 weeks,242 
and which did not show any differences between the two drugs according 
to scores on the ADAS-Cog, MMSE and ADL scales. The other two studies 
that compared donepezil and rivastigmine, one 12-week single blind243 and 
another 2-year double-blind one,244 did not fi nd any differences with respect 
to cognitive function, behavioural disorders, ADL or global functioning, 
assessed by means of the SIB, GDS, ADAS-Cog, ADCS-ADL, MMSE 
and NPI scales. Despite the slight variations in the action mechanism of 
the three ACE inhibitors, current evidence does not provide proof of any 




The majority of the available RCTs last for 6 months The effect of the ACE inhibitors cannot 
be demonstrated in a longer term, although there are observational studies that show that the 
long-term benefi t continues after the control year.
Patients treated with ACE inhibitors have a probability of 2.5 points 





In a SR of 22 RCT241 (12 studies with donepezil, six with galantamine 
and four with rivastigmine) with 9,883 participants who presented mild 
to moderate AD, the results showed an improvement or maintenance of 
the cognitive function for all three drugs, compared with placebo and a 
favourable effect in ADL
SR of RCT, 
1+
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Donepezil
Donepezil has proven to be effective in patients with mild, moderate 
and severe AD. The recommended starting dose is 5mg/day for 4 weeks, 
increasing afterwards to 10 mg/day.246,235 the duration of the majority of 
the RCT has been 12-24 weeks, except for two lasting for 12 months and 
another that lasted for more than 24 months. The majority were carried 
out on patients with mild to moderate AD (MMSE: 10-26 points), two 




In a Cochrane SR240 until 2005, 23 multi-centre, double blind RCT were 
included in a MA, all of them with parallel groups, except for one crossed247 
and another with one part crossed and another with parallel groups248, with 
a total of 5,272 participants, to assess the benefi t of donepezil after 12, 24 
and 52 weeks. The results of the MA based on 14 RCT were as follows: 1) 
cognition: Donepezil showed a statistically signifi cant improvement with 
respect to placebo in the ADAS-Cog scale after 24 weeks, both with 5 mg/
day (-2.01 points) and with 10 mg/day (-2.80 points). An improvement was 
also observed in MMSE after 52 weeks with 10 mg/day (1.84 points); 2) 
global clinical status: The number of patients with mild or moderate AD 
who showed an improvement in score on the CIBIC-plus scale after 24 
weeks was greater in patients treated with donepezil, 5 mg/day (OR = 2.18) 
and 10 mg/day (OR = 2.38) than with placebo; 3) ADL: Donepezil has 
shown an improvement in ADL with respect to placebo.
SR and MA 
of RCT,
1++
In a study 249 on patients treated with donepezil at a dose of 10 mg/day, 
an improvement was observed in functionality according to the PDS 
scale (3.8 points) after 52 weeks. In one of the studies, a decrease was 
observed in the open phase, in the score of the total NPI scale after 6 to 
12 weeks with respect to the basal; patients who had received donepezil 
continued to improve whilst those who had received placebo got worse. The 




Donepezil showed a delay in institutionalisation of patients in one study but 
not in the other, both with limited methodological quality.42
RCT, 
1-
According to a RCT performed on patients with mild or moderate AD,248 the 
modest improvement in cognitive function of patients treated with donepezil 
is maintained for 2 years, although a reduction in the institutionalisation rate 
is not observed. In this study no signifi cant differences were observed either 
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The dose of 10 mg/day showed a greater benefi t than the dose of 5 mg/
day on the symptoms of AD in the majority of the studies. The evidence 




Rivastigmine has confi rmed its effi cacy in patients with mild and moderate 
AD. The recommended dose is 6-12 mg/day (oral), starting treatment with 
1.5 mg/12 h and increasing to 1.5 mg/12 h every 4 weeks. The recommended 
dose via transdermal route is 4.6-9.5 mg/day starting with 4.6 mg for 4 
weeks and then increasing to 9.5 mg.246,235
RCT,
1+
A Cochrane SR239 until 2008 included nine RCT, with a total of 4,775 
patients with mild to moderate AD, in outpatient regime, with maximum 
control of 26 weeks, except for one that lasted for 12 months, and it showed 
the following results: 1) cognition: Rivastigmine at a dose of 6 to 12 mg/
day showed an average improvement of -1.99 points on the ADAS-Cog 
scale compared with placebo at 26 weeks. Two SR252,253 showed a benefi t 
in cognitive function in patients treated with rivastigmine. One CPG235 
referred to the existence of a benefi t with rivastigmine in cognitive function; 
2) global clinical status: rivastigmine at a dose of 6 to 12 mg/day showed 
a slight statistically signifi cant improvement in global function, assessed 
by means of the CIBIC-plus, CGIC or GDS scales254; ADL: rivastigmine 
at a dose of 6 to 12 mg/day was associated with an average improvement 
of 2.15 points on the PDS scale after 26 weeks, which was not observed 
at a dose of 4 mg/day. the same CPG235 refers to the existence of a modest 
benefi t for ADL; 4) behavioural alterations: No signifi cant benefi t compared 





Galantamine has proved to be effective in patients with mild and moderate 
AD. The recommended dose is from 16 to 24 mg/day, starting treatment 
with a dose of 8 mg/day (non-therapeutic dose) and increasing 8 mg/day 
every 4 weeks.246,235 Available in tablets (taken twice a day) or capsules of 
extended release (taken once a day) with similar effi cacy.
RCT,
1++
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A Cochrane SR253 until 2005 that included 10 RCTs, with a total of 6805 
patients, observed a favourable effect of the treatments with galantamine, at 
doses of between 16 and 36 mg/day, in outpatients with mild-to-moderate 
AD compared with placebo, assessed after 3 and 6 months. The benefi t 
was observed for doses of 16 to 24 mg/day with no signifi cant difference 
between both doses, but this was not observed for the dose of 8 mg/day, 
according to the following results: 1) cognition: Galantamine proved to be 
benefi cial in patients with mild-to-moderate AD, on the cognitive function 
(a dose of 16 mg/day) after 6 months:253,241,5,235 2) global clinical status: 
The number of patients with an improved score or with no change on the 
CIBIC-plus or ADCS-CGIC scale was greater with galantamine than with 
placebo with all doses except for 8 mg/day (or = 1.6-1.8 at dose of 16 to 36 
mg/day) after 6 months; 3) ADL: Galantamine showed a lower decrease in 
the ADCS-ADL score with respect to placebo for 16 mg/day (3.1 points) 
and for 24 mg/day (2.3 Points) after 6 months. An improvement was also 
observed in DAD disability scale of 3.7 points with the dose of 24 mg/day; 
4) behavioural alterations: An RCT that assessed the change in score of the 
NPI after 3 months showed no effect of the treatment with galantamine at 
doses of 24 and 32 mg/day. In three RCTs lasting for 6 months, an average 
reduction was observed of 2.1 points on the NPI scale with doses of 16 mg/
day, but not with doses of 16 to 24 mg/day.
SR of RCT,
1++/1+
The effect of galantamine on severe AD has been recently assessed in a 
RCT255 that included 407 institutionalised patients (MMSE 5-12 points), 
who received 24 mg/day galantamine or placebo for 3 years. The average 
score on the SIB scale improved by 1.9 points, especially in memory, Praxis 
and visual spatial capacity, in the group treated with galantamine and it 
worsened by three points in the group treated with placebo. The average 
score in MDS-ADL worsened by 1.2 points in the galantamine group and 




Memantine has proved to be effective in patients with moderate and severe AD. The 
recommended dose is 20 mg/day, starting treatment with 5 mg/day and increasing 5 mg/every 
week.246,235
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One Cochrane SR256 on patients with moderate to severe AD treated 
with memantine at doses of 20 mg/day showed a signifi cant difference 
in cognitive function assessed via the SIB scale, in the global function 
according to the CIBIC-Plus scale, in ADL according to ADCS-ADL scale 
and in mood and behaviour according to NPI scale, after 24 and 28 weeks. 
Out of fi ve RCT that assessed behavioural alteration, only two showed 
statistically signifi cant differences with respect to placebo. Three RCT 
carried out on patients with mild to moderate AD, treated with memantine, 
showed signifi cant differences in cognitive function (ADAS-Cog scale), 
global function (CIBIC-Plus scale), and no differences were found with 
respect to mood and behaviour (NPI scale).
The data of three RCTs lasting for 6 months on patients with MMSE between 
10-24, showed a minimal benefi t of memantine 20 mg/day compared to 
placebo, in cognition (average improvement of 0.99 points in ADAS-Cog 
scale) and in global clinical status (average improvement of 0.13 points of 
CIBIC-plus), clinically not relevant. No effect was observed on ADL or on 
behavioural alterations.256
SR of RCT, 
1+
Not many studies have been carried out on patients with moderate and 
severe dementia. The data from three RCT lasting for 6 months on patients 
with MMSE between 3-15 showed the benefi t with memantine 20 mg/day 
over placebo in the following aspects: 1) cognition: Average improvement 
of 2.97 points on the SIB scale. One study257 also assessed the change in 
the MMSE scale and no signifi cant differences were observed between 
memantine and placebo; 2) global clinical status: Average improvement of 
0.28 points on the CIBIC-plus scale; ADL: average improvement of 1.27 
points on the ADCS-ADLsev scale; behavioural alterations: improvement 
of 2.76 points on average in the total NPI. Patients who received memantine 
proved to have a slightly less probability of experiencing agitation, but there 
is no proof of an effect on already existent agitation.
RCT,
1++
One MA that included 1,826 patients belonging to six RCTs258 with moderate 
to severe AD treated with memantine or placebo showed the benefi t of the 






The effect of the ACE inhibitors on the cognitive functions in mild to moderate 
AD is similar, with an improvement compared to placebo of 1 point in MMSE 
and 2.70 points on the ADAS-Cog scale after 6 months.239
172 CLINICAL PRACTICE GUIDELINES IN THE SNS
1++
No signifi cant differences have been observed with respect to effi cacy in 




In one Cochrane SR, on patients with mild to moderate AD, donepezil showed 
a statistically signifi cant improvement compared to placebo in the ADAS-Cog 
scale after 24 weeks, with 5 mg/day (-2.01 points) and with 10 mg/day (-2.80 
points), and in the MMSE after 52 weeks with 10 mg/day (1.84 points).246,235
1++
The number of patients with mild or moderate AD who showed an improvement 
in score on the CIBIC-plus scale after 24 weeks was greater in those treated with 
donepezil than with placebo, both for 5 mg/day (OR = 2.18) y 10 mg/day (OR 
= 2.38)240,247,248
1+/1-
Donepezil showed an improvement compared to placebo in ADL of 3.8 points 
on the PDS scale with a dose of 10 mg/day at 52 weeks in one study.249 In another 
study,250 a longer period of time was observed until impairment was clinically 
observable in functionality, with donepezil 10 mg/day at 54 weeks.
1+/1-
Donepezil 10 mg/day showed an average improvement in total NPI at 6 weeks 
(6.2 points) and at 24 weeks (-3.26 points).249,250
1+/1-
In the open phase of one study, patients who continued treatment with donepezil 
maintained the decrease of NPI whilst the change to placebo produced a 
worsening.249,250
1+
The benefi t of donepezil according to the NPI scale has been observed in 
outpatient and institutionalised patients. 259
1+
Donepezil showed no benefi t in quality of life of the patient either after 12 or 
after 24 weeks. The quality of life has not been assessed with other drugs.248
1+
Treatment with donepezil did not show a delay in institutionalisation patients 
with AD. 248
1+
The dose of 10 mg/day showed a slightly greater benefi t over the symptoms of 




Rivastigmine at a dose of 6 to 12 mg/day was associated with an average 
improvement of 1.99 points on the ADAS-Cog scale compared with placebo 
at 26 weeks in patients with mild to moderate AD, in a Cochrane SR.239,252,253,235
1++/
1+
Rivastigmine 6 to 12 mg/day showed a slightly signifi cant improvement in global 
function, assessed by means of the CIBIC-plus, CGIC or GDS scales.239,254
1++/
1+
Rivastigmine 6 to 12 mg/day was associated with an average improvement of 
2.15 points on the PDS scale of ADL after 26 weeks.239,235
1+
Rivastigmine showed no signifi cant benefi t compared to placebo in two studies 
that assessed mood and behaviour measures.239,254
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Galantamine
1++
Galantamine at doses of 24 mg/day showed an improvement of 3.7 points on the 
DAD scale.253
1++
Changes have been observed in the NPI score in one RCT receiving treatment 
with galantamine at doses of 24 and 32 mg/day, after 3 months.253
1++ The dose of galantamine 8 mg/day is not effective.246,235
1+
In one RCT on patients with severe AD, galantamine at a dose of 24 mg/day 
improved 1.9 points on the SIB scale compared with a worsening of 3 points 
with placebo, after 3 years.255
Memantine
1++
Memantine at a dose of 20 mg/day was associated with an average improvement 
of 2.97 points on the SIB scale compared with placebo at 6 weeks in patients 
with moderate to severe AD, in a Cochrane SR.256 No differences in score were 
observed in MMSE
1++
Memantine 20 mg/day showed an average improvement of 0.28 points in CIBIC-
plus after 6 months on patients with moderate to severe AD.256
1++
Memantine 20 mg/day showed an average improvement of 1.27 points in ADCS-
ADLsev after 6 months on patients with moderate to severe AD.256
1++
Memantine 20 mg/day showed an average improvement of 2.76 points in 
total NPI after 6 months on patients with moderate to severe AD. A slightly 
higher percentage of patients remained free from agitation, delusions and 
disinhibition.256,258
1++
In patients with mild to moderate AD, memantine 20 mg/day showed an average 
improvement compared to placebo in ADAD-Cog and CIBIC-plus at 6 months 
no benefi t in ADL or behaviour.Was observed. 256
Recommendations
A
Treatment is recommended with ACE inhibitors (donepezil 5-10 mg/day, 
galantamine 16-24 mg/day or rivastigmine 6-12 mg/day oral/4.6-9.5 mg/day 
transdermal) in patients with mild or moderate AD.
B
An ACE inhibitor can be used (donepezil or galantamine) in severe AD, although 
there is less evidence of its benefi t.
A
Treatment with memantine is recommended, at a dose of 20 mg/day in patients 
with moderate to severe AD.
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10.2.4. Which specifi c pharmacological treatment is effective in 
cognitive, behavioural, functional manifestations and/or quality of 
life in AD?
Specifi c pharmacological treatment (ACE inhibitors and memantine), in AD, has a different 
effect depending on the stage of the disease (mild, moderate or severe) and according to the 
manifestations of the AD (cognitive, behavioural, functional and/or quality of life) as recorded 
in several CPG5,25,140,42,235 y SR.239,240,241
Cognitive manifestations
The effect of the ACE inhibitors on the cognitive functions in AD has been statistically 
signifi cant in the different RCT performed; an improvement has been observed of 1 point in 
MMSE scale and 3 points in the ADAS-Cog scale, compared with placebo.42
Donepezil
According to one MA of RCT included until 2005, in a Cochrane SR, 
donepezil showed a statistically signifi cant improvement compared to 
placebo in patients with mild to moderate AD according to the ADAS-
Cog scale after 24 weeks, with 5 mg/day (-2.01 points) and with 10 mg/
day (-2.80 points). An improvement was also observed in the MMSE score 




According to one MA of RCTs included until 2005, in a Cochrane SR239 
rivastigmine at a dose of 6 to 12 mg/day showed an average improvement 
of 1.99 points on the ADAS-Cog scale compared with placebo at 26 weeks 




According to one MA of RCT included until 2005, in a Cochrane SR252 
galantamine at a dose of 16-24 mg/day in patients with mild to moderate 
AD showed an average decrease of 3.1 points on the ADAS-Cog scale 
compared to placebo after 6 months.
MA of RCT,
1++
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Memantine
According to one MA of studies included until 2006, in a Cochrane SR,256 
memantine at a dose of 20 mg/day showed an average improvement of 2.97 
points on the SIB scale compared to placebo in patients with moderate to 
severe AD after 6 months.
MA of RCT,
1++
In one RCT, no signifi cant differences were observed between memantine 
and placebo, according to assessment using the MMSE scale.254 In patients 






In a Cochrane MA240 donepezil at a dose of 10 mg/day showed an improvement 
in total NPI at 6 weeks (-6.2 points) and at 24 weeks (-3.26 points). In the 
open phase of one of the RCTs, a decrease was observed in the score of the 
total NPI scale after 6 and 12 weeks with respect to the basal; patients who 
received donepezil in this stage continued to improve and those who had 
received placebo got worse. The benefi t of donepezil assessed by means of 




No signifi cant benefi t compared with placebo was shown in two studies that 




According to three RCTs of a Cochrane MA253, galantamine only showed 
a reduction of the NPI score (average of 2.1 points) after 6 months with 
doses of 16 mg/day, but not with doses of 16 to 24 mg/day. In another RCT 
no changes were shown in NPI at doses of 16 or 24 mg/day after 5 months.




In patients with moderate to severe AD, treatment with memantine at doses 
of 20 mg/day showed an average improvement of 2.76 points in the total 
NPI after six months.256 Patients who received memantine showed they 
had a slightly less likelihood of experiencing agitation, but no effect of 
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One MA that included 1,826 patients belonging to six RCT258 with 
moderate to severe AD, treated with memantine vs. placebo, showed a 
benefi t of memantine in the total NPI score. Fewer symptoms (agitation/
aggressiveness, delusions and disinhibition) were observed in patients at 
week 12, and fewer symptoms (agitation/aggressiveness, irritability/lability 
and disturbed nocturnal behaviour) at week 24/28. No item was worse with 





According to a Cochrane SR240, one RCT showed an improvement on the 
PDS scale (3.8 points) with 10 mg/day after 52 weeks. A reduction in the 
time elapsed until clinically observable impairment was also observed, with 
donepezil at doses of 10 mg/day at 54 weeks in another RCT. The number 
of patients with mild or moderate AD who showed an improvement on the 
CIBIC-plus scale was greater in patients treated with donepezil at a dose of 





At a dose of 6 to 12 mg/day there was a slightly signifi cant improvement 
in global functioning according to assessment via CIBIC-plus, CGIC or 
GDS,254 and an improvement of 2.15 points on the PDS scale, which was 




According to a Cochrane MA,253 galantamine showed a lower decrease in 
the ADCS-ADL score at a dose of 16 mg/day (3.1 points) and at a dose of 24 
mg/day (2.3 Points) compared with placebo. An improvement was observed 
in DAD scale of 3.7 points with a dose of 24 mg/day after 6 months. The 
number of patients with an improved score or with no change on the CIBIC-
plus or ADCS-CGIC scale was greater in those treated with galantamine at 
a dose of 16 to 36 mg/day, than in the placebo group (OR = 1.6-1.8).
SR and MA 
of RCT,
1++
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Memantine
In patients with moderate to severe AD256 treated with memantine at a dose 
of 20 mg/day, an average improvement of 0.28 points on the SIB scale and 
1.27 points on ADCS-ADL was observed, after 6 months. In patients with 
mild-moderate AD, the improvement in the average score of 0.13 points of 





Quality of life has only been assessed in studies performed with donepezil, 
and no benefi t was observed on quality of life with a dose of 5 or 10 mg/day, 






One Cochrane MA240 on patients with mild to moderate AD, receiving treatment 
with donepezil showed a statistically signifi cant improvement in cognitive 
function according to assessment via the ADAS-Cog scale after 24 weeks, with 
5 mg/day (-2.01 points) and with 10 mg/day (-2.80 points), and in the MMSE 
after 52 weeks with 10 mg/day (1.84 points).
1++
One Cochrane MA239 on patients with mild to moderate AD receiving treatment 
with rivastigmine at a dose of 6 to 12 mg/day showed an improvement in cognitive 
function (-1.99 points in ADAS-Cog) compared to placebo at 26 weeks.
1++
One Cochrane MA253 on patients with mild to moderate AD receiving treatment 
with galantamine at a dose of 16 to 24 mg/day showed an improvement in 
cognitive function (-3.1 points in ADAS-Cog) compared to placebo at 6 months.
1++
One Cochrane MA256 of patients with moderate to severe AD receiving treatment 
with memantine at a dose of 20 mg/day showed an average improvement of 
2.97 points on the SIB scale compared to placebo in after 6 months. No score 
differences were observed in MMSE.257,254
Behavioural manifestations
1++
According to one Cochrane MA240 treatment with donepezil at a dose of 10 mg/
day showed an average improvement in total NPI (-6.2 points) after 6 weeks and 
-3.26 points after 24 weeks
1++
Rivastigmine showed no signifi cant benefi t compared with placebo in two 
studies that assessed mood and behaviour measures.239,254
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1++
One Cochrane MA of three RCT253, on patients receiving treatment with 
galantamine at a dose of 16 mg/day showed an average reduction of the NPI 
score of 2.1 points after 6 months, which was not observed at doses of 16.24 mg/
day, or in another RCT at doses of 24 and 32 mg/day.
1++
Memantine 20 mg/day showed an average improvement of 2.76 points in total 
NPI on patients with moderate to severe AD after 6 months.256,258
Functionality
1++
In patients with mild or moderate AD treated with donepezil, an improvement in 
functionality according to the CIBIC-plus scale was observed at a dose of 5 mg/
day (OR = 2.18) and 10 mg/day (OR = 2.38) after 24 weeks.240
1++
Treatment with rivastigmine at a dose of 6 to 12 mg/day was associated with 
an average improvement of 2.15 points on the PDS scale of ADL after 26 
weeks.254,239
1++
The number of patients treated with galantamine at a dose of 16 to 36 mg/day, 
who showed an improved score or with no change on the CIBIC-plus or ADCS-
CGIC scale, was greater than the number of patients treated with placebo (OR = 
1.6-1.8) after 6 months.53
1++
In patients with moderate to severe AD, treatment with memantine at a dose 
of 20 mg/day showed an average improvement of 1.27 points on the ADCS-
ADLsev scale after 6 months.56
Quality of life
1++
Quality of life has only been assessed in one study with donepezil, and no benefi t 
was observed on the quality of life of the patient either at 12 or at 24 weeks.240
Recommendations
A
Treatment with ACE inhibitors is recommended in patients with mild to moderate 
AD, to manage the cognitive and functional symptoms.
A
Treatment with ACE inhibitors is recommended in patients with mild to moderate 
AD, to manage behavioural alterations (apathy, anxiety and depression), despite 
the benefi t being modest.
A
Treatment with memantine is recommended in patients with moderate to severe 
AD, to manage the cognitive and functional symptoms.
B
There is no evidence to recommend treatment with ACE inhibitors to improve 
the quality of life of patients with AD.
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10.2.5. What adverse effects and contraindications exist for the 
specifi c pharmacological treatment in Alzheimer’s disease?
Adverse effects
Pharmacological treatment with ACE inhibitors is well-tolerated.5,140,252,239 RCT,
1++/ 1+
According to several SR240,260,256,253,254,241,261,262,263,264,265,149, the most common 
side effects of treatment with ACE inhibitors are gastrointestinal ones 
(nausea, vomiting and diarrhoea). The following appear less frequently: 
Abdominal pain, anorexia, weight loss, sleep disorders, muscle cramps, 
urinary incontinence, bradycardia and syncope.
Donepezil at a dose of 10 mg/day. nausea (9%), vomiting (3%), diarrhoea 
(3%), insomnia (3%), fatigue (5%), anorexia and muscle cramp. Rivastigmine 
at a dose of 6-12 mg/day. nausea (9%), vomiting (4%), diarrhoea (3%), 
fatigue (14%), muscle cramps (10%), anorexia, drowsiness and insomnia.
With galantamine at a dose of 8 mg/day, the side effects were not statistically 
signifi cant compared with placebo. At a dose of 16 mg/day. nausea (4%), 
vomiting (2%), diarrhoea (5%), and anorexia (2%). At a dose of 24 mg/day. 
nausea, vomiting, dizziness, weight loss, anorexia, tremors and headaches. 




A MA of 16 RCT and a total of 7,954 patients that assessed adverse effects of 
the different ACE inhibitors showed 6% of adverse effects with donepezil, 
8% with rivastigmine and 12% with galantamine compared to placebo.
MA of RCT,
1+
The main side effects of memantine are: nausea (2.8%), vomiting (3%), 
dizziness (6.9%), confusion (7.9%), fatigue (2.3%), headache and 
hallucinations.246
In the RCTs, the percentage of side effects that appeared in patients treated 
with memantine was similar to that observed in the placebo group.256
RCT,
1++
In general, some of the side effects are mild, transient or dose-dependent. 
Their appearance can be prevented or minimised by starting treatment with 
low doses and administering progressive ascending doses of each drug until 
the optimal tolerated therapeutic dose is reached.
Technical 
data sheet
180 CLINICAL PRACTICE GUIDELINES IN THE SNS
The recommended starting dose for donepezil is 5 mg/day for 4 weeks, 
progressively increasing to 10 mg/día;246,235 for rivastigmine it is 6-12 mg/
day (oral), starting treatment with 1.5 mg/12 h and increasing 1.5 mg/12 
h every 4 weeks. Via transdermal route it is from 4.6-9.5 mg/day, starting 
treatment with 4.6 mg for 4 weeks and increasing to 9.5 later on.235,246 For 
galantamine the recommended dose is 16 to 24 mg/day, starting treatment 
with a dose of 8 mg/day (non-therapeutic dose) and increasing 8 mg/day 
every 4 weeks.246,235 The recommended dose for memantine is 20 mg/
day started the treatment with 5 mg/day and increasing 5 mg/day every 
week.246,235
Domperidone can be used to treat mild gastrointestinal side effects of ACE 







Epilepsy, asthma or chronic obstructive lung disease, arrhythmias, (with the exception 
of auricular fi brillation), past history of syncopes, third-degree atrioventricular blocks, 
sinus node disease, low blood pressure, presence of bradycardia or long QT, active peptic 
ulcer and urinary retention. They must be used with caution in the case of renal or hepatic 
insuffi ciency.246,140
Memantine: There are no absolute contraindications for its use, but it must be used with 
caution in cases of epilepsy, renal insuffi ciency or urinary retention.246,140
Summary of evidence
1++
Treatment with ACE inhibitors is generally well tolerated.5,140,252,239 The 
most common adverse effects are gastrointestinal, and other less frequent ones 
are anorexia, weight loss, sleep disorders, muscle cramps, urinary incontinence, 
bradycardia and syncope. The adverse effects are usually mild, transient and 
dose-dependent.260,256,253,254,241,264,265,149
1++ The percentage of side effects of memantine in the RCTs was similar to placebo.256
4
To prevent the appearance or to minimise adverse effects, progressive ascending 
doses of all ACE inhibitors and memantine are recommended.234
4
Domperidone can be used to treat mild gastrointestinal effects secondary to ACE 
inhibitors.234
CLINICAL PRACTICE GUIDELINE ON THE COMPREHENSIVE CARE 
OF PEOPLE WITH ALZHEIMER’S DISEASE AND OTHER DEMENTIAS 181 
Recommendations
✓
Following the indications of the technical data sheet of the drug it is recommended 
to assess adverse effects and contraindications of the ACE inhibitors and 
memantine.
D
The administration of a progressive dose of the drug is recommended to avoid 
or reduce the adverse effects of the ACE inhibitors, starting the treatment at low 
doses, to reach the optimal tolerated therapeutic dose.
D
ACE inhibitors must be use with caution in patients with a background of epilepsy, 
asthma or obstructive lung disease, arrhythmias, syncopes, low blood pressure, 
presence of bradycardia or long QT, active peptic ulcer, urinary retention, renal 
or hepatic insuffi ciency. Memantine must be used with caution in patients with a 
background of epilepsy, renal insuffi ciency and urinary retention.
D
Domperidone can be used to treat mild gastrointestinal effects secondary to ACE 
inhibitors.
10.2.6. How effective and safe is the combination of two or more 
specifi c drugs in mild, moderate and severe Alzheimer’s disease?
In a RCT that included 404 patients with moderately severe or severe AD 
(MMSE 5-14) who received treatment with donepezil at a dose of 5-10 mg/
day, memantine was added at a dose of 20 mg/day for 24 weeks to half of 
the patients. The combination of memantine and donepezil was associated 
with a signifi cant improvement of the cognitive function (0.9 vs. -2.5 on 
the SIB scale), with less impairment of ADL (-2.0 vs. -3.4 on the ADCS-
ADL scale 54 points) and an improvement in global clinical status (4.41 
vs. 4.66 on the CIBIC-plus scale of 1 to 7), compared to those treated only 
with donepezil. The results were statistically signifi cant but with little or 
no clinical relevance. 266,215,267In a subsequent analysis of this RCT, it was 
observed that treatment with memantine improved the scores in agitation 
and irritability on the NPI scale after 24 weeks.268
RCT,
1+
A SR of RCT,149 two CPG,140 and consensus of experts269 recommend the 
addition of memantine in patients with moderate to severe AD who received 
treatment with stable doses of donepezil to provide a greater benefi cial 
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A RCT270 performed with 433 patients with mild-moderate AD and MMSE 
between 10-22 receiving stable treatment with any one of the three ACE 
inhibitors, received 20 mg/day of memantine vs. placebo for 24 weeks. No 
signifi cant differences were observed between the group with the addition of 
memantine and the placebo group in any of the variables analysed (ADAS-





In a RCT on patients with moderately severe or severe AD treated with donepezil, 
the addition of memantine produced a minimal improvement compared to 
placebo, in cognitive scales (SIB), of ADL (ADCS-ACL), impression of change 
(CIBIC-plus) and some items of the statistically signifi cant NPI, but with no 
clinical relevance, after 6 months.6
1++/4
A SR of RCT,149 recommends the addition of memantine in patients with 
moderate-severe AD who receive treatment with stable doses of donepezil to 
provide a greater benefi cial effect in cognitive and functional symptoms. That 
same recommendation is formulated in two CPG,140 and in an expert consensus 
document.269
1+
In a RCT on patients with mild to moderate AD, treated with ACE inhibitors, 
the addition of memantine did not give rise to any change after 6 months in any 
variable (ADASCog, CIBIC-plus, ADCS-ADL, NPI or MMSE).270
Recommendations
B
The addition of memantine is recommended in patients with moderate to severe 
AD, treated with donepezil at stable doses in combined therapy.
B
The addition of memantine to donepezil is not recommended to treat patients 
with mild to moderate AD.
10.2.7. When must specifi c pharmacological treatment in 
Alzheimer’s disease end?
There is no scientifi c evidence about the recommended duration of specifi c pharmacological 
treatment in AD, as there are no RCT that assess this item, and therefore the maintenance of 
the treatment or its suspension cannot be recommended, beyond the period studied in the RCT.
In a study where donepezil was interrupted for 6 weeks and was started up 




CLINICAL PRACTICE GUIDELINE ON THE COMPREHENSIVE CARE 
OF PEOPLE WITH ALZHEIMER’S DISEASE AND OTHER DEMENTIAS 183 
Bearing in mind that the disease gets worse in some patients when the 
specifi c pharmacological treatment is withdrawn, this suspension must be 






There are no RCT that assess the duration of specifi c pharmacological treatment 
in AD.
1+
In one study where treatment with donepezil was interrupted for 6 weeks and 
was started up again later, neither cognition nor function returned to the level 
achieved before the interruption.271
Recommendations
✓
Individual assessment of the suspension of specifi c pharmacological treatment 
is recommended, as we have no studies that assess this item, and in the only 
study where the treatment with donepezil was interrupted, neither cognition nor 
function returned to the level achieved before the interruption.
Parkinson’s disease dementia 
10.2.8. What specifi c pharmacological treatment is effective in 
Parkinson’s disease dementia?
There are studies with the three ACE inhibitors in PDD, but the majority are 
open-ended and small in size (<30 patients).5
There is only one RCT272 with rivastigmine, which included 541 patients 
with Parkinson's disease and mild or moderate dementia. Patients treated 
with rivastigmine presented an average improvement of -2.1 points on the 
ADAS-Cog scale compared with placebo group (0.7 points) after 6 months. 
Signifi cant improvements were observed in the scores of ADCS-CGIC in 
19.8% of the patients of the group treated with rivastigmine and in 14.5% 
of the group treated with placebo. A signifi cant improvement was also 
observed in all secondary variables including NPI and ADAS-ADL The 
differences were moderate and similar to the trials with rivastigmine in AD. 
The benefi t was maintained in the extension study for another 6 months.
RCT,
1+
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There are three small sized RCT with donepezil: One crossed pilot trial 
with donepezil in two 10-week periods on 14 patients with PDD273 showed 
an improvement in 42% of the patients treated with donepezil on the 
CIBIC-plus scale, and an improvement of 17% in the placebo group An 
improvement of 2.1 points was observed on the MMSE scale. No changes 
were observed in the NPI scale.
RCT, 
1-
In another RCT with 16 patients treated with donepezil an improvement 
was observed in the memory subscale of the Dementia Rating Scale after 
15 weeks, but not in other scales.274
RCT,
1+
In another crossed trial in two 10-week periods with 22 patients, a signifi cant 
improvement of 2 points was observed in MMSE and 0.37 points in CGI 
in the group treated with donepezil, with no signifi cant improvement in 




In an RCT on PDD (n = 40) and DLB (n = 32) patients to assess the effect of 
memantine at a dose of 10-20 mg/day, a slight but signifi cant improvement 
was observed in the CGI-C scale. No differences were observed in any of 





In one RCT that included 541 patients with PDD, rivastigmine has shown an 
improvement of cognitive function (-2.1 points in ADAS-Cog vs. +0.7 points 
in the placebo group), and a modest improvement in ADCS-CGIC, NPI and 
ADCS-ADL, after 6 months. The results are similar to the studies in AD.272
1+/1-
In three RCTs with the reduced number of patients and short duration,273,274,275 
donepezil has proved to be benefi cial in some variables but not in a consistent 
manner.
1-
In one RCT that included 40 patients with PDD and 32 with DLB,276 memantine 
only showed a slight improvement in CGI-G.
Recommendations
B The use of rivastigmine is recommended in PDD.
B
The use of donepezil may be considered to treat cognitive and functional 
symptoms in PDD.
C There is not enough evidence to recommend the use of memantine in PDD.
CLINICAL PRACTICE GUIDELINE ON THE COMPREHENSIVE CARE 
OF PEOPLE WITH ALZHEIMER’S DISEASE AND OTHER DEMENTIAS 185 
10.2.9. What adverse effects and contraindications exist in 
the specifi c pharmacological treatment of Parkinson’s disease 
dementia?
In one RCT, patients treated with rivastigmine presented a higher 
percentage of nausea, vomiting, dizziness and increase in the intensity of 
tremors (10.3%), than those of the placebo group. A lower mortality rate 
was observed in the group treated with rivastigmine.272
RCT,
1+
In one RCT with a reduced number of patients treated with donepezil, the 
rate of adverse effects was similar to the placebo group and no worsening 
of the parkinsonism was observed.274,273,275
RCT,
1+
In one RCT with memantine, the rate of side effects observed in the group 





In one RCT on patients with PDD and treated with rivastigmine a greater 
incidence of adverse effects was observed as well as an increase in tremors and 
a lower rate of mortality compared with the placebo group.272
1+
In one RCT with donepezil, the rate of adverse effects were similar to the placebo 
group and no worsening of parkinsonism was observed.274,273,275
1+ In RCT with memantine, the rate of adverse effects was similar to the placebo.276
Recommendations
B
In patients affected by PDD, treatment with donepezil and memantine is 
associated with a rate of adverse effects similar to the placebo group, unlike with 
rivastigmine, which showed a higher rate of side effects, an increase in tremors 
and a lower rate of mortality than the placebo group.
10.2.10. How effective and safe is the combination of two or more 
specifi c drugs in Parkinson’s disease dementia?
No RCT has been published in literature that has evaluated the effi cacy and safetyº of combining 
two or more specifi c drugs in Parkinson’s disease dementia.
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Dementia with Lewy bodies
10.2.11. What specifi c pharmacological treatment is effective in 
dementia with Lewy bodies?
One RCT that included 120 patients with DLB treated with rivastigmine 
at a dose of 6-12 mg for 20 weeks showed a modest improvement in 
the "cognitive velocity" variable and in the NIP-4 variable (delusions, 
hallucinations, apathy and depression). 40% of the patients treated and 20% 
of the placebo group showed more than a 30% reduction of the score in 
NPI-4 and in other scores of NPI 10. There were no signifi cant differences 
between both groups on the MMSE scale and no worsening was observed 
in the motor scale of UPDRS.277
Another RCT lasting for 20 weeks that included 92 patients showed an 
improvement in attention, work memory and episodic memory assessed 
according to the Cognitive Drug Research Computerized Cognitive 
Assessment. 278The benefi t observed reverted to the suspension of treatment.
RCT,
1+
Open-ended studies with donepezil and galantamine have shown an 
improvement in cognitive function and BPSD.279,280
RCT,
1-
In the only RCT performed with memantine, which included 72 patients 
(40 with PDD and 32 with DLB) 34 of whom received memantine at a dose 
of 20 mg/day and 38 with placebo for 6 months, the group with memantine 
showed an improvement on the CGIC scale in the group of patients with 
PDD, but this was not statistically signifi cant in the group of patients with 
DLB. The results are not conclusive.
RCT,
1-
Studies on treatment of DLB, with the exception of the McKeith RCT, are scarce, of limited 
methodological quality and low evidence level.277 There are no specifi cally designed studies 
to determine when treatment must be suspended
Summary of evidence
1+
Two RCT with rivastigmine at a dose of 6-12 mg/day, lasting for 20 weeks, 
showed an improvement in cognitive velocity, attention, work memory, episodic 
memory and in BPSD: Delusions, hallucinations, apathy and depression, 
assessed according to the NPI scale.277,278
1-
In open-ended studies, donepezil and galantamine have shown an improvement 
in BPSD and cognitive function.279,280
1-
In one RS T that included a reduced number of patients with PDD and DLB, 
treatment with memantine did not show any clinical improvement.276
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Recommendations
B The use of rivastigmine is recommended to treat BPSD in DLB.
C
The use of donepezil or galantamine may be considered to treat cognitive 
symptoms and BPSD in DLB.
C There is no evidence to recommend the use of memantine in DLB.
10.2.12. What adverse effects and contraindications exist in the 
specifi c pharmacological treatment of dementia with Lewy bodies?
In one RCT with rivastigmine,277 92% of the patients with DLB who received 
an active drug and 75% of those that received placebo presented adverse 
effects. The most frequent were nausea (37%), vomiting (25%), weight loss 
(19%) and drowsiness (9%). In the group treated with rivastigmine, there 
were more dropouts (30% vs. 16%) than in the placebo group.
RCT,
1+
In one RCT with patients with DLB treated with memantine276 the number 
of adverse effects and dropouts was not greater compared with the placebo 





One RCT with rivastigmine,277 showed adverse effects in 92% of the patients 
with DLB who received an active drug and 75% of those that received placebo. 
In the group treated with rivastigmine there were more dropouts (30% vs. 16%).
1+
In one RCT with patients with DLB treated with memantine276 the number of 
adverse effects and dropouts was not greater, compared with the placebo group, 
nor was there any worsening of the motor symptoms.
Recommendations
✓
The most frequent adverse effects observed in treated patients with DLB are: 
nausea, vomiting, weight loss and drowsiness. These were more frequent in 
patients treated with rivastigmine compared to placebo.Those treated with 
memantine compared to placebo had the same adverse effects. The potential 
adverse effects of rivastigmine must be detected and monitored during treatment.
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10.2.13. How effective and safe is the combination of two or more 
specifi c drugs in mild, moderate and severe DLB?
There are no studies that assess the effect of the combination of several specifi c drugs in patients 
with DLB.
10.2.14. How useful are drugs with dopaminergic action in 
dementia with Lewy bodies?
The effi cacy of levodopa on extrapyramidal symptoms in DLB has not been 
assessed in methodological quality studies. In retrospective observational 
studies, both a lack of response to levodopa or a limited response as well 
as a marked response have been described; the results are diffi cult to 
interpret.281 In the few open-ended prospective studies that exist, with a 
reduced number of patients, the motor benefi t associated with the levodopa 




In a study that included patients with DLB (n = 20), PD and PDD, the 
response to the levodopa test (200 mg) was similar in the three groups; 
however, the proportion of responders in the DLB group was less. The 
good response to the levodopa test was indicative of the greater effi cacy of 




In another study,281 a levodopa test was performed (100 mg) on 14 patients 
with DLB, and an average improvement of 13.8% was observed in the 
UPDRS III (less than 20.5V% in PD and 23% in PDD). In 36% of the 




In another study with 19 patients and an average control of 3 months with 
low doses of levodopa (368 mg), only one third of the patients obtained a 
motor improvement (defi ned as an improvement > 10% in UPDRS) and only 





There are no RCTs that assessed the use of dopaminergic agonists in DLB. 
The use of dopaminergic and anticholinergic agonists in DLB can be 
associated with a worsening of the cognitive and psychotic symptoms and 






In open-ended studies with a limited number of patients, levodopa has shown a 
varying degree of improvement on motor symptoms in approximately one third 
of patients with DLB.283
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4
There are no RCT that assess the use of dopaminergic agonists in DLB. According 
to experts, the use of dopaminergic agonists and anticholinergics in DLB can be 
associated with a worsening of the cognitive and psychotic symptoms, producing 
sleep disorders and orthostatic hypotension.6,47
Recommendations
C Levodopa can be used in monotherapy to treat the motor symptoms of DLB.
D
It is advisable to avoid the use of dopaminergic and anticholinergic agonists 
in DLB due to their potential effect of worsening the cognitive and psychotic 
symptoms and producing sleep alterations and orthostatic hypotension.
Frontotemporal lobar degeneration
10.2.15. Which pharmacological treatment is effective in 
cognitive and behavioural manifestations of frontotemporal lobar 
degeneration?
No drug has been specifi cally approved today by the European Medicines Agency (AGEMED) 
or the American Food and Drug Administration (FDA) to treat patients with FTLD. No RCT 
has been published with large samples of patients.
In the three SR,149,284,285 that included RCT, open-ended studies and case 
series published until June 2008, none of the drugs assessed, which included 
donepezil (an open-ended study), galantamine (an open-ended study), 
rivastigmine (an open-ended study), selegiline (an open-ended study), 
methylphenidate (a RCT), selective serotonin reuptake inhibitors (SSRI) 
(two RCTs, four open-ended studies), trazodone and atypical neuroleptics, 
showed a benefi cial effect on the stabilisation or improvement of cognition 
of patients with FTLD.
SR of RCT, 
1+/1-
One randomised open-ended study286 did not show any cognitive improvement 




Three studies performed with memantine (two open-ended studies)285,287 and 
a series of cases285 did not prove to be effective on cognition, and showed 
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With respect to behavioural alterations, two SR284,285 and the experts support 
the use of SSRI (three open-ended studies, one RCT), trazodone (one RCT) 
and atypical neuroleptics (one open-ended study) for the symptomatic 
treatment of behavioural disorders in FTLD, especially in the treatment of 
inappropriate, compulsive behaviour, stereotypies and agitation. The SSRI 
could be considered as fi rst-line drugs to treat behavioural alterations as 
they have a low percentage of side effects. Trazodone may produce hyper-
drowsiness and atypical neuroleptics, hyper-drowsiness, weight increase 
and extrapyramidal effects.
SR of RCT, 
1+/1-
One open-ended study with rivastigmine showed a slight behavioural 





ACE inhibitors or memantine are not effective to treat cognitive-behavioural 
symptoms of patients with FTLD.149,284,286
1+/1-
ACE inhibitors, trazodone and atypical neuroleptics are effective to treat 




The use of ACE inhibitors or memantine to treat cognitive-behavioural symptoms 
of patients with FTLD is not recommended.
B
The use of selective serotonin reuptake inhibitors, trazodone or atypical 
neuroleptics is recommended to treat agitation, inappropriate behaviour, 
compulsions or stereotypies in patients with FTLD
Vascular Dementia
10.2.16. Which specifi c pharmacological treatment is effective in 
mild, moderate and severe vascular dementia?
It has been observed that ACE inhibitors may improve the cognitive symptoms of VD and mild 
to moderate dementia with vascular brain lesions, although they are not authorised by the FDA or 
by the EMEA for this indication.
One SR288 on the treatment of VD with ACE inhibitors showed that donepezil was the 
most effective and best tolerated treatment. Galantamine was also effective but worse tolerated. 
Rivastigmine has proven to have a benefi cial effect in patients with dementia and high scores on 
the Hachinski scale, as well as an improvement in some scales in patients with VD diagnosed ac-
cording to NINDS-AIREN criteria. Memantine has not proved to be effective in cognitive func-
tions or in global clinical function and it is well tolerated.
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Different vascular pathologies are included under the title of VD, with lesions at different 
levels and a different therapeutic response and course of evolution. Two RCT with donepezil289,290 
proved to be more benefi cial in patients with VD who had cortical or multi-territorial lesions 
compared with those who had subcortical lesions.
The studies carried out are short in duration and include an heterogeneous population (patients 
with AD, VD or mixed), and they do not assess either behavioural disorders or quality of life.140
Donepezil
In two RCT with donepezil on mild-to-moderate VD, lasting for 6 months, 
one of them289 with 603 patients. treated with donepezil, showed an 
improvement on the ADAS-Cog scale compared to placebo (5 mg/day,-
1.90 points; 10 mg day,-2.33 points); with respect to global function, an 
improvement was observed in the CIBIC-plus for 5 mg/day and in the 
CDR for 10 mg/day; a benefi t was observed compared to placebo in ADL 
(average difference in ADFACS: 5 mg/day, –1,31 points; 10 mg/day, –1,31 
points).289,290 In the other RCT 290 with 616 patients, donepezil showed 
an improvement in ADAS-Cog (5 mg/day, –1,65 points; 10 mg/day, –2,09 
points) and in the CIBIC-plus (25% improvement of the placebo group, 
39% of the group of 5 mg/day and 32% of the group of 10 mg/day).
A Cochrane RS, in a study with donepezil observed a cognitive benefi t but 
inconsistent effects on global measures and on ADL291. Donepezil showed 
an improvement in cognitive scales after 12 and 24 weeks with 5-10 mg/
day (ADAS-Cog, MMSE), in global clinical impression (CDR-SB after 24 
weeks with 10 mg > 5 mg > placebo, CIBIC-plus only with 5 mg/day) and 
in functional capacity (improvement in IADL with the dose of 10 mg/day, 
ADFACS with 5 10 mg/day), with good tolerance.291,140,5
RCT,
1+
Another RCT with 974 patients with VD showed the effi cacy of donepezil 
in cognitive scales (V-ADAS-Cog), but not in the other variables.292
RCT,
1+
In an open-ended study, on patients treated with donepezil at doses of 
5 and 10 mg/day, during a period of up to 156 weeks, the improvement 




In a RCT with 168 patients with CADASIL a benefi cial effect of donepezil 
was observed in secondary variables (tracking test, executive functions), 
but not on the main variable ((V-ADASCog).293
RCT,
1+
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Rivastigmine
In one single RCT performed with rivastigmine on VD238 with the 
participation of 710 patients, rivastigmine was effective to exclusively 
improve cognitive symptoms (ADAS-Cog, VADAS, MMSE) after 6 months. 
This improvement was only observed in older patients who supposedly had 
more possibility of having concomitant AD.
RCT,
1+
In a RCT on 208 patients with VD with subcortical lesions treated with 
rivastigmine vs. acetylsalicylic acid, a benefi t on cognition was observed 





Two RCT on VD that included 592 patients with dementia and 
cerebrovascular disease, receiving treatment with galantamine at a dose 
of 16-24 mg/day showed a benefi t, at 24 weeks, in coordination (ADAS-
Cog DMP -2.29 points), in global clinical status (CIBIC-plus: Number of 
patients without changes or worse OR = 1.97), in ADL (DAD DMP 4.1 
points) and behaviour (NPI DMP –2.06 points). This effect was maintained 
after 12 months in an open-ended extension study. 295It was not possible to 
demonstrate this benefi t in the subanalysis of the patients that would satisfy 
NINDS-AIREN criteria for VD. In the subgroup of patients with probable 
VD (188 patients), the scores on the ADAS-Cog improved by 2.4 points vs. 
0.4 points in the placebo group, and the proportion of improved scores on 




786 patients were included in the other study. 298 Galantamine was effective 
for cognition at 26 weeks (improvement of-1.8 points on the ADAS-Cog 
scale,-0.3 points in the placebo group), with no signifi cant difference in the 
percentage of patients who responded (ADAS-Cog and ADCS-ADL), or in 
the CIBIC-plus or NPI score. A slight improvement in cognitive function 
was detected (2.4 points on the EXIT-25 scale in the galantamine group 
compared with -1.4 in the placebo group.
RCT,
1+
Another two RCTs assessed the effect of galantamine at a dose of 16-24 
mg/day in patients with VD or with AD associated with cerebrovascular 
disease. One of them with 396 patients in the active group and 196 in the 
placebo group299 and another study with 740 patients, treated for 26 weeks,298 
show that galantamine was effective for cognition (ADAS-Cog) and that it 
stabilised or slightly improved the CIBIC-plus.
RCT,
1+
CLINICAL PRACTICE GUIDELINE ON THE COMPREHENSIVE CARE 
OF PEOPLE WITH ALZHEIMER’S DISEASE AND OTHER DEMENTIAS 193 
According to a Cochrane MA300, galantamine can be useful in VD, although 





In a Cochrane SR,256 the data of two studies performed on patients with 
mild to moderate VD treated with memantine at a dose of 20 mg/day, for 28 
weeks, showed a slight benefi cial effect on cognition (1.85 points in ADAS-
Cog) and on behaviour (less cases of agitation than in the placebo group, 
4.3% vs. 7.7%, OR = 0.54). No benefi t was observed in global function. 
In the fi rst study301 with 321 patients, a signifi cant improvement in ADAS-
Cog was achieved at 7 months (0.4 points compared with -1 point in the 
placebo group). The response rate for CIBIC-plus, defi ned as improvement 
or stability, was not different in either group. In the other study302 with 579 
patients, an improvement was also observed in ADAS-Cog at 7 months 
(-1.75 points), but not in CGI-C or in functional capacity variables (CGB, 
NOSGER). A post hoc analysis of both studies suggests that memantine 
may be more effective in people with small vessel VD.303,279
RCT,
1+
One RCT MA concludes that patients with mild to moderate VD who 
received memantine suffered less cognitive impairment at 28 weeks, but 





Donepezil 5-10 mg/day has shown an improvement with respect to placebo in 
cognitive scales, global clinical impression and in functional capacity at 12 and 
24 weeks in patients with VD.292,289,290
1+
In a study of patients with CADASIL, donepezil did not prove to be benefi cial 
in the V-ADAS-Cog score.292,293
1+
Rivastigmine only improved the cognitive symptoms in a study on patients with 
VD.238
1+
In patients with VD, galantamine has shown an improvement at 6 months with 
respect to placebo in cognitive symptoms (ADAS-Cog), and stability or slight 
improvement in global clinical impression.298,295,297,296
1+
Galantamine has not proved to be benefi cial in ADL or behaviour in patients 
with VD.296,298
4
According to the opinion of the authors of the RCT, the benefi t of all ACE 
inhibitors on VD could be due to the associated AD component.299,298,300
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1+
Memantine has shown an improvement at 6 months with respect to placebo in 
patients with VD, only in cognitive symptoms (ADAS-Cog).301,256,279
1++
The ACE inhibitors and memantine have proved to be effective on cognitive 
improvement in VD.237,289,290,292,301,302,256
Recommendations
A The use of ACE inhibitors is recommended in mild to moderate VD.
A
ACE inhibitors are recommended to improve the cognitive symptoms of mild 
to moderate VD.
A
Donepezil is recommended to improve the global clinical impression and 
functional defi ciencies (ADL) in VD.
A
The use of galantamine is recommended to treat cognitive symptoms, functional 
defi ciency and BPSD in patients with mild to moderate VD, mixed dementia 
and/or AD with cerebrovascular disease.
C Rivastigmine may be used to improve cognition in VD.
A
Memantine may be used to treat cognitive symptoms of moderate and severe 
VD.
10.2.17. What infl uence does specifi c pharmacological treatment 
have on vascular dementia with respect to cognitive, behavioural, 
functional manifestations and/or quality of life?
In studies of VD, treated with ACE inhibitors or memantine, the benefi cial 
results are conclusive with respect to its action on cognitive manifestations. 
The benefi t on cognition and in these patients has been assessed via the 
ADAS-Cog scale and a change has been observed of -2.17 points for 
donepezil, -1.18 points for memantine, -1.60 points for galantamine and-
1.10 points for rivastigmine. Donepezil at a dose of 5 mg/day did not show 
any benefi t in the ADL assessed using the ADCS-ADL, DAD, ADFACS 
scales. At a dose of 10 mg/day the benefi t was limited 256,289,290,292,301,302
The quality of life of patients with VD and of their caregivers was not 
assessed in any study.
RCT, 
1+
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Summary of evidence
1+
In VD, the cognitive improvement assessed with the ADAS-Cog scale was -2.17 
points for donepezil, -1.60 points for galantamine, -1.10 points for rivastigmine 
and -1.88 points for memantine.256,289,290,292,301,302
1+
In VD, neither ACE inhibitors nor memantine have shown an improvement in 
behavioural symptoms.289,290,292,301,302,256
1+
Donepezil showed an improvement or no change on the CIBIC-plus scale of 
clinical impression at a dose of 5 mg/day, and an improvement of ADL at a dose 
of 10 mg/day, in two of the three available studies.302,289,292
-
There is no evidence in VD of the infl uence of ACE inhibitors and/or memantine 
on the quality of life of patients and of their caregivers.
Recommendations
B ACE inhibitors may be used to treat cognitive symptoms of VD.
B
ACE inhibitors and/or memantine are not recommended to manage behavioural 
symptoms in VD.
10.2.18. What adverse effects and contraindications exist in the 
pharmacological treatment of vascular dementia?
The adverse effects and contraindications of all ACE inhibitors and/or memantine in VD, 
mixed dementia or AD associated with cerebrovascular disease are the same as commented in 
the chapter on specifi c pharmacological treatment of AD (question 10.2.5). However, patients 
with VD usually have more vascular risk factors and the treatment of these factors increases 
the possibility of pharmacological interactions.
In the RCTs of VD, patients treated with ACE inhibitors (donepezil, 
galantamine, rivastigmine) presented more adverse effects than in the 
placebo group. In general they were slight, they went away when treatment 
was withdrawn, and it was rarely necessary to discontinue it.300
RCT, 
1++
In one RCT, 21.8% of dropouts was observed due to the appearance of 
adverse effects on patients treated with donepezil at a dose of 10 mg/day 
vs. 11.1% of dropouts in the placebo group.289 In another RCT, 8.8% were 
withdrawn due to adverse effects with donepezil at a dose of 5 mg/day and 
16.3% at a dose of 10 mg/day vs. 10.1% in the placebo group.290
RCT, 
1++
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The percentage of people treated with donepezil at a dose of 10 mg/day, 
who dropped out, was 26.3% compared with placebo (15.8%), in those 
treated with galantamine (24.4%) with respect to placebo (15.7%) and 
with rivastigmine (24.7%) compared with placebo (13.9%). There were 
no differences in the percentage of dropouts between those treated with 
donepezil 5 mg/day placebo or between those treated with memantine and 
placebo.300
The most serious adverse effects were syncopes, bradycardia and the 
possibility of a stroke. Deaths attributed to donepezil in patients with VD 
are rare and controversial. 42Bearing in mind that patients with VD usually 
have a high cardiovascular risk, the possibility of the ACE inhibitors being 
able to cause potentially serious effects requires caution in their use and 
stepping up surveillance in their management
RCT,
1++
In patients with mild to moderate VD who received 20 mg/day of memantine 
for 28 weeks, the dropout rates and the number of people with adverse 






The adverse effects of ACE inhibitors and memantine on patients with VD are 
similar to those observed in patients with AD.256
1++
The number of dropouts from the treatment in the RCT for VD was higher with 
ACE inhibitors (around 25%) than with placebo (around 15%) for a dose of 10 
mg/day.300
1++
In people with VD treated with specifi c drugs, there were no differences in the 
percentage of dropouts between those treated with donepezil 5 mg/day and 
placebo or between those treated with memantine and placebo.300
1++
In VD treated with all ACE inhibitors, serious adverse effects (syncope, 
bradycardia, stroke) are not very frequent.42
1++
Patients with mild to moderate VD treated with 20 g/day of memantine, for 28 




Bearing in mind that patients with VD usually suffer a high cardiovascular risk, 
treatment with ACE inhibitors should be assessed individually, paying special 
attention to how the treatment is managed.
✓ It is advisable to follow the indications given in the product technical data sheet.
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Other pharmacological treatments
10.2.19. Are any other pharmacological treatments effective to treat 
cognitive and function al functions in people affected by any type of 
dementia?
Drugs placed on the market today have been included in this section and whose effi cacy in AD 
or any other type of dementia has been proven in quality RCT, and which have not been included 
in any other sections of this guideline. Drugs that have been exclusively approved in clinical trial 
context (current or past) have not been included.
Hormone treatments
Therapy with adrenocorticotropic hormone analogues (ACTH) and 
prednisone has not proved to be effective in the treatment of AD.304
RCT,
1++
Two CPGs5,235 conclude that there is no evidence of the effi cacy of oestrogen treatment or 
hormonal replacement therapy (HRT) to treat or prevent AD, and some studies even suggest 
an increased risk of cognitive impairment associated with their use.
One SR149 concluded that the available evidence did not support the effi cacy 
of dehydroepiandrosterone in improving memory or other cognitive aspects 
in healthy elderly people, although there are no quality studies that assess 
its effi cacy in individuals with dementia.
SR of RCT, 
1++
Non-steroid Anti-infl ammatory drugs (NSAID)
One SR149 concluded that there is evidence about the lack of effi cacy of 
ibuprofen, indometacine or low doses of naproxen in the treatment of AD.
SR of RCT, 
1++
Piracetam
One SR149 assessed the effi cacy of the treatment with piracetam in AD and 
other types of dementia, analysing 68 studies. Only three were controlled over 
a period of more than 3 months and many of them had low methodological 
quality. The conclusion of the reviewers was that the results did not support 
the use of piracetam in dementia or in MCI, as the benefi t on the global 
change impression was small and not confi rmed in more specifi c measures.
SR of RCT, 
1++
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Propentofylline
One SR149, which included four RCT published until February 2003, 
concluded that propentofylline did not show any benefi t in the treatment of 
cognition, global function or ADL in patients with AD or VD.




One Cochrane SR305 that included studies published until August 2001 on 
the effi cacy of nimodipine in the treatment of AD or VD, concluded that it 
may be benefi cial at a dose of 90 mg/day, in global cognitive function at 12 




A later RCT with VD306 did not show any benefi t either at 52 weeks. RCT,
1+
Selegiline
One RCT that assessed the effi cacy of selegiline in AD showed certain 
effi cacy at 3 months, which was not corroborated in subsequent RCT at 6 
months or 2 years. 304The EFNS CPG5 concludes that there is not enough 





One RCT that assessed the effi cacy of idebenone in AD showed no relevant 




One Cochrane RS307 that included 19 RCT published until November 2000 
concluded that although mesylate dihydroergotoxine showed benefi t when 
assessed with global impression scales, due to the fact that the majority 
of the studies were old, with not very specifi c assessment or diagnosis 
criteria, a benefi cial effect of mesylate dihydroergotoxine on the treatment 
of dementia in general and on certain subtypes (AD or VD) in particular 
could not be concluded.
SR of RCT, 
1++/1+
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Citicholine or Citidindiphosphocholine (CDP-choline)
One Cochrane SR308 assessed 14 RCT published until 2004 on the effi cacy of 
citicholine in the treatment of cognitive alterations in patients with vascular 
cognitive impairment of different degrees, although some of them are not 
valid for analysis, given that they included a small number of individuals 
and only one presented a control of less than 3 months. A second benefi t 
of citicholine was objectifi ed in memory, behaviour and global change 
impression, although this conclusion was limited by the short duration of the 
studies, the different dosages and administration pathways (5 intravenous, 5 
intramuscular and 4 oral), inclusion criteria and methodology.
The only RCT at 12 months included in the Cochrane SR308 did not 
objectify any benefi t of citicholine administered orally in the treatment of 
VD, although the number of individuals included in the study was small. 
No relevant side effects were observed, but it must be highlighted that the 
tolerability and applicability of the parenteral administration pathways 
limits its prolonged use both in research and in clinical practice.
SR OF RCT, 
1+
No quality studies have been found that assess the effi cacy of citicholine in the treatment of 




Hormone treatments, ACTH, prednisone304, oestrogens304 and dehydroepian-
drosterone149 are not effective in AD and may have harmful effects.5,235,149,304
NSAID
1++
Neither ibuprofen, indometacine nor low doses of naproxen are effective in the 
treatment of AD.149
Piracetam
1++ Piracetam has not proved to be effective in the treatment of AD.149
Propentofylline
1++ Propentofylline is not effective in the treatment of AD or VD.149
Nimodipine
1+ Nimodipine is not effective in the treatment of VD.305,306
Selegiline
1++ Selegiline is not effective in the treatment of AD.304,5
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Ibedenone




Dihydroergotoxine mesylate has not proved to be effective in the treatment of 
dementia in general or on subtypes (AD or VD).307
Citicholine or CDP-choline
1+
The oral administration of citicholine or CDP-choline is not effective in the 
treatment of VD.308
1+
The parenteral administration of citicholine or CDP-choline could have a certain 
benefi cial effect on the treatment of vascular cognitive impairment in the short-
term 308
4
Parenteral administration limits the use of citicholine or CDP-choline in clinical 




Hormonal therapies (ACTH, prednisone, oestrogens, dehydroepiandrosterone) 
are not recommended as treatment of AD.
NSAID
A
Neither ibuprofen, indometacine nor low doses of naproxen are recommended 
to treat AD.
Piracetam
A Piracetam is not recommended to treat AD.
Propentofylline
A Propentofylline is not recommended to treat AD or VD.
Nimodipine
B Nimodipine is not recommended to treat VD.
Selegiline
A Selegiline is not recommended to treat AD.
Ibedenone
A Ibedenone is not recommended to treat AD.
Dihydroergotoxine mesylate
B Dihydroergotoxine mesylate is not recommended to treat AD or VD.
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Citicholine or CDP-choline
B
The oral administration of neither citicoline nor CDP-choline are recommended 
to treat VD.
D
The parenteral administration of neither citicoline nor CDP-choline are 
recommended to treat vascular cognitive impairment..
10.3. Non-pharmacological treatment of dementias
Questions to be answered
Cognitive intervention or stimulation
10.3.1. What is cognitive intervention or stimulation?
10.3.2. What types of cognitive intervention exist?
10.3.3. Are cognitive intervention programmes effective in dementia? 
10.3.4. Are computer-based cognitive intervention programmes effective in patients with 
Alzheimer’s disease?
10.3.5. Are cognitive intervention programmes indicated in illiterate individuals or in patients 
with severe sensory limitations? 
10.3.6. Are individual cognitive interventions recommendable?
Intervention programmes on activities of daily living
10.3.7. What do intervention programmes on activities of daily living consist of in patients 
with dementia?
10.3.8. Do intervention programmes on activities of daily living improve the functionality of 
people with dementia?
Physical activity programmes
10.3.9. Are physical activity programmes effective in improving or stabilising the functional 
capacity and cognitive functions of patients affected by dementia?
Other non-pharmacological treatments
10.3.10. Are there any other non-pharmacological treatments that are effective in cognitive, 
functional, motor and/or quality of life manifestations in dementias?
Safety of non-pharmacological treatments
10.3.11. May non-pharmacological treatments used in dementia have harmful effects?
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Cognitive intervention or stimulation
10.3.1. What is cognitive intervention or stimulation?
There is no agreement in literature about the most appropriate nomenclature to name those ac-
tivities that promote the fostering, maintenance or recuperation of cognitive skills and/or favour 
independence for ADL and socialisation. The most common terms are cognitive intervention,309 
cognitive stimulation,6 psycho-cognitive therapy or psychosocial therapies.25 In this guideline we 
will use the term cognitive intervention.
10.3.2. What types of cognitive intervention exist?
The NICE CPG classifi es psycho-cognitive therapies into cognitive stimulation, cognitive reha-
bilitation and cognitive training. Cognitive stimulation in this sense would include those therapies 
that entail exposure and participation in activities and materials that require a type of general 
cognitive processing and which is normally done in a group with a social context. On the other 
hand, cognitive training would include those therapies focused on one single cognitive domain 
and cognitive rehabilitation would refer to those therapies specifi cally designed to cover the needs 
of a specifi c individual, and therefore are done individually.
Other authors310 classify cognitive interventions into compensatory and restorative therapies. 
Compensatory strategies would be those whose objective is to teach new ways of carrying out 
cognitive tasks. They can use internal strategies, such as organising information, classifying or 
visualising information to remember, encoding through multiple sensory channels, asking and 
paraphrasing during learning, and focusing on one single task or else external strategies such as 
details of the environment, memory notebooks, calendars or agendas. Training in procedures can 
also be used to be able to carry out complex behaviours mediated by higher-order cognitive pro-
cesses. Restoration strategies seek to improve functioning in specifi c domains in order to recuper-
ate the functioning of these domains at premorbid level.
More specifi cally, the main cognitive intervention techniques described in literature are re-
ality counselling techniques, reminiscence, validation, memory training or other basic cognitive 
functions, sensory stimulation and ADL training (question 10.3.9.)6,311
Reality therapy counselling: This is a group technique that aims to improve the patient’ cogni-
tive and behavioural defi cits, using all possible sensory modalities to provide updated and true 
information about the patient and his or her environment.
Reminiscence therapy: This is based on the fact that by reviewing patients’ own past with the 
help of signifi cant stimuli, this will foster their coherence and adjustment to their environment. Its 
aim is to improve memory, favour creativity and increase the re-socialisation of patients, stimu-
lating conversation. It also aims to increase self-esteem, personal satisfaction, well-being and 
satisfaction with life.
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Validation therapy: It purports to establish a communication with patients with dementia by 
means of accepting reality and convictions as these are experienced by the patient.
Cognitive training: This consists in the supervised repetition of a series of activities designed to 
exercise a specifi c cognitive function, such as memory, attention or planning, and it can be carried 
out in different environments and formats (individual, group, computer-based, etc). Cognitive 
training is based on the hypothesis that the repetition of an activity can improve or maintain the 
functional capacity in the area trained, going beyond the actual training session.
Sensory stimulation: It purports to offer sensory stimuli, either of a certain sensory modality 
(music therapy, aromatherapy, massages, etc), or in a multisensory way (snoezelen), to patients 
with dementia to favour their cognitive activity.
10.3.3. Are cognitive intervention programmes effective in 
dementia? 
A series of limitations can be seen in the review of literature, which make it diffi cult to 
answer the question formulated. One of these limitations is the small number of high-quality 
methodological studies, as well as the use of different terminology and of programmes that 
include different combined cognitive interventions (so it is not possible to assess each one of 
them separately), different measurement instruments, and the possibility of the existence of a 
publication bias towards the studies that prove to be effective.
A MA of RCT310 that assessed 19 controlled studies carried out until 
December 2004, of which only fi ve were considered "quality", on different 
cognitive interventions in patients with AD or dementia in general, in mild 
or moderate stages, concluded that cognitive interventions can improve 
the cognition and functionality of patients with AD or dementia in mild 
or moderate stages, although the magnitude of the effect is very variable 
among the different aspects assessed and the different studies.
The greatest benefi t was detected in the executive capacity, in verbal and 
visual learning and in ADL. This MA found differences in the results of 
different cognitive interventions. Four of the fi ve interventions that turned 
out to be more benefi cial used general cognitive stimulation techniques, 
which, according to the authors, supports the idea that maintaining high 
mental activity levels can have a benefi cial effect. The restorative techniques 
presented a greater effect, although not a signifi cant one, than compensatory 
therapies, but this difference was not noticed when restricted to the fi ve 
studies with the greatest methodological rigour.
MA of RCT,
1+
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This MA underlines that the magnitudes of the effects of the intervention 
were greater in those studies that used individuals on the waiting list, 
respect to those that used placebo intervention (higher quality studies), and 
it suggests that part of the effect of the intervention may be mediated by the 
attention received and the social interaction programme rather than by the 
actual cognitive intervention. These studies, which provided control data 
following the interruption of the therapy, showed a positive effect up to 4.5 
months.
The NICE CPG25 included 19 RCT in its review on the topic (until 2006), 
in six of which cognitive intervention entailed reality counselling, in six 
reminiscence therapy, in six memory training, cognitive rehabilitation in 
one and multisensory therapy in 1 study. All of them were carried out on 
patients with dementia, mainly AD in mild or moderate stages. Only the 
multisensory therapy study included patients in severe stage.
SR of RCT,
1+/1-
Four of the RCT included, specifi cally compared the effect of the stable 
therapy with ACE inhibitors (donepezil or rivastigmine) combined with 
cognitive stimulation compared with treatment with ACE inhibitors in 
an isolated manner,25 three of which showed improvements or cognitive 
stabilisation in those individuals who received combined treatment 
compared with those that only received the drug, whilst the only study that 
did not notice any differences was, on the other hand, the only one that 
used a cognitive activity as control. The authors concluded that there was 
reasonable evidence to support the use of cognitive intervention programmes 
in people with mild to moderate dementia, mainly AD, due to signs of 
improvement in quality of life that accompanied the modest improvements 
in cognitive function. They conclude, too, that cognitive training does not 
appear to be associated with benefi ts beyond the tasks trained, and that there 
is not enough evidence to assess the effects of reminiscence therapy and of 
cognitive rehabilitation in connection with the cognitive function in patients 
with dementia.
The CPG of the Canadian Consensus Conference on the Diagnosis and 
Treatment of Dementia (CCCDTD) of 2007,152 after reviewing three RCT, 
concludes that there is not enough evidence to make a recommendation 
(grade C) on cognitive training or cognitive rehabilitation with reference 




One RCT carried out in Spain312 objectifi ed cognitive stabilisation at six 
months in patients with AD in mild or moderate stages receiving stable 
treatment with ACE inhibitors after carrying out a combined activity 
programme that included cognitive stimulation, physical exercise and social 
activities with respect to controls that only received psychosocial support.
RCT,
1+
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The CCCDTD 2007,152 based on a RCT, considers that there was not enough 
evidence to recommend the execution of cognitive interventions in VD. A 
later RCT313 did not demonstrate the effi cacy of cognitive stimulation in 
VD. Similar cognitive interventions were applied in these two studies to 
those carried out on individuals with AD.
RCT,
1+
Several low quality methodological studies (case or series of clinical cases 
due to the low frequency of the disease) suggests that cognitive training can 
be effective in re-learning words in semantic dementia, although they did 
not assess the possible relevance of these improvements on the nomination 








Cognitive intervention programmes are effective with mild or moderate AD, to 
maintain their cognitive function, their functionality and quality of life, although 
the magnitude of the effect attributable to the actual cognitive intervention is not 
well established.310
1+
There is no direct evidence about whether one cognitive intervention is more effec-
tive than another in patients with mild or moderate AD, although interventions that 
require a general processing type seem to have a greater overall benefi t than those 
where cognitive training of specifi c functions is carried out.152
1+




The participation in cognitive intervention programmes is recommendable in pa-
tients with mild or moderate AD, to maintain their cognitive function, their func-
tionality and quality of life, although the magnitude of the effect attributable to the 
actual cognitive intervention is not well established.
C
There is currently no evidence of the effi cacy of cognitive stimulation in individu-
als with VD to recommend its use in this dementia subtype.
–
A type of specifi c cognitive intervention cannot be recommended at the present 
time, based on the degree of effi cacy in patients with mild or moderate AD, al-
though interventions that require a general processing type seem to have a greater 
overall benefi t than those where cognitive training of specifi c functions is carried 
out.
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10.3.4. Are computer-based cognitive intervention programmes 
effective in patients with Alzheimer’s disease?
Several studies in literature use computer support as part of a broader cognitive stimulation pro-
gramme, but only three RCT have been detected that assessed the usefulness of computer-based 
cognitive stimulation in an isolated way.25
One of them315 did not show any benefi t of a memory training programme 
compared with the social support programme.
RCT,
1-
Another of these RCT316 observed a slight improvement in global cognitive 
functions over a 24 week period when comparing the effect of a multimedia 
programme associated with a global cognitive intervention programme, and 
ACE inhibitors compared with the stimulation programme with ACE inhibi-
tors or ACE inhibitors alone in initial AD.
RCT,
1-
A third RCT did not show signifi cant benefi ts on comparing an intensive com-
puter-based intervention programme with passive computer-based activity on 





There is contradictory evidence about the benefi ts of computer-based cognitive 
intervention programmes in initial AD or mild cognitive impairment.315,316,317
Recommendation
C
The use of computer-based cognitive intervention programmes in initial AD or 
mild cognitive impairment cannot be recommended at the present time.
10.3.5. Are cognitive intervention programmes indicated in illiterate 
individuals or in patients with severe sensory limitations?
The majority of the studies exclude those individuals with sensory defi cits in the stimulus pres-
entation modalities or those for whom the intervention result measurement instruments are not 
valid. However, no evidence has been found in literature to answer this question.
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10.3.6. Are individual cognitive interventions recommendable?
An MA of RCT310 that assessed 19 controlled studies on cognitive interven-
tions in AD carried out until December 2004, show that the studies that as-
sessed individualised interventions (eight studies) presented a positive effect 
with respect to control intervention, with a small effect magnitude, although 
this was greater when the control condition was the waiting list than when 
it was a programmed activity. The individual interventions also presented a 
greater positive effect magnitude, although not a signifi cant one, than studies 
on group interventions (10 studies), although this difference appeared when 
the fi ve higher quality methodological studies were analysed. This MA con-
cludes that it cannot be established if the possible greater effect of individual 
therapy is due to greater individual attention or to the design of the most ap-
propriate therapy for the individual. The authors point out that whatever the 
reason, this fi nding provides evidence of the potential therapeutic effect of 
individualised attention to patients, administered by their relatives on the pa-






Individual cognitive interventions are effective to stabilise the cognitive function 
and functionality of individuals with AD.
1–
There is not enough evidence to establish if individual interventions are more ef-
fective than group interventions or vice versa.
Recommendation
B
Individual cognitive interventions are recommendable to stabilise the cognitive 
function and functionality of individuals with AD.
-
The use of individual interventions rather than group interventions cannot be rec-
ommended or vice versa.
Intervention programmes on activities of daily living
10.3.7 What do intervention programmes on daily living consist of in 
patients with dementia?
Activities of daily living (ADL) are the series of actions that people execute every day or almost 
on an everyday basis to live autonomously and integrated into their environment and play their 
social role.318,319
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The most normal way of classifying ADL320 is into basic activities (BADL), instrumental 
activities (IADL) and advanced activities (AADL).318,319 ADL have a hierarchical structure and 
increase in complexity as the level increases and, in the majority of the cases, if the activities of 
one level can be carried out, this means that those of the lower levels can also be carried out. Thus, 
BADL are essential to survive, IADL are necessary to live independently and AADL are neces-
sary for a socially satisfactory life. 321
Intervention programmes on ADL are actions whose aim is to maximise the autonomy of 
patients in their daily lives. These programmes are based on the statement that functional depend-
ence is a multi-cause phenomenon and they cannot only be attributed to the organic conditioning 
factors of the disease, but that they must also take into account the psychological and contextual 
factors (physical and social environment) which may contribute to maintaining it and increasing it.
Excess disability refers to the impairment caused by the lack of use of preserved capacities 
that are not the direct consequence of a state of physical fragility or disease and which have a 
reversible nature. Thus, excess disability means attributing dependence behaviours to the disease 
when, in fact, they are also derived from another more benign source which is reversible. 322It 
must also be taken into account that excess care also fosters excess disability: Providing unneces-
sary aid eliminates opportunities to stimulate, exercise and practice self-care skills. 323Based on all 
of this, the intervention programmes on ADL consist of giving caregivers adequate strategies to 
maximise the functional independence behaviours of people with dementia. These strategies are:
The graded assistance technique:324 this covers a whole spectrum of assistance for people with 
dementia, consisting in providing the minimal aid that the person needs at a given moment of 
the evolution, to thus be able to develop their activities of daily living. This spectrum of actions 
contemplates the following grades, which go from minimum to maximum care. a) verbal guide-
lines; b) demonstration of the activity; c) physical guideline; d) partial physical assistance; e) full 
physical assistance.
Functionality retraining sessions: An individual intervention where objective behaviours are 
established and the person is asked to practice them at different times of the day, applying positive 
reinforcement and using the techniques of intensive practice, repetition and graded assistance.
Use of compensatory strategies: Used to adapt the activities of daily living to the patients’ dis-
abilities (use of agendas, alarms, notebooks, etc).
Environmental modifi cations: Changes made in the physical environment to minimise the dis-
ability.
Training the caregiver: To increase their perception of competence and control over the situa-
tions.
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Occupational therapists play an outstanding role in ADL intervention programmes, both in 
the assessment of needs and in the design of the intervention programme.
10.3.8. Do intervention programmes on activities of daily living 
improve the functionality of people with dementia?
There are very few studies that analyse the effects of intervention programmes 
of ADL. Two RCTs have been identifi ed that use different populations of indi-
viduals: People with dementia who live at home with a caregiver325 compared 
with people with dementia that live in geriatric homes.326 Different types of in-
terventions were used in both studies: Group training in ADL for 20 weeks326, 
and individual intervention that consisted of teaching compensatory strategies 
and environmental modifi cations, and training for the caregiver for 5 weeks.325
Both studies showed an improvement in the individuals’ functionality, which 
was maintained in the Graff study325 after suspending the intervention, and 
they pointed out that it is possible to improve functionality if direct action is 
taken on the ADL and this is consistent with the theory of excess disability. 
Both studies also highlight the importance of training the caregivers (formal 
or informal) in the acquisition of adequate strategies to maximise functional 





The execution of intervention programmes on activities of daily living is effective 
to improve the functionality of patients with dementia and decrease the strain on 
the caregiver in the medium term, both in institutionalised individuals and indi-
viduals who live in the family home.325,326
Recommendation
B
Intervention programmes on activities of daily living are recommended to improve 
the functionality of patients with dementia and decrease the strain on the caregiver 
in the medium term, both in institutionalised individuals and individuals who live 
in their family homes.
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Physical activity programmes
10.3.9. Are physical activity programmes effective in improving 
or stabilising the functional capacity and cognitive functions of 
patients with dementia?
One SR that includes six studies of different designs published between the 
years 1974 in 2005327 concludes that physical activity programmes can have a 
benefi cial effect on the functional activity of institutionalised individuals with 
dementia, but only when a long-term physical activity programme is carried out.
SR of different 
designs,
1+/2+
A later RCT328 analysed the effects of a physical activity programme lasting 
for one hour twice a week for 1 year on institutionalised patients with demen-
tia, and it found a slighter decline in the functionality of patients treated.
RCT,
1+
There are no RCT on the effect of physical activity on cognitive functions or on the functionality 
of individuals living at home.
Summary of evidence
1+/2+
Long-term physical activity programmes are effective to maintain the functionality 
of institutionalised patients with dementia.327,328
Recommendation
B
Long-term physical activity programmes are recommended to maintain the func-
tionality of institutionalised patients with dementia.
Other non-pharmacological treatments
10.3.10. Are there any other non-pharmacological treatments that 
are effective in cognitive, functional, motor and/or quality of life 
manifestations in dementias?
Therapeutic touches massages
In one Cochrane SR329 about the use of therapeutic touch massages on 
patients with dementia, which identifi ed 34 references in the initial searches, 
of which only seven were RCT and only two satisfi ed the requirements 
of the series of minimum methodological criteria, no data regarding the 
effi cacy of this intervention on cognition or functionality of patients with 
dementia were found, although in the majority of these studies, the main 
objective was to study behavioural disorders.
SR of RCT,
1-
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Transcutaneous electrical nerve stimulation
Another SR330 on the use of transcutaneous electrical nerve stimulation in 
AD and VD in mild stage, included eight RCT, although complete data 
were only available in three. The conclusions of the review were that 
transcutaneous electrical nerve stimulation could have a benefi cial effect 
on memory, recognition of faces or motivation immediately after the 
application of the therapy, but it had no effects on other cognitive functions 
and its effect was not maintained in time, although the small number of 
individuals included in each study and the non-availability of all the data of 




One SR on the use of music therapy in dementia331 carried out until January 
2006 included fi ve RCT and concluded that the methodological quality and 
the results shown were poor, which did not permit drawing conclusions. 
Only one of the RCT assessed the cognitive function of the patients included, 
and compared a music therapy session with a conversation session. The 
authors of this RCT referred to an improvement in verbal fl uency and in the 
contents of the discourse, with no improvement in the MMSE or in other 
language tests. The authors of the SR pointed to defects in the methodology 





One SR332 on multi-sensory stimulation (snoezelen) on individuals with 
dementia, which selected six randomised or quasi-randomised controlled 
studies of' 23 published until June 2006, concluded that there was no 
evidence about the effi cacy of multi-sensory stimulation to treat dementia, 
including cognitive and functional data, although it was not possible to 
carry out a MA due to the limited number of the study and the heterogeneity 





Behavioural change, programmed hygiene and induced urination
In the CPG of the AAN304 on the management of dementia, two RCT were 
reviewed that showed that behavioural change, programmed hygiene and 
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Summary of evidence
1–/1+
The use of therapeutic touch massages,329 transcutaneous electrical nervous stimu-
lation,330 music therapy331 or multi-sensory therapy332 have not proven to be effec-
tive to treat cognitive or functional manifestations in patients with dementia or 
specifi cally with AD.
1+




The use of therapeutic touch massages, transcutaneous electrical nervous stimula-
tion, music therapy or multi-sensory therapy cannot be recommended at the present 
time to treat cognitive or functional manifestations in patients with dementia or 
specifi cally with AD.
B
Behavioural changes, programmed hygiene and induced urination are recommend-
able to reduce urinary incontinence in individuals with dementia.
Safety of non-pharmacological treatments
10.3.11 May non-pharmacological treatments used in dementia 
have harmful effects?
Short-term adverse emotional consequences of cognitive interventions have 
been described in narrative reviews.309 Reactions of anger against the car-
egiver, frustration and depression have especially been described with reality 
counselling therapies and frustration reactions for the patient and the caregiver 
with cognitive training therapies, although these are not normally refl ected in 





Cognitive interventions may have adverse emotional reactions when they do not 
adapt to the patient's context and possibilities.309
Recommendation
✔
Cognitive intervention programmes, especially those based on reality counselling 
therapies and cognitive training, must be adapted to the cognitive skills and to the 
emotional tolerance of each patient, in order to avoid adverse emotional conse-
quences.
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10.4. Treatment of behavioural and psychological 
symptoms of dementiaQuestions to answer:
Questions to be answered
10.4.1. What do we understand by behavioural and psychological symptoms of dementia? 
10.4.2. Why are BPSD important in dementia?
10.4.3. How can the intensity and frequency of BPSD be quantifi ed? 
10.4.4. At what moment in time do BPSD appear in the evolution of dementia? 
10.4.5. Are there some BPSD that are characteristic of some types of dementia? 10.4.6. 
Which non-pharmacological measures are indicated in each BPSD in dementia?
10.4.7. What are the general recommendations for the pharmacological treatment of BPSD?
10.4.8. What is the optimal pharmacological treatment for each BPSD?
10.4.9. What adverse effects and contraindications do drugs used to control BPSD have?
10.4.10. How effective is it to combine pharmacological and non-pharmacological treatment 
to treat behavioural and psychological symptoms in mild, moderate and severe de-
mentia?
10.4.11. Which are the most effective recommendations to avoid BPSD in patients with de-
mentia?
10.4.12. How must BPSD, which are diffi cult to monitor in outpatient, be treated?
10.4.13. What attitudes must the caregiver satisfy to deal with patients with BPSD?
10.4.1. What do we understand by behavioural and psychological 
symptoms of dementia?
In 1996, the IPA (International Psychogeriatric Association) proposed using the expression 
Behavioural and Psychological Symptoms of Dementia to defi ne a series of symptoms related to 
the alteration of perception, the content of thought, mood and behaviour that can appear in people 
affected with dementia, and which form part of the expression of the disease.333,5
In some CPG and manuals, they are called neuropsychiatric symptoms or neuropsychiatric 
and behavioural disorders. In this guideline, we will refer to them by calling them, as in the major-
ity of recommended CPGs, behavioural and psychological symptoms of dementia (BPSD).
BPSD are complex symptoms with multifactor aetiology (genetic, neurochemical, neuro-
pathological and biopsychosocial factors) infl uenced by the prior personality and interaction with 
the environment. 334,333,335The existence of other causes that might generate the appearance of 
behavioural systems must be considered, such as: The presence of pain, decompensated heart 
disease, dehydration, infections, the effect of some drugs or an inadequate environment.5
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The presence of BPSD in AD, FTLD, DLB, PDD and VD is very frequent. They vary a great 
deal in their presentation and the stage of dementia when they appear. Knowing the triggering 
factors enables us to manage, implement and develop the interventions better.5,25
People with dementia can present three main types of BPSD:
• Mood disorders (depression, anxiety and apathy).
• Agitation (aggressiveness, irritability, unrest, shouting and erratic wandering).
• Psychotic symptoms (visual, auditory hallucinations and delusions).
In the study carried out by the European Alzheimer Disease Consortium,336 whose objective 
was to identify possible neuropsychiatric syndromes in a broad sample of patients with AD, 2,354 
patients were included from 12 European centres who were assessed via the NPI scale. A group 
of 12 symptoms from the NPI was observed in four factors that explained 51.8% of the total vari-
ance:
• The fi rst factor, “hyperactivity” (23.1% of the total variance), included an increase in the 
scores on agitation, disinhibition, irritability and aberrant motor behaviour.
• The second factor, “psychosis” (10.5% of the total variance), included delusions, halluci-
nations and disruptive behaviour during the night.
• The third factor, “affective” (9.3% of the total variance), with an increase in score of the 
depression and anxiety items..
• The fourth factor, “apathy” (8.9% of the total variance), with an increase in score in the 
apathy and changes in intake items.
The most common of the symptoms was apathy (65%), followed by hyperactivity (64%), 
affective (59%) and fi nally psychosis (30%). The combination of the hyperactivity and psychosis 
syndromes occurred in 28%; the combination of hyper-activity and affective in 38%; hyperactiv-
ity and apathy in 42%; psychosis and affective in 24%; psychosis and apathy in 25%; and affec-
tive and apathy in 37% of the patients.
Apathy
This is the most frequent syndrome among the BPSD. 336,25,337,335By apathy we understand the 
absence or loss of feelings, emotions or interest in the environment This lack of activity can be 
caused by a combination of different factors: a) cognitive: cognitive impairment and feeling of 
fatigue faced with the effort represented by mental activity, b) volitional: Lack of willingness to 
start an activity, c) motor: Akinesia or tendency towards psychomotor slowdown, d) emotional: 
Anhedonia and emotional poverty.
It can appear in early stages of the disease and is normally gets worse as AD evolves and it 
can give rise to a greater impairment in patients suffering from it.338,336 It usually generates a 
great impact on patients and their surroundings, possibly with respect to the loss of self-care and 
the disappearance of the emotional transmission with their caregivers increasing the risk of family 
claudication and institutionalisation Apathy is related to the affectation of the anterior cingulate 
medial prefrontal cortex and dorsolateral prefrontal cortex.
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Depressed mood
This is characterised by sadness, decrease of reactivity towards external stimulation, decrease of 
interpersonal contact, sleep alterations, feeling of uselessness, delusions, psychomotor slowdown, 
decrease of mime, limited dialogue initiative, monosyllable answers and rather unhelpful attitude. 
Irritability is also frequent and this can turn into psychomotor agitation and carrying outbursts. 
There is usually an abandonment of self-care, loss of appetite, tendency to reject intake, as well 
as avoidance behaviour, above all of social contact. Patients with dementia and depression symp-
toms are more susceptible to presenting more behavioural alterations, agitation and alterations of 
sensory perception than those who do not present depression.339,25,338,340
Anxiety
Anxiety is more frequent in the initial stages of AD than in the geriatric population without de-
mentia. Its range of appearance varies between 0 and 50% with an average frequency of 32%.269 
Anxiety may arise as a result of patients realising their defi ciency and when they have to cope 
with unknown circumstances.341
Aggressiveness
There are several degrees of aggressiveness that go from irritability, verbal and/or gestural ag-
gressiveness, to psychomotor agitation with aggressiveness. It is often the result of the presence 
of paranoid type delusions, threatening hallucinating states and depressive-anxious pictures.
Delusions
This is an idea whose content is perceived by the patient as real, departing from objective reality, 
with a trait of persistence and non-infl uenceability, despite an external attempt to confront reality. 
10 to 73% of patients with dementia developed delusions. In AD this percentage is 19.4%.336,337
The most common delusions in dementia and in AD are:342,339
• Paranoid delirium: The most frequent. Patients believe they are being conspired against, 
being robbed, deceived, spied upon, pursued, poisoned, drugged, harassed or obstructed 
in achieving their objectives. Here we include abandonment delirium, when patients 
believe that their caregivers want to get rid of them.
• Self-referential delirium: This is a delirious interpretation of a feeling that reaches them 
from their immediate environment. Feelings that would normally go unnoticed or would 
cause a neutral feeling, take on a new meaning and have an impact on the person. The 
intensity may vary from the feeling that something of what is happening around them is 
vaguely related to them, or interpreting certain signals in a clearly delirious manner, such 
as reference being made on the television to them or that somebody is weaving a plan 
against them.
• Delusional delirium (Othello syndrome or spouse paranoia): Delirious and unjustifi ed 
conviction of the spouse’s infi delity. More frequent in dimensions associated with binge 
drinking.
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• Somatic delirium: Delirious conviction of suffering from a disease. On other occasions, 
patients even believe that certain parts of their bodies do not work properly (nihilist de-
lirium or Cotard’s syndrome).
Hallucinations
These are perceptions without an object. They involve any sensory path, but in dementia, the most 
frequent is visual. Generally speaking, the hallucinations are threatening, terrifying and they can 
cause anxiety, fear, distress, fl ight or aggression.
Identifi cation alterations.
These are a type of illusion associated with a secondary delirium. In AD, we can observe:
• Errors of own identifi cation: Patients do not recognise themselves in the mirror, which 
normally generates a feeling of intrusion, discomfort, fear and even aggressiveness.
• Self-referentiality: Patients believe that the people on the television are really in their 
homes and that what they say has a direct relationship with them.
• Capgras or sosias syndrome: Patients believe that a person, normally their spouse, has 
been replaced by an imposter, which fosters fear, rejection, paranoid attitudes, aggressive-
ness, agitation, etc.
• Reduplicative paramnesia: This is the belief that a certain place has been duplicated and 
exists in two or more places at the same time. It is not very common in AD; it is more fre-
quent in vascular dementia and is associated with simultaneous lesions in the right hemi-
sphere and frontal lobe.
10.4.2. Why are BPSD important in dementia?
BPSD are important due to:
• Frequency in appearance: 92% of the patients presented at least one BPSD when assessed 
with the NPI scale.334,335
• The presence of these symptoms may facilitate the differential diagnosis of the different 
types of dementia; in some dementias it forms part of the diagnosis criteria (visual halluci-
nations in dementia with Lewy bodies, disinhibition in FTLD).25,5
• Certain BPSD permit a predictive approach of the cognitive alteration.5
• Their presence must be taken into account when the healthcare plan is structured.343
• The persistence or intensifi cation of some BPSD such as agitation, aggression or hallucina-
tions usually require urgent healthcare.
• The appearance of BPSD increases caregivers’ stress and burden, it predisposes them to 
depression and is usually the most frequent reason for family claudication and early insti-
tutionalisation.344,215
• Emerging BPSD may indicate the existence of concomitant diseases, so they must be sys-
tematically detected, assessed and treated.215,5
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Summary of evidence
-
There is no scientifi c evidence that enables us to formulate evidence-based recom-
mendations but a series of recommendations can be drawn up as points of good 
practice based on the above.
Recommendation
✔
The systematic assessment of the presence of BPSD is recommended as it is a fun-
damental component of the clinical picture, it appears very frequently, it is diffi cult 
to manage, it has an impact on the quality of life and is a frequent reason for urgent 
care, family claudication and institutionalisation.
10.4.3. How can the intensity and frequency of BPSD be quantifi ed?
The diagnosis and treatment of dementia must include identifi cation, quantifi cation and recording 
of the BPSD using appropriate documentation. There are different instruments or scales to quan-
tify the intensity and frequency of BPSD:
• General dementia assessment scales, which include items that evaluate BPSD, among 
others.
• Specifi c assessment scales for several BPSD.
• Scales that evaluate one single BPSD.
General assessment scales that include several BPSD: 
• Cambridge mental disorders of the elderly examination (CAMDEX): This is a scale 
aimed at diagnosing dementia, comprised of 344 items distributed into eight sections. 
Sections A, C and H assess the pathopsychological status of the patient via a structured 
interview. It is a useful instrument in clinical and epidemiological studies, but the time 
required makes it diffi cult to apply in other fi elds.345,346
• Geriatric mental state (GMS-AGECAT): This is a standardised clinical interview com-
prised of 154 items grouped into 30 sections and its applicability is focused on clinical and 
epidemiological studies.340,347
• Alzheimer’s disease Assessment Scale (ADAS): The ADAS is a test that assesses cogni-
tive changes and behavioural disorders in patients with AD. It comprises 21 items divided 
into two subscales: Cognitive (ADAS-Cog) and behavioural (ADAS-Noncog), with 11 
and 10 items respectively, whose information is obtained through the actual patient and 
relative or caregiver. In practice, the administration of the ADAS-Cog has become very 
popular, so the ADAS-Noncog has been relegated due to the existence of more accurate 
behavioural scales.8,349,350
Specifi c assessment scales for several BPSD: 
• Neurobehavioral Rating Scale (NRS): This scale assesses the presence of different BPSD. It 
comprises 27 items that are scored in an intensity from 1 to 7.351,352 
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• Behaviour pathology in Alzheimer’s Disease Rating Scale (BEHAVE-AD): This scale 
assesses psychiatric disorders in patients with AD and their impact on the caregivers. 25 
symptoms are scored based on seven neuropsychiatric symptomatology domains. It pro-
vides a global score of non-cognitive symptomatology.353,354
• Neuropsychiatric Inventory (NPI): the NPI335 is the most commonly used instrument 
to assess behavioural and psychological symptoms in patients with dementia. It assesses 
frequency and severity of each one of the behavioural disorders and symptoms. It is com-
prised of 12 items to evaluate frequency (on a scale from 0 to 4) and severity (on a scale 
from 1 to 3) of the symptoms: Delusion, hallucinations, agitation, depression/dysphoria, 
anxiety, euphoria/jubilation and, apathy/indifference, disinhibition, irritability/lability, 
motor behaviour without a purpose, sleep alteration and eating disorder. Subscales of 
depression and agitation/aggressiveness can also be obtained. It is available in Spanish 
version355,356,350,342,335,357,152 and abridged versions (NPI-Q) or Neuropsychiatry Inventory-
Nursing Home (NPI-NH). 358,359
• Cohen Mansfi eld Agitation Inventory (CMAI): This is considered to be the standard in-
strument to assess agitation. It comprises 29 items that assess the presence of anomalous 
behaviours, organised around four behaviour components: Agitation, aggression, non-
aggressive motor alterations and recollection of objects. Each item is scored on a scale of 
7 points according to the severity and frequency of the altered behaviour.340,347
• Hamilton Anxiety Depression (HAD): This is an assessment instrument that quantifi es 
anxiety and depression.360,361,362
Scales that evaluate one single BPSD: 
• Cornell Scale for Depression in Dementia (CSDD): This scale permits making a diag-
nosis of major depression according to DSM-IV criteria; it is the most commonly used 
instrument for this indication. It comprises 19 items and it has a maximum score of 38. 
It is based on an interview held with the patient and caregiver; the opinion of the latter 
prevails if there are differences between the two.345,346 It is available in Spanish version.363
• Yesavage Geriatric Depression Scale: Comprised of 30 items with an abridged version 
of the Yesavage geriatric depression scale of 15 items.364,365,366
• Rating of Aggressive behaviour in the elderly (RAGE): This is a scale to assess aggres-
siveness, comprised of 23 items, the majority of which are evaluated on a scale of 4 points 
according to frequency.367 It is available in Spanish version.368
Summary of evidence
4
There are general scales to assess BPSD: el CAMDEX (Cambridge mental dis-
orders of the elderly examination), with 344 items it is a useful instrument in 
clinical-epidemiological studies;345,346 the Geriatric mental state (GMSAGECAT) 
is a standardised clinical interview comprised of 154 items, applicable in clinical 
and epidemiological studies;340,347 the behavioural subscale (ADAS-Noncog) of the 
Alzheimer’s disease Assessment Scale (ADAS), with 10 items.348,349,350
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4
There are specifi c scales to assess several BPSD, such as the Neurobehavioral 
Rating Scale (NRS), with 27 items that score in an intensity from 1 to 7.351,352 
The Behaviour pathology in Alzheimer’s Disease Rating Scale (BEHAVE-AD) as-
sesses psychiatric disorders in patients with AD and their impact on the caregiv-
ers; 25 symptoms are scored based on seven neuropsychiatric symptomatology 
domains, and it provides a global score of non-cognitive symptomatology.353,354 
The Neuropsychiatric Inventory (NPI)335 is the most commonly used instrument; 
it assesses frequency and severity of 12 items: Delirium, hallucinations, agitation, 
depression/dysphoria, anxiety, euphoria/jubilation and, apathy/indifference, disin-
hibition, irritability/lability, motor behaviour without purpose, sleep alteration, eat-
ing disorder. There is an abridged version (NPI-Q) or Neuropsychiatry Inventory-
Nursing Home (NPI-NH).358,359
4
The Cohen Mansfi eld Agitation Inventory (CMAI): This is the standard instrument 
to assess agitation, with 29 items and for behavioural components: Agitation, ag-
gression, non-aggressive motor alterations and recollection of objects.340,347
4
The Hamilton Anxiety Depression (HAD) is an assessment instrument that quanti-
fi es anxiety and depression.360,361,362
4
The most commonly used instrument to assess depression in dementia is the 
Cornell Scale for Depression in Dementia (CSDD), which comprises 19 items and 
a maximum score of 38. It is based on an interview held with the patient and car-
egiver.345,346,363 The Yesavage Geriatric Depression Scale is also useful, with two 
versions of 30 and 15 items.364,365,366
4
The Rating of Aggressive behaviour in the elderly (RAGE): This is a scale to assess 




The use of specifi cally designed instruments is recommended to evaluate BPSD in 
dementia independently from cognitive and functional alterations.
✔
NPI (Neuropsychiatric Inventory) is recommended as an instrument to assess the 
intensity and frequency of BPSD, the CSDD scale (Cornell Scale for Depression 
in Dementia) to assess depressive symptomatology and CMAI (Cohen Mansfi eld 
Agitation Inventory) to assess agitation.
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10.4.4. At what moment in time do BPSD appear in the evolution of 
dementia?
BPSD can appear at any stage of the disease. Sometimes it is the appearance of the BPSD that 
alert the family and lead them to consult the PCT. If one of these symptoms is found, the exist-
ence of other BPSD must be explored, which may go unnoticed if the intensity is light.370
A door to door epidemiological study, evaluating 108 people with dementia, 
showed that 76.9% presented at least one BPSD. In AD the percentage was 




BPSD (apathy, depression, anxiety) may appear in the initial stages of dementia, which may help 
us differentiate between AD, VD, FTLD, DLB and PDD.
There are certain BPSD in FTLD and in DLB that, due to their prevalence, form part of their 
diagnostic criteria.51,6 There are usually multiple BPSD in the different types of dementia, unlike 
idiopathic psychiatric diseases where psychosis or depression appear exclusively.
As the dementia progresses, the prevalence and intensity of the BPSD increases. In the mild to 
moderate dementia stage, parallel to the impairment of IADL, sleep disorders and eating and 
sexual disinhibition behaviours appear.372
In a cohort study on people with moderate to severe dementia, the presence of 




In more advanced stages of AD, delusions, hallucinations and agitation may 
appear. All the degenerative dementias occur with BPSD; in AD they have been 
observed in 73.5-94.6%; in VD, in 78.6-96.4%; in FTLD, in 100% of those 
affected, and in DLB and PDD dementia, the percentage reaches 80%.5,25,373
Cohort study,
2++
Apathy is the most prevalent BPSD in all types of dementia (53.70%). In AD, 




In a prospective cohort study with 91 people with MCI, 344 with AD (99 
mild, 245 moderate, 45 moderate-severe) and 50 healthy controls, depression 
is found in 8% of the healthy controls, 33% of the MCI, 41.4% in mild AD 
and 44.1% in moderate to severe AD.372 In another study by the same authors, 
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In another study, depression was present in 18.4% of the normal population; 
in 44.1% of people with MCI and in 19.5% of those with AD.375 In another 
prospective study with 119 patients with AD, 126 with MCI, depression was 




The frequency of anxiety in the normal population may vary between 4.0-
24.9%.375 In cohort studies people with MCI presented anxiety in 46.8% of 
the cases, and with dementia in 35.2%.374,371 In AD this may vary between 




Other frequent BPSD in MCI and dementia are: Agitation, irritability, sleep 
alterations and eating behaviour disorders. Irritability was observed in 15% of 
patients with MCI and in 30% of those affected by AD. Agitation, in 50% of 
the patients with Parkinson‘s disease dementia (DLB-PDD).374,371
Cohort study,
2++
Aberrant motor activity appears in moderate and advanced stages of dementia; 
in 24.3% of people with AD, it is not normal in VD and appears in practically 
all the cases of FTLD.374,371,38 When it appears at early stages of AD, it is due 
to dysfunction of the frontal lobe.377
Cohort study,
2++
Disturbances of the sleep-wake cycle may be present in normal population, ac-
cording to different studies, between 3.6 and 55.7% of people.378 In dementias, 
it appears in 30.4%.374,371
Cohort study,
2++
A cohort study with 155 people with AD and 420 healthy controls, using the 
Mayo Sleep Questionnaire and the NPI, show that 71% of people with AD 
presented some type of sleep disturbance.378
Cohort study,
2++
Others studies showed sleep disorders in 3.6% of people in VD, and in 50% of 
those affected by DLB and PDD.374,371,378,379
Cohort study,
2++
The most frequent sleep disorders in mild dementia were insomnia (29.9%), 
night cramps (24.1%) daytime drowsiness (22.6%), restless legs syndrome 
(20.7%) and REM sleep behaviour disorders (18.5%).378,379
Cohort study,
2++
In DLB, REM sleep behaviour disorders can precede the onset of dementia by 
many years. Sudden sleep crises are more frequent in PDD.379
Cohort study,
2++
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There is little information about sleep alterations in FTLD. A control study of 
13 people with FTLD, controlled with a sleep diary and prolonged actigraphic 
recording, and compared with the normal population and with patients with 
AD, showed disturbances of wake-sleep cycle characterised by ineffective 
sleep, increase of nocturnal activity, shortening of sleep duration and decrease 
of morning activity. These are early disturbances in the evolution of the dis-
ease and enable it to be differentiated from AD.250
Case series,
3
Sleep disorders increase in parallel with the severity of dementia and they are 
one of the factors that favour institutionalisation.379
Cohort study,
2++
A door to door epidemiological study showed the existence of eating disorders 
in 37.8% of patients with AD, in 14.3% of those affected by VD, and in 50% 




Delirium is exceptional in healthy population (0.4%); it is observed in 3.4% 
of MCI, it is more frequent in the initial stages of FTLD and it may appear in 





BPSD can appear at any stage of the evolution of dementia and it may be the fi rst 
manifestation.
2++
A door to door epidemiological study, which included 108 people with dementia, 
showed that 76.9% presented at least one BPSD. In AD, 73.50%, in the DLB/PDD 
group, 80%, in VD, 78.60%, and 100% in FTLD.371,374
2++
There are some BPSD in FTLD and in DLB that form part of the diagnostic criteria 
of both diseases. Delusions and hallucinations usually appear in the earlier stages 
in FTLD and DLB.51,6
2++
As the dementia progresses, the prevalence of BPSD increases, new BPSD appear 
or the already existing ones increase in intensity.372 In the mild to moderate demen-
tia stage, parallel to the impairment of IADL, sleep disorders and eating and sexual 
disinhibition behaviours appear. The presence of BPSD is signifi cantly correlated 
to the scores on the functional scales (P = 0.039) in moderate-severe dementia.372 
Delusions, hallucinations and agitation may appear in more advanced stages in 
AD.5,25,373
2++
Apathy is the most frequent BPSD of dementia from the onset: 51.3- 64.6% in mild 
AD; 78.4% in moderate to severe AD; 42.9% in VD; 100% in FTLD, and more 
than 50% of DLB and PDD.371,374,372,376
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2++
Depression appears in 41.4% of people with mild AD, 44.1% in moderate to severe 
AD.372 In another study by the same authors depression appears in 49.6% of people 
with AD and in 42.9% of VD.371,374 In other series, the depression percentage varied 
between 19.5 and 49.6%. 376
2++
Anxiety occurs in dementia in 35.2% of the cases. 371,374 In AD it varies between 
16.3 and 32.10%.375,371,374 In VD it appears in 42.9%371,374 and in FTLD in 100% 
of the cases371,374
2++
Other frequent BPSD in dementia are irritability, agitation, sleep disturbances and 
eating behaviour disorders.376 Irritability in 30% of people with AD; agitation in 
50% of people with Parkinson's disease dementia.371,374
2++
Aberrant motor activity appears in moderate and advanced stages of dementia. 
24.3% of people with AD; it is not normal in VD, and it appears in all FTLD.371,374,38,377
2++
Disturbances of the wake-sleep cycle appear in 30.4% of people with demen-
tia.378,371,374 A cohort study using the Mayo Sleep Questionnaire and the NPI, show 
that 71% of people with AD presented some type of sleep disturbance.378
2++
In VD, sleep disorders appear in 3.6% of those affected. In DLB and PDD they are 
more intense and appear in 50% of the cases.371,374,378,379
2++
The most frequent sleep disorder in mild dementia is insomnia (29.9%), night 
cramps (24.1%) daytime drowsiness (22.6%), restless legs syndrome (20.7%) and 
REM sleep behaviour disorders (18.5%).378,379
2++
In DLB, REM sleep behaviour disorders can precede the onset of dementia by 
many years. Sudden sleep crises are more frequent in PDD.379
3
A control of 13 people with FTLD, compared with the normal population and with 
patients with AD, showed ineffective sleep in FTLD, with an increase of noctur-
nal activity and morning tiredness, early disturbances that permit differentiating it 
from AD.380
2++
Sleep disorders increase with the severity of dementia and they favour institution-
alisation.379
2++
Eating disorders were observed in 37.8% of patients with AD; 14.3% in VD, and in 
50% of people with DLB and PDD.371,374
2+
Delirium is exceptional, in healthy population (0.4%), rare in 3.4% of people with 
MCI, frequent in the initial stages of FTLD and it may appear in moderate to severe 
stages of AD.5,25,373
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Recommendation
B
It is advisable to bear in mind that BPSD may appear at any time during the evolu-
tion of dementia, whatever its aetiology, and it is not unusual for it to be the fi rst 
manifestation.
B
If delusions and hallucinations appear in a person with early stage dementia, FTLD 
or DLB must be suspected. If there are REM sleep behaviour disorders, the fi rst 
suspicion will be DLB.
10.4.5. Are there some BPSD that are characteristic of some types 
of dementia?
No BPSD is specifi c of any of the types of dementia, however their frequency, combination, spon-
taneous evolution and response to treatment may be signifi cant characteristics for the diagnosis.334
Alzheimer’s Disease (AD)
The presence of BPSD in AD was investigated in a prospective clinical 
study. The presence of one or more BPSD were found in 88% of the 
cases,338 whilst they appeared in 60% of the sample in a population based 
study. 20% presented one single symptom; affective symptoms prevailed in 
28% and the prevailing symptoms in 13% were psychotic.381
Cohort study,
2++
Apathy is the most frequent BPSD in AD, increasing with its progression 
and correlated with the progression of cognitive impairment and the loss of 
functionality. It is correlated with executive dysfunction and disturbances in 
the frontal lobe. It may or may not coincide with depression.371,374,372
Cohort study,
2++
Depression is present in 38-49.6% of people with AD. It may, on its own, 
cause cognitive impairment similar to that of the initial stage of AD. The 
differential diagnosis between the two may be diffi cult.338,371,374,372
Cohort study,
2++
Anxiety is very frequent in people with mild AD; it is observed in 32-




Psychosis in AD includes delusions and hallucinations that are correlated 
with agitation, aggressiveness and apathy. Visual hallucinations are more 
frequent as they coincide with alterations in visual acuity.381
Cohort study,
2++
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The profi le of behavioural alterations varies with the progression of AD; 
apathy, irritability, depression and anxiety are frequent in mild stage. 
Delusions of persecution, jealousy, illusions, hallucinations (visual, 
auditory or olfactory), agitation and aberrant motor behaviours may appear 
in moderate AD. 371,374,38,377
Cohort study,
2++
Disorders of the wake-sleep cycle in initial stage may differentiate AD from 
DLB and from FTLD (question 10.4.4). 378,379,380
Cohort study,
2++
Functional neuroimaging in AD, using SPECT reinforces the role of the anterior cingulate 
in apathy, with a reduction of the bilateral activity in people with AD. In depression, the 
hypometabolism area is observed in the upper temporal lobe, anterior cingulate and bilateral 
frontal lobe. In hallucinations, the decrease of the metabolism is observed in right parietal 
lobe, left medial temporal lobe and left prefrontal dorsolateral cortex.334
Frontotemporal lobar degeneration (FTLD)
BPSD in FTLD (compulsions, altered social behaviour, emotional 
incontinence, loss of empathy, anosognosia and disinhibition) are present in 
FTLD from the fi rst stages.382
Cohort study,
2++





In a cohort study that compared BPSD in 30 patients with FTLD, 75 with 
AD and 34 with VD, it showed that patients with FTLD showed apathy, loss 
of emotions and of insight, disinhibition, negligence, bulimia and preference 
for sweet food, wandering, stereotypies, loss of sensitivity to pain, echolalia 
and mutism. This series of BPSD enable it to be differentiated from AD. It 
is more diffi cult to differentiate it from VD.383
Cohort study,
2++
Different patterns are distinguished in FTLD. Compulsive symptoms are 
more frequent in semantic dementia. There are differences depending on 
the hemisphere affected. FTLD of the right side causes antisocial behaviour 




Dementia with Lewy bodies (DLB) and Parkinson’s Disease Dementia (PDD)
DLB and PDD share the majority of BPSD, cognitive and motor disorders, and the 
pharmacological response to the ACE inhibitors.
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The profi le of BPSD is dominated in both by delusions and hallucinations, 
but there are quantitative differences between them. In DLB, delusions are 
observed in 57% of the cases and hallucinations in 76%, whilst in the PDD 
group, delusion were observed in 29% of the cases and hallucinations in 
54%. Hallucinations are associated with greater severity of the dementia, 
major depression and less visual acuity.381
Cohort study,
2++
DLB and PDD are characterised by progressive cognitive impairment, 
motor and non-motor fl uctuations, recurrent visual hallucinations and 
parkinsonism. Behavioural disorders of the REM phase are very typical of 




The most typical BPSD in VD are apathy, depression and delusions.382 






One or more BPSD are observed in 80% of the people with AD attended in demen-
tia units.338 The prevalence was less in studies (60%). One single symptom existed 
in 20% of the cases; affective symptoms prevailed in 28% and psychotic symptoms 
in 13%.38
2++
Apathy is the most common BPSD in AD, increasing with the progression of the 
disease and correlating with the worsening of the cognitive impairment and func-
tional loss. It is correlated with executive dysfunction and frontal lobe alterations.376
2++
Depression occurs in 38-49.6% of people with AD and it may cause cognitive im-
pairment very similar to the initial stage of AD; the differential diagnosis may be 
diffi cult.338,372,371,374,376
2++ Anxiety appears in 32-71% of people with AD.371,374,375
2++
Psychosis in AD includes delusions and hallucinations, at the same time as agita-
tion, aggressiveness and apathy. Visual hallucinations are more frequent if there are 
alterations in visual acuity.381
2++
The most frequent BPSD in mild AD are apathy, irritability, depression and anxi-
ety. Delusions of persecution, jealousy, illusions, hallucinations (visual, auditory or 
olfactory), agitation and aberrant motor behaviours may appear in moderate AD. 
371,374,38,377
2++
Disorders of the wake-sleep cycle in initial stage may differentiate AD from DLB 
and from FTLD (question 10.4.4). 378,379,380
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Frontotemporal lobar degeneration (FTLD)
2++
BPSD (compulsions, altered social behaviour, emotional incontinence, loss of em-
pathy, anosognosia and disinhibition) are present in FTLD from the fi rst stages.382
2++
Apathy was observed in all the cases of FTLD, as well as anxiety, irritability and 
aberrant motor activity.371,374
2++
BPSD in FTLD are characterised by apathy, loss of emotions and of insight, disin-
hibition, negligence, bulimia and preference for sweet food, wandering, stereotyp-
ies, loss of sensitivity to pain, echolalia and mutism. This series of BPSD enable 
it to be differentiated from AD. It is more diffi cult to differentiate it from VD.383
2++
In FTLD, there are differences depending on the hemisphere affected. If the right 
side is affected antisocial behaviour and aggressiveness appear, if the left side is 
affected changes in personality and a change in values appear.381
Dementia with Lewy bodies (DLB) and Parkinson’s Disease Dementia (PDD)
2++
The BPSD profi le in DLB and PDD is characterised by delusions and hallucina-
tions. In DLB, delusions were observed in 57% of the cases and hallucinations 
in 76%. In PDD, delusion in 29% and hallucinations in 54%. Hallucinations are 
associated with more severe dementia, major depression and less visual acuity.381
2++
DLB and PDD are characterised by progressive cognitive impairment, motor 
and non-motor fl uctuations, recurrent visual hallucinations and parkinsonism. 
Behavioural disorders of the REM phase are very typical of DLB and may precede 
motor or cognitive sings by several years.382
Vascular Dementia (VD)
2++ The most typical BPSD in VD are apathy, depression and delirium.382
Recommendation
B
BPSD must be detected as soon as possible, in mild dementia stages, or throughout 
its subsequent evolution; they must be quantifi ed and grouped into syndromes that 
facilitate differential diagnosis between the different dementias.
B
It is advisable to know and recognise the BPSD that appear in AD, VD, FTLD, 
DLB and PDD.
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10.4.6. Which non-pharmacological measures are indicated in each 
BPSD in dementia?
Pharmacological management of BPSD can be accompanied by adverse 
effects for the patient. So it is normal in CPG to recommend the use of non-
pharmacological strategies as fi rst line therapy for BPSD when these are not 




The non-pharmacological treatment of BPSD has not been assessed via extensive and 
methodological quality RCT, but by studies with a limited sample and variable design, mainly 
of cases and controls that include different types of dementia in different stages, not specifying 
the response on behavioural alterations or specifying the therapeutic effect on a specifi c 
BPSD.42,235,385,386 There are no well-designed studies either that assess the combined 
effi cacy of pharmacological and non-pharmacological treatment.387
Some recommended general standards235,388 to manage BPSD in AD 
include: Preventing their appearance and treating them early on, using an 
adequate tone of voice, maintaining visual contact, routine exercise patterns, 
eating and bathing, avoiding erratic wandering, maintaining the patients 
orientated in time, avoiding hyperstimulation, providing a safe and well-lit 
environment, without mirrors, with identifi cation notes on the doors of the 
home, programming distraction and re-orientation activities, and providing 
music of the patient's liking during some activities.






It is especially important for relatives to receive good information and training about the 
BPSD to enable them to develop co-therapeutic work when managing and preventing them. It 
is important for them to understand that the BPSD appear as a result of brain damage, which 
may be transient and may improve with treatment.42
A MA of observational studies that assessed the effi cacy of 13 different non-
pharmacological intervention programmes on the delay in institutionalisation, 
including a total of 9,043 patients with dementia, concluded that the active 





Non-pharmacological treatment includes behavioural interventions, reminiscence therapy, 
cognitive stimulation and sensory stimulation therapies (music therapy, aromatherapy, 
massage, phototherapy).390
Depression
The pharmacological measures must be accompanied by psychotherapy, eliminating risk 
elements from the environment and increasing supervision and hospitalisation if necessary42 
Options must be selected depending on the intensity of suicidal thinking and on the patient’ 
family and social support.
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Behavioural intervention techniques prove to be benefi cial, in general during 
the execution time of the therapy on some BPSD, including depression, but 
there are no well-designed RCT with a broad sample.235,388




Stimulation oriented therapies such as recreation activities and other formal 
or informal means to maximise the patients’ pleasurable activities have 
proven to be effective on depression in some studies of a small sample size, 




One SR of RCT concluded that reality counselling therapy has not very 
effective on apathy and depression.391 Reminiscence therapy is not very 




25-50% of patients with dementia present severe sleep disorders.393 There are many different 
causes: Fragmentation of physiological sleep in advanced age, excess daytime sleep, neuronal 
damage in the suprachiasmatic nucleus, untreated pain and presence of medical and psychiatric 
comorbidity.42 Diagnostic criteria for sleep disorders associated with AD have been proposed. 
394 The objectives of the treatment are to increase the patient's comfort, reduce the strain on the 
caregivers, reduce nocturnal wandering and avoid accidents and falls.
Non-pharmacological management of sleep disorders is based above all on 
establishing appropriate sleep hygiene. Some general rules are: Establish sleep 
routines, maintain physical and mental activity in the morning and fi rst thing 
in the afternoon, limiting daytime sleep hours, avoid nicotine, caffeine, diuret-
ics and the intake of liquids at night; taking hot milk, having a bath in warm 
water and dimmed night lights may also be effective.235
RCT,
1-
It must be taken into account that some ACE inhibitors may alter sleep, in 
which case they can be administered at midday. The use of low beds or with 





If it has appeared recently, possible triggering causes must fi rstly be identifi ed, such as pain, urine 
infection, dehydration, constipation, delirium, depression and adverse effects of drugs. Other 
causes may be hunger, sleep, changes in caregiver or room companion, isolation or hyperstimula-
tion. Aggression prediction activities must be identifi ed and eliminated when possible. Sequential 
activities such as getting dressed or eating may cause frustration and agitation, so they must be 
simplifi ed by, for example, using clothes with Velcro or preparing simple and repeated meals 
instead of one large meal.42
230 CLINICAL PRACTICE GUIDELINES IN THE SNS
One Cochrane SR329 concluded that there is some evidence that therapeutic 
massages may be effective to decrease anxiety and agitation.
SR OF RCT,
 1+
Another Cochrane SR detected fi ve studies where music therapy may be ben-
efi cial for the emotional control of people with dementia, but the low meth-
odological quality did not permit establishing conclusions.331
SR of RCT,
 1-
Another Cochrane SR332 did not fi nd any evidence of effi cacy of integrated 
multi-sensory stimulation (snoezelen) on behaviour, mood or social interac-
tion in the short or long term.
SR OF RCT,
1+
Erratic wandering or vagrancy
Wandering, within a safe environment, fosters circulation and oxygenation; it is a physical 
exercise and an indicator of good physical health.395 On the contrary, wandering away from the 
home may lead to the patient going astray, represent a risk of falls and fractures, cause strain on 
caregivers and may precipitate institutionalisation.396
The prevalence is very variable (15-60%) and it may be more frequent in advanced stages of 
dementia. It is diffi cult to calculate because often it is included with agitation and anomalous 
motor behaviours.397 The aetiology is not known and it often depends on individual environmental 
factors, so it is diffi cult to establish therapeutic strategies.
Interventions aimed at preventing and reducing wandering may be classifi ed into several 
groups: a) therapies with exercises and walks (walking and conversation groups, therapy with 
exercises, parks to walk in), b) changes in environment (subjective barriers such as mirrors, 
apartments grilles, door handle camoufl age, etc.), safety devices (childproof locks, alarms, etc.), 
home environment programmes, c) behavioural modifi cation interventions, d) occupational 
therapy in the form of recreational activities, and e) electronic identifi cation techniques.
One SR that included RCT and low quality cohort studies,397 with multi-
sensory stimulation, music therapy, aromatherapy, physical activity and 
behavioural therapy, concluded that there is no evidence to establish 
recommendations on any non-pharmacological therapy to reduce or avoid 
erratic wandering.






Electronic location devices are very useful, especially personalised 
wristbands that transmit a tracking signal, coordinated with search and rescue 
teams. In the Project Lifesa study developed in USA (www.projectlifesaver. 
org) the search time in a series of 1000 cases was reduced from days or 
hours to an average of 30 minute and no serious injury or death occurred.
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One Cochrane SR398 analysed the existence of quality RCTs performed with 
the above-mentioned therapeutic strategies and did not fi nd any appropriate 
clinical trial on non-pharmacological interventions for the prevention and 
treatment of wandering in the domestic environment, so no recommendation 
in this regard could be established.




Some strategies to prevent and treat BPSD are to use an adequate tone of voice, 
maintaining visual contact, routine exercise patterns, eating and bathing, avoiding 
erratic wandering, maintaining the patients orientated in time, avoiding hyperstim-
ulation, providing a safe and well-lit environment, without mirrors, with identifi ca-
tion notes on the doors of the home, distraction and re-orientation activities, and 
providing music to the patient's liking.42,235,388
2++
The active involvement of the caregiver is essential for the effi cacy of non-pharma-
cological intervention programmes in patients with dementia.389
2+
Recreational and pleasurable activities may improve depression in mild, moder-
ate235 and advanced388 AD.
1-
Reality counselling therapy is not very effective on apathy and depression in de-
mentia.391
1+/1-
Sleep hygiene and other measures such as drinking hot milk, having a bath with 
warm water and dimmed night lights improve sleep disorder.390
1+
Therapeutic massages may be effective on anxiety and agitation in patients with 
dementia.329
1-
Music therapy may be benefi cial on the emotional control of people with demen-
tia.331
1+
Integrated multi-sensory stimulation (snoezelen) is not effective on behaviour, hu-
mour or social interaction in patients with dementia.332
1-
There are no quality RCT on non-pharmacological interventions for the prevention 
and treatment of wandering in the domestic environment, so no recommendation 
in this regard could be established.398
Recommendation
✔
Starting treatment with non-pharmacological strategic measures to manage BPSD 
is recommended.
C
It is especially important for caregivers to receive information and training that 
capacitates them to prevent the appearance of BPSD and act as co-therapists when 
they are already present.
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C
Stimulation-oriented treatment with recreational activities and pleasurable activi-
ties have proved to be effective to cope with depression.
✔
Non-pharmacological sleep management mainly consists of establishing guide-
lines and good sleep hygiene.
C
There is limited evidence that therapeutic massages may be effective to treat agita-
tion.
D
The use of electronic identifi cation techniques on dementia patients who present 
erratic wandering is recommended.
10.4.7. What are the general recommendations for the 
pharmacological treatment of BPSD?
Two CPG42,235 recommend starting treatment of BPSD with non-pharmacological measures 
and reserving pharmacological treatment for the most severe or refractory cases. There are few 
studies available on non-pharmacological treatments; the RCT are practically non-existent and 
the availability of trained professionals is scarce and insuffi cient respect to the needs of this 
population. Therefore, the pharmacological approach is imposed in the majority of the cases. 
For appropriate pharmacological management of BPSD, it is essential to appropriately identify 
the symptom to be treated, assessing its possible causes, identifying the possible precipitating 
factors, those that relieve them or eliminate them, and the consequences that the symptom 
entails for patients and their environments.
ACE inhibitors and memantine
There is evidence of moderate but greater effi cacy than placebo of ACE 
inhibitors on BPSD. 239,240,253
MA of RCT,
1++
The evidence about memantine is also positive, but of lesser magnitude; it 
is more specifi c for the agitation symptom.256,258
MA of RCT,
1++
The effi cacy on individual symptoms varies from one study to another 
and from one drug to another. Noteworthy is the use of all ACE inhibitors, 
especially rivastigmine, in DLB or PDD, where the use of psychotropic 
drugs such as antipsychotics is especially problematic.272,277
RCT,
1+
The combination of ACE inhibitors and memantine also improves the 
BPSD, assessed using scales such as the NPI. All of this reinforces the 
indication of ACE inhibitors and/or memantine as treatment of dementia, 
both for cognitive symptoms and for non-cognitive ones.268
RCT,
1+
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Psychotropic drugs
The same psychotropic drugs as in primary psychiatric disorders are used. There is no quality 
evidence in primary psychiatric disorders to prefer one molecule over another within the same 
therapeutic group or for BPSD.
The RCT that compare antipsychotics have limited power, but they do not suggest differences 
in effi cacy in the treatment of psychotic symptoms or agitation/aggressiveness. Although 
these medications are used for long periods in practice, there is hardly any evidence about 
their effi cacy in periods over 8-12 weeks.
The RCT do not generally specify which symptoms improve specifi cally with each molecule, 
and when they do so, they do not always coincide from one trial to another. The majority do 
not distinguish the types of dementia and usually include AD, VD and mixed dementia. The 
degree of dementia is variable. The quality of the studies is moderate; some are well designed 
but the high dropout rates reduce their quality.149
The effects on global scales such as NPI or on psychotic symptoms in general are generally 
assessed. Furthermore, the majority of RCT do not assess which drugs are useful for each 
symptom, but rather, what effect each drug has on certain scales and some symptoms or 
groups of symptoms. In the technical data sheet, only risperidone is indicated for states of 
agitation and aggressiveness in dementia.
Summary of evidence
4
According to CPG and bearing in mind the adverse effects of the drugs, it is 
considered reasonable to start with the non-pharmacological management of 
BPSD and use drugs in severe or rebellious symptoms.42,235
1++
ACE inhibitors have proven to be more effective than placebo on BPSD, 
generally assessed by means of the change in NIP score.239,240,253 Memantine has 
shown modest effi cacy on agitation.256,258
1+
Rivastigmine has shown a moderate improvement on the NPI score in patients 
with DLB and PDD.272,277
1-
There are very few studies on treatment of BPSD with specifi c psychotropic 
drugs on patients with dementia, and they usually have a low quality.
Recommendation
D
The target symptom that must be treated as well as its possible causes or triggers 
must be identifi ed.
D
The general recommendation respect to pharmacological treatment of BPSD 
is to start with ACE inhibitors and/or memantine and, if the response is not 
suffi cient, add a psychotropic drug.
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✔
Bear in mind the special sensitivity of these patients to adverse effects, especially 
the risk of anticholinergic effects, orthostatic hypotension, falls, extrapyramidal 
effects, worsening of cognitive function, confusion and delirium.
Start with low doses and slowly reach the minimum effective doses. 
Preferential use of oral route.
✔
Review the dose and the actual treatment need at regular intervals, generally 
every 3 months.
ACE inhibitors and/or memantine
B
The use of ACE inhibitors and/or memantine is recommended as treatment of 
dementia, not only for cognitive symptoms but also for non-cognitive ones.
B




The use of psychotropic drugs is recommended to treat BPSD, although evidence 
about their effi cacy in patients with dementia is generally low and the risk of 
adverse effects is high.
10.4.8. What is the optimal pharmacological treatment for each 
BPSD?
We have the basic treatment with ACE inhibitors and/or memantine for the pharmacological 
treatment of BPSD. If this treatment is not «enough, psychotropic drugs have to be used. Both 
treatments are not incompatible and are usually prescribed together if required. Given that AD, 
DLB and PDD have a specifi c treatment with ACE inhibitors and/or memantine, it is to be 
expected that these drugs will improve the BPSD as supported by the RCT (question 10.2.3)
Psychotic symptoms (delusions and hallucinations).
One SR of RCT on the treatment of delirium in AD400 showed the benefi t of 
risperidone (0.5-2 mg/day) and contradictory results for olanzapine. With 
respect to ACE inhibitors, an improvement was observed in the intensity of 
the delirium in one RCT with donepezil; no benefi t was observed in a small 
open-ended study with rivastigmine or in one RCT with galantamine. Both 
the typical antipsychotics and the ACE inhibitors could play a role in the 
treatment of delirium, but the existing information is scarce and there are no 
comparative data between them.
SR of RCT and 
of open study,
1++/1+/1–
There are not enough data to establish the benefi t of atypical antipsychotics 
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Rivastigmine may improve psychotic symptoms in DLB. In one RCT277 
twice the number of patients with rivastigmine (average dose of 9.4 mg/
day) showed a signifi cant improvement in the NPI-NH with respect to 
placebo at 20 weeks.
RCT,
1+
There is no evidence of effi cacy of antipsychotics in DLB and up to 50% of the people showed 
marked sensitivity.6
There is moderate-high evidence in patients with AD and VD regarding the 
effi cacy of a typical antipsychotics (aripiprazole, olanzapine, quetiapine and 
risperidone) compared with placebo, with a small clinical benefi t measured 
as a score of NPI or BEHAVE-AD.25 Clozapine is useful for psychotic 
symptoms in PDD and DLB, and could be useful for patients with AD who 
are sensitive to the extrapyramidal effects of the antipsychotics.42
RCT,
1++/ 1+
There is no data about the use of ziprasidone in elderly people.42
In one Cochrane SR401 on antipsychotics in AD, an improvement of the 
psychosis was observed with risperidone 1.0 mg/day respect to placebo 
(DM – 0.14) assessed by the BEHAVE-AD subscale in three studies and 
the secondary score of the NPI in another. In one study, aripiprazole (2-15 
mg/day) showed a benefi t compared with placebo at 10 weeks in the BPRS-
PSYCHOSIS (DM-0.66), but not on the NPI psychosis subscale.
SR OF RCT,
1+
Another MA of four RCT with risperidone 1.5-2 mg/day on patients 
with dementia, mainly AD, showed a signifi cant reduction of 46% on the 
BEHAVE-AD psychosis subscale with risperidone and 33% with placebo, 
accompanied by an improvement in CGI at 8-12 weeks.. The difference was 




Treatment of depression in dementia is probably similar to the population 
without dementia but there are no appropriate RCT for the majority of the 
drugs. The evidence of effi cacy of antidepressants in dementia depression 
is weak. Studies have been carried out on patients with mild to moderate 
dementia, but there is only one on severe dementia. The SSRI are preferred 
due to the lower risk of confusion and anticholinergic effects.5,42,152 One 
Cochrane SR of 2002 found few studies and with few patients that analysed 
drugs not commonly used in practice. No evidence was found for venlafaxine 
or mirtazapine in patients with dementia and depression.
SR of RCT,
 1-
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Studies have been performed with citalopram, fl uoxetine, sertraline, 
imipramine, maprotiline, clomipramine and moclobemide. Some proved 
to be superior with respect to placebo and others not, seemingly due to 
differences in the selection of patients and in the sensitivity of the scales 
used. Sertraline and citalopram have proved to be effective with respect to 
placebo. One study that did not show any effect of sertraline was carried out 
on patients with severe dementia where the administration of scales could 




The results in tricyclics are confl ictive (for example no effect of imipramine 
or maprotiline was found but an effect of amitriptyline and clomipramine was 
found) and there is limited evidence of effect on depression in dementia.149
RCT, 
1+
Comparative studies between SSRI and tricyclics (amitriptyline vs. 
mianserine, imipramine vs. paroxetine, amitriptyline vs. fl uoxetine and 
citalopram vs. mianserine) and between sertraline and venlafaxine showed 
similar effi cacy for depression, but the SSRI were tolerated better and the 
tricyclics worsened the cognitive function.42,149
RCT, 
1+
Only one small retrospective study on 31 patients, the majority with vascular 




There is minimal evidence based on clinical cases about the usefulness 
of psychostimulants (d-amphetamine, methylphenidate), amantadine, 




There are no RCT or SR about the use of benzodiazepine in BPSD.140
Olanzapine (5-10 mg/day) proved to be benefi cial in the treatment of anxiety 




There are no RCTs on non-pharmacological interventions in erratic wandering.398





There are no RCT on pharmacological treatment of insomnia specifi cally in patients with 
dementia.
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Trazodone, zolpidem or zaleplon may be useful to primarily treat insomnia, 
but there are little information about their effi cacy. Benzodiazapines, 
preferably with short half-life are only recommended in the short term due 
to the risk of tolerance, rebound insomnia and adverse effects. If the patient 
also requires medication for other psychiatric symptoms, an agents can be 
used with sedative properties at night, but antipsychotics must not be used 
just to treat sleep alteration.42
Expert opinion,
4
One RCT did not show any benefi t of 10 mg or 2.5 mg of melatonine on 




In one Cochrane SR it was not demonstrated that haloperidol (0.25-6 mg/
day) signifi cantly improved agitation in dementia in treatments lasting for 
3 to 16 weeks. Only aggressiveness was reduced in treated patients, but 
there was no improvement in other aspects of the agitation, global clinical 
impression of change, burden of the caregivers and ADL in studies that 
analysed them. Studies with haloperidol have shown that extrapyramidal 
effects already appear at lower doses than those that improve agitation.149
SR of RCT,
1+
In one Cochrane SR on atypical antipsychotics in AD,401 risperidone 1 
mg/day was better than placebo in improving aggressiveness according 
to Cohen-Mansfi eld Agitation Inventory (DM –1.17) in three RCT and 
according to the aggressiveness subscale of BEHAVE-AD in two RCT (DM 
-0.84 41 mg/day, DM -1.50 for 2 mg/day); olanzapine 5-10 mg/day also 
showed a benefi t with respect to placebo for aggressiveness in the NPI-NH 
(DM –0.77). The response rate of risperidone 1-2 mg/day was also greater 
than for placebo in aggressiveness in patients with severe dementia with 
agitation and/or psychosis in three RCT (45-63%), although the response 
rate to placebo was also high (33-47%).
SR of RCT,
1++
Olanzapine showed a higher rate of response in one RCT at a dose of 5, 10 
and 15 mg/day but not in another two (one at low doses and another at doses 
of between 1 and 7.5 mg/day).42
RCT,
1+




In one study on acute treatment of agitation in hospitalised patients with 
dementia, olanzapine 2.5 and 5 mg via intramuscular way was superior 
than placebo, with the response rate after 2 hours of 62, 66.7 and 37.3% 
respectively. In one RCT that compared lorazepam vs. olanzapine via 
intramuscular way in the treatment of agitation there was no difference at 2 
hours but lorazepam was inferior at 24 hours.42
RCT,
1+
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One small controlled study showed the benefi t of several SSRI on agitation 
of FTLD. One RCT of paroxetine in FTLD did not show any improvement 
and worsened cognition. One RCT of citalopram vs. perphenezine on 
agitation and psychosis showed the benefi t of citalopram in agitation and 
aggressiveness; citalopram presented less adverse effects.42
RCT,
1+/1-
There was no improvement with respect to placebo in agitation in the only 
RCT with trazodone in AD. A small RCT of trazodone in FTLD did show a 
benefi t over placebo. One small RCT of trazodone vs. haloperidol showed a 
reduction of agitation when this was accompanied by depressive symptoms 
in patients with dementia. Trazodone and some SSRI could be appropriate 




Donepezil 10 mg/day for 12-52 weeks showed benefi ts on agitation and 
aggressiveness with respect to placebo. There are not enough data for 
galantamine and memantine. The addition of memantine to treatment with 
donepezil also showed less agitation in one study.5
RCT,
1+
Carbamazepine showed a modest benefi t for agitation, with good tolerance 
at low doses and in a short treatment in two RCT, whilst valproate showed 
no effi cacy in four RCT.42
RCT,
1+
There is no consistent evidence that antipsychotics improve undesired 
behaviour other than aggressiveness,5401 and this is usually at the expense of 
sedation, increased weight, extrapyramidal signs and falls.
SR and MA of 
RCT,
1++




There are no RCTs for lamotrigine, gabapentine or topiramate.
Inappropriate sexual behaviours
There are no RCT of drugs to treat inappropriate sexual behaviours in 
dementia. Data of uncontrolled studies or case series suggest the effi cacy 
of antidepressants, antipsychotics, mood stabilisers, hormonal agents, 





No improvement of emotional incontinence or compulsive behaviours has 




There are no studies that assess the effect of any treatment specifi cally on false recognitions, 
personality alterations or eating disorders.
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Summary of evidence
ACE inhibitors or memantine
1++
The specifi c treatment with ACE inhibitors or memantine may non-
specifi cally improve some of the BPSD in patients with dementia when this is 
indicated.239,240,253,256,400
1-
Neither rivastigmine nor galantamine showed an improvement of delirium in 
AD.400
1+ Rivastigmine may improve psychotic symptoms in DLB.277
Antipsychotics
1-
The effi cacy of antipsychotics is similar among all of them in comparative low-
power and short duration studies.42,399,400
1+
To treat delirium in AD, an improvement has been observed with risperidone 
and donepezil.400,401,337
1+
Atypical antipsychotics (aripiprazole, olanzapine, quetiapine and risperidone) 
have shown a slight benefi t with respect to placebo in the treatment of psychotic 
symptoms in patients with AD and VD.25,42
Antidepressants
1++
Sertraline and citalopram have proven to be effective respect to placebo in the 
treatment of depression in patients with mild and moderate dementia in small 
studies.42 Fluoxetine was not effective.149
1++
Effectiveness is similar between antidepressants in comparative studies, but the 
SSRI are better tolerated and the tricyclics worsen cognitive function.42,149
Apathy
3
Psychostimulants ((d-amphetamine, methylphenidate), amantadine, 












Trazodone, zolpidem or zaleplon, or short half-life benzodiazepines may be 
useful for insomnia in the short term.42
1+
Melatonine is not effective to prolong nocturnal sleep or to reduce nocturnal 
activity in AD.42
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Agitation and aggressiveness
1++
Haloperidol 0.25-6 mg/day improves aggressiveness in patients with dementia, 
but not other aspects of the agitation, global clinical impression of change, 
burden of the caregivers and ADL.402
1++
Risperidone 1 mg/day and olanzapine 5-10 mg/day improve aggressiveness in 
patients with AD. 401
1+
Olanzapine and quetiapine has not proved to be benefi cial in agitation in patients 
with AD.42
1+
In hospitalised patients with dementia and agitation, olanzapine and lorazepam 
via intramuscular route have shown twice the response rate of placebo after 2 
hours.42
1+
Some SSRI, such as citalopram or trazodone have shown an improvement of 
agitation in FTLD. Paroxetine did not show any improvement and cognition got 
worse.42
1–
Trazodone did not show an improvement of agitation in patients with AD without 
associated depression.42
1+
Donepezil 10 mg/day for 12-52 weeks showed benefi ts on agitation and 
aggressiveness with respect to placebo in patients with AD.25
1+
Carbamazepine has shown a modest benefi t for agitation in patients with 
dementia.42
1+ Valproate has not proven to be effective for agitation in patients with dementia.42
1++
There is no consistent evidence that antipsychotics improve undesired behaviour 
other than aggressiveness, and this is usually at the expense of sedation, increased 
weight, extrapyramidal signs and falls.5
Inappropriate sexual behaviours
3
To treat inappropriate sexual behaviours in dementia, there are data of possible 
effi cacy of antidepressants, antipsychotics, mood stabilisers, hormonal agents, 
cimetidine and pindolol. 403
Emotional incontinence and compulsive behaviours
3
Emotional incontinence and compulsive behaviours in FTLD have improved 
with SSRI in some cases.5
Recommendation
ACE inhibitors or memantine
B
The use of these drugs in patients on whom the use of ACE inhibitors or memantine 
is indicated, is recommended for the initial pharmacological treatment of BPSD.
B
Donepezil may be used in patients with AD and psychotic symptoms. 
Rivastigmine may be used to treat psychosis in DLB.
✔
If the ACE inhibitors and/or memantine are not effective on the BPSD, the most 
adequate psychotropic drugs will be used for each type of symptom, considering 
their adverse effects.
CLINICAL PRACTICE GUIDELINE ON THE COMPREHENSIVE CARE 
OF PEOPLE WITH ALZHEIMER’S DISEASE AND OTHER DEMENTIAS 241 
Antipsychotics
A Risperidone may be used in patients with AD and psychotic symptoms.
D




Antidepressants, preferably sertraline and citalopram may be used in patients 
with dementia and depression. Tricyclic antidepressants are not recommended 
due to their adverse effects, despite their similar effectiveness.
Apathy
D
Psychostimulants, amantadine, bromocriptine or bupropion may be used in 
patients with dementia and severe apathy.
Anxiety
-
There is not enough evidence to make recommendations about the treatment of 
anxiety in dementia.
Erratic wandering
D Risperidone may be effective in erratic wandering in AD.
Sleep problems
D
Benzodiazepines, trazodone or hypnotics may be used to treat sleep disorders in 
dementia. Melatonine is not recommended.
Agitation and aggressiveness
B
The use of neuroleptics is recommended to treat agitation and aggressiveness. 
The evidence is greater for risperidone than for other drugs.
D
In the case of intolerance to antipsychotics, donepezil (if indicated), SSRI or 
carbamazepine may be used to treat agitation and aggressiveness.
Inappropriate sexual behaviours
D
Antidepressants, antipsychotics, mood stabilisers, hormonal agents, cimetidine 
or pindolol may be used to treat inappropriate sexual behaviours.
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10.4.9. What adverse effects and contraindications do drugs used 
to control BPSD have?
Antipsychotics
The use of antipsychotics is associated with the following adverse effects: 
Increase in mortality, stroke, sedation, confusion, drowsiness, parkinsonism, 
dystonia, tardive dyskinesia, akathisia, malignant neuroleptic syndrome, 
hyperlipidemia, hyperglycaemia, weight increase, orthostatic hypotension, 




In one Cochrane RS on haloperidol in dementia, greater frequency of adverse 
reactions was observed such as extrapyramidal symptoms, drowsiness and 
fatigue, compared with the controls.402
SR of RCT,
 1+
Haloperidol induces undesired extrapyramidal effects, which already appear 
at lower doses than those required to reduce agitation.149 The extrapyramidal 
effects and drowsiness limit their use.140
RCT,
1+
In one MA of RCT405 the most frequent adverse effects with atypical 
antipsychotics (aripiprazole, olanzapine, quetiapine or risperidone) 
compared with placebo were drowsiness (OR = 2.84) and urinary infections 
(OR = 1.28). Extrapyramidal symptoms (OR = 1.51), movement disorders 
(OR = 3.42) and peripheral oedema (OR = 1.99) were the most frequent 
with risperidone and olanzapine. A relevant increase of lesions, falls or 
syncope was not detected.
MA of RCT,
1+/1-
In a small and low quality study faster cognitive impairment was seen in 




Also in a MA of RCT with atypical antipsychotics in dementia, patients 
treated with aripiprazole, olanzapine, quetiapine or risperidone worsened 
more with respect to cognitive scores than those treated with placebo.405
MA of RCT,
1+/1-
Patients treated with risperidone duplicate the risk of extrapyramidal 
symptoms compared with placebo (more with 2 mg/day than with 1 mg/day), 
according to different MA of RCT (12% vs. 6% in one of them). 404,401,337 in 
the short-term, no differences are detected in the impact of extrapyramidal 
effects for risperidone and olanzapine compared with a placebo.399
MA of RCT,
1++
Drowsiness is 5-8 times more frequent and movement disorders 7.5-11 times 
more frequent with olanzapine than with placebo in one RCT. In two MA of 
RCT, drowsiness was more frequent in patients treated with risperidone or 
olanzapine than with placebo (18% vs. 8% in one of them).404,337
RCT, MA of 
RCT,
1+/1++
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The dropout rates were similar among dementia patients treated with 
haloperidol and controls in a Cochrane review,402 and also among those 
treated with atypical antipsychotics and the controls in one MA,405 which 




There is little information about the long-term safety of atypical 
antipsychotics in the elderly with dementia.399




Clozapine is associated with agranulocytosis that may be mortal, so the 




If typical antipsychotics via intramuscular route are used, the appearance of 
acute dystonias and other extrapyramidal effects must be controlled.25
Expert opinion,
4
The use of atypical antipsychotics has been associated with an increase in 
the risk of stroke and mortality in patients with dementia.5,42,235,149 The risk 
with typical antipsychotics may be similar according to a large retrospective 
review,406 above all at the start of treatment and with high doses.
Cohort study,
2+
The risk of stroke with antipsychotics has not been clearly established. 
In a joint analysis of 11 RCT407 2.2% of those treated with olanzapine 
and risperidone compared with 0.8% of those treated with placebo in 
the RCT had a stroke (RR = 2.7). In a MA on atypical antipsychotics for 
dementia, an increase in risk of stroke was detected (OR = 2.13), especially 
with risperidone.405 The cause of this association is not clear and large 
observational studies have not confi rmed an increase in the risk of stroke 
compared with typical antipsychotics or untreated patients.152,149




An increase in mortality has also been observed in patients treated with 
risperidone, quetiapine and olanzapine respect to placebo (4% vs. 3.1%, 
5.51% vs. 3.2%, 3.5% vs. 1.5% respectively). In a MA of 15 RCT, there 
were 3.5% of deaths with atypical antipsychotics compared with 2.3% with 
placebo, OR = 1.54.405 In two studies that included patients treated with 
haloperidol, the magnitude of the risk was similar. According to data from 
RCT, with risperidone, the risk of death during treatment and up to 30 days 
after its suppression, was slightly greater than that of placebo (4% vs. 3.1%) 
but with no statistical signifi cance and with no relation with the dose. The 
adverse effects most associated with death in risperidone were pneumonia, 
cardiac insuffi ciency, cardiac arrest and cerebrovascular disease.408
RCT, MA of 
RCT,
1+
244 CLINICAL PRACTICE GUIDELINES IN THE SNS
As occurs with the risk of stroke, observational studies do not support these 
differences, as some suggest a somewhat greater mortality with the typical 




In patients with DLB, observational studies suggest that up to 50% may 
have marked sensitivity to antipsychotics, leading to extrapyramidal 






The adverse effects of the benzodiazepines include: Sedation, worsening 
of cognition, confusion, delirium, worsening of the memory, paradoxical 
disinhibition, increase in the risk of falls, worsening of respiratory disorders, 
tolerance and dependence. Sleep apnoea is a relative contraindication for 
the use of benzodiazepines. 42,235
RCT, 
1+
Long-lasting benzodiazepines produce more cognitive alterations in 





Anticholinergics may worsen confusion and psychosis, and they must 




Anticholinergics are contraindicated in patients with cardiovascular 
diseases, prostatism or urinary bladder diseases. They may worsen cognition, 
produce confusion and delirium. Orthostatic hypotension may be caused by 
medications or worsened by them and consequently, patients with dementia 
have a greater propensity to falls and fractures.42
RCT,
1+
The SSRI produce less anticholinergic effects than classical antidepressants, 
although they may produce other limiting adverse effects (gastrointestinal, 
weight loss, sleep alterations, hyponatraemia). They have been associated 
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Amitriptyline has been clearly associated with cognitive alterations due to 
its anticholinergic activity, both in elderly people and in depressed patients. 
Other tricyclics such as imipramine, lofepramine and maprotiline seem to 
have less impact on the cognitive function. Mirtazapine and mianserine also 
seemed to produce these adverse effects whilst they have not been observed 





All the anticonvulsants may produce dose-dependent cognitive alterations. 








Antipsychotics may produce an increase in mortality, stroke, sedation, confusion, 
drowsiness, parkinsonism, dystonia, tardive dyskinesia, akathisia, neuroleptic 
malignant neuroleptic, hyperlipidemia, hyperglycaemia, weight increase, 
orthostatic hypotension, arrhythmias, ECG alterations, anticholinergic effects 
and cognition worsening.5,42,404
1++
Haloperidol produces extrapyramidal symptoms, drowsiness and fatigue more 
often in patients with dementia than in controls.402
1++
Atypical antipsychotics (aripiprazole, olanzapine, quetiapine or risperidone) 
produce greater drowsiness (OR = 2.84) and urinary infections (OR = 1.28) in 
patients with dementia than in controls.405
1++
Risperidone and olanzapine produce more extrapyramidal symptoms (OR = 
1.51), movement disorders (OR = 3.42) and peripheral oedema (OR = 1.99), in 
patients with dementia than in controls, but not more lesions, falls or syncope.405
1++
Patients with dementia treated with aripiprazole, olanzapine, quetiapine or 
risperidone worsened more in cognitive scores than those treated with placebo 
in the RCT.405
1++
Risperidone doubles the risk of extrapyramidal symptoms compared with 
placebo in patients with dementia.404,401,337
1+
Drowsiness is more frequent and movement disorders are more frequent with 
risperidone or olanzapine than with placebo.297,404,337
1++
The dropout rates among patients with dementia treated with haloperidol or 
atypical antipsychotics were similar to the controls.402,405
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1+ Clozapine is associated with agranulocytosis which may be mortal.42
1++/
2+
The use of atypical antipsychotics (risperidone, olanzapine) has been associated 
with a slight increase in risk of stroke and mortality in patients with dementia. 
On the other hand, observational studies do not support the fact that there are 
differences between atypical, typical and placebo.129,407,405,152,149,408,406
2++
50% of patients with DLB may have marked sensitivity to antipsychotics, 




Benzodiazepines may produce sedation, worsening of cognition, confusion, 
delirium, worsening of the memory, paradoxical disinhibition, increase in the 
risk of falls, worsening of respiratory disorders, tolerance and dependence.42,235
1+
Long-lasting benzodiazepines such as diazepam produce more cognitive 
alterations in the elderly.149
Antidepressants
1+
Anticholinergics may worsen confusion and psychosis in patients with dementia. 
The SSRI produce less confusion than tricyclics.5
1+
Anticholinergics are contraindicated in patients with cardiovascular diseases, 
prostatism or urinary bladder diseases.42
1+
The SSRI may produce adverse gastrointestinal effects, weight loss, sleep 
alterations or hyponatraemia, and they have been associated with falls and 
fractures.152
1+
Amitriptyline has been associated with cognitive alterations. Other tricyclics 
such as mirtazapine and mianserine have less impact on the cognitive function. 
SSRI have not been associated with cognitive alterations.5,42,152,149
Antiepileptic drugs
1+
Anticonvulsants may produce cognitive alterations. Phenobarbital produces 
more alterations than carbamazepine, phenytoin or valproate.149
Recommendation
A
Antipsychotics must be used with caution in patients with dementia, due to the 
risk of adverse reactions, always considering the risks of treating compared with 
the risks of not treating.
B Antipsychotics are contraindicated in DLB due to the high risk of adverse effects.
C Treatments with benzodiazepines must be short-term due to the adverse effects.
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10.4.10 How effective is it to combine pharmacological and non-
pharmacological treatment to treat behavioural and psychological 
symptoms in mild, moderate and severe dementia?
There is little evidence about the effi cacy of combined treatment (pharmacological and non-
pharmacological) to manage behavioural and psychological symptoms of dementia.
One RCT with 150 patients with mild or moderate AD that compared 
the effi cacy of treatment with donepezil with treatment with donepezil 




Studies performed on patients affected by severe AD, with depression 
or psychosis, recommended the joint use of pharmacological and non-
pharmacological treatments, not specifying what they based themselves 
upon to make this recommendation 152.
RCT,
1-
One SR of RCT149 recommends, as a strategy to treat BPSD, to associate 
non-pharmacological and pharmacological measures, not describing the 





One RCT with 152 patients with mild or moderate AD to assess the effi cacy 
of cognitive stimulation and ACE inhibitors, compared with ACE inhibitors in 
monotherapy, did not show any signifi cant differences.25
1-
One SR of RCT recommends associating non-pharmacological measures with 
pharmacological ones to treat BPSD.149
Recommendation
✔
The association of non-pharmacological and pharmacological measures is 
recommended to treat behavioural and psychological symptoms of dementia.
10.4.11 Which are the most effective recommendations to avoid 
BPSD in patients with dementia?
The etiopathogeny of the BPSD is varied and affects many different factors: A predisposing 
genetic factor, a biological factor derived from specifi c degenerative changes that occur in 
specifi c areas of the brain, the presence of concomitant diseases, an inadequate environmental 
surrounding, and the different caring styles of the caregiver may have a signifi cant infl uence on 
the appearance and variability of the BPSD.409
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We can act upon these latter factors, by detecting and treating the concomitant diseases and 
providing optimal environmental conditions that do not generate the appearance of BPSD.398
There is a specifi c intervention group in areas:
• Structured activities: The inclusion of physical activity, walks and recreational activities 
reduce the appearance of agitation behaviours.410
• Behavioural therapy: By reinforcement techniques of relaxed behaviours and control of 
stimuli.
• Environmental modifi cations: Consisting in reducing unnecessary stimulation, maintaining 
safety, autonomy and independence. A natural surrounding and light therapy may reduce the 
frequency of appearance of agitated behaviour.
• Social contact: This consists of creating strategies to improve the frequency and quality of 
social interactions among people affected by dementia.
• Sensory stimulation and relaxation: Manual massage, therapeutic contact and isolated sen-
sory stimulation activities, or combined ones, may induce relaxation and reduce the preva-
lence of behavioural symptoms and agitation.329,331,332
In one SR411,25 of seven RCT, which assessed therapeutic touch massage, 
as a non-pharmacological alternative to reduce anxiety, agitated behaviour 
and depression, only two satisfi ed minimal methodological criteria. 
These studies assessed two specifi c applications: Manual massage for the 
immediate reduction of agitated behaviour and the addition of therapeutic 
touch to verbal stimulus, to normalise nutritional intake. The results indicated 
that manual therapeutic touch massages may be useful as alternatives in 
behavioural and emotional treatment.
RCT,
1-
We have no scientifi c evidence to be able to draw conclusions and recommendations on the 
effect of these interventions.
Summary of evidence
4
Many different factors affect the etiopathogeny of BPSD (genetics, type of 
dementia, concomitant diseases, environmental surrounding, lifestyles).409 
We can act upon the comorbidity and on the environment,398 and carry out 
specifi c structured interventions,410,410 behavioural therapy;387 environmental 
modifi cations; social contact; sensory stimulation and relaxation.329,331,332
-1
One SR411,25 of seven RCT, which assessed therapeutic touch massage showed 
that they can be useful to reduce anxiety, agitated behaviour and depression.
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Recommendation
✔
A meticulous assessment is recommended if BPSD appear, to rule out concomitant 
pathology and achieve optimal environmental surroundings.
✔
Sensory stimulation, behavioural therapy, structured activities and social contact 
may be used to reduce the incidence of BPSD, although there is no scientifi c 
evidence to support this.
10.4.12 How must BPSD, which are diffi cult to monitor in 
outpatients, be treated?
Any person with dementia may, at some moment in the evolution of the disease, present BPSD 
that do not go away easily with verbal contention, non-pharmacological manoeuvres or with 
psychotropic drugs. (question 10.4.8).
These symptoms cause critical situations that are diffi cult to control in outpatients and often 
require the coordinated action of the PCT and of the SDCT. If they are not controlled properly, 
they must be referred for admission to the emergency service of the hospital or to specifi c 
units.412
In situations of refractory crises, admission into a hospital may be useful to 
diagnose possible comorbidities, optimise the pharmacological treatment 






In situations where the crises do not go away when treated in outpatients, 
admission into hospital is necessary to be able to diagnose possible comorbidities, 
optimise the pharmacological treatment of the symptom and guarantee the safety 
of the patients and of their environment413,25
Recommendation
D
If the behaviour crises do not respond to the normal pharmacological measures 
in the home/residence, admission into hospital or into specifi c units is advised to 
diagnose the symptoms and aetiology, treat comorbidities, optimise the treatment 
of BPSD and guarantee the safety of the patient and of his environment.
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10.4.13. What attitudes must caregivers satisfy to deal with patients 
with BPSD?
There is no scientifi c evidence respect to the qualities that caregivers must satisfy to deal with 
patients with BPSD.5,409 The available information sources today are basically manuals and 
monographs aimed at caregivers of patients with dementia.
To respond to this question we must take a series of aspects into account: The different 
personality profi les of caregivers, the level of relationship and involvement in the care tasks, 
the voluntary acceptance or imposition of the function of caring, differences in age and sex 
of the caregivers and if the caregiver is one single member or they receive support (family, 
professionals). To prepare recommendations that may help caregivers manage BPSD, it is also 
important to evaluate the following aspects:
• The previous relationship of the caregiver with the patient: Type of relationship and its 
quality.
• Level of involvement of the caregiver in the care of patient: Direct care, emotional support 
and organisation of care.
• Degree of voluntariness in the care relationship.
• Stress that is generated during the relationship between the patient and the caregiver.
• Degree of knowledge and understanding of the disease by the caregiver.
• Degree of strain and help received from other relatives and from other support sources 
(Association of families, institutional help, etc).
• Expectations of the caregiver about the intervention of the physician and health personnel 
in general.
• Ideas of the caregiver about the future of the patient: Institutionalisation, probability of 
imminent death and denial of the defi ciencies.
Faced with the appearance of BPSD, the caregiver's attitude must be one of:
• Acceptance of the progressive nature of the disease, and the lack of "curative" treatment at 
the present time.
• Understand that many of the BPSD do not have a specifi c treatment and that we can use 
limited effi cacy therapeutic measures.
• Have a patient and tolerant attitude.
• Inform the caregiver that the patient's attitudes, beliefs and anomalous behaviour are 
symptoms of the actual disease. as is the case of memory defi ciency or other cognitive 
defi ciencies.
• Understand that the solution of the BPSD does not depend on them being explained to the 
patient nor on his or her willpower to solve them. 
• Observe the context in which the BPSD appear, as well as the predisposing, triggering 
factors and manoeuvres or interventions that reduce or eliminate them.
• Request help from other members of the family, institutions and associations so as not to 
undertake the role of caregiver alone.
• Request professional aid if symptoms or signs of strain or claudication appear in the task 
of caring.409,5
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Recommendation
✔
It is advisable to inform and train caregivers of dementia patient in strategies 
to address and manage the BPSD so that it is possible to adopt and promote an 
appropriate attitude towards patients and prevent strain and claudication of the 
caregivers.
10.5. Alternative treatments of dementias
Questions to be answered
10.5. Are there any plant-based medications or food supplements that have proved to be useful 
in the treatment of dementia?
10.5. Are there any plant-based medications or food supplements 
that have proved to be useful in the treatment of dementia?
Vitamin E
One Cochrane SR that found one high-quality RCT concluded that there 




One MA of RCT with an extensive number of individuals concluded that 
large vitamin E supplements (400 UI/day) could increase mortality.415
MA,
1++
The CPG of the EFNS (2007)5 and the Canadian CPG (CCDTD)(2006)416 concluded in 
their recommendations that there was not enough evidence about the risk-benefi t profi le to 
recommend the treatment of AD with vitamin E.
Vitamin B1, B6, B12 and folic acid







vitamin or folic acid supplements to treat cognitive impairment, as their 
effi cacy has not been demonstrated except for those cases where there is a 




One RCT that assessed the effi cacy of administering copper supplements 
to patients with AD did not show benefi cial effects on cognition of treated 
individuals compared with the placebo group.417
RCT,
1+
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Ginkgo biloba
The CPG of the AAN, based on a RCT, concluded that treatment with 
ginkgo biloba was safe although it affi rmed that it lacked quality evidence 
about its effi cacy.304
RCT,
1-
A review of published case series suggested a possible association between 
treatment with ginkgo biloba and brain haemorrhage, with an increase of 




The CPG of the EFNS (2007),5 based on three low-quality RCT considered 
that there is not enough evidence to recommend the use of ginkgo biloba in 
the treatment of AD or VD.
The Canadian CPG (CCCDTD)(2006) considered that there was not enough 
evidence to make a recommendation about the use of gingko biloba.416
RCT,
1-
A Cochrane SR (2009)419 included 36 RCT that assessed the effect of ginkgo 
biloba at different doses on cognitive impairment (of different aetiologies 
and different severity) of which only nine RCT were controlled for a period 
of more than 6 months. Three of the four most recent studies did not show 
effi cacy with respect to placebo, whilst only one showed effi cacy of the 
treatment. The conclusions of this SR were that the use of ginkgo biloba 
seems to be safe within a short-medium term research context. No major 
incidents about side effects compared with placebo have been reported, 
although evidence about the clinical benefi ts of ginkgo biloba in individuals 




A Cochrane SR concluded that there is not enough evidence to recommend 





One Cochrane SR (2009) concludes that failing a RCT that assesses the 
effect of alpha-lipoic acid in patients with dementia, its use cannot be 




One RCT that included a small number of participants did not objectify the 
effi cacy of the use of Omega-3 fatty acids to treat AD.422
RCT,
1-
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Ginseng
A recent SR (2009) that included two RCT that assessed the effi cacy of 
ginseng (Panax ginseng) in AD, concluded that although both studies showed 
a positive effect on cognitive variables, they had relevant methodological 




A RCT that included patients with AD, DLB or mixed dementia did not 







Vitamin E supplements have not proven to be effective in the treatment of AD 
and they could increase mortality.5,416
Vitamin B1, B6, B12 and folic acid
1++






 or folic acid supplements is not effective in 








The evidence on the effectiveness of ginkgo biloba in the treatment of AD or VD 
is inconsistent.304,418,5,416,149,419
Lecithin, alpha-lipoic acid, omega-3 fatty acids, ginseng or yokukansan (TJ-54)
1+
There is no quality evidence about the effi cacy of the use of lecithin, alpha-
lipoic acid,421 omega-3 fatty acids422 ginseng423 or yokukansan (TJ-54)424 in 
the treatment of cognitive symptoms of AD, although the analysis of available 
studies suggests that these are not effective in this treatment
Recommendation
Vitamin E
B Vitamin E supplements are not recommended in the treatment of AD.
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Vitamin B1, B6, B12 and folic acid
A






 or folic acid supplements is not recommended in 
patients with cognitive impairment that do not present a clear defi ciency of these 
elements.
Copper supplements
B The use of copper supplements is not recommended to treat patients with AD.
Ginkgo biloba
B
There is not enough evidence in literature about the effi cacy of ginkgo biloba to 
recommend its use in the treatment of AD or VD.
Lecithin, alpha-lipoic acid, omega-3 fatty acids, ginseng or yokukansan (TJ-54)
C
Existing evidence does not permit recommending the use of lecithin, alpha-
lipoic acid, omega-3 fatty acids, ginseng or yokukansan (TJ-54) in the treatment 
of cognitive symptoms of AD.
10.6. Assessment of the treatment of dementias
Questions to be answered
10.6. How must the response to the treatment of dementia be assessed in clinical practice?
10.6. How must the response to the treatment of dementia be 
assessed in clinical practice?
There are no studies that establish the parameters that must be monitored 
in the evaluation of the therapeutic response and control of patients with 
dementia. However, given that the patients present cognitive, functional, 
motor, behavioural and global alterations throughout the disease, clinical 
experts suggest carrying out a longitudinal evaluation of all of them.25,5
Given that the care of patients with dementia may have negative repercussions 
on the caregiver's health, this must also be taken into account in the control 
of the process, assessing the degree of strain (Section 11).
Expert opinion,
4
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The NICE (2007)25 CPG recommends the use of the MMSE to monitor 
the global cognitive function. This is the most commonly used short global 
cognitive test to longitudinally evaluate the cognitive function of patients 
with dementia and their response to therapy in both a research context and 
in clinical practice, and it has shown good inter-observer reliability and test-
retest validity
There are several versions of the MMSE in use in Spain. standardised 




There is no consensus about which magnitude of change in the MMSE 
must be used to consider that a patient responds or does not respond to 
treatment. The NICE (2007)25 CPG underlines that a specifi c treatment 
must be considered as effective and, therefore, must be maintained, when 
the patient shows an improvement or at least no impairment in the score 
of the MMSE 2-4 months after having reached the maintenance dose. 
Other authors consider that a patient responds to the medication when an 
impairment of less than 2 points occurs within 6 months or of less than 3 
points in the MMSE in 12 months.425
Expert opinion,
4
For patients in moderately advanced or advanced dementia stages, there is 
a version of the MMSE, the “Severe MMSE”, which permits carrying out a 
cognitive control of these patients with MMSE scores of less than 9 points 




With respect to the other aspects (behavioural, functional, motor disorders or strain on the 
caregiver), each one of these may be assessed in a qualitative or semi-quantitative manner 
through a directed history or quantifi ed through scales, tests or specifi cally designed 
questionnaires for this purpose, as has been dealt with in each one of the relative sections 
(sections 8, 10.4 and 11).
There are no studies that compare the usefulness of both methodologies 
in the monitoring of patients with dementia, although published CPG25,5 
specifi cally recommend the use of quantitative instruments, as they consider 
that these would enable changes to be detected at an earlier stage. However, 
there is no consensus about which specifi c instruments are more useful to 
assess each one of the aspects longitudinally or about what degree of alteration 
in each of these must represent a modifi cation in the management or in 
the therapy of patients with dementia, although the quantitative assessment 
would permit establishing intra- and inter-individual comparisons.
Expert opinion,
4
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Summary of evidence
2+
Patients with dementia present cognitive, functional, motor, behavioural changes 
during its evolution. Caregivers also present changes in the degree of strain 
throughout the disease.
4
The use of tests, scales or standardised questionnaires is useful to quantify 
the therapeutic response and the appearance of complications in patients with 
dementia.25,5
2+
The MMSE, of which there are several Spanish versions,142,143,144 is useful to 
evaluate the response to treatment in patients with dementia;426,425,25  it is the most 
commonly used test in clinical practice for this purpose.
Recommendation
D
The periodic assessment of cognitive, functional, motor and behavioural aspects 
is recommended, as well as of the degree of strain on the caregiver in the 
monitoring of patients with dementia.
D
The use of tests, scales or questionnaires is recommended to quantify the 
therapeutic response and the appearance of complications in patients with 
dementia.
✔
The choice of a test, scale or questionnaire will be based on the physician’s 
experience and on its applicability in the context.
C
The use of the MMSE is recommended to assess the response to dementia 
treatment in clinical practice.
CLINICAL PRACTICE GUIDELINE ON THE COMPREHENSIVE CARE 
OF PEOPLE WITH ALZHEIMER’S DISEASE AND OTHER DEMENTIAS 257 
11. Caregivers of patients with dementia
Questions to be answered
11.1. What is understood by primary caregiver of a patient with dementia? 11.2. Are the char-
acteristics of caregivers the same for people with different types of dementia?
11.3. What repercussions does caring for a person with dementia have on the caregiver?
11.4. What scales are useful to assess caregiver burden?
11.5. Are there effective interventions to prevent caregiver burden? 
11.6. Are there effective interventions to deal with caregiver burden? 
11.7. What are mutual aid groups (MAG)?
11.8. What benefi ts are obtained from participating in MAG?
11.9. In what cases is psychological treatment of the caregiver necessary? 
11.10. What are associations of families of people affected by dementia and what role do they 
play in a comprehensive approach to dementia?
11.11. What must the relationship between the associations and the public social and health 
network be like?
11.1. What is understood by primary caregiver of a patient 
with dementia?
The caregiver has been defi ned as “the person who helps or cares for another 
person affected by any type of disability, handicap or invalidity that makes 
it diffi cult or prevents them from carry out their life activities or their social 
relations in a normal manner”. 427,25,428
Primary caregivers of people with dementia assume the primary care tasks 
and responsibilities, without receiving any economic payment for their 
work, and they are accepted as such by the rest of the members of the 
family.427 Their commitment is signifi cant and long-lasting.
Expert opinion,
4
In the majority of the cases they are direct family members or very close 
friends. Normally, they are wives or daughters aged between 45 and 70 
years old, who live with the patient, or who spend a considerable amount of 
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Often, the caregivers attend to the patient alone, without there being any 
network of secondary caregivers to support them. The majority of their work 
is carried out in the home and their tasks include accompanying patient in 
transport, going shopping, doing the household chores, preparing meals, 
and helping them in their basic activities of daily living such as getting 




Professional caregivers, with or without specifi c training, are those people who directly care 
for the person affected by dementia, and receive an economic compensation for their work.432
Over the last few years, due to many different factors such as the change 
in family structure, incorporation of women into the working markets and 
the need to reduce expenses caused by caring for people with dementia, 
a progressive increase of professional caregivers without specifi c training 
has been observed. The percentage reaches 8.7% of caregivers in Spain. 
They are usually people of both sexes, immigrants, the majority originating 
from Latin America and aged between 26 and 50 years old. They are often 
married people who live with their companions, with unfi nished university 






Caregivers are people who help or care for other people affected by any type of 
disability, handicap or invalidity that makes it diffi cult or prevents them from 
carrying out their living activities or their social relations in a normal manner.427,25 
the primary caregiver assumes the main tasks and responsibilities of caring, not 
receiving any economic payment, and this role is accepted by the rest of the 
members of the family.427
2++
They are direct family members or friends. Wives or daughters aged between 
45 and 70 years old. They live with the patient or spend a lot of time with 
them.25,429,430,431
2++
Professional caregivers, with or without specifi c training, are those who carry 
out the care work directly, receiving an economic compensation for their work.432 
Over the last few years a progressive increase of professional caregivers has 
been observed, with no specifi c training, young immigrants, Latin Americans, 
Christian, with unfi nished university studies.433
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11.2. Are the characteristics of caregivers the same for 
people with different types of dementia?
People with dementia may present different clinical manifestations and 
different evolution, which may pose diffi culties and specifi c needs.430,25 
Furthermore, personal, family and contextual circumstances of the 
caregivers may pose differential elements in the care of patients.
Expert opinion,
4
Current research is aimed at discriminating these differential aspects: 
Gender, relationship, economic-cultural status, etc. With respect to gender, 
women suffer a greater level of burden, generally because they assume 
the care in a much more intense manner. With respect to relationship, 
caregiving children seem to have a greater level of burden than husbands or 





The problems posed by Alzheimer's disease (AD) are related above all to 
cognitive losses, to which we can add, to a greater or lesser degree, BPSD, 
even from the mild-moderate stage of the disease. Basic functionality 
losses, including sphincter control and mobility alterations will only appear 





Frontotemporal lobar dementia (FTLD) usually appears in younger people, 
in whom the BPSD are relevant from the start and have an early effect on 
the family, occupational and social environment. The primary caregivers 
in these cases are either the spouse, who still usually and needs to work, 
and must make their task of caring compatible with other unavoidable 
obligations such as looking after their children, often in school age. In other 





In dementia with Lewy bodies (DLB) and in Parkinson’s Disease Dementia 
(PDD), the work of the primary caregiver is complicated due to the actual 
characteristics of the disease. These patients are diffi cult to understand, accept 
and manage the motor, cognitive, behavioural fl uctuations, parkinsonism, 
autonomous-sphincter disorders, frequent falls, REM sleep behaviour 
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In vascular dementia (VD), focal alterations may be present from the onset 
or appear early on. Cognitive impairments may have a subcortical, cortical 
or mixed variable origin, and BPSD are not infrequent. The fact that in 
this type of dementia, communication between patients and caregiver is 
possible until very advanced stages, enables the emotional contact between 






Every person with dementia and their centre of coexistence have different 
characteristics and needs, which require individualised care.430,25
2++
Female caregivers usually have a greater burden in the task of caring. Caregiving 
children have a greater burden than husbands or wives.434,435,436
2++
AD, in the mild-moderate phase, poses problems related to cognitive defi ciency, 
and to a lesser extent with BPSD. Basic functionality losses, including sphincter 
control and mobility alterations are added in advanced stages.6,44
2++
FTLD usually occurs in younger people and presents relevant BPSD from the 
onset. The primary caregivers are their young companions with many different 
obligations to make compatible (work, family).6,45
2++
In DLB and in Parkinson’s Disease Dementia (PDD), patients are diffi cult to 
manage due to their motor, cognitive, behavioural fl uctuations, parkinsonism, 
autonomic-sphincter disorders, frequent falls, REM sleep behaviour alterations, 
hallucinations and delusions with paranoid ideation.6,47
2++
VD is associated with early focal signs, variable cognitive impairment 
(subcortical, cortical or mixed) and frequent BPSD. Communication is preserved 
until very advanced stages.6,46
4
There is no specifi c caregiver for each type of dementia. Every person with 
dementia and their environments are a different reality; however, each type of 
dementia has its own individual characteristics that may have an infl uence on the 
burden that the caregiver is going to suffer, and on the needs generated.
Recommendation
C
During the care of every person with dementia, their individual characteristics 
and the actual characteristics of the disease must be evaluated to be able to 
evaluate and prevent the burden and needs of the caregiver, and act consequently 
to optimise their support network.
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11.3. What repercussions does the care of a person with 
dementia have on the caregiver?
Dementia generates concern, uncertainty and fear in the family. It causes 
changes in roles occupied by each one of its members, which may represent 
important modifi cations in their lives. The role of caregiver evolves with 
time; it starts with assimilating the diagnosis, supervising and helping in the 
instrumental activities of daily living (IADL), progressive tolerance faced 
with the behaviour disorders and attention to the basic activities of daily 
living (BADL). The physical and psychological burden that the primary 
caregiver has to support will increase with the evolution of the disease. 
Their tasks will increase, they must assume new responsibilities, and they 
will lose their freedom and independence to continue carrying out their own 
activities, which may fi nally represent a change in their life project. This 
situation endangers their physical and emotional health, above all if they 
are fragile or elderly people. When the stress is continuous, and especially 
if there is no adequate support network, the possibility of psychological, 




The caregiver burden is defi ned as the extent to which physical and emotional health, social life 
or the fi nancial situation of the caregiver, are negatively affected as a result of caring for the 
patient. The term “caregiver burden” refers to the psychological and physical consequences, as 
well as changes derived from the care because of the dementia.438
For different reasons, although usually due to an emotional bond with the patient, caregivers 
assume a greater burden than they are able to support, not taking into account their real 
capacities and their own state of health. The strain that entails the risk of claudication depends 
on a lot of factors such as the type and severity of the symptoms, the duration of the dementia, 
the caregiver's personal characteristics and the support received from health resources and from 
the family environment.
Often, when the caregivers are sons or daughters, and they live with the 
patient and assume other family responsibilities, they will accumulate 
feelings of blame and disorders will appear such as anxiety, depression, 
feeling of loneliness and isolation. This strain decreases if the patient 
is admitted into a nursing home. However, when the caregiver is the 
companion, these symptoms intensify at the moment of institutionalisation. 
The morbidity and mortality of the caregivers increase signifi cantly in all 
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Summary of evidence
3
Dementia generates concern, uncertainty and fear in the family and causes 
changes in roles among its members. The caregiver’s tasks change throughout 
the process, and the physical and psychological burden increases progressively, 
free time decreases and health problems may appear, above all if there is no 
suitable support network.437,436
3
The caregiver burden is understood as all those negative consequences on their 
physical and emotional health, social life or fi nancial situation, derived from the 
task of caring.438 The children are those who undergo a greater burden in the 
care, if they live with the patient and assume other family responsibilities.437,436 
They often accumulate feelings of blame, and disorders appear such as anxiety, 
depression, diffi culty in expressing feelings, and the feeling of loneliness and 
isolation increases. Morbidity and mortality signifi cantly increase.437,436
Recommendation
D
Dementia is a dynamic process which commits and compels the caregiver 
more. It is recommendable to meticulously evaluate the burden supported by 
the primary caregiver and the support he / she receives in their task of caring. 
If the burden is too much, it is advisable to establish the appropriate measures 
to prevent this from affecting his or her physical and psychological health, thus 
giving rise to the risk of claudication.
11.4. What scales are useful to assess caregiver burden?
The Zarit scale is the most commonly mentioned in the studies and clinical 
practice guidelines. It is a self-administered questionnaire, with subjective 
frequency measurements on 22 items. The test is very consistent and has a 
high test-retest concordance. It has been adapted and validated in its Spanish 
version with a score of each item from 1 to 5 (evaluating the frequency of 




Some authors have carried out a factor analysis of this scale, grouping the 
items into different factors: Social burden, psychological stress, feelings of 
blame, emotional pressure, and dependence relationship.438,439,440 There are 
abridged versions that may be equally useful.441
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Many of the studies that assess the degree of caregiver burden also use 
other scales designed to assess the consequences of the burden, evaluating 
anxiety, depression or quality of life related to health. In the case of anxiety, 
an appropriate scale is the Beck Anxiety Inventory,442 in depression, the 







The Zarit scale is a self-administered questionnaire that is used to evaluate 
the caregiver burden. It has 22 items grouped into sections on social 
burden, psychological stress, and feelings of blame, emotional pressure and 
dependence relationship. This scale is very consistent and has a high test-retest 
concordance.438,439,440 There are also short versions that may be equally useful.441
2++
There are different scales to evaluate the consequences of caregiver burden; the 
Beck Anxiety Inventory to evaluate anxiety,442 the GDS scale, for depression,394 
and the SF-36 or the SF-12 for physical and mental health.444,443
Recommendation
C
The use of the Zarit scale (long and short versions) is recommended to quantify 
the caregiver burden.
✔
The use of specifi c adapted and validated instruments is recommended to assess 
other aspects they may be affected by the caregiver burden.
11.5. Are there effective interventions to prevent caregiver 
burden?
There are studies that assess the factors that have an infl uence on the burden 
perceived by the caregiver (e.g. Financial repercussions, behavioural 
disorders, bad social acceptance, previous psychological history, caregiver 
of presenile onset patient, age of the caregiver and duration of care) that 
might identify caregivers with a greater risk of suffering unfavourable 
effects due to caring for a patient. The objective would be to focalise the 
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Caregivers who are better informed about the disease seem to have less 
depression, but similar levels of stress and perception of their own health 
than those who are worse informed, so offering caregivers complete 
information about the disease, possible complications, its management 
and available resources, both clinical as well as social and legal, could 
prevent the stress. However, some of the studies analysed warn that this 
information in very early stages of the disease could also increase the level 




The NICE guideline recommends establishing regular assessment and care 
programmes for the caregivers, which will include group or individual 
psychoeducation, support groups, telephone or online support, educational 
programmes on the disease, problem-solving and available resources, and 
inclusion of other members of the family apart from the primary caregiver, 
at meetings of the therapeutic team. These support interventions could be 
effective both at a strain prevention and treatment level.25
Expert opinion,
4
Clinical experience suggests that completing the clinical assessment with data of the patients’ 
and caregivers’ families and social context, has a preventive purpose, in so far that it is going 
to enable us, from the onset of the process, to identify the social needs that may arise in the 
care of a person with dementia and in their immediate social environment. Detection of these 
needs, which has a direct effect on the strain of the caregiver, will permit the implementation 
of the most suitable available measures.
Summary of evidence
3
There are factors that affect caregiver burden; the assessment of these factors 
permits identifying risk caregivers: a) the existence of previous psychological 
pathology, b) age of the caregiver, c) young dementia, d) behavioural disorders, 
e) bad social acceptance, f) duration of the care, g) little support in task of caring 
and h) economic repercussion.445
3
Caregivers who are better informed about the disease seem to have less 
depression.25
4
Support interventions for the caregiver are effective to prevent and treat their 
excessive burden. These are programmes with regular assessments and activities. 
The actions they develop include group or individual psychoeducation, support 
groups, telephone or online contact, involvement of the family, educational 
programs, problem-solving and provision of available resources.25
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Recommendation
D
A basal evaluation of caregiver of a person with dementia is recommendable 
in order to identify the factors that affect the burden of caring, the diffi culties 
that might arise in the course of the disease and the degree of burden that the 
caregiver already has at the time of the diagnosis.
D
The caregiver should be informed well and progressively about the disease and 
its possible complications, offering him or her available social resources, as well 
as the formal or informal support systems to prevent strain.
11.6. Are there effective interventions to deal with 
caregiver burden?
Reviews about support experiences with caregivers provide different perspectives.
In one SR, nine of 11 studies showed that interventions with caregivers 
are benefi cial. The combination of educational support, emotional support 





Another SR on RCT of 15 articles with an experimental group and control 
group indicated that interventions regarding caregivers had signifi cant 
although moderate effects on strain (40%), anxiety (50%) and depression 
(90%). Various coincident with other authors in that strain is the most 
diffi cult variable to modify, as it is a stressful element that may be maintained 
throughout the time the care lasts.447
RCT,
1++
Another SR on 44 studies showed little evidence of the effectiveness 





Another SR on observational studies showed that therapeutic interventions 
with caregivers of people with dementia had a moderate effect on anxiety, 
depression or strain. There are differences in opinion between the perception 





Better results were obtained with individualised interventions carried 
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Dementia is a disease of the family, in the sense that it involves patients and their closest 
environment (family and friends). The support and attention given to the family by the 
professionals of the different health and social levels, associations of families of people with 
Alzheimer type dementia and other related dementias (AFA), and above all by the actual family, 
as the closest resource, is essential both to cope with the disease and adapt to the process, and 
to distribute responsibilities. The burden is minimised and supported better if there is internal 
and external support, and if the different people involved can enjoy time to care for themselves 
and to continue improving in their task of caring.
The best treatment for strain is its prevention and this is achieved and exercised through 
information, education, professional support, a solid family and social network, and by 
obtaining resources. Recognising that dementia is changing process, with new burdens and 
needs throughout time, with new challenges to solve, and that the losses usually appear in 
a hierarchic and predictable manner, make it easier to design personalised strategies. Every 
caregiving family has its own dynamics with factors that have a positive or negative infl uence 
and on which action can be taken.
All the measures that facilitate the task of caring are understood as support for caregivers, they 
make the task more tolerable, they favour the maintenance of free time to develop their own 
needs and activities, and enable them to rest.
The caregiver’s position and attitude with respect to the different problems linked to dementia 
is heterogeneous and variable. Caregivers can accept, refuse, participate and get involved in the 
care of the family member. The task of caring is diffi cult, it causes tiredness and in 30% of the 
cases, it can cause secondary psychological alterations, and a large number of them are at risk 
of claudication There are signs that enable us to detect the risk of claudication and that help us 
take action soon to prevent or reduce the consequences to a minimum.
Caregivers must be offered solutions and help to respond to their needs and 
strain. When caregivers refuse aid and are not aware of the problem and 
risk, it is advisable to inform them again or do so in the network that cares 
for them, to guarantee the most appropriate approach in each case. There 
is evidence that caregivers will need training at some time to improve their 
care skills and, on the other hand, have suffi cient capacity to cope with the 
situation. Social resources, educational and emotional support, would sum 




The aspects that must be contemplated in the comprehensive support to 
caregivers, to care, prevent and treat strain, avoid claudication and re-
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• Establishing a welcome programme for people with dementia and 
their caregivers, by professionals from the primary care team (PCT), 
with the collaboration of the AFA and of the specialised dementia care 
(SDC). Contact with the AFA is important in order to bring community 
resources closer to families.
• Personalised information sessions for each family unit. The infor-
mation offered must be clear and adapted to the recipients and it must 
include clinical information about the treatments, prognosis and exist-
ing resources. These sessions must be given by professionals from the 
PCT. The attendance of relatives is advisable after dementia is diag-
nosed. Information about the disease and its updates should be repeated 
or reinforced, depending on the needs of the family group, and it must 
be done in a regular manner.
• Theoretic and practical training aimed at family caregivers to pre-
pare for daily problems and to act appropriately to cope with the diffi -
culties that are going to arise, due to the loss of cognitive skills, appear-
ance of behavioural disorders and alteration of the functional capacity.
• Counselling: Economic, legal, on health and social resources. The AFA 
are a good source of counselling.
• Emotional support to caregivers and to families, individual or group; 
in this type of support, we can fi nd therapeutic aid groups (TAG) and 
mutual aid groups (MAG).
• Adaptation of resources: Detection of needs, help in formalities, ex-
plained the circuits, evaluate compliance with needs and expectations. 
Identify the most appropriate resource: Social workers, day hospitals, 
day centres, night care centres, respite admission, care of crises.
• Pharmacological treatment of the caregiver, if necessary, which will 
help solve insomnia, anxiety, depression, and other concomitant pathol-
ogies that may appear (example: Control of vascular risk factors, treat-
ment of osteoarticular pain, etc.
• Accompaniment at end-of-life stage, co-participating in palliative care 
(PC) strategy and in grief care.
Mixed strategies, which combine different support measures, are the most effective. The team 
of professionals caring for these families must evaluate on a regular basis if the interventions 
have been adequate, if their objectives have been achieved, and if the situation should be 
reconsidered, designing new strategies, programmes or revising the old ones.
One of the aspects that must continuously be reinforced is the proximity family support 
network. Good information, from the onset, to all members of the family involved, is the 
basic pillar of this network. A continuous attempt must be made for this network to enjoy good 
physical, psychological, emotional health and communication.
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Summary of evidence
2++
Caregivers must be offered solutions and help to respond to their needs and 
strain. Caregiver support interventions are benefi cial, above all the combination 
of educational, emotional support and resources.446,455
1++/
2++
Their benefi ts, slight or moderate, are signifi cant on the burden, anxiety and dep
ression.447,449,450,451,448Families usually have a very positive opinion of educational 
and emotional support interventions.449.
2+
Interventions held in the home or in a personalised manner are the most 
benefi cial.452,453,454
4
The following aspects must be contemplated in the comprehensive support to the 
caregiver: welcome programme, information sessions, theoretical and practical 
training, economic and legal counselling; adequate resources; individual or group 




To improve the care of caregivers of people with dementia and reduce their 
burden in the task of caring, as well as anxiety and depression, a programme that 
combines educational support, emotional support and the provision of resources 
may be benefi cial.
B
Interventions carried out in the caregiver’s own home and in a personalised 
manner are recommendable.
D
Comprehensive care of the caregiver must contemplate many different actions: 
Welcome programme, information sessions, theoretical and practical training, 
advisory services, emotional support, adaptation of resources, pharmacological 
treatment if required and accompaniment throughout the entire process.
11.7. What are mutual aid groups (MAG)?
At the fi rst International Conference for Health Promotion in Ottawa in 1986, the bases were 
established to boost community participation in the care of its health and the creation of social 
networks to favour the social participation of the different groups within the community. The 
WHO supported this proposal with the creation of a European Centre of Mutual Aid Groups 
(MAG) in Leuven (Belgium).456
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In general terms, we can defi ne the MAGs as movements that are characterised by the existence 
of quality, horizontal, symmetric and generalised reciprocity among their members. Comprised 
of people who share the same health problem or social situation, in this case of caregivers of 
people affected by dementia, united on a voluntary basis.455
The MAGs take advantage of the human being’s natural need to share, seek contact and trust 
in other people faced with a situation of joy, sadness, disease, danger or anxiety. Mutual aid is, 
therefore, an exchange, giving and receiving between two or more people, with positive results 
for their own health and with an impact on the social welfare of the community.457
The MAGs are comprised of a group of people whose aim is to mutually help each other 
to achieve a certain objective. In general, they are comprised of people who share the same 
problem, who fi nd themselves in the same situation. The membership is free, with no supervision 
from any professional.
The MAGs place emphasis on personal interaction and the individual assumption of 
responsibilities by its members. Meetings are informal and are programmed depending on 
the needs of the group. In some cases professional counselling is accepted, although only as a 
consultant fi gure.455
Some of the functions of the MAG are: a) to provide and exchange information (exchange 
of experiences and knowledge among its members); b) offer emotional support among the 
members (empathise and verify that other people are in the same or similar situation); c) provide 
services; d) organise social activities and defend interests, and e) lobby with the institutions.455
Professional support can have different functions within the group: 
Launch the group, disseminate its existence, develop it, be a consultant, 
assume responsibilities within it and offer help so that the group can be 
independent. However, the relative position of the professional should 
avoid the professionalisation of the members of the group, as well as the 
possible dependence on experts. An optimal intervention must consider the 




With respect to the types of MAGs, we can fi nd the model proposed by:460
• Type I: Self-care groups focused on diseases
• Type II: Groups focused on positive lifestyles.
• Type III: Mutual aid groups focused on coping with stress
• Type IV: Lobby groups, focused on social action
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Summary of evidence
4
The mutual aid groups (MAG) for caregivers of people with dementia, are 
comprised of people who freely share their problems of caring, which enables 
them to exchange information and experiences, and give each other emotional 
support. Group work is benefi cial for the health of each one of them and for 
the welfare of the rest of the group. The MAG satisfi es common needs, it helps 
overcome problems, it achieves social and personal changes.459,458,455
4
If there is a professional in the MAG, his or her function is to favour and foster 
the skills of the other members of the group.459,458
Recommendation
D
There should be a professional in the MAGs to favour and foster the skills of the 
group members.
11.8. What benefi ts are obtained from participating in 
MAG?
Forming part of a MAG permits:456,457
• Finding information and sharing experiences.
• Increasing knowledge about people in dependent situations.
• Access to information about the resources of the administrations.
• Share, with normality, painful experiences, doubts and fears.
• Find ways of having free time.
• Improve the knowledge of oneself and manage the day-to-day problems.
• Find understanding from other people who are in the same situation.
• Create a meeting place to coincide with people in a similar situation.
• Make friends with people who understand and accept us.
• Offer emotional support.
• Reduce the feeling of isolation and loneliness.
• Increase one's self belief and confi dence.
• Offer services and resources.
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A study carried out on 70 MAGs of caregivers of people with Alzheimer's 
disease, through a survey sent to participants, showed that the group 
provided them with benefi ts in aspects related to education, socialisation, 




Notwithstanding these potential benefi ts, the evidence observed in literature 
did not show signifi cant results in a reduction of aspects such as anxiety or 
depression. The different methodologies, the size of the groups, the ethical 
problem of using a control group, comorbidity between different pathologies 
in the caregiver, the multidimensional nature of the care, the number of 
intervention groups used, as well as the assessment instruments used, could 




Despite the possible benefi ts commented about the MAGs, focused basically 
on the positive effects of sharing experiences and overcoming isolation, 
it must be pointed out that there is also another type of group, where the 
presence of professionals is normal: The therapeutic aid groups (TAG) 
or the so-called educational and emotional support groups (EESG). The 
interventions in this type of group usually have more ambitious objectives: 
Provide care skills and strategies, relieve the strain, reduce anxiety and 
depression, either with brief structured programmes or with extensive 




However, there are more and more studies that point out the mistake of 
dealing with the caregivers of Alzheimer patients as homogeneous group. 
The interventions will be more effective the more individualised they are; in 
any case they must be designed bearing in mind some differential variables: 
Level of strain, gender and relationship, as the content will vary when these 






There are many benefi ts provided by the MAG to the caregivers. It gives them 
all kinds of information, they share experiences with normality, they compile 
opinions and suggestions, they improve self-knowledge, they learn how to 
manage confl icts better, they are accepted and understood, they establish 
friendship bonds and reduce isolation, and they increase their security and 
confi dence. There are studies that demonstrate that caregivers benefi t each other 
subjectively.456,457,461
3
The therapeutic aid groups (TAG) or educational and emotional support groups 
(EESG) aimed at specialised professionals, provide the group members with 
strategies and skills to improve the care function, relieve their burden and reduce 
their anxiety and depression.464,463
3
Effectiveness is improved if the interventions in TAG (therapeutic aid groups) 
are adapted to the strain, gender and relationship of its members.466
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Recommendation
D
It is advisable and desirable for the caregivers of people with dementia to 
participate in MAGs, as they provide many different benefi ts, which will enable 
them to cope better with the care work and improve their personal situation.
D
Participation in TAGs or EESG to improve the strategies to cope with dementia 
is recommendable, relieving the burden and improving the level of anxiety and 
depression that might affect the caregiver.
D
Professionals that run the TAG or EESG must personalise their interventions to 
be more effi cient.
11.9. In what cases is psychological treatment of the 
caregiver necessary?
An assessment of this type of intervention is included n the NICE guideline,25 
Descriptive and it concludes that psychotherapy, especially cognitive-
behavioural study, psychotherapy has a benefi cial effect on the levels of 3 
depression and anxiety, strain and well-being of the caregiver, although in 
some of these aspects the magnitude of the effect was small and variable 
between the studies, whilst the combined interventions (psychoeducation, 
training in managing symptoms, support groups, etc. presented a magnitude 




There are no studies that compare the effectiveness of the therapy in different types of 
caregivers, but as the effective psychotherapy was more obvious in depression and anxiety 
symptoms, it can be concluded that this is probably more effective when applied to caregivers 
whose levels of anxiety and depression are within or close to pathological levels.25
On a practical level, in our medium, caregivers are not normally patients of the professional 
who visits the patient with dementia, or the professional is not a specialist in mental health, 
so if signs of strain are seen in the caregiver he cannot make out a prescription but rather 
recommend a specifi c evaluation through their primary health care physician; specialists in 
mental health are responsible for carrying out the clinical evaluation and for establishing the 
most adequate therapy in each case.193
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Summary of evidence
3
If the caregiver of a person with dementia presents anxiety and/or depression, 
he or she can benefi t from cognitive-behavioural psychotherapy, which will help 
reduce the intensity of the systems, the strain and improve global well-being.25
3
Therapeutic interventions that combine psychoeducation, training in managing 
systems and support groups are more effective to improve the clinical 
manifestations of the caregivers.25
4
Caregivers who present anxiety and/or depression benefi t from the assessment 
and treatment offered by the primary care team and/or specialised care.193
Recommendation
✔
It is recommended for those caregivers who express a signifi cant degree of stress 
and/or depression to be referred to their primary care physician and/or mental 
health specialists for their assessment and treatment.
C
Psychotherapy, especially cognitive-behavioural therapy would be recommended 
to treat stress or depression due to strain of the caregiver when he or she presents 
clinically relevant symptomatology.
11.10. What are associations of families of people 
affected by dementia and what role do they play in a 
comprehensive approach to dementia?
Associationism of families and people affected by a chronic neurological problem, including 
dementia, is relatively recent. The Association of Families of Patients with Alzheimer’s Disease 
of Barcelona (AFAB) was the fi rst to be created in Spain in 1987.
Over the last 20 years many different associations have been created all over the Spanish 
territory. Today there is scarcely no large town that does not have a support group for relatives 
affected by dementia. Later on, they grouped together into a confederation, the Spanish Con 
federation of Associations of Families of Alzheimer’s Disease (CEAFA).467
The main objective of the associations of families of Alzheimer’s disease 
and/or other dementias is to improve the quality of life of the patient and of 
the families affected. Other objectives include:467
• Promoting the need for a correct diagnosis.
• Counselling towards the comprehensive care of the patient
Expert opinion,
4
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• Helping families support the psychological impact represented by the 
disease.
• Giving advice and informing about health, psychological, legal, 
economic or social assistance questions related to dementia. 
• Help in fostering scientifi c research.
• Informing and raising awareness of society.
• Representing the interests of patients and their families before the 
administration and other institutions.
The AFA play an essential role in the comprehensive approach of dementia 
throughout the entire process; they start their specifi c work with the family 
affected, at the time of the diagnosis and throughout the entire life of the 
patient. The AFA accumulate the experience of families that have lived with 
people affected by dementia for years. They act as a support group of people 
who are able to give information based on experience and provide many 
different solutions to specifi c problems of day-to-day life.467
Expert opinion,
4
Despite the existence of the AFA and the consensus about their effi ciency 
and effectiveness, less than 30% of the families affected ever get in contact 
with the relative AFA to get information or any other type of resources. 
There are many different reasons, including the lack of information about 
their existence, the refusal of the patient and/or family to do so for reasons 
of confi dentiality, culture, education or due to rejection on considering it to 




The approach and joint work of the healthcare teams (primary, specialised 
or social health resources) and the AFA is recommendable. It is advisable 
for the health teams to inform of the existence of this resource. A closer 
approximation between the two organisations would be desirable to 
achieve a more complete and quality care; however no express indication 
of the advisability of this approximation is found in literature. There are 
no evidence-based publications that guarantee the benefi ts provided by the 
contact and participation in the associations' activities, but there is consensus 




A resource provided by the association are the TAG or EESG managed by 
professionals, where families with mild and moderate dementia can socialise 
and learning, exchange experiences and feelings, and receive psychological 
and emotional support. In a review based on 8 support groups, participants 
positively informed about the educational aspects, the socialisation and 




Other contributions of the AFA are summed up in Table 4.193
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Table 4. Activities carried out by t he associations of families of people affected by dementia
Concept Activities
Information • Dissemination and diffusion of knowledge about dementia
• Activities of the world Alzheimer’s Day
• General advice
• Conferences, courses, seminars
• Congresses, symposium, conferences
• Publications, journals, books, videos
• Online information
Training • Training of family caregivers
• Training of professional caregivers
• Training of volunteers
• Monographic workshops on different topics
Support to the patient and/or family • Psychological assistance to both caregiver and patient
• Mediation of family confl icts:
• Mutual aid groups (MAG)
• Psychological and emotional support groups
• Pleasure-recreational activities programme
• Therapeutic holidays




• Provision of technical aid
• Evaluation and counselling in resources
• Legal advice
Provision of services • Health control
• Psycho-stimulation programmes





• Evaluation and adaptation of the environment
• Music therapy
• Miscellaneous workshops: Laughter therapy
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Summary of evidence
4
The main objective of all of them is to improve the quality of life of the 
patient and of the families affected. They are interested in promoting a correct 
diagnosis, counselling towards comprehensive care, helping families support the 
psychological impact represented by the disease; giving advice and informing 
about medical, psychological, legal, economic and social questions; stimulate 
scientifi c research; raise the awareness of society, and represent their interests 
before the Administration and other institutions.467
4
The AFA play an essential role in the comprehensive approach of dementia; 
they act specifi cally with the family affected, at the time of the diagnosis and 
throughout the entire life of the patient, and they are able to provide experience 
and many different solutions to the specifi c day-to-day problems.467
3
The AFA are an underutilised resource, as only a percentage of less than 30% of 
the caregivers of people with dementia get into contact with them.467
4
The approach and coordination between the different healthcare levels (PC, SC, 
SHC) and the AFA is useful for the caregivers to improve their knowledge and 
manage the disease, receive emotional support, relieve their burden and increase 
their quality-of-life.468
3
The MAG, TAG and/or EESG are all resources of the AFA that benefi t caregivers, 
improving information, socialisation and coping capacity.461
Recommendation
D
Health practitioners and social services professionals who care for people with 
dementia and their families should comment on the existence of the AFAs and 
the benefi ts that they can obtain from them, and insist on their experience in 
living with people with dementia.
D
To achieve optimisation in the approach and management of dementia 
throughout the entire process, from diagnosis until after death, the existence 
of good coordination between the different healthcare levels and the AFAs is 
recommendable.
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11.11. What must the relationship between the associations 
and the health and social public network be like?
The public administration, at autonomous community level and at State 
level, evaluate the essential role of the AFA in the direct care of families 
affected by Alzheimer's disease and other dementia. It expresses this through 
communications supporting their work, and gives them explicit support 
through subsidies to programmes that they develop. This collaboration is 




A lot still has to be done, in this recommendable symbiosis, as the primary 
care teams (PCT), specialised dementia care teams (SDCT) and social 
services professionals do not always place emphasis on the important 
contribution of the AFA in the care of patients and of their families.193,467
Expert opinion,
4
The AFA are experts in the knowledge provided by coexisting for years 
with dementia in its different stages and having qualifi ed professionals who 
are able to give a good evaluation of the case, provide information and 




The AFA have a very positive effect on the lives of people with dementia 
and their families. They facilitate the work of the public administrations 
(health and social services). They help lighten the workload of the primary 
care centres, of the specialised units and they provide families with their 
own resources. The public health care network must recognise this role of 
the AFA and provide specialised, complementary and quality aid.467
Expert opinion,
4
The relationship between the tertiary sector and the Public Administration must not be limited 
to giving subsidies, but it must extend to the joint execution of care programmes for those 
affected by dementia and establishing collaboration agreements. An example of this common 
interest is the promotion of specialised training courses that the AFA organise for family and 
professional caregivers who work or live with people affected by the disease.
The underlying benefi t of this mutual work between public administration 
and the AFA is the benefi cial impact on the quality of life of people with 
dementia and of their relatives. It also permits redistributing the workloads 
of the network and partly releasing it from the weight of the dementia, and 




278 CLINICAL PRACTICE GUIDELINES IN THE SNS
There are a series of aspects that must be taken into consideration in the dynamic and changing 
process of care of dementia:
• The social services and health network must include information and referral of families 
to the AFA in its protocols.
• Recognise that the AFA are adequate institutions where specialised and quality training 
can be received in coping with dementia.
• The EESG and the TAG developed in the AFA are a good resource for caregivers which 
will enable them to cope with the disease.
• The AFA can create classical specifi c workshops or use the new technologies (connect-
Alzheimer, touch screens).
• It is advisable to have day hospitals and day centres that satisfy the approval criteria 
established to satisfy their function adequately and with quality indicators.
• Increase the endowment of resources, if necessary, so that the AFA can continue to 
develop their activities in a complementary manner to the activities offered by the health 
and social services, with effi ciency, security and effectiveness criteria.




The public administrations of the autonomous community and of the State 
positively value the role of the AFA.193,467
4
The symbiosis in the healthcare and social network with the AFA is not optimal, 
as the caregivers of people with dementia are not systematically informed about 
the existence and contribution of the AFA.193,467
4
The AFA are experts in living with dementia and have qualifi ed professionals for 
a comprehensive approach.467
4
The AFA provide the health and social services system with quality, 
complementary and specialised bonus.193,467
4
There are many benefi ts of the collaboration between public administration and 
the AFA: better quality-of-life of the people with dementia and their families; 
redistribution of workloads in the healthcare network, and visualisation and 
recognition of the work carried out by the actual associations.193,467
Recommendation
D
There must be a close relationship between the tertiary sector and the Public 
Administration with continuous dialogue, thus favouring the exchange of 
knowledge both on the needs and collaboration proposals (programmes, 
subsidies, agreements, etc.).
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D
It is recommendable to continue improving the relationship between the Public 
Administration and the AFAs to improve the quality of life of the people affected 
by dementia and their families, by drafting referral protocols, recognising the role 
of the AFAs in the training of caregivers and professionals; fostering the creation 
of TAG and/or EESG and therapeutic programmes (DH, DC, rehabilitation 
workshops) and aid for the development of complementary activities.
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12. Early onset or pre-senile dementia
Questions to be answered
12.1. What is understood by early onset or pre-senile dementia?
12.2. What are the most frequent causes of early onset or pre-senile dementia? 
12.3. Do patients with early onset dementia have different clinical manifestations to patients 
with later onset?
12.4. Must the diagnostic process in people with early onset dementia be different to the pro-
cess of a patient who is more than 65 years old when the disease starts? 
12.5. Is the pharmacological treatment of a person with early onset dementia different to that 
of a person with late onset dementia?
12.6. Is the non-pharmacological treatment prescribed to a person with early onset dementia 
different to that of a person with late onset dementia? 
12.7. Are there differences in impact and psychological, social, family, occupational and eco-
nomic repercussion between a group of people diagnosed with early onset dementia and 
a group of people with late onset dementia?
12.8. What health and social-health resources do people with early onset dementia require?
12.1. What is understood by early onset or pre-senile dementia?
It is considered, by convention, that dementia has presenile or early onset when the symptoms 
start before the age of 65.25 Some authors469 operatively differentiate, among patients with early 
onset dementia, those with onset under the age of 45 (young onset dementia).
12.2. What are the most frequent causes of early onset or 
pre-senile dementia?
AD is the most frequent cause of presenile or early onset neurodegenerative dementia (43-58%), 
followed by FTLD.11,25,470,471,469 The most frequent causes among secondary early onset dementia 
are vascular, post-traumatic and alcohol. In individuals whose symptoms appear before the age of 
45, AD is not very frequent and FTLD is the most frequent degenerative dementia; self-immune 
and metabolic aetiologies represent almost one third of the cases and in up to one fi fth of the 
cases, the cause of dementia cannot be objectifi ed despite extensive studies.471
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12.3. Do patients with early onset dementia have different 
clinical manifestations to patients with later onset?
As a whole, patients with early onset dementia present a higher percentage of BPSD than patients 
with late onset dementia and a lower degree of cognitive and functional impairment at the time of 
the diagnosis.470 However, as the clinical manifestations are determined by the type of dementia, 
part of these group differences may possibly be attributed to the different relative frequency of 
each type of dementia among individuals of early and late onset, rather than the onset age per 
se. Patients with early onset dementia present a greater risk of death than patients with late onset 
dementia, compared with control individuals (43.3 compared with 3.4).472
When we analyse the main neurodegenerative aetiologies, patients with early onset AD, 
compared with those with late onset, as a group, present more severe language disorders, dif-
fi culties in carrying out tasks that require sustained attention and BPSD in initial stages of the 
disease.473 Atypical forms of presentation of AD, such as posterior cortical atrophy or corticobasal 
syndrome are also more frequent in cases of presenile onset. An early onset age of AD is also as-
sociated with a greater frequency of myclonus during the course of the disease.473 These clinical 
differences are also refl ected in comparative structural neuroimaging studies, that show a greater 
neocortical affectation in initial stages in early onset cases.474,475 On the other hand, there are con-
tradictory studies about whether the evolution of early onset AD is or is not more aggressive than 
late onset disease.476,470
With respect to FTLD, one study did not detect differences between the symptoms of pa-
tients with early onset and late onset,477 although another study478 objectifi ed a greater degree of 
apathy and amnesic and visuospatial problems in patients with late onset with respect to patients 
with early onset.
12.4. Must the diagnostic process in people with early 
onset dementia be different to the process of a patient who 
is more than 65 years old when the disease starts?
The diagnostic process of dementia should not be affected by the age of the individual, as the most 
broadly used defi nitions of this syndrome, DSM-IV16,17 and ICD-1018, do not include age as a 
criterion (Section 8). However, patients with early onset dementia in our medium, suffer a greater 
average delay in diagnosis (37 months) than patients with senile onset dementia (29 months),470 
attributed both to the delay in the initial medical consultation and to the delay in referrals to spe-
cialised units and to the diffi culty in making a correct diagnosis in this age group.
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To objectify cognitive defi ciency, the majority of the cognitive impairment, 
memory and dementia screen tests in Spanish are not validated in individuals 
under the age of 60, so they are not valid in this age group, and appropriate 
neuropsychological test batteries, available in specialised units, usually 
have to be resorted to.6
Expert opinion,
4
With respect to the aetiological study of dementia syndrome, the CPG 
reviewed25,479,129 do not include differences in the basic diagnostic process 
depending on age. The distribution of frequencies in dementia aetiology 
changes with age groups. In early onset dementia, the aetiological 
possibilities extend to causes that could be considered rare in older age 
groups. On the other hand, even in AD, the clinical form of presentation 
may differ from that presented by patients with late onset AD, so the degree 
of experience of the assessment team must be greater to evaluate patients 
of this age. Thus, the diagnosis test battery is often more extensive and 
complex in early onset individuals.
Expert opinion,
4
No specifi c protocols have been assessed and published of aetiological 
diagnosis in early onset dementia, although Sampson and collaborators471 
have proposed an approach to the diagnosis, suggesting a list of routine tests 
for all patients, including a complete cognitive study, structural neuroimage, 
complete blood analysis with levels of vitamin B
12
, folic acid, thyroid 
hormone, luetic serology and basic immunology, electroencephalographic 
and electrocardiographic study, and a list of specifi c tests depending on the 
clinical characteristics and onset age of the symptoms. In some cases, these 





The majority of the cognitive impairment, memory and dementia screen tests in 
Spanish are not validated in individuals under the age of 60, so they are usually 
not valid in this age group.6
4
The causes of early onset dementia include aetiologies that have little impact on 
older age groups, and frequent atypical presentations of dementia.471
Recommendation
D
The use of neuropsychological test batteries validated for this age group is 
recommended in the assessment and characterisation of cognitive impairment in 
people with pre-senile dementia.
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D
The aetiological study of a patient with early onset dementia should also include 
the study of low incident causes in later age groups and atypical presentations of 
frequent dementias.
✔
It is recommendable for patients with early onset dementia to be assessed by 
professionals with experience in this age group and at centres that have the 
appropriate supplementary tests to carry out this study.
12.5. Is the pharmacological treatment of a person with 
early onset dementia different to that of a person with late 
onset dementia?
Four drugs, approved by the Spanish Medicine Agency (AGEMED) for 
the specifi c treatment of AD (donepezil, rivastigmine, galantamine and 
memantine) are currently used with no age restriction. However, no RCT 
have been specifi cally carried out on this population group. No post hoc 
studies have been carried out either on this population group in MA of 
RCT, which assessed the effectiveness of ACE inhibitors or memantine in 
patients with Alzheimer's disease, probably due to a lack of sample to carry 
out an appropriate statistical study, given that the average age was 74 in 
the former and 76.2 in the latter. Therefore, there is no clinical evidence 
to support or rule out the fact that the onset age of AD is a decisive factor 
in pharmacological response. There are no studies that assess the specifi c 





There are no specifi c studies on the effectiveness of drugs in the treatment of 
patients with early onset dementia.263,480
Recommendation
✔
Although there is no scientifi c evidence in presenile dementia, it is advisable to 
follow the same therapeutic guidelines used for older people.
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12.6. Is the non-pharmacological treatment prescribed to 
a person with early onset dementia different to that of a 
person with late onset dementia?
Patients with early onset dementia have not been included in many of the studies that assess the 
effectiveness of non-pharmacological therapies, although the proportion of them is marginal and 
they are not analysed differentially. Therefore, no evidence has been found in favour of or against 
the non-pharmacological treatment, prescribed to patients with dementia, having to be different 
depending on the age of the individual (Section 10.3).
However, when non-pharmacological therapy has to be planned for pre-senile onset indi-
viduals, it must be taken into account that young patients with dementia are a minority and the 
proportion of non-Alzheimer’s dementia in the group of patients with young dementia is higher. 
Consequently, it is diffi cult to integrate them into standard programmes, especially in mild or 
moderate dementia stages, due to the fact that group interventions carried out normally focused 
on older patients and with typical AD symptoms.
Summary of evidence
-
There are no studies that specifi cally evaluate the effectiveness of non-
pharmacological therapies on patients with early onset dementia.
Recommendation
✔
It is advisable for people with presenile dementia to carry out the same non-
pharmacological therapies that have proved to be effective in people over the 
age of 65.
✔
If we wish to favour their adherence to individual or group non-pharmacological 
therapeutic programmes, these must be adapted to the specifi c needs of the 
person with early onset dementia.
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12.7. Are there differences in impact and psychological, 
social, family, occupational and economic repercussion 
between a group of people diagnosed with early onset 
dementia and a group of people with late onset dementia?
Firstly, on a psychological level, the perception of loss of independence is 
greater in these individuals as they are forced to drop out of activities that 
are normal for their age, such as work, driving cars, managing fi nancial 
affairs, travelling independently etc. Furthermore, having to stop work, 
apart from the actual economic loss that this may represent, as well as the 
loss of independence, may have a negative impact on patient’ self-esteem 
and their actual perception of patient.473 All of this is accompanied by the 
diffi culties of the medium to understand and adapt to the individual's new 
situation, which often produces social isolation and withdrawal.
On a family level, during the stage prior to the diagnosis, the family 
relations may have deteriorated as a result of an erroneous interpretation of 
the symptoms, especially when the behavioural disorders are relevant. Once 
diagnosed, in the majority (82%) of the cases, it is an informal caregiver 
who takes responsibility for providing the patient with the necessary 
health care, normally the spouse who like the patients, belongs to an 
occupationally active population and also have responsibilities with respect 
to young children.473 For these spouses, the project of a couple or of a family 
is broken, and they must assume the responsibilities acquired on their own, 





Studies carried out show that informal caregivers of patients with early 
onset of dementia present a greater level of strain than the caregivers of 
patients with late onset dementia, and the majority (66%) perceive that 
their emotional state is bad or very bad, and they present anxiety and/
or depression symptoms. The female sex, the presence of disrupting 
behavioural symptoms and the bad marital relationship prior to the onset of 
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On an occupational level, individuals with early onset dementia, unlike 
those with late onset dementia, are normally occupationally active, which 
generates an added problem in these cases. After the diagnosis of dementia, 
patients usually stop their occupational activity. In our medium, after a 
period of leave, patients have access to a disability pension (normally with 
a degree of “total disability"). However, even in the initial stages when the 
cognitive impairment does not clearly interfere with the individuals’ activity 
and they wish to continue maintaining a certain amount of occupational 
activity, the labour environment is not likely to favour the continuity of 
their active lives, offering them an activity that adapts better to their new 
cognitive situation. On the other hand, during the last years of active life, a 
low occupational performance is often referred to, which may have resulted 
from a lack of promotion or even dismissal or bad economic management, 




At a global economic level, there are no studies in our medium that quantify the economic 
cost of a patient with early onset dementia. In one study carried out in the United Kingdom in 
the 1990s, the direct cost of a year's care of presenile patient was similar to the cost of a patient 
in senile age.473 The majority of this cost was attributable to institutionalisation costs. Indirect 
costs such as morbidity, mortality, informal care and loss of income due to interruption of 
occupational activity were not included in this study, so the real total annual costs are expected 
to be greater in patients with early onset dementia than in those with later onset.
Summary of evidence
2-
The perception of loss of independence is greater in people with early onset 
dementia than in those with late onset dementia due to the abandonment of normal 
activities, such as: Work, driving cars, managing fi nancial affairs, travelling, 
etc. The loss of work may have a negative impact on their self-esteem. Social 
isolation and withdrawal often occur as a reaction.473
2-
Relevant behavioural symptoms may change family relationships. Their 
caregivers are usually young, active and with other responsibilities and many 
of their life projects have to be interrupted.473 They have a greater level of 
strain than caregivers of patients with late onset dementia, and the majority of 
the cases perceive their emotional state as bad or very bad, and they present 
anxiety and/or depression symptoms. Being a woman, the presence of relevant 
behavioural symptoms and the bad previous marital relationship is correlated to 
greater strain.481
288 CLINICAL PRACTICE GUIDELINES IN THE SNS
4
Young people diagnosed with dementia usually stop their occupational activity 
and after a period of leave have access to a disability pension. In initial 
stages, although individual may wish to continue working, their occupational 
environment does not usually favour continuity, adapting their work to their 
capacity. Decreases in occupational performance are often verifi ed prior to the 
diagnosis of dementia.481
4
The direct cost of caring for a person with early onset dementia is similar to the 
cost of caring for a person with senile dementia.473 The majority of this cost was 
attributable to institutionalisation costs.
In short, if dementia causes psychological, social, family and economic diffi culties at any age 
both for the patients suffering from it and for the environment, the impact is more negative in the 
case of patients with early onset dementia in areas such as the perception of loss of independence, 
social isolation, strain of the caregiver or loss of income.473,481
12.8. What health and social-health resources do people 
with early onset dementia require?
At a social health level, there are no specifi c studies in this sense in 
our medium, but resources such as day hospitals, centres where non-
pharmacological therapies are carried out, home care, medium-stay centres, 
long-stay centres, nursing homes or support groups seem to be adequate 
resources so long as they are specifi cally focused on caring for patients with 
early onset dementia,473 but they are still scarce in our medium.
On the other hand, the existing services for patients with late onset dementia 
are either not available for individuals with early onset dementia or are not 
considered appropriate. Patients with early onset dementia, apart from 
presenting differential clinical characteristics, especially due to the greater 
prevalence of behavioural disorders that are diffi cult to manage, present 
generational differences with different cultural habits, lifestyles and family 
dynamics than those of patients with late onset dementia. Likewise, the 




In a study conducted in Ireland, only 40% of patients with early onset 
dementia had access to some type of social support service.473
Cohort study,
2-
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On the other hand, in a study conducted in the United Kingdom, access to 
home social support services was observed to be scarce in this group of 
patients compared with older patients and that, on the contrary, up to 29% 






There are no studies that determine which social health resources are the most 
suitable for individuals with early onset dementia and their families. On the 
other hand, only a minority of patients with early onset dementia have access to 
social health resources in countries of our environment.473,481
Recommendation
✔
It is recommendable for patients with early onset dementia to have access to 
social-health and health resources that focus specifi cally on their care.
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13. Ethics and legal aspects of dementias
Questions to be answered:
Abuse of people with dementia.
13.1.1. What is understood by abuse of people with dementia?
13.1.2. How frequent is abuse in dementia and what are the risk factors? 
13.1.3. What intervention strategies exist to detect a case of abuse? 
13.1.4. What must professionals do when a case of abuse is detected? 
13.1.5. What social resources exist to address abuse?
Advance directives
13.2.1. When must the possibility of drafting advance directive documents, living wills and/or 
granting powers of attorney be suggested to people with dementia?
Evaluation of competences
13.3.1. Are there instruments that have been strictly designed to assess the competence of pa-
tients with dementia?
13.3.2. How are the specifi c competences assessed: driving licence, fi rearms licence and par-
ticipation in clinical trials?
13.3.3. Which are the indications to start the legal incapacitation process of a patient with de-
mentia?
Aspects relating to the patient’s legal protection
13.4.1. What does legal incapacitation consist of?
13.4.2. What type of legal protection exists for a patient with dementia? 
13.4.3. What is guardianship?
Restraint of the patient
13.5.1. What are the indications for pharmacological and/or psychological restraint of a patient 
with dementia?
13.5.2. What are the indications for physical restraint of a patient with dementia?
13.5.3. What are the ethical and legal aspects of restraint?
13.5.4. What are the indications for involuntary admission and what process must be followed?
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Abuse of people with dementia
13.1.1. What is understood by abuse of people with dementia?
The concern of society for the abuse of older people with dementia is an 
emerging topic.482,483 There is no universal defi nition of abuse of people 
with dementia. Cultural differences must be taken into account, as there are 
different interpretations of the same events.
In the Almeria Declaration (1996) abuse would be any act or omission 
suffered by a person aged 65 or more, which violates their physical, psychic, 
sexual or economic integrity, or else the principle of autonomy or one of 
their essential rights regardless of the intentionality or of the medium where 
it occurs (family, community and institutions).484
According to the Toronto Declaration (2002), elder abuse is a single or 
repeated act, or lack of appropriate action, which causes harm or stress 
to an older person, and which occurs in any relationship where there are 
expectations of trust.485
Detecting abuse is often diffi cult due to the social isolation suffered by these 
people, their refusal or inability to communicate it, the limited awareness 
of the professionals and the discrimination that this group usually suffers.
Expert opinion,
4
Abuse can occur anywhere, either in the home (domestic or family violence), 
or in institutions by professionals or other residents. There is abuse by act or 
omission.486,487,484,488
Depending on the characteristics, the abuse can be:
• Physical: Bodily harm, pain or physical impairment, produced by non-
accidental violence.
• Sexual: Gestures, insinuations, exhibitionism, etc. or sexual contact of 
any type, due to non-consented consummation or intention.
• Psychological: Cause anxiety, shame, and feeling of indignity, fear, 
stress, insults, mockery, intimidation, humiliation, infantilisation, 
indifference, isolation and lack of respect.
• Economic: Illegal or inadequate use of funds, properties or resources, 
falsifi cation of signatures, signing documents with intimidation, 
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• Neglect: Lack of attention to basic health, food, clothing, personal 
hygiene and housing needs.
• Abandonment: By the caregiver.
• Violation of rights: To privacy or intimacy or belongings, to decide, to 
receive visits, to mix with friends, involuntary admission, to remain in 
their homes.
Abuse causes unnecessary suffering, injuries, pain, loss or violation of 




Abuse of people with dementia is a personal, family, intergenerational and 
health problem, as well as one of justice and human rights. Alerting about 
abuse, knowing of its prevalence, its consequences for the person affected 
and the aggressor, permits establishing prevention strategies, change of 





There is an emerging concern by society for the abuse of the elderly or people 
with dementia.482,483
4
Elder abuse is defi ned as a single or repeated act, or lack of appropriate 
action, which causes harm or stress to an older person, and which occurs in 
any relationship where there are expectations of trust,485 or any act or omission 
suffered by people aged 65 or over, which violates their physical, psychic, sexual 
or economic integrity, or else the principle of autonomy or an essential rights, 
regardless of the intentionality or of the medium where it occurs, which may be 
family, community or institution.484
4
Detecting abuse is often diffi cult in elderly people or people affected by dementia 
due to the social isolation they suffer, their refusal or inability to communicate it, 
the limited awareness of the professionals and the discrimination that this group 
usually suffers.484
3
Abuse can occur anywhere: Domestic violence or in the institutional area. It 
can be by act or omission. Depending on the characteristics, it can be: Physical, 
sexual, psychological, economic, neglect, abandonment and violation of 
rights.484,488,486,487
3
Abuse causes unnecessary suffering, injuries, pain, loss or violation of human 
rights, and a decrease in quality of life.489
4
Abuse of people with dementia is a personal, family, intergenerational and 
health problem, as well as one of justice and human rights. Alerting about abuse, 
knowing of its prevalence, its consequences for the person affected and the 
aggressor, permits establishing prevention strategies, change of attitudes and 
seeking solutions.490
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Recommendation
D
It is necessary for health practitioners, the social services and society in general 
to be concerned and become aware of the abuse that many elderly people 
suffer, whether they are affected or not by dementia. It is a personal, family, 
intergenerational, health problem, as well as one of justice and human rights. Its 
detection permits establishing prevention strategies, changes in attitude and the 
promotion of solutions.
13.1.2. How frequent is abuse in dementia and what are the risk 
factors?
Frequency of abuse in dementia
Elder abuse is estimated at 6% according to the WHO.485 According to the 
International Network for the Prevention of Elder Abuse (INPEA), domestic 




According to one study, less than 0.02% of people diagnosed with abuse 
are admitted into hospital, with a 2:1 proportion of women and men; the 
average stay is longer, the cost is higher and the destination, on discharge, 




A survey, carried out on 2,111 people in the United Kingdom (2006)493 
and another on 5,111 people in the USA (2010)494. showed the existence 
of abuse in 2.6 and 10%, respectively. Depending on causes, the abuse 
was due to neglect (1-5.1%), economic abuse (0.6-5.2%), psychological 
(0.4-4.6%), physical (0.4-1.6%) or sexual (0.2-0.6%). In another study, the 
global percentage of abuse reached 6% and prevailed in women, and varied 




One SR of 21 studies on abuse with 5,325 professionals that assessed the 
capacity to detect it and to declare it, showed an under-evaluation of their 
prevalence, as only 25% knew of the existence of an elder abuse guideline, 






In people with dementia, the average abuse incidence is 25% (12-52%), 
the majority is psychological and 5% is physical. It may be a one-off act, 
but in 34% of the cases it is repetitive. 487,492,490A survey by the Alzheimer’s 
Association of Florida (USA) on 254 caregivers, verify the existence of 
verbal aggression in 60.1% of the people with dementia,495 which is 
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Abuse may cause depression, reduction of self-esteem, alteration of 




Family dynamics also changes and if the situation is not solved soon, the 




Risk factors of abuse in dementia
The risk of abuse is usually multifactorial (personal, family, social and 
cultural factors). Some depend on the patient, others on the aggressor or on 




The vulnerability and fragility of the person affected may favour the 
appearance of abuse, the same as with social isolation, unfavourable 




Many of the women attended in mental health services, in PC or in 
emergency services, suffer domestic violence. There are no specifi c data of 




Caring for a person with dementia without external help throughout the 
entire illness is a factor that may predispose to abuse, above all if the 
caregiver has not been adequately trained and/or is under extreme strain 
due to having to attend to other sick relatives. This risk increases if there is 
a background of violence, psychiatric disorders of the caregiver, strain and 





People with dementia who are more likely to receive abuse are those 
people with BPSD where there is a prevalence of hostility, aggressiveness, 
provocative attitudes, and who also require assistance for ADL, without 




The person responsible for the abuse is usually a family member who acts 
as a caregiver, with symptoms of anxiety, depression and excessive stress 
derived from the burden of caring, aggravated by the characteristics of the 





Frequency of abuse in dementia
3
6% of the elderly suffer abuse,485 5% domestic abuse and 10% institutional 
abuse.491
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3
Surveys in the United Kingdom (2006)493 and in the USA (2010)494 showed 
abuse in 2.6% and 10% of the sample, respectively. The causes were: neglect 
(1-5.1%), economic abuse (0.6-5.2%), psychological (0.4-4.6%), physical (0.4-
1.6%) or sexual (0.2-0.6%).
3
In hospital, less than 0.02% of the admissions are diagnosed with abuse, a 
greater proportion of women, longer average stay, high cost and destination on 
discharge to nursing homes.492
3
Health practitioners underestimate the prevalence of abuse, in the majority of 
the cases they are not aware of elder abuse guidelines, they detect few cases and 
they do not always declare them.
3
In people with dementia, abuse occurs in 25% of the cases, the majority is 
psychological and 5% is physical. It may be one-off or repetitive. Verbal 
aggression is very frequent.495,487,492,490
3
Abuse can cause depression, reduction of self-esteem and alteration of immunity 
and an increase in mortality.496
3
Family dynamics change with abuse, and the quality of life of its members gets 
worse.495
Risk factors of abuse in dementia.
3
The risk of abuse is multifactorial, combining personal, family, social and 
cultural elements. They can be associated with the person affected, the person 
responsible for the abuse or the circumstances surrounding it.497
3
The vulnerability and fragility of the person affected, social isolation, 
unfavourable economic conditions and a climate of hostility in the home may 
favour the appearance of abuse.498
3
Many of the women attended in mental health services, in PC or in emergency 
services, suffer domestic violence. There are no specifi c data of women affected 
by dementia.499,500,501,391
3
Prolonged care without having external aid or support may favour abuse, 
especially if the caregiver has not been trained, is stressed, has a background of 
violence, low self-esteem, psychiatric disorders and too many responsibilities, 
economic diffi culties and inadequate housing.502,503
3
Very dependent people with dementia with BPSD (aggressiveness and 
provocative attitudes), are more likely to receive abuse, especially if there is no 
adequate social support network.502
3
The profi le of an abuser is usually a family caregiver, with symptoms of anxiety, 
depression and excessive physical and emotional stress, who must care for an 
extremely dependent and hostile patient.503
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Recommendation
D
Health and social services professionals must be trained and made aware to 
detect, declare, prevent and treat problems derived from the abuse of people 
with dementia.
D
It is important to identify the type of abuse (action or omission), and determine 
its characteristics (psychological, physical, sexual, economic).
D
If abuse is suspected, the person must be questioned in private and with 
delicacy, given their fragility, bearing in mind their state of mind and fear of the 
consequences that discovery of abuse may entail, in their environment.
D
For a complete diagnosis of abuse, it is advisable to evaluate the risk factors, 
those that depend on the patient, on the abusing caregiver and the circumstances 
that surround it.
D
The possibility of the existence of abuse must be suspected, if the person with 
dementia is hostile, aggressive, provocative, dependent for ADL and there is a 
lack of an appropriate support network.
D
Caregivers must be suspected as abusers if we observe symptoms of anxiety, 
depression, strain in the task of caring, low cultural level and when the patient 
they are looking after is very dependent for ADL and/or presents BPSD.
13.1.3. What intervention strategies exist to detect a case of 
abuse?
Many countries have action protocols if abuse is suspected and if there are alarm signals that 
might point towards this possibility. There are scales to detect abuse and the abused person, but 
few of them translated and validated into Spanish.
To diagnose abuse in people affected by dementia, the risk values and the 
alarm signals must be evaluated. A clinical record and a complete physical, 





In mild-moderate dementia, clinical interviews help obtain information 
about the care the patient receives from the caregiver and from the closest 
environment (family and social). In advanced stages, patients are unable to 
express their desires and emotions due to the actual disease.
Expert opinion,
4
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Communication with the person affected must always be attempted in 
conditions of tranquillity, comfort, intimacy, guaranteeing confi dentiality 
and using clear and simple language, fostering trust and facilitating the 
verbalisation of problems and attitudes, as well as feelings and emotions 
derived from them.
It is advisable to interrogate the patient alone and with the caregiver, and 
observe all those signs and symptoms that will give us clues to the detection 
of abuse; among them, concern, fear, passivity, facial expression, anxiety, 
depression, etc., placing direct emphasis on risk factors.
Physical examinations must be extremely meticulous, looking for injuries 
or bruises; evaluating the state of the skin and the presence of malnutrition 
with no cause that justifi es it.
There are standardised scales to detect abuse in people with dementia: 
Elder Abuse Suspicion Index (EASI) is brief (2 minutes) and has proven 
its utility with 0.47% sensitivity and 0.75% specifi city in a sample of 953 
people.505 the Indicators of Abuse (IOA) is an instrument with 22 items that 




The Caregiver Abuse Screen (CASE) is an instrument that enables us to 
suspect abuse. It is a sensitive and specifi c instrument that can be used as 




Table 5. Suspect possible abuse if any of the following circumstances exist488,502,503
• Inconsistent explanations with respect to injuries
• Delay in requesting care
• Repeated visits to the emergency services and to hospitals
• Administration of drugs without medical indication
• Lack of response to adequate treatment
• Bad evolution of the injuries
•  Malnutrition and dehydration due to non-clarifi ed causes.
• Repeated unexpected falls
• Contradictory information about the facts from patient and abuser
• Detection of fear, concern or passivity in the patient
• Symptoms of depression and anxiety in patient and caregiver
• Refusal by the caregiver for the patient to be interviewed alone
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Summary of evidence
3
If abuse is suspected, a clinical record and a complete and meticulous physical, 
neurological, cognitive, behavioural and functional examination must be carried 
out.504
4
People with dementia in mild to moderate stage may be able to give information; 
if there are fl uctuations we must seek the most appropriate and reliable moment 
to obtain it. In advanced stages, this will only be possible if we take advantage 
of the moments of lucidity.504
4
Detecting abuse requires expertise on behalf of the professional and be surrounded 
by an adequate environment. The information obtained from patients must be 
compared with the information from reliable relatives/caregivers.504
4
A meticulous clinical examination permits detecting signs that suggest abuse: 
Ulcers, wounds, bruises, signs of malnutrition and dehydration.504
3
Identifying alert signals and suspicion of abuse permits setting up correction 
measures as soon as possible.504
2++
It is advisable to systematically ask about aspects related to abuse and use 
standardised scales to detect them.505,506,507,508
Recommendation
D
If the person has mild to moderate dementia, we must get them to give us 
information about their physical and psychic state of health through fl uent and 
true communication. In initial stages, this can be relatively easy to obtain; in 
fl uctuating dementia, the most appropriate and reliable moment must be sought; 
in advanced stages, it will be possible to obtain information at moments of 
lucidity.
D
A meticulous and thorough clinical examination is recommendable to detect 
signs that lead us to suspect the possibility of abuse, evaluating physical, 
psychological and behavioural aspects.
D
It is advisable to be mindful of the possibility of abuse, as this facilitates its 
detection and permits protection, prevention and correction measures.
B
We must systematically interrogate about aspects related to the abuse of any 
elderly person, with or without dementia, and use standardised scales to detect it.
B
We must assess the caregiver of a person with dementia to detect a possible 
person responsible for abuse. Scales can be used to detect it.
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13.1.4. What must professionals do when a case of abuse is 
detected?
Health and social services professionals must be trained to prevent, detect, 




The fundamental rights of the person with dementia to dignity, participation, 
autonomy and self-determination must be preserved, if possible. People 
suffering abuse must be informed, respecting their right to confi dentiality, 
in order to cover their basic needs, and to preserve their social relationships.
Expert opinion,
4
If the person is in an advanced stage of dementia preventing them from 
having autonomy and self-determination, and there is a certain suspicion 
of abuse, the health professionals must activate the judicial resources, 
both because this is a way of defending a victim of abuse and, if the 
health personnel have the administrative category of civil servant, because 
communicating any situation that might be an offence and which they know 
about due to their position, is a legal obligation.
Judicial resources will be activated depending on the specifi c circumstances 
of the case, namely;
- If there are physical injuries, a judicial report of injuries will be drafted.
- If there are no physical injuries at that time and/or acute contingencies, 
the Public Prosecutor can be informed of the case in order to adopt the 





Health and social services professionals must be trained to prevent, detect, 
care for, protect, declare and recuperate a person with dementia suffering from 
abuse.488
4
The fundamental rights of the person with dementia suffering from abuse to 
dignity, participation, autonomy and self-determination must be preserved.488
4
People receiving abuse must be informed, respecting their right to confi dentiality, 
in order to cover their basic needs, and to preserve their social relationships.488
Applicable 
legislation
If abuse is defi nitely suspected, the health and social services professionals have 
the ethical and legal obligation to protect the victim, so they must activate the 
judicial resources. If there are physical injuries, they will draw up a judicial 
report of injuries; if there are no injuries, they will inform the Public Prosecutor 
of the case in order to adopt the measures established by law.509
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Recommendation
D
Health and social services professionals must be trained to prevent, detect, care 
for, protect, declare and recuperate a person with dementia suffering from abuse.
✔
The fundamental rights of the person to dignity, participation, autonomy and 
self-determination must be preserved.
✔
People suffering abuse must be informed, respecting their right to confi dentiality, 
in order to cover their basic needs, and right to preserve their social relationships.
✔
If there is probable suspicion of abuse, the health personnel must activate the 
judicial resources that permit the defence of the victim of abuse. If there are 
physical injuries, a judicial report of injuries will be drafted. If there are no 
injuries or other acute contingencies, the Public Prosecutor will be informed.
13.1.5. What social resources exist to address abuse?
Once the abuse has been detected and diagnosed, action strategies must be put into motion with 
the victim and the aggressor, and monitor the problem. The action of the professional who de-
tected the case must be coordinated with the social worker and specialised services.
The data corresponding to the patient, the type of abuse, the measures or interventions applied 
must recorded in the clinical record.
To present and correct the abuse, we have a series of social health 
interventions and strategies:510
• Avoid social isolation: Through home care services; day centres; 
guardianship by the social services.
• Optimise and organise the patient's care, providing means and simplifying 
the treatment.
• Adapt the house to the limitations of the person with dementia.
• Institutionalise the patient if the family cannot guarantee their care.
Expert opinion,
4
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To improve the conditions of the abusing person, when this is the caregiver 
or relative, and present and correct the abuse:488
• The stress of the family or of the caregiver must be reduced: Sharing the 
task of caring, moving house, support groups, guaranteeing rest periods 
for the caregiver.
• If the caregiver suffers a psychiatric problem, consumes alcohol or 
drugs, or suffers some type of gaming problem, an attempt must be made 
to get to know their emotional state, provide support and treatments for 
the psychiatric or drug abuse problems if these exist.





There are strategies, interventions and social resources for the person who 
receives abuse: Avoid social isolation, facilitate and simplify the patient's care, 
adapt the home and institutionalise if necessary.510
4
There are strategies, interventions and social resources to improve the situation 
of the caregiver or relative who abuses: Sharing the work of caring, moving 




When abuse is detected and diagnosed, it is recommendable to launch strategies 
that permit improving the situation of the victim and of the aggressor. The 
actions of the different professionals must be coordinated, recording all the data 
of the abuse in the clinical record.
D
To prevent and treat abuse, avoiding social isolation, optimising the patient’s 
care, adapting their home and institutionalising them if the family cannot 
guarantee their care, are recommended.
D
It is advisable to attend to the abuser, who is often a stressed or sick relative, 
or with an excessive burden. The burden can be reduced by sharing the task 
of caring, removing the patient from the family environment, participating in 
support groups, guaranteeing rest and offering medical treatment if required.
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Advance directives
13.2.1. When must the possibility of drafting advance directive 
documents (ADD), living wills and/or granting powers of attorney 
be suggested to people with dementia?
People with dementia lose their autonomy and capacity to take decisions. In 
the initial stages of dementia, patients, if they wish, should be able to freely 
express their preferences about medical treatment, tube feeding, artifi cial 
life support, etc. In moderate or severe stages, they lose this capacity and 
consequently the decision-making must be assumed by others. Health and 
social services professionals, and their relatives must try to discover their 
wishes and respect their medical, legal and fi nancial preferences.511,512,513
Expert opinion,
4
The Spanish legislation in force and, more specifi cally basic Law 41/2002, 
14 November, on the autonomy of patients and their rights and obligations 
with regard to clinical information and documentation, in its article 11 
(“Previous instructions”) pertaining to Chapter V (” Respect for the patient’s 
autonomy”) establishes that “by means of the advanced care document, an 
elderly person, able and free, expresses his or her wishes in advance, in 
order for these to be fulfi lled in the event that such situations should arise 
whereby he or she is not able to express them personally, regarding their 
health care and treatment or, in the event of death, about the destination 
of his or her body or the organs therein. The executor of the document 
may also appoint a representative to act, if the case arises, as his or her 
interlocutor with the physician or health team to procure compliance with 
the prior instructions".514
The prior instructions document or ADD may be formalised in a public 
document (before notary) or be private. The advance directive document, 
also called living will, must be considered as an expression of freedom 
of choice that must be respected and fostered. The legal system does not 
establish any time or specifi c moment to draw up the ADD document. This 
is an exercise of right that is recommended to be carried out in adult age and 
being of sound mind.
Applicable 
legislation
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In the case of a person who is diagnosed with dementia, the recommendation 
to draw up the ADD should accompany the diagnosis. That is, that both acts 
should be consecutive in time and as soon as possible after the diagnosis in 
order to be able to guarantee maximum possible integrity.
Although it is true that the diagnosis will not always coincide with the onset 
of dementia when this is mild, the health practitioner in contact with the 
sick person may also consider if the recommendation is equally appropriate.
Under these terms, whenever these people come to the health sector, 
professionals must advise them to have their degree and level of dependence 
and/or disability and their resources evaluated, so they must refer them to 
the relative social services. With this measure, it is guaranteed that the 
intervention of the professional contributes to bringing the affected people 
and their families nearer to the healthcare and/or protection measures 
included in Law 39/2006, 14 December, on Promotion of Personal 
Autonomy and Care of dependent people.
The Law does not specify the content of the ADD document, which may 
contain all those indications the person executing it considers of interest. 
Those aspects of the prior instructions documents that are not permitted 
by Law or are expressly forbidden, will not be taken into consideration. 
This will not represent the loss of validity of the other indications contained 





The ADD document must be registered in each autonomous community, 
normally at the Regional Ministry of Health, and it must be added to the 
patient's clinical record. It would be advisable for it to be incorporated by 
computer links into the health card. The prior instructions document may be 
freely revoked at any moment in time, leaving record in writing.
The National Registry of prior instructions documents or ADD created by 
the Ministry of Health and Consumer Affairs ensures the effectiveness in the 
entire national territory of the ADD/prior instructions documents expressed 
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Summary of evidence
4
People with dementia lose their autonomy and capacity to take decisions. Health 
and social services professionals, and their relatives must try to discover their 
wishes and respect their medical, legal and fi nancial preferences.511,512,513
Applicable 
legislation
Basic Law 41/2002, 14 November, on patients’ autonomy and on their rights 
and obligations with regard to clinical information and documentation, indicates 
that the prior instructions document or advance directive (ADD) includes the 
advanced will of a person of full legal age, able and free, for their desires to be 
fulfi lled at a moment in time when they are not able to express them personally, 
about the care and treatment they must receive. It also serves to appoint a valid 
representative who may decide on his or her behalf in each health circumstance 
and, in the event of death, about the destination of their organs. This ADD or 
living will may be formalised in a public or private document.514
4
The legal system does not establish any specifi c moment or time to draw up the 
ADD; it is advisable to do so in adult age and in being of sound mind. In respect 
of people with dementia, this must be attempted as soon as possible after the 
diagnosis to guarantee their cognitive integrity to the utmost.193
4
Health professionals must recommend the ADD to their patients, and especially 
if they detect emerging cognitive impairment.516
4
All those indications considered of interest by the person executing it, can be 
noted down in the ADD. Those aspects that are not permitted by Law or are 
expressly forbidden, will not be taken into consideration. This will not represent 
the loss of validity of the other indications contained therein and that are not 
contrary to law. These AD documents may be freely revoked at any moment in 
time, leaving record in writing.193
Applicable 
legislation
There is a National Registry of Prior instructions document or ADD of the 
Ministry of Health and Consumer Affairs and registry in the autonomous 
communities.515 For it to be easier to know the ADD of a person, this must be 
incorporated into their clinical record, and it would be advisable to do so by 
computer link to their health card.
Recommendation
D
Health and social services professionals, and relatives must try to discover the 
ADD of the sick person to be able to comply with his or her wishes and respect 
his or her medical, legal and fi nancial preferences.
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D
It is important to continue informing and raising the awareness of the population 
at large as well as of the health and social services professionals, about the 
need for able and free adult people to exercise their rights to draw up an ADD 
containing their wishes regarding the care and treatment they accept to receive, 
as well as the appointment of a valid representative that can decide on their 
behalf in each health circumstance, and after death, about the destination of their 
organs.
D
It is advisable to draw up the ADD in adult age and being of sound mind. In 
respect of people with dementia, this must be attempted as soon as possible to 
guarantee their cognitive integrity to the utmost.
D
Health professionals must recommend the ADD to their patients, and insist upon 
it especially if they detect emerging cognitive impairment.
D
It is recommendable for the ADD to include everything that is important for the 
person, bearing in mind that another person, on whom they delegate, will have 
to decide in their name, following their own indications.
D
To make it easier for a person to have access to the ADD, the ADD must be 
registered in the autonomous community and at the National Registry Offi ce for 
advance directives or ADD of the Ministry of Health and Consumer Affairs, and 
it must be attached to the clinical record and to the health card.
Evaluation of competences
13.3.1. Are there instruments that have been strictly designed to 
assess the competence of patients with dementia?
The legal need arises in people suffering from dementia to evaluate their 
capacity for self-determination, to decide about their property, ability to 
drive vehicles, use fi rearms or participate in clinical trials.517
Expert opinion,
4
There are no universally accepted CPG to assess the competence of patients 
with dementia.518,519,520,521 In Spain we have the Sitges Document, in two 
versions, the 2005 version522 and the revision of 2009206, drawn up using the 
Delphi techniques as a consensus methodology.
Expert opinion,
4
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Five topics are developed in the Sitges Document: 1) capacity and self-
management; 2) decision-making in the personal fi eld and regarding assets; 
3) neurological conditions required to take decisions; 4) examination 
of neurological conditions, and 5) correlation between the neurological 
state and the capacity to take decisions. A decision capacity assessment 
instrument has been drawn up in the Sitges Document, using a graphic and 
comprehensible table, indicating all the neurological and cognitive aspects 
that must intervene in the decision making. Each function is assessed 
and quantifi ed using the necessary tests and examinations; the maximum 
permissible alterations are established to be able to recognise  the capacity 
or incapacity to take decisions on personal aspects and/or aspects related to 
assets. The Sitges Document (2009)206 is a document aimed at raising the 
awareness of social agents on the exquisite and fair treatment that people 
with dementia deserve, whatever their condition. It contributes to improving 
the quality of the medical act relating to the care of these patients and their 
families, and to preventing these people, who are no longer in a situation to 
decide, from being able to be exploited by third parties.
Summary of evidence
4
As the dementia progresses, the clinical, social and legal need arises to evaluate 
the capacity of these people for self-determination, to decide about their assets, 
and other responsibilities, such as drive vehicles, use fi rearms or participate in 
clinical trials.517
4
There are no universally accepted CPG to assess the competence of patients 
with dementia.518,519,520,521 In Spain we have the Sitges Document (2005)522 and its 
updated version of 2009,206 drawn up by consensus methodology.
4
The Sitges Document (2009)206 refers to capacity and self-management; taking 
decisions that affect their person and their assets; the neurological conditions 
required to take decisions, and it provides a decision capacity assessment 
instrument, through a graphic and comprehensible table, indicating all the 
neurological and cognitive aspects that intervene in decision-making. Each 
function is assessed and quantifi ed. Maximum alterations are established that 
permit recognising decision incapacity, bearing in mind personal aspects as well 
as those related to assets.
Recommendation
D
The utmost efforts should be made to maintain the autonomy of people affected 
by dementia, respecting their decision-making capacity, whenever possible, 
even at the end of their lives.
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D
It is recommendable for health and social services professionals, as well as 
the legal institutions that attend to them, to use a common language and share 
knowledge.
D
The decision capacity of any person affected by dementia should be assessed, 
using the assessment instrument of the Sitges 2009 document.
D
It is advisable to involve the patient, if possible, in decisions made about the 
treatment. The patient’s desire must prevail; however, differences in opinion 
between patient and caregiver must be evaluated.
D
Total or partial incapacitation must be used as a legal resource to protect the 
person with dementia.
D
When carrying out a comprehensive and multidisciplinary assessment of a 
person with dementia, the evaluation of their decision-making capacity must be 
included, as well as if there is appropriate legal protection or not.
13.3.2 How are the specifi c competences assessed: driving 
licence, fi rearms licence and participation in clinical trials?
Driving licence
Driving vehicles is a complicated activity that requires the coordinated 
functioning of multiple cognitive functions. Driving provides autonomy 
and independence, freedom and mobility.
The decision to drive must bear in mind, on the one hand, the individual 
freedom, and on the other hand, the safety of the actual patient and public 
safety for third parties. The driving capacity is affected in dementia and as 
a result the risk of accidents increases.517
Expert opinion,
4
Although driving can already be affected in MCI and in the fi rst stages 
of dementia, these people may still maintain their driving capacity. As 
dementia progresses, the risk of accidents signifi cantly increases.523
The dementia diagnosis, therefore, does not mean stopping driving. The 
decision will be made based on the severity or on a demonstration of 
incompetence in their ability to drive.
Expert opinion,
4
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To obtain a driving licence, a medical certifi cate of the person’s 
psychophysical capacity must be provided, issued by an authorised driver 
examination centre according to Royal Decree 1277/2003, 10 October. In 
article 15 of the new Regulation of 2010, it establishes that the results of the 
psychophysical examination will be included in a report that will be issued 
on an offi cial form, specifying if the person may be affected by cognitive 
impairment. There is no defi nition on how the capacity must be assessed.525
The assessing process comprises a clinical record and an examination 
carried out by a general practitioner, an ophthalmologist and a psychologist. 
The results may be ordinary fi t (no defi ciency and/or pathological processes 
that represent a risk for driving); extraordinary fi t (this includes people with 
pathological processes and/or defi ciencies accepted as causes of risk to 
maintain an adequate road safety level); not fi t (people with disorders that are 
incompatible with driving temporarily or that may have a permanent nature). 
Reliable and validated methods and scales are used. The psychological 
evaluation includes mental disorders, behaviour and cognitive disorders.
Applicable 
legislation
People with mild dementia should not drive, as they do not pass the test that 
determines this ability when evaluated with the entire ASDE Dritest driving 
battery (which is the one used at the Examination Centres in Spain).523
Patients with MCI should be studied comprehensively to determine their 
competences as only about 50% pass these tests.523
The neuropsychological tests that correlate with these competences and 
that can help detect people with a driving risk are Kohs Block test, word 
learning test, logical memory, delayed memory and TMT-A.523
Cohort study,
2++
In MCI and in the initial stages of dementia, it is diffi cult to identify which 
people should stop driving. Both the compulsory and optional examinations 
and tests established must be carried out, if we wish to detect people with 
mild-moderate risk. A practical interactive driving exam based on road 
skills can give additional information. The British Psychological Society 
considers that there is no test battery that can be recommended.526 One 
SR of the cognitive tests used (including the clock test or the Trail Test, 
recommended by the American Medical Association),527 concludes that 
they are suffi cient in clinical practice to determine if a more extensive 
neuropsychological assessment is necessary.
Cohort study,
2++
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A driving limitation must be proposed when alterations are detected in 




The physician must warn the patients and family about the advisability of 
stopping driving. If there is a reasonable risk, which endangers third parties, 




Although people with dementia pass the assessment tests, and they are given 
a licence, new assessments should be repeated within a short period of time, 
every 6-12 months. It is important to inform the patients and family that 
the driving capacity is going to be turned down. This will enable them to 
plan the appropriate moment to stop driving in time and the most adequate 





There is little information in CPG that defi ne the capacity to manage 
fi rearms in people with dementia. If there are behavioural disorders with 
false interpretations and alteration of the perception of reality, with violent 
and aggressive responses, the possibility of handling a fi rearm is a risk to 
themselves and to third parties. It is important for the caregiving family 
and the professionals to evaluate the circumstances and establish the most 
adequate protection measures.
To obtain the fi rearms permit a medical certifi cate of psychophysical 
fi tness must be provided. There is no specifi c medical report model or an 
assessment of their physical, cognitive or behavioural capacity.140,25
Expert opinion,
4
Participation in clinical trials/research
Research is regulated by scientifi c and ethical principles. Clinical, genetic 
research, the donation of brains and trials with new drugs are all important 
in dementia.
Over the last few years, codes, documents and declarations have appeared 
that have established ethical principles that must be fulfi lled to participate in 
experiments. The contents of documents, codes and declarations have been 
updated and improved since Nuremberg in 1949, until Helsinki in 2002.
Expert opinion,
4
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Participating in research is an opportunity that benefi ts patients and their 
families. People wishing to participate must be informed in depth and in 
detail about the objectives of the study, its possible benefi ts and safety. The 
content of this information must make it easy to understand. Candidates 
must be able to understand and ask questions to clear up their doubts before 
signing their consent. Researchers must bear in mind their decision-making 
capacity. When patients are not capacitated, it will be the family or legally 
authorised person who must take the decision.
Law 29/2006, 26 July, in its article 60, section 4, offers guarantees in the 
rational use of medication and demands the free and informed consent of 
the person participating in the trial.528
Applicable 
legislation
Good Clinical Practices must be implemented in research studies. A 
series of conditions must be fulfi lled to carry out clinical trials: a) correct 
methodology and competent team; b) acceptable risk-benefi t ratio; c) 
independent supervision; d) fair load distribution, random distribution, with 
equal probability of effi cacy and safety in all groups; e) informed consent 
and confi dentiality; f) an insurance that guarantees the risks are covered, 
and g) appropriate payment.
In biomedical research, the professionals who intervene must know about the 
convention relating to human rights and biomedicine (Oviedo convention) 
and the Helsinki declaration529 as well as the international ethical guidelines 





Driving licence and dementia
4
People with MCI and mild dementia may have driving problems that increase 
the risk of accidents and endanger their own safety and that of third parties.517,523
4
Driving vehicles provides autonomy and independence, freedom and mobility 
to people with MCI or mild dementia, too. This autonomy must be respected, 
but the evaluation of their capacity enables the professional to advise if it is 
necessary or not to stop driving for safety reasons.525,517
2+
A full psychological evaluation at drivers' examination centres, systematically 
using compulsory and optional tests, permits the detection of people with 
cognitive impairment in mild dementia and determines their risk of suffering 
accidents.526,517
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2++
People with mild dementia should not drive as they do not pass the tests that 
determine this ability when evaluated with the entire ASDE Dritest driving 
battery (which is the one used at the Examination Centres in Spain). Patients 
with MCI should be studied comprehensively to determine their competence as 
only about 50% pass these tests. The neuropsychological tests that correlate with 
these competences and that can help detect people with a driving risk are Kohs 
Block test, word learning test, logical memory, delayed memory and TMT-A.523
3
Alterations of attention, orientation, executive functions or visuospatial 
perception limit the driving capacity.517
4
When a signifi cant risk for driving is acknowledged in a person with dementia 
who has been suitably assessed, their physician is under the obligation to inform 
the person affected and the caregiving family.526,517
3
The severity of the cognitive defi ciencies progress in people with dementia and 
with it their driving capacity can decrease in months. A revision of their capacity 
at shorter intervals than normal, between 6 and 12 months, permits detecting the 
problem and avoids risks of accidents.517
Firearms permit and dementia
4
People with dementia, especially if they present agitation, aggressiveness, 
violence, delirium and hallucinations, may use fi rearms inappropriately and thus 
cause danger for themselves or for others.140,25
Research and dementia
4
The participation of people with dementia in research studies is well regulated. 
There are documents, codes and declarations that protect their rights. Their 
participation must be free. Before taking decisions and signing consent 
to participate, they must receive understandable, extensive and detailed 
information.528
4
Any research study today requires that the research team is aware of the latest 
versions of the Good Clinical Practice Guidelines.
4
The importance of the clinical trials, due to the possible benefi t, risk and cost, 
always requires the research team to fulfi l a series of conditions: a) correct 
methodology and competent research team; b) acceptable risk-benefi t ratio; c) 
independent supervision; d) fair load distribution, random distribution, with 
equal probability of effi cacy and safety in all groups; e) informed consent and 
confi dentiality; f) safety guarantees, and g) appropriate payment.529,530
4
There are conventions and ethical guidelines to preserve the human rights of 
people who participate in biomedicine studies (Oviedo, Helsinki, Geneva).529,530
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Recommendation
Driving licence and dementia
D
The ability of people with dementia to drive a vehicle should be assessed, even 
during the initial stages, as an increase in the risk of suffering accidents has been 
proven.
D
A full psychological evaluation should always be carried out at drivers' 
examination centres to detect people with cognitive impairment in mild dementia.
D
Health professionals must inform patients with dementia and their families about 
the risk that continuing to drive may entail.
D
If a person with mild dementia continues to hold a licence, their ability to drive 
must be reviewed every 6 to 12 months, or earlier if necessary, to evaluate their 
risk.
D
A driving limitation must be proposed when alterations are detected in attention, 
orientation, executive functions or in visuospatial perception.
Firearms permit and dementia
D
It is advisable to keep fi rearms or elements that might be dangerous to them or to 




People with dementia and their relatives must be informed of the possibility of 
participating in clinical trials.
D
People participating in research studies must receive extensive, detailed and 
understandable information, and they must sign an informed consent.
D Good Clinical Practice Guidelines must be implemented in research studies.
D
The RCT should satisfy a series of conditions: a) correct methodology and 
competent research team; b) acceptable risk-benefi t ratio; c) independent 
supervision; d) fair load distribution, random distribution, with equal probability 
of effi cacy and safety in all groups; e) informed consent and confi dentiality; f) 
safety guarantees, and g) appropriate payment.
D
Professionals taking part in research studies must know about the agreements 
relating to human rights and biomedicine as well as the standards established by 
international ethical guidelines.
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13.3.3. Which are the indications to start the legal incapacitation 
process of a patient with dementia?
The decision capacity is decreased in dementia. This poses specifi c problems 
that family and society must solve. In AD, FTLD, DLB and PDD, both at 
the onset and throughout its evolution, they lose awareness of the disease, 
and the cognitive and behavioural impairment entails taking inappropriate 




Few people, even today, have expressed their advance directives, or have decided to protect 
themselves, through decision-making powers. They may, with time, also change their way 
of viewing things and their decisions. Their right to autonomy and to benefi cence must be 
respected, ensuring safety of means and treatment.
In DLB, PDD and VD, their capacity may vary with fl uctuations. There can 




The decision-making capacity must be analysed with great care, carrying 




If there are high risk situations, the control and protection measures 
must be stepped up, proceeding to start the incapacitation process. The 
incapacitation process must be started: a) if there is dementia; b) if the 
symptoms are persistent; c) it prevents self-management (ability to solve 




Based on the respect for free decisions taken by an adult if they do not harm 
the rights of others and are legal,531 one of the most important problems 
in daily clinical practice is that they do not leave a record of their advance 
directives and the professionals and their families have to decide.532
Expert opinion,
4
Self-management has an external dimension: Related to legal acts that have 
to do with third parties; and an internal dimensional: relative to one's own 
acts, such as self-care.
Something to always be taken into account is the fact that the main objective 
of the legal incapacitation process is to defend people who, due to their 
pathology, have become disabled to a greater or lesser degree, for their self-
management, and therefore in a clear situation of personal and social risk.
Expert opinion,
4
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The evaluation of the loss of self-management must be carried out 
in agreement with different criteria, which affect different fi elds and 
professions, so the indication to start the legal incapacitation process must 
be the result of a multidisciplinary evaluation.
These criteria are: Diagnostic, clinical, dependence, social, use of services 
and evolution.
Diagnostic criterion (at least one is a necessary and essential condition):
 – Stable, severe psychiatric diagnosis with more than two years’ evolution.
 – Mental retardation or borderline intelligence.
 – Other diagnoses related to non-reversible important cognitive defi cien-
cies.
Clinical criterion (at least two criteria must be fulfi lled):
 – Instrumentally assessed persistent cognitive defi ciency.
 – Markedly affected judgement of reality, not including acute
 – situations.
 – Lack of awareness of disease or of the defi ciency and/or non-adherence 
to the treatment.
 – Impulsiveness and risk behaviour derived or closely related to the dis-
ease or to the defi ciency.
Physical and/or mental dependence criterion (one of the two is a necessary 
condition):
 – The person examined requires constant supervision.
 – Lack of objectifi ed autonomy (scales, GAF).
Social criterion (at least two),
 – Social and economic precariousness.
 – Loneliness, isolation and lack of social support network.
 – Inadequate use of money: Putting their assets or own future at risk.
 – Family claudication or lack of reference family.
 – Evidence or reasonable suspicion of manipulation by third parties or that 
somebody is taking decisions for them.
 – In hospitalised people: Involuntarily admitted into a centre for more than 
2 years and discharge not predictable. The person is hospitalised without 
any awareness and has no reference family bond.
 – Different resources and work plans have been applied and the objective 
has not been achieved, and the person is dissociated from the social and 
health services network.
 – Need for forward thinking.
 – Person who has an assistant for a long time.
 – Any other cause of risk of social marginalisation.
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Criterion of use of services:
 – Frequent hospitalisations over the last year (normally involuntary).
 – The patient does not accept outpatient treatments, although this has been 
attempted on several occasions.
 – The patient does not accept rehabilitation although they need it..
 – Evolution criterion:
 – Prognosis towards stability of the impairment or towards a greater de-
gree of impairment.
 – High frequency of relapses related to not following the prescriptions.
Summary of evidence
3
The decision capacity is decreased in dementia. Even at the onset of AD, FTLD, 
DLB, PDD and VD, and throughout their evolution, the awareness of the disease 
may decrease: Cognitive and behavioural impairments entail inadequate decision 
making which may harm them and/or other people. This poses specifi c problems 
that family and society must solve.522
3
In DLB, PDD and VD, the decision capacity may vary with fl uctuations. There 
can also be intermittent periods of lucidity in other dementia.522
4
The capacity to take decisions is diffi cult to assess at times. A meticulous and 
comprehensive analysis of the cognitive functions permits defi ning their decision 
capacity degree.206
4
The incapacitation process must be started: a) if there is dementia; b) if the 
symptoms are persistent; c) it prevents self-management (ability to solve one's 
own matters, ability to attend to basic needs and reach objectives or fulfi l 
desires).531
4
One of the most important ethical and legal problems in daily clinical practice 
with people affected by dementia is the lack of a record of advanced directives.532
4
The main objective of the legal incapacitation process is to defend people who, 
due to their pathology, have become disabled to some extent to manage for 
themselves, and therefore in a clear situation of personal and social risk. The 
evaluation of the loss of self-management must be carried out in agreement 
with different criteria (diagnostic, clinical, degree of dependence, social aspects, 
use of services and evolution of the process), which affect different fi elds and 
professions, so the indication to start the legal incapacitation process must be the 
result of a multidisciplinary evaluation.
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Recommendation
D
It is very important to respect the autonomy and freedom of the people at the 
time of the diagnosis and throughout the entire evolution process, bearing in 
mind that, despite the existence of advance directives, people, with age, due to 
circumstances and/or due to the actual disease process, may change their way of 
seeing things, and thus change their decisions.
D
Beginning the incapacitation process must be recommended when the dementia 
progresses and the cognitive and/or behavioural impairment determines taking 
inadequate decisions that might harm the person affected by dementia and their 
environment.
D
The incapacitation process must be the result of a multidisciplinary evaluation, 
and must contemplate many different aspects such as: Diagnostic, clinical 
manifestations, degree of dependence, social aspects, use of services, and 
evolution of the process.
Aspects relating to the patient’s legal protection
13.4.1. What does legal incapacitation consist of?
Civil capacity encompasses two concepts, namely:
A) Legal capacity or legal personality: This is the aptitude that any person, 
because they are holders of rights and obligations, and which is characterised 
by: all people possess it in themselves (art. 29 Civil Code), it is acquired 
with birth (art. 30 Civil Code), and it ends with death (art. 32 Civil Code), 
it is the same throughout life and cannot be modifi ed.
B) Capacity to act: This is the aptitude of the person to exercise their rights 
and obligations, and which is characterised by: It is not possessed by all 
people in themselves; it is acquired when coming of age (18 years) (art. 315 
Civil Code), it is not the same throughout life and it can be modifi ed.
Depending on the degree of loss of capacity to act, two types of disability 
are differentiated:
A) Total incapacity: The person is not able to take any kind of decision 
that refers to the attention and care of any person, or to carry out any legal 
business or acts related to the administration and disposal of their assets, 
legal rights and interests and those related to assets of any kind.
Applicable
legislation
318 CLINICAL PRACTICE GUIDELINES IN THE SNS
The person who has to take all the decisions that are withdrawn by ruling 
from the incapable person is the guardian and what they exercise is called 
guardianship (question 13.4.3).
B) Partial incapacity: The person is incapable only or exclusively for acts 
related to assets (administration of assets) or related to other areas such as 
care of their health (e.g. monitoring and control of medical treatments that 
the person is following to treat the disease; access to medical information; 
giving consent, etc.) or the promotion of social integration (e.g. request 
access to social services, represent the incapacitated person in administrative 
acts, etc), indicated by the ruling.
The person who has to take the decisions that are withdrawn by ruling 
from the incapable person is the conservator and what they exercise is 
conservatorship (question 13.4.3).
In article 199, the Civil Code indicates: "Nobody can be declared incapable 
unless by judicial ruling by virtue of the causes established by law". 
Therefore, the necessary condition to declare a person incapable requires 
the existence of the judicial ruling in this sense.
Likewise, article 200, of the Civil Code indicates: “Causes of incapacitation 
are persistent, physical or psychic diseases or impairments that prevent a 
person from managing on their own”.
Therefore, the legal requirements that must exist to declare a person 
incapable are: Suffer a disease (a process in progress that alters and impairs 
health) or defi ciency (dysfunction, limitation or impediment that is defi nitely 
established); persistent nature of the disease or defi ciency which cannot be 
cured and whose limiting effects cannot be mitigated in a controlled and 
constant manner.
These effects will have an impact on the person's capacity, making them 
generally incapable self-management.
The incapacitation process is comprised of different steps that are established 
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1) Onset: People who can start the process (presentation of the demand) 
(a.757 LEC): Alleged incapable person, spouse or person who is in a 
comparable situation, descendants, ascendants or siblings. The Public 
Prosecutor will start the process in the following cases: If the above do not 
exist or have not requested it, after having being informed by a person who 
is aware of the situation (neighbours, private doctor, any family member…), 
after having been informed by a public servant who, because of their job, is 
aware of this (physician, etc.) and who, due to their administrative category 
(civil servants) is under the obligation to do so; in the case of minors: Only 
the person with parental authority or guardianship.
2) If the Public Prosecutor’s offi ce acts jointly and severally, it will carry out 
different steps: Interview with the people for are aware of the existence of 
the alleged incapable person, forensic medical examination of the alleged 
incapable person, request for reports from institutions believed appropriate 
(social services, primary care centres, etc).
3) Decision by the Public Prosecutor about whether or not to present a 
demand (decision against which it is not possible to bring any appeal).
4) Personal interview (hearing) between the judge and the alleged incapable 
person and relatives believed appropriate. They will be asked both about 
the state of the alleged incapable person and about which of them would 
be willing to assume the guardianship; and all those who the judge believes 
appropriate as witnesses.
5) Medical-forensic decision about the alleged incapable person.
6) Intervention by the Public Prosecutor: a) As plaintiff when it starts the 
process: researching the situation of the alleged incapable person to prevent 
them from being left unprotected as a result of the declaration of incapacity, 
plus the appointment of a judicial defender for the alleged incapable person; 
b) as defendant when it does NOT start the process: To prevent people from 
being declared incapable when they are not.
7) Judicial declaration (RULING) respect to: Whether the person is 
incapable, establishing the type of incapacity (what they can or cannot do), 
establishing the protection system for the incapable person.




The declaration of incapacitation or modifi cation of the capacity to act recognises 
that a certain person, as a result of the disease they suffer, has no capacity (total 
incapacitation) or has partially limited capacity (partial incapacitation) (Law 
1/2009 m. Civil Registration Law).533 This declaration can be requested, through 
a demand, by the actual person, the spouse or partner, descendants, ascendants, 
siblings and the Public Prosecutor (Law 41/2003, 18 November, article 757 of 
the Code of Civil Procedure).534 It will be opposed by the Public Prosecutor 
or a lawyer after an examination by the judge and by the forensic doctor and 
a hearing with closest family members. The judge will pronounce a ruling in 







To request the incapacitation or modifi cation of the capacity to act, the procedure 
laid down by the Spanish Procedural and Civil Registration Law must be 
followed, whereby, based on a demand, the case is studied, opposed and the 
judge gives judgement.
13.4.2. What type of legal protection exists for a patient with 
dementia?
During the fi rst stages of dementia, in order to plan the future of the person affected and 
predicting the possibility of being judicially incapacitated, and providing that the person still 
preserves his or her capacity to take decisions, any of the three legal fi gures below may be 
chosen: Self-guardianship, special power and advance directive document (question 13.2.1)
Self-guardianship: regulated in article 223 of the Civil Code, it permits any 
person, with suffi cient capacity to act, in anticipation of being declared 
incapable, to appoint the person they wish as their guardian, as well as 
adopt any provision referring to their personal care or the administration 
of their assets, identifying any person who should not be appointed, under 
any circumstances. The "self-guardianship" must be formalised in deed 
executed before notary, which will send a copy of it to the Civil Registry 
where the person is registered.
Applicable 
legislation
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In the event that this person were declared incapable, the judge who agrees 
to the incapacitation will request the Civil Registry to send him a copy of the 
deed on self-guardianship drawn up, in order to bear in mind the provisions 
of the person that executed it. The provisions contained within the self-
guardianship deed binds the judge, unless the benefi t of the person should 
demand otherwise. In this case, the judge must issue a reasoned decision.
Special power or preventive power: The current drafting of article 1732 
of the Civil Code foresees the possibility of conferring powers in favour 
of a third person, via the execution of a power, establishing that this can 
continue to be used at the time when ensuing incapacitation should concur 
in the person granting the power. This type of power is called special power 
or preventive power.536
The same article foresees that the power, if it is not special or preventive, will 
no longer be effective if the person who has granted it, incurs incapacitation. 
To this end, there is no need for there to be any change in capacity; just by 
proving that the person has lost his or her sound mind, the power would not 
longer be valid. For that reason, any person who knows or believes that he or 
she is going to lose his decision-making capacity, may grant a special power 
for another person, conferring upon this person the powers to act on their 
behalf, being able to represent them even in the event that incapacitation is 
incurred. The importance of this assignment and its consequences (someone 
may act on behalf and in the interest of a certain person when this person is 
not able to understand the scope of the acts carried out on his or her behalf 
nor be able to revoke the special power granted at the time) require that a 
special power should only be granted in favour of someone in whom the 
person explicitly trusts. «Finally, and as in all notary documents, a special 
power may only be signed if the person is fully able to understand and 






When people affected by dementia still preserves their capacity to take decisions, 
foreseeing the subsequent evolution towards a situation of incapacity, they may 
protect themselves legally with three options:
Self-guardianship: Appoint a guardian as well as adopt any provision referring 
to their personal care or the administration of their assets, identifying any person 
who should not, under any circumstances, be appointed.535
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Special power or preventive power: conferring powers in favour of a third person, 
via the execution of a power, establishing that this can continue to be used at 
the time when ensuing incapacitation should concur in the person granting the 
power.536
Advance directives (question 13.2.1)
Recommendation
✔
People with mild cognitive impairment and mild dementia should be advised to 
protect themselves through self-guardianship, or giving special power or writing 
the advance directive document.
✔
Any person with dementia who still has suffi cient capacity to act, should appoint 
a guardian, foreseeing the possibility of being declared incapable. As well as 
adopt any provision referring to their personal care or the administration of 
their assets, identifying any person who should not be appointed, under any 
circumstances.
13.4.3. What is guardianship?
Guardianship is the true protection mechanism of a person who has lost 
their capacity for self-management (modifi cation of the capacity would 
be the means), as it is through the guardian that the person obtains the 
complement of self-management that the disease has reduced or annulled. In 
Law 13/1983, 24 October, of the Civil Code these terms are defi ned and the 
procedures, rights and obligations of all the players are specifi ed.537,538,539,540
Guardianship means caring, attending, covering both the personal aspect and 
also the aspect related to the administration of assets that the person owns. 
Guardianship is a responsibility that is subject to different control measures, 
such as the drawing up of an initial inventory, annual accountability, the 
need to obtain prior authorisation for certain acts of economic importance 
and the presentation of the fi nal statement of accounts when it ends.
Applicable 
legislation
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Both physical persons and legal non-profi t persons may be guardians, 
including among their objectives or purposes, the protection of people 
whose capacity has been modifi ed. It is preferable to appoint the person or 
entity named by the actual person in the self-guardianship, rather than the 
spouse, parents, descendants, ascendants or siblings appointed by the judge. 
The judge may, exceptionally, based on reasoned decision, alter the order 
mentioned or rule out the people indicated, if this is deemed to benefi t the 
person.
Other guardianship fi gures are conservatorship, asset administration and judicial 
defence.537,538,539,540
Conservatorship would be guardianship with a reduced scope, which is usually assigned in 
cases of partial modifi cation of capacity. The conservator must attend to the person under 
conservatorship to carry out those acts determined by the ruling. This is a person who 
accompanies, counsels or assists, but who under no circumstances can substitute the will of 
the person, as they do not hold their representation.
The asset administrator is usually appointed when the assets of the person are so great that, to 
attend to them adequately, it is advisable to differentiate personal care from the administration 
of property.
The judicial defender may be appointed to cope with urgent situations if the guardian has still 





Guardianship means caring, attending, covering both the personal side and also 
the administration of the assets that the person owns:537,538,539,540
Guardianship is a responsibility that is subject to different control measures, 
(drawing up an initial inventory, annual accountability, the need to obtain prior 
authorisation for acts of economic importance and the presentation of the fi nal 
statement of accounts). Both physical persons and legal non-profi t persons may 
be guardians whose objectives include the protection of people whose capacity 
has been modifi ed.
Curatorship is a guardianship of reduced scope for cases of partial modifi cation 
of capacity, when the function assigned is to accompany, counsel or assist, but 
who under no circumstances can substitute the will of the person, as they do not 
hold their representation.
Asset Administrator is the person named to administer the assets of the person 
with reduced decision capacity.
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Judicial defender appointed to cope with urgent situations if a tutor has still not 
been named or when important differences arise between guardian and the ward.
Recommendation
✔
People with dementia who have lost their self-management capacity, should 
have a legal representative or guardian to protect them, and substitute them.
✔
People with dementia with reduced decision capacity should name a representative 
who shall care for their conservatorship, accompanying them, advising them and 
helping them take decisions.
✔
People with dementia with reduced decision capacity should name an 
administrator for their estate to administer their assets if these were considerable.
✔
A judicial defender of the person with dementia must be named, to cope with 
urgent situations if a tutor has not been named or when important differences 
arise between guardian and the ward.
Restraint of the patient
13.5.1. What are the indications for pharmacological and/or 
psychological restraint of a patient with dementia?
States of psychomotor agitation and aggressive behaviour are relatively 
frequent behavioural disorders in people with dementia in moderate to 
advanced stage, whatever the aetiology of the process.369,374 They are 
characterised by a signifi cant or inappropriate increase of the motor activity, 
accompanied by alterations in the emotional sphere which may become 
violent and dangerous, causing harm to the person affected or to other 




Aggressiveness, vagrancy or false interpretations of reality may appear 
from time to time and be unpredictable, or be persistent. Patients may fl ee 
from stimuli they interpret as harmful, or on the contrary they may confront 
them with belligerent actions and attitudes. Other times, situations that 
entail a risk of them harming themselves or falling down, arise as a result of 
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To prevent these expressions of aggressiveness or recklessness, the 
triggering factors can be corrected, modifying the patient’s environment, 
fostering psychosocial skills and optimising resources (Table 6). 541,542
If agitation arises, systematised and hierarchical interventions must be 
carried out, starting with verbal dissuasion measures, and modifi cations in 
the environment (question 10.4.6.). If these are not suffi cient they must 
be accompanied by the use of psychotropic drugs (questions 10.4.7 and 
10.4.8) and only extraordinarily should mechanical restraint (MR) measures 
or physical restriction be used (question 13.5.2). The limitation or control 
of movement and of their behaviour aims to protect the patients, providing 






Table 6. Dementia: prevention of aggressive and reckless behaviour541,542
Correct the triggering factors:
• Relieve any type of pain.
• Correct sensory defi cit: Auditory and visual.
• Evaluate and correct alterations of the nutritional state.
• Control current medication and its possible side effects,
• Adequately treat comorbidity (infections, etc).
• Improve gait, equilibrium and posture with physiotherapy.
• Improve functionality in ADL.
Modify the environment:
• Use adequate furniture (adapted chairs, etc).
• Adequately use the brakes on beds and on wheelchairs.
• Improve lighting and access to bells.
• Step up safety measures.
• Remove the sidebars, adapting the height of the bed.
• Remove unnecessary utensils.
• Place nonslip strips (baths, at the foot of the bed, etc).
• Facilitate conditions of comfort and intimacy.
Foster psychosocial skills:
• Control, reduce or eliminate provocative stimuli.
• Carry out cognitive and sensory stimulation programmes.
• Foster social activities., walks
• Provide company, therapeutic treatment, active listening.
• Favour reality counselling.
Optimise resources:
• Increase control and surveillance.
• Support the caregiving family
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Table 7. Dementia: Treatment of psychomotor agitation541,542
Verbal restraint:
• Listen carefully and actively: As the person needs to speak and express his emotions.
• Calm the person down: Offering help, protecting him from himself, from the disease and from the 
hostile environment (real or imagined). With a professional and non-paternalistic attitude.
• Approach with empathy: For the patient to realise that the professional is concerned with his wel-
fare, showing interest and understanding.
• Reinforce his feeling of reality: Responding to questions, analysing options, offering aid.
• Not shouting, speaking slowly, showing interest in what he says.
• Not intimidating, preventing him from feeling trapped, penned in, humiliated.
Pharmacological treatment: (questions 10.4.7 and 10.4.8).
• Atypical antipsychotics
− Quetipaine at a dose of 25-300, gradual start at 25 mg.
− Risperidone, solution, tablets and mouth dispersible tablets). Initial dose of 0.5-1 mg, gradual 
start, increase 0.25 mg/day, maximum 1.5 mg/day
− Olanzapine (tablets and fast absorption tablets), a dose of 2.5-5 mg
• Typical antipsychotics:
– Inject. haloperidol 1 vial of 5 mg. I5 mg. IM.
• Benzodiazepine type sedatives:
– Lorazepam 1 mg oral.
− Diazepam 5-10 mg orally, sublingual or rectal.
− Midazolam 1-15 mg, im, iv.
Summary of evidence
2++
Psychomotor agitation, aggressive, violent or dangerous behaviour may appear 
quite frequently in moderate or severe dementia, and it may cause harm to the 
person affected or to other people, or to the physical environment.541,542,369,374
3/4
To prevent aggressiveness or recklessness in people with dementia, action 
can be taken on the triggering factors, modifying the environment, fostering 
psychosocial skills and optimising resources.541,542
2++
The treatment that has to be followed in the event of psychomotor agitation/
aggressiveness in people with dementia, must be started with verbal persuasion 
measures, modifi cations in the environment, and if these are not suffi cient, drugs 
and only, extraordinarily, mechanical restraint measures can be used.140,541,542
1++/
1+
Atypical antipsychotic drugs (quetiapine, risperidone, olanzapine) are the fi rst 
line pharmacological treatment of psychomotor agitation and aggressiveness in 
people affected by dementia. (Questions 10.4.7 and 10.4.8).
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Recommendation
B
It is recommendable to prevent and detect psychomotor agitation and 
aggressiveness of people with dementia at an early stage and treat it. The 
measures to be followed may be pharmacological or non-pharmacological, 
using mechanical restraint if required.
A
The use of atypical antipsychotic drugs is recommendable as fi rst line 
pharmacological treatment of psychomotor agitation and aggressiveness of 
people affected by dementia.
13.5.2. What are the indications for physical restraint of a patient 
with dementia?
Mechanical restraint (MR) must be used in people with dementia who 
present considerable psychomotor agitation, which is not controlled with 
verbal and/or pharmacological measures, and providing this does not entail 
a danger of injury or damage to the actual patient or his surroundings. 
Pursue physical restriction or control by means of any mechanism, material 
or equipment, tied to the body or very close to it, that the patient cannot 
control or easily remove and which prevents him from moving freely and/






It is a therapeutic measure, used exceptionally, which must only be applied 
under medical prescription, if other restraint methods are not applicable or 
have failed. The objective is to protect the actual patient and in turn, other 
people, objects or facilities around them. With this measure no greater harm 






MR is usually used in moderate and advanced stages of dementia in people 
who are hospitalised or who live in nursing homes. It is a measure which, 
in our country, is used with a frequency of 40%, and in other countries the 
frequency is less: Australia (27%), France (17%), Italy (17%), USA (16%) 
or Sweden (15%).544 It is advisable for the MR to be maintained for a short 
period of time (hours, some days); however, it is usually prolonged up to 




MR is advised in people with dementia and agitation to achieve certain 
objectives:545,546,543
To prevent injury to the actual patient.
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To avoid interferences in the treatment (routes, tubes, etc.) 
To avoid material harm in the patient's environment.
To avoid escapes and prevent falls.
To help maintain the correct position of the body. 
To achieve the centre’s organisational objectives. 
To maintain a comfortable social environment.
MR is used a lot on people with dementia who live in homes for the elderly. 
Its justifi cation is doubtful in some cases. MR can become complicated, 
it represents a loss of autonomy, it alters their dignity, it affects their self-
esteem and it may entail physical and psychological consequences.543
MR must not be carried out543 if:
• It is not indicated by the responsible health professional.
• There are alternative methods with similar effectiveness.
• The physician indicates that it should not be applied.
• It is prescribed as punishment or a show of force.
• It is applied to replace surveillance, convenience or comfort for the 
health and/or social staff, or residents of the centre.
• The state of health and comorbidities are not known.




MR can be achieved by using a series of fastening elements approved in 
agreement with the legislation in force, and in perfect conditions. They can 
secure them to the chair or to the bed, or they can be protective bars, mittens 






The decision to use MR must be prescribed by the responsible physician 
or doctor on duty. It is advisable for the decision to be shared with other 
members of the team. The nursing or medical staff is authorised, in 
emergency situations, to start the procedure. The decision must be signed 







Four or fi ve well-trained, coordinated, meticulous people are necessary for 
the MR, who will secure arms and legs and head, acting calmly and fi rmly, 
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MR requires certain conditions, which are: a) padding and inspecting the 
fastenings each shift, verifying the state of the skin and/or possible injuries; 
b) when possible, maintain communication and contact when applying the 
care; c) frequently observe the patient and remove all dangerous objects 
from around him;d) prevention of pressure ulcers; e) use of technical 
aid (mattresses, local protections, silicone cushions, etc.); f) carry out 
necessary postural changes, mobilisation; g) provide periods of mobility 
and/or exercise, at least 10 minute every 2 hours; h) regulate and control 
the room temperature; i) help in personal hygiene, cleaning, drying, care of 
skin creases/folds, good skin hydration; j) offer liquid food, ensure adequate 






Additional measures must be taken to permit respect for the person's dignity 
and preserve their privacy. It is essential to involve the family in the care, as 
this favours comfort, accompaniment, proximity control, shortening of the 
procedure and reduction of the complications. The room must be quiet, well 







Monitoring the person submitted to MR must avoid, detect and deal with 
complications. Medical evaluation must be guaranteed during the fi rst 
hour. All remarks must be written down on the medical record. The risk 
of thromboembolism will be prevented, administering low molecular 










The nurse will observe patient every 15 minutes, monitoring their vital 
signs, adapting diets, controlling liquid intake, urine output, and minimum 
personal hygiene care, postural changes, and erosions to the contact areas 
between the fastening straps and skin every 4-8 hours. During the fi rst days 
of CR, there must be close supervision to detect any complications and 
changes early on. The training, qualifi cation and attitude of the staff caring 






The MR must be brought to an end when there is a certainty of having 
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Table 8. Mechanical restraint: Risks and complications547,542,541,543
Direct injuries:
Nervous compression: Plexus, nerves




Asphyxia on getting caught up with the fastenings
Sudden death after a prolonged period of agitation and struggling
Indirect effects:
Worsening of cognitive, social and functional Impairment, isolation, depression, increase of the state of 
confusion 





• Respiratory insuffi ciency
• Thromboembolism




Mechanical or physical restraint (MR) is used to control agitation/aggressiveness 
in people with dementia in moderate or severe stage, when there is a danger for the 
patient and for the environment, and these symptoms cannot be controlled with 
other restraint means (verbal or pharmacological). Fastening materials are used 
which prevent them from moving freely; they must be approved in agreement 
with the legislation in force, and in perfect state of preservation.541,546,543 Safety 
and comfort measures must be stepped up. 4 or 5 trained, coordinated, meticulous 
people are necessary, who will secure arms and legs and head, acting calmly and 
fi rmly, safely and with respect.547,542,541
The dignity and privacy of the person must be respected at all times. The family 
must be involved in the care and observation of the patients subject to MR. The 
room must be quiet, well lit, ventilated and safe.548
3/4
MR is a therapeutic protection measure, of exceptional use, which must only be 
applied under medical prescription. The benefi ts must exceed the risks of the 
measure.543,541,542
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2+
It is used frequently in Spain: 40% of people with moderate or severe dementia 
who present psychomotor agitation in hospitals or nursing homes.544
3/4
The decision about MR must be prescribed by the responsible physician or 
doctor on duty, signed, described in the medical record, informed and accepted 
by the family and shared with the other members of the team.541,543
2+
The objectives of the MR are: a) to prevent the patient from injuring himself and 
harming the environment; b) to avoid interferences in the treatment; c) to avoid 
escapes and prevent falls; d) to help maintain the correct position of the body; e) 
organisational objectives of the centre; f) comfortable social environment.545,546,549
2+ MR must not be used if it is not indicated.543
2+
It is advisable for MR to be maintained for a few hours or days; however it is 
usually prolonged for weeks (average of 86.5 days).544
2+/3/4
During the monitoring of CR, complications must be avoided, detected and dealt 
with. Medical evaluation and observation must be a constant feature during the 
fi rst hour, taking note of all the changes. All remarks must be written down in the 
medical record. The nurse will carry out an extensive control every 15 minutes 
during the fi rst hour, which will be spaced out later on.547,542,541
3/4
The MR will end when there is certainty of having managed to control the 
situation correctly. This will be done progressively.547,542,541
2+
There is a risk of multiple direct and indirect complications in people submitted 
to MR (Table 8). 547,542,541,543
Recommendation
D
When it has not been possible to control a person with dementia with pronounced 
psychomotor agitation using verbal and/or pharmacological measures, and they 
continue to be dangerous or at risk of causing harm to themselves or to others, 
mechanical restraint (MR) must be proposed.
D
Approved fastening elements must be used in the MR, in agreement with the 
legislation in force, and they must be in perfect conditions to be effective and 
safe.
D
To achieve adequate and safe MR, a coordinated team is required, comprised of 4 
or 5 well-trained people, who secure the patient properly, taking care not to harm 
him or her, and acting calmly and serenely, but fi rmly and surely. Throughout 
the entire treatment of MR, all those measures aimed at preventing direct or 
indirect complications must be maximised, guaranteeing the patient’s comfort, 
privacy and respect. The MR measure will be stopped as soon as possible, and 
progressively, when the symptoms are under control.
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D
MR is a therapeutic physical restriction measure that must only be applied under 
medical prescription. It must only be used if other restraint methods are not 
applicable or have failed. Their objective is to protect the actual patient and other 
people, objects or surrounding environment. It cannot cause greater harm than 
the harm aimed to be avoided.
D
Excessive use of MR should be avoided in people with dementia, only using 
it when it is really justifi ed, either due to the intensity of the symptoms and 
the possibility of them harming themselves or others. It must be as brief as 
possible to preserve the dignity and freedom of the person and reduce the risk 
of complications.
D
It is advisable for the MR to be a shared decision, agreed upon by the other 
members of the interdisciplinary team. The parentage details, the type and date 
of application of the measure, the reason for the restriction, the care guideline 
to follow, the periodicity of the controls, as well as the information given to the 
patient and to the family, as well as the informed consent, must be described in 
the clinical record, and signed by the physician.
C
The MR must be used in the following cases: to prevent injuries to the patients 
and to other people around them; to avoid interferences in the treatment (route, 
probes, etc.) and material damage to the patient’s surroundings; to avoid escapes 
and prevent falls and maintain the correct position of the body; to achieve the 
centre’s organisational objectives and maintain a comfortable social environment.
C
The contraindications of the MR must be respected and it must not be carried 
out if not explicitly indicated by the health professional responsible, or if, on 
the contrary, there are medical orders not to apply it. It must not be used, either, 
if there are equally effective alternative measures or procedures that have not 
been tried. They must never be used as punishment or as a show of force, or as 
a substitute for surveillance, or for the exclusive convenience or comfort of the 
professionals caring for them.
C
It is advisable for the MR to be maintained for a short space of time (hours, 
days). With monitoring in order to guarantee adequate observation, to avoid 
risks and complications. When appropriate control has been achieved, it must 
gradually be brought to an end.
13.5.3. What are the ethical and legal aspects of restraint?
The ethical aspects of restraints focus on a series of points:
Benefi cence: The decision to apply a restraints purports to protect, in the 
most adequate manner, the person with dementia and his environment.
Expert opinion,
4
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Non-malefi cence: Applying the restraints with good care practice, respecting 
indications and contraindications, and using the best, most effective and 
safest procedure, with a control and monitoring plan that permits reaching 
the objective with the minimum risk of producing physical or psychological 
harm.
Autonomy: The procedure interferes with the freedom of movement of 
the person and the management of their body. It represents a loss of free 
decision and choice.
Justice: The decision to use a restraint must be in keeping with the 
behavioural disorder and the consequences that are to be avoided.
With respect to the legal aspects of the restraint, the following coercive 




• Forced medical treatment
To start with, it must be pointed out that, with the exception of the case of 
involuntary internment (question 13.5.4), in the Spanish legislation there is 
no regulation about these coercive measures, thus understanding that they 
form part of the therapeutic arsenal available to the practitioner, who will 
apply them according to clinical criterion and at a moment in the evolution 
that he deems appropriate, and whose possible application is, in one case, 
known and specifi cally agreed to by the patient when he is voluntarily 
admitted into hospital and, in another case, authorised by the judge when 





Having established the above, noteworthy is the fact that, focusing on 
involuntary internment, during the course of it and during the application of 
the treatments, situations may arise that entail the limitation of other basic 
rights, as occurs with mechanical restraints, especially costly treatments, 
imposition of limitation of communications, etc. Thus, the question arises 
about whether a limited judicial control is suffi cient to determine the origin 
of the internment or if this must be extended to the actual development of 
the treatment, as a guarantee of the patient's fundamental rights.
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In this sense, it is worth repeating that article 5 of the European Convention 
for the Protection of Human Rights and Fundamental Freedoms (Oviedo 
Convention, CEDH)550 and the jurisprudence of the European Court of 
Human Rights (ECHR)551 liken internment to detention and that, when its 
origin lies in a criminal process, detainees, prisoners and convicts possess a 
whole series of rights and obligations established in the Spanish Constitution, 
the Criminal Procedure Law, Criminal Code and LOGP (General Organic 
Law on Prisons), in such a way that if they come to harm, they can implore 
the relative legal guardianship.
Based on these considerations, there are more than a few –O’Callaghan 
Muñoz, Peces, Morate, García García, Aznar López, Bardají Gómez– who 
sustain, to a greater or lesser extent, the following:
1. The need for the judicial control of treatment when measures are applied 
that entail an extra restriction of the patient's fundamental rights, for 
example, mechanical restraints, isolation rooms, electroconvulsive 
treatments, psychosurgery, etc.
2. The approval of these practices for all centres, in order to identify the 
cases when it would be fi tting to adopt these restrictions and integrate 
them into the so-called lex artis. Thus, this would also prevent it from 
being left to the free will of the management of the establishment or of 
the nursing staff.
3. The compulsory nature of a judicial review in inspections of the 
internment.
4. The appointments of a judicial defender for prolonged internment, 
pursuant to article 758.2 of the Law of Civil Procedure.
Thus, entering into a more detailed analysis of some of the confl ictive cases 
mentioned above, we see:
Isolation rooms and mechanical restraints: As we have seen above, the 
former consist of confi ning a person, on their own, in a closed room, used 
for this purpose, for a limited period of time, to prevent the patient from 
being able to infl ict serious harm on themselves or to third parties, including 
other patients or staff of the centre. The latter are defi ned as the use of 
physical or mechanical procedures aimed at limiting the movements of all 
or part of the body, in order to control their physical activity and protect 
them from injuries that they may cause to themselves or to others.
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The Parliamentary Assembly of the Council of Europe on psychiatry and 
human rights of 12 April 1994552 indicates that mechanical restraint measures 
will not be used and that isolation will be applied very restrictively. In any 
case, the Ruling of the European Court of Human Rights pronounced in the 
case HERCZEGFALVY affi rms that the use of coercive means form parts 
of the treatment, although the authors mentioned above state that this is 
only legally feasible when it is a question of controlling the patient’s hetero-
aggressive outburst, pharmacological treatments have no effect, they are 
adopted by prescription and under the control of the psychiatry specialist, 
and the dignity of the person is respected at all times. It would not be legal 
to resort to them, under any circumstance, to solve problems of lack of staff 
- which was the reason for the sentence by the ECHR in the matter referred 
to.
Right to be informed, both of the medical and legal aspects, when their 
mental state permits this. This means that they will be informed about both 
the medical and legal resources and means available to them to cope with 
their situation. In this sense, the general assembly of the World Association 
of Psychiatry held in Madrid on 25 August 1996 declared, on stating that 
the patient must be accepted as a common law partner in the therapeutic 
process.
Right to privacy: This is recognised in article 10.3 of the General Law on 
Health.163 The aforementioned Parliamentary Assembly of the Council of 
Europe on psychiatry and human rights, 12 April 1994,552 expresses that 
accommodation in large size rooms must be avoided.
Adequate treatment: The jurisprudential doctrine of the Supreme Court is 
consistent in the sense that the doctor-patient relationship only imposes on 
the former an obligation regarding activity and resources and not results, 
aimed at providing all the care required according to the state of science. In 
those cases where, following prolonged internment, an improvement does 
not occur and the Administration does not provide an adequate device in a 
reasonable length of time, some of the authors mentioned sustain that the 
transfer of the patient to an adequate centre must be ordered.
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Based on the above considerations, some authors propose -the 
aforementioned and Silvia Ventura- that legislative reforms should be 
carried out in order to describe the regulation of involuntary internment 
is in such aspects as the application of especially aggressive treatment, 
rights to privacy, and to the communication and effectiveness of the 
advance directive. What does seem obvious, at least from a current judicial 
perspective, is that there are no mechanisms that permit establishing a 
jurisdictional control of the development of psychiatric treatment, beyond 
the cases of medical responsibility, if negligent action or omission, a real 
danger and an adequate causal relationship between them concur. But, it 
is an action of redress and not of control.
Finally, and given its especial importance in the psycho-geriatric population, 
mention must be made of article 4 of Spanish Law 39/2006, 14 December, 
on the Promotion of Personal Autonomy and Care for dependent persons516, 
whereby it establishes that dependent people will enjoy all the rights 
established in the applicable legislation, and especially the following:
 – To enjoy basic freedoms and human rights, with full respect for their 
dignity and privacy.
 – To receive, in understandable and accessible terms, full and ongoing 
information related to their situation of dependence.
 – To be informed about whether the procedures applied to them can be 
used in agreement with a teaching or research project, in which case 
the prior express written authorisation from the dependent person or 
the person representing them is necessary.
 – For confi dentiality to be respected in the compilation and processing 
of their data pursuant to Spanish Organic Law 15/1999, 13 December 
(RCL 1999, 3058) on Personal Data Protection.553
 – To decide, when they have suffi cient capacity to act, about the guardi-
anship of their person and their assets, in the event that they lose their 
self-management capacity.
 – To freely decide about admission into a home. - To the full exercise of 
their jurisdictional rights in the case of involuntary internment, guar-
anteeing a contradictory process.
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Article 8 of Basic Law 41/2002, 14 November, regulating the patient's 
autonomy and rights and obligations with respect to clinical information 
and documentation, deals with informed consent for all types of procedures, 
including restraints, which in this case is protective but represents risks and 
negative effects on health. The patient must be duly informed, if possible, 
and failing this, the legal representative or person responsible de facto for 
the person affected. Written consent must be requested from family and/or 
representatives, and if possible also from the patient.
Applicable 
legislation
There are a series of principles of the United Nations514 in favour of older 
person and among them those affected by dementia. In point 9.1 it says that 
all patients are entitled to be treated as least restrictively as possible and to 
receive the least restrictive and altering treatment that corresponds to their 
health needs and the need to protect the physical safety of third parties.554
In point 11.1 it declares that no patient will be submitted to physical 
restrictions, or only when this is the only means available to prevent 
immediate or imminent harm to the patient or to third parties. These 
practices will not be prolonged more than the time strictly necessary to 
reach this objective.
This measure must be noted down in the medical record, (reason, nature and 
duration). A qualifi ed person must regularly supervise the person in restraint. 







Mechanical restraint (MR) has its indications, contraindications, limitations, 
risks and complications in people with moderate or severe dementia (question 
13.5.2).140
4
Ethical aspects about restraint:
Benefi cence: protect, in the most adequate manner, the person with dementia 
and his environment.
Non-malefi cence: Do so using good practices, respecting indications, contrain-
dications and using the best procedure, effectively and safely.
Autonomy: interferes with the freedom of movement of the person and the man-
agement of their body.
Justice: It must be in keeping with the behavioural disorder and the consequenc-
es that are to be avoided.
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Legal aspects about restraint: a) involuntary internment; b) therapeutic isolation; 
c) therapeutic immobilisation, and d) forced medical treatment.
Applicable 
legislation
Legislation only exists in Spain on involuntary internment (question 13.5.4.) 
Coercive measures form part of the therapeutic arsenal, they must be applied 
according to clinical criterion, at the right time, prior authorisation or consent 
from the patient or from the judge if the admission is involuntary. Spanish 
and European legislation compare internment with detention, with rights and 
obligations of the holders (in this case, the patients). (Spanish Constitution, 
Criminal Procedure law, Criminal Code and LOGP):
Expert opinion: 1) need for judicial control when treatment measures are applied 
that entail a restriction of the patient's fundamental rights; 2) approval of such 
practices for all centres; 3) compulsory nature of the judicial examination in 
inspections of the internment, and 4) appointment of the judicial defender for 
very prolonged interments (article 758.2 of the Civil Procedural Law)
Aspects with legal implication: Isolation rooms and mechanical restraints, right 
to be informed, right to privacy and adequate treatment.
Article 4 of Spanish Law 39/2006, 14 December, on the Promotion of Personal 
Autonomy and Care for dependent persons516, whereby it establishes that 
dependent people will enjoy all the rights established in the applicable legislation, 
and especially the following:
Enjoy basic freedoms and human rights, with full respect for their dignity and 
privacy.
Receive, in understandable and accessible terms, full and ongoing information 
related to their dependent situation.
Be informed about whether the procedures applied to them can be used in 
agreement with the teaching or research project, in which case the prior express 
written authorisation from the dependent person or the person representing them 
is necessary.
Respect confi dentiality in the compilation and processing of their data pursuant 
to Spanish Organic Law 15/1999, 13 December (RCL 1999, 3058) on Personal 
Data Protection.553
Decide, when they have suffi cient capacity to act, about the guardianship of their 
person and their assets, in the event that they lose their capacity to manage for 
themselves. Freely decide about admission into a home.
Full exercise of their jurisdictional rights in the case of involuntary internment, 
guaranteeing a contradictory process.
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Applicable 
legislation
Informed consent (Law 41/2002, article, 14 November):514 The patient must be 
duly informed, if possible, and failing this, the legal representative or person 
responsible de facto of the person affected. Written consent must be requested 




Any patient will have the right to be treated as least restrictively as possible and 
to receive the least restrictive and altering treatment that corresponds to them 
for their health needs and the need to protect the physical safety of third parties 
(Principle 9.1 of United Nations).554 No patient will be submitted to physical 
restrictions are only when this is the only means available to prevent immediate 
or imminent harm to the patient or to third parties. These practices will not be 
prolonged more than the time strictly required to reach this objective (principle 
11.1 of United Nations).554 This measure must be noted down in the clinical 
record (reason, nature and duration). A qualifi ed person must regularly supervise 




As restraint measures affect people’s freedom of movement, and their free 
of decision, and they are also not free from complications, before starting to 
apply them, the legal regulations that govern them must be carefully and 
strictly observed and enforced. The action must contemplate the principles of 
benefi cence, non-malefi cence and justice, and respecting the right to personal 
autonomy.
13.5.4. What are the indications for involuntary admission and 
what process must be followed?
People with moderate or advanced dementia, Alzheimer's or other related dementias may 
present behavioural disorders such as aggressiveness, states of agitation, delusions, aberrant 
motor activity and disinhibition, which if severe, may become dangerous for the actual patient 
and/or for the people around them. If they cannot be controlled with non-pharmacological or 
pharmacological measures by oral route, they will require more decisive measures, and will 
require admission to control the crisis and at the same time give the family a rest and provide 
them with the possibility of reorganising themselves again. If admission is possible, it should be 
carried out in units that are specialised in this type of alteration.543
The crises, or behavioural decompensations, may be caused by different reasons, includ-
ing systemic processes, worsening of sensory alterations or the actual evolution of the disease. 
Programmed or urgent, voluntary or involuntary admission must be used to clear up the aetiol-
ogy of the process, establish the most adequate treatment strategy. It may be even require verbal, 
pharmacological and physical restraint manoeuvres.556,545
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The admission indications for crisis control are:543
• Situations or behaviours that threaten the physical integrity of the person affected, or of 
other people of their family/social environment.
• Psychomotor agitation that is not controlled with fi rst level therapeutic procedures: Verbal 
restraints, modifi cation of the environment, oral sedation pharmacological measures.
• Need for isolation from the environment to try to decrease or eliminate the stimuli that 
generate the behavioural decompensation and/or the state of agitation.
• Optimise the treatments, when safe parenteral treatment is required and specialised 
personnel.
People with dementia, from moderate to advanced, are not usually able to decide on their 
admission. Sometimes they vehemently refuse or oppose it. The family may be overwhelmed by 
the clinical situation and be close to claudication.
The clinical situation set out above may, following a therapeutic criterion, be tributary of 
the admission of the patient into a health institution in order to control their symptoms and their 
evolution better. It is an admission that is specifi cally characterised because it is carried out in re-
spect of patients who, due to their own pathology, are not able to decide for themselves about the 
therapeutic proposal which, according to clinical criterion, is made by the practitioner, regardless 
of the fact that the patient are submitted to parental authority or to guardianship. The existence 
in these clinical situations of two circumstances that have special legal relevance, such as, on the 
one hand, the situation of defencelessness of the actual patients (derived from their pathology) 
and, on the other hand, the restriction of individual freedom represented by the therapeutic intern-
ment measure, led to the enforcement of a legal regulation in civil law (legal fi eld that encom-
passes all physician-patient relationships and which differentiates it from the criminal internment, 
which occurs in other circumstances and is governed by other criteria). This legal regulation is 
established today in article 763 of Law 1/2000, 7 January, on Civil Procedure (LEC).557 Special 
mention must be made of the sensitivity of the Offi ce of the Public Prosecutor towards the special 
characteristics of the psychogeriatric population and their health care, and, more specifi cally, their 
admission into Geriatric Centres, and which led, in 1990, to the issuance of Instruction 3/1990 
of the Offi ce of the Public Prosecutor, which especially mentions the admission of people into 
psychogeriatric homes,558 and which recalls the obligation for informed consent from the patient 
for admission into a health centre. This consent is set out as an expression of free and conscious 
will, referring to the aforementioned article 763 of the LEC, when these circumstances are not 
present in the patient.557
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Figure 13.1. Types of internment
CRIMINAL LAW CIVIL LAW
JUDICIAL INTERNMENT
CRIMINAL INTERNMENT CIVIL INTERNMENT
VOLUNTARY CIVIL INTERNMENT INVOLUNTARY CIVIL INTERNMENT
URGENT INVOLUNTARY CIVIL
 INTERNMENT
URGENT OR ORDINARY 
INVOLUNTARY CIVIL INTERNMENT
This article 763 of the LEC differentiates two types of involuntary civil internment, according to 
an emergency criterion, namely: Urgent involuntary civil internment and non-urgent or ordinary 
involuntary civil internment, respectively (Figure 13.1).
Urgent involuntary civil internment: This is internment which, due to the patient's clinical situa-
tion, must be carried out immediately. The following legal requirements must be fulfi lled:
• Communication of the internment by the person responsible for the centre where it takes place, 
to the court corresponding to the place where the centre is located as soon as possible, and in 
any case within 24 hours.
• Judicial ratifi cation within 72 hours at the latest from the moment the court is informed of the 
internment and after having been carried out by the responsible judge:
– Examination by them of the person to be interned.
– Listen to the decision of a practitioner appointed by him (in practice and in the majority 
of the cases this is the forensic medical examiner).
– Listen to Public Prosecutor’s Offi ce and any other person whose appearance is deemed 
advisable or is requested by the person affected by the measure.
– Practice any other test deemed relevant for the case.
– In all the actions, the person affected by the hospitalisation measure may have their own 
representation and defence. If this is not the case, the person will be defended by the 
Public Prosecutor, providing that this is not the party promoting the procedure.
• Evolution: Obligation of the doctors attending to the interned person to periodically inform the 
court, and every six months at the latest (unless the court, depending on the nature of the disorder 
that gave rise to the internment, indicates that this should be done in a shorter period of time).
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 about the need to maintain the measure, without prejudice of other reports that the court may 
require when it deems this relevant. After receiving the aforementioned reports, the court, after 
carrying out, where fi tting, the actions it deems essential, will resolve on what has to be done 
about the continuation or not of the internment.
• Discharge: When the doctors attending to the interned person consider that it is not necessary to 
maintain the internment, they will discharge the patient, immediately informing the same court 
that was notifi ed when the internment began.
Thus, urgent involuntary civil internment is defi ned as (Table 9).
• It is considered as a therapeutic measure that is governed by clinical criteria.
• The legal requirements set out above must be fulfi lled: Notifi cation to the court, plus subsequent 
judicial ratifi cation plus regular information obligation.
• It will be carried out in the most adequate type of centre according to the characteristics of the 
individual's age and mental pathology.
• Its duration in time will depend on the doctor’s criterion.
• There are two possibilities of evolution, and the responsible court must be notifi ed of them: 
Discharge by order of a doctors or the internment becomes voluntary, respectively.
• It is recommendable to inform the responsible courts of any possible contingencies that might 
occur during the internment (e.g. escapes, etc).
• It may be revoked by the judge, if after practising the legally established diligences within a pe-
riod of 72 hours after admission, its need is no longer observed
Non-urgent or ordinary involuntary civil internment: This is internment which, due to the patient's 
clinical situation, must not be carried out immediately.
In this case, and unlike urgent internment, as there is no clinical situation that requires im-
mediate internment, the judicial authorisation will be prior to the admission and therefore it will 
not be a ratifi cation of a doctor’s decision. This authorisation will also fulfi l the requirement for 
the judge to examine the patient, hearing the decision of a doctor appointed by him (in practice 
and in the majority of the cases this is the forensic medical examiner), Public Prosecutor and any 
other person whose appearance the judge deems advisable or is requested by the person affected 
by the measure.
Likewise, on the one hand, the compulsory nature of regularly informing the court, and 
every six months at the most (unless the court, in agreement with the nature of that cause the 
internment, indicates a shorter period of time) on the need to sustain the measure, is maintained 
regardless of any other reports that the court may request when it deems this relevant and, on the 
other hand, to inform of the discharge of the patient when the doctors attending to the interned 
person clinically deem this appropriate.
Thus, non-urgent or ordinary involuntary civil internment has the same characteristics as ur-
gent internment, except for (Tables 9 and 10).
• The judicial authorisation (which fulfi ls the same requirements regarding procedure as the ur-
gent one) is prior to the admission of the patient in the centre.
• It may be revoked by the centre if the centre believes that the criteria established by the doctors 
for admission are not satisfi ed.
CLINICAL PRACTICE GUIDELINE ON THE COMPREHENSIVE CARE 
OF PEOPLE WITH ALZHEIMER’S DISEASE AND OTHER DEMENTIAS 343 
Table 9. Urgent or involuntary civil internment
Legislation Article 763 of the Civil Procedure Law.
Consideration Internment is a therapeutic measure
Requirements
1) Notifi cation to the judge where the centre is located in less 
than 24 hours.
2) Judicial ratifi cation in less than 72 hours and after exami-
nation of the person affected + hearing of any person
3) Evolution report to the court every 6 months




Judicial authorisation not prior (or after), admission Gratifi ca-
tion
Type of centre
The most adequate for the characteristics of the individual's 
age and mental pathology.





(Escapes, permits, changes of units, etc)
Not compulsory but recommendable
Revocation of the internment by the cen-
tre and/or by its doctors
Yes by the judge
Table 10. Non-urgent or ordinary involuntary civil internment
Legislation Article 763 of the Civil Procedure Law.
Consideration Internment is a therapeutic measure
Requirements
1) Prior judicial notifi cation of the individual + hearing of any 
person deemed appropriate.
2) Evolution report to the court every 6 months
3) Notifi cation to the court of discharge on the doctor’s orders
Criteria Clinical
Judicial decision
Judicial authorisation prior to admission from the court where 
the affected person
Type of centre
The most adequate for the characteristics of the individual's 
age and mental pathology.





(Escapes, permits, changes of units, etc)
Not compulsory but recommendable
Revocation of the internment by the cen-
tre and/or its doctors
Yes by the centre’s doctors
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Summary of evidence
4
People with moderate or advanced dementia, Alzheimer's or other related 
dementias may present behavioural disorders such as aggressiveness, states of 
agitation, delirium, aberrant motor activity and disinhibition, which is severe, 
may become dangerous for the actual patient and/or for the people around them.
If these BPSD cannot be controlled with non-pharmacological or pharmacological 
measures by oral route, in outpatients (primary or specialised care) they will 
require more decisive measures, which will require admission to control the 
crisis, to give the family a rest and the possibility of reorganising themselves 
again. Admission should be carried out in units specialised for this type of 
alteration.543
4
The crises or behavioural decompensations may be caused by systemic 
processes, worsening of sensory alterations or the actual evolution of the disease. 
Programmed or urgent, voluntary or involuntary admission must be used to 
clear up the aetiology of the process, establish the most adequate treatment 
strategy. Verbal, pharmacological and physical restraint manoeuvres may even 
be required.556,545
3
The admission indications for crisis control are:543
• Situations or behaviours that are threatening for the physical integrity of the 
person affected, or for other people of their family/social environment.
• Psychomotor agitation that is not controlled with fi rst level therapeutic 
procedures:
• Need for isolation from the environment to try to decrease or eliminate the 
stimuli that generate the behavioural decompensation and/or the state of 
agitation.




If involuntary internment is urgently required, for a person with dementia and 
severe BPSD, it will be the physician attending to that person who shall take 
the decision. In this case, the person responsible at the centre must inform the 
competent court as soon as possible.
4
Admissions in order to control crisis situations must be as short as possible, 
guaranteeing, at the time of discharge, that the symptoms have been controlled, 
that the environment and the receiving family are adequate, the caregiver’s 
burden has been reduced and support measures for them to continue with their 
care work have been established.543, 556,545
Applicable 
legislation
The legal regulation that protects people who are involuntarily submitted to 
admission into hospital must be respected. The opinion and consent of the 
family will be required as well as the judicial authorisation before carrying out 
the admission. The reasons must be suitably justifi ed, ensuring their benefi cence 
and respect for the dignity and freedom of the person affected.
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People with moderate to advanced dementia are defenceless with respect to 
their own pathology. Instruction 3/1990 of the Public Prosecutor, which makes 
special mention of the admission of people into psychogeriatric homes, recalls 
the obligation for informed consent by patients; however, they are usually 
able to decide on their admission. Voluntary admission represents a restriction 
of individual freedom, it is legally regulated in article 763 of Law 1/2000, 7 
January, on Civil Procedure. This article 763 of the LEC differentiates two 
types of involuntary civil internment, according to an emergency criterion, 
namely: Urgent involuntary civil internment and non-urgent or ordinary 
involuntary civil internment, respectively,
Applicable 
legislation
Urgent involuntary civil internment: This is internment which, due to the 
patient's clinical situation, must be carried out immediately. It is legislated in 
article 763 of the Civil Procedure Law. Internment is considered as a therapeutic 
measure. The following requirements must be fulfi lled: 1) notifi cation to the 
court where the centre is located in less than 24 hours; 2) judicial ratifi cation in 
less than 72 hours and after examining the person affected, plus hearing of any 
other person; 3) evolution report to the court every six months; 4) notifi cation 
to the court of discharge ordered by a physician. The criteria are clinical. The 
judicial decision gives authorisation not prior to the admission, which is later 
ratifi ed. The internment centre must be the most adequate for the characteristics 
of the individual's age and mental pathology. The duration will be based on the 
doctors’ criterion. The internment may be revoked by the judge.
Applicable 
legislation
Non-urgent or ordinary involuntary civil internment: This is internment 
which, due to the patient's clinical situation, must not be carried out im-
mediately. It is legislated in article 763 of the Civil Procedure Law. Internment 
is considered as a therapeutic measure. The requirements are: 1) prior judicial 
examination of the individual plus hearing of any person deemed appropriate; 
2) evolution report to the court every six months; 3) notifi cation to the judge of 
discharge on doctors’ orders. The criteria are clinical. Judicial authorisation is 
required prior to admission from the court where the affected person resides. 
The centre must be the most adequate for the characteristics of the individual's 
age and mental pathology. The duration will be based on the doctors’ criterion. 
The revocation of the internment is carried out by the doctors of the centre.
Recommendation
C
People with dementia with severe behavioural disorders that entail a risk for the 
actual patient and/or for the people around them, and which are not adequately 
controlled in outpatients (primary and specialised care), should be admitted to 
control the crisis and enable the family to rest. Admission into these centres 
should satisfy the dual objective of diagnosis and treatment.
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D
Admissions in order to control crisis situations must be as short as possible, 
guaranteeing, at the time of discharge, that the symptoms have been controlled, 
that the environment and the receiving family are adequate, the caregiver’s 
burden has been reduced and support measures for them to continue with their 





The legal regulation that protects people who are involuntarily submitted to 
admission into hospital must be respected. The opinion and consent of the 
family will be required as well as the judicial authorisation before carrying out 
the admission. The reasons must be suitably justifi ed, ensuring their benefi cence 
and respect for the dignity and freedom of the person affected.
D
If involuntary internment is urgently required, for a person with dementia and 
severe behavioural disorders, it will be the physician attending to that person 
who shall take the decision. In this case, the person responsible at the centre 
must inform the competent court as soon as possible.
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14. Care of people with advanced 
dementia and at end-of-life stage
Questions to be answered
14.1. Which criteria defi ne an advanced and terminal situation with prognosis of limited life 
in patients with dementia?
14.2. Is it possible to determine, in people with advanced dementia at end-of-life stage, if 
their survival is going to be less than 6 months?
14.3. When must palliative care be started on people with dementia?
14.4. Which are the most suitable health resources to care for people with dementia at end-
of-life stage?
14.5. How are the clinical manifestations and the needs of people with dementia and their 
caregivers identifi ed and managed in the advanced and terminal stage of the disease?
14.6. How can worsening due to the natural evolution of the illness be differentiated from 
worsening caused by a potentially reversible concomitant process?
14.7. What are the objectives of caring for people with dementia in terminal phase?
14.8. What extraordinary or greater measures should be questioned in the care of people with 
advanced dementia?
14.9. What therapeutic intermediate measures should be questioned in the care of people 
with advanced dementia?
14.10. What information and aid must be provided to the families of people with terminal 
dementia?
14.11. What legal regulations and ethical principles exist relating to communication with peo-
ple with advanced dementia or with their families at the end-of-life stage?
14.12. In what cases is a post-mortem pathoneurological study recommended?
14.1. Which criteria defi ne an advanced and terminal 
situation with prognosis of limited life in patients with 
dementia?
Advanced stage of dementia corresponds to stages 6 and 7 of the GDS,559 
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Although the scales have been designed for AD, they can be applied to VD and to other 
degenerative dementia.
In these stages of the disease, patients have great diffi culty carrying out BADL (getting dressed, 
having a bath, washing and keeping control of the sphincter). There is a hierarchical order of 
functional loss in the GDS and FAST scales, which sub-classifi es the stages of dementia, 
adding more severity in each one of them. In stage 7, ability to walk, remain seated, hold their 
head upright, smile, and communicate through verbal language and gestures is altered.559,560
The terminal stage of dementia is diffi cult to identify as it is a progressive 
and chronic degenerative process. It could be defi ned by the following 
characteristics:562,563,564,565,566,567
1. Severe cognitive impairment (score of under 6 on the MMSE or 
cognitive impairment that prevents its execution).
2. Loss of the reasonable possibility of benefi ting from specifi c 
pharmacological treatment.
3. Stage GDS 7 (severe disability for BADL, unable to speak or does not 
make sense when communicating).
4. Multiple comorbidity with severe, multifactorial and changing 
symptoms (aspiration pneumonia, dyspnoea, infections of the upper 
urine tract, sepsis, pressure ulcers, pain, serious eating disorder).
5. Serious diffi culty to intake food, either due to dysphagia or rejection, 
with a weight loss or more than 10% in the previous 6 months and 
serum albumin of less than 2.5 mg/dl.
6. Unable to carry out any voluntary activity with a certain purpose. 
Unable to recognise the caregivers.
7. Great emotional impact on the patient, family and professional team 
caring for them, related partly to the proximity of death.
8. Relatively short vital prognosis, depending on the age and comorbidity 
(it varies between a few months and 2 years, although it may be greater).




Although the survival time or life prognosis has traditionally been used 
as a basic element in defi ning terminal disease, recently the concept of 
“advanced and terminal situation of chronic evolution disease with limited 




These patients generate a great demand for attention and the main objective is to promote the 
comfort and quality of life of the patient and of the family, based on controlling symptoms, 
providing emotional support and good communication.
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A screen method has recently been decribed that permits identifying patient, 
with or without dementia, in SEAT state. The assessment must be carried 
out by a traditional multidisciplinary team and the GSF (Gold Standards 




Table 11. Gold Standards Framework Criteria.57
1. A question: Would you be surprised if this patient were to die within the next year?
 2. Expectations or demand for limitation of the therapeutic effort or palliative measures (patient, relatives 
or members of the professional team)
3. General clinical criteria:
a. Existence of comorbidity.
b. Limitation of functional state.
c. Fast and sustained deterioration attributable to dementia (reject potentially reversible intercurrent 
processes)
d. Clinical and analytical signs of malnutrition (10% weight loss over the last six months, serum 
albumin under 2.5 mg/dl
4. Additional parameters (above all in fragile elderly, with pluripathology and dependence):
a. Resources consumption (more than three urgent admissions in the previous 3 months)
b. Repeated opportunistic infections (more than three in the previous 3 months)
c. Decubitus ulcers resistant to traditional treatment (more than 3 months’ evolution)
5. Other elements to consider:
a. Frequent situations that require ethical-clinical decisions (nutrition, hydration, resources, institu-
tionalisation, etc.) and planning of advanced care
 6. Frequent crisis of needs, which appear in a more or less predictable manner, which require manage-
ment of the case as a work method
Summary of evidence
3
Advanced stage of dementia corresponds to stages 6 and 7 of the GDS and FAST 
scales and to stage 3 of the CDR.559,560,561
4
The term SEAT is useful to defi ne the "advanced and terminal evolution situation 
and with limited life prognosis of a chronic disease", as is the case of dementia.571
2++
The identifi cation of people with SEAT is carried out by assessment made by a 
traditional multidisciplinary team using the GSF screen instrument.570
2++
The main objective of the assessment using the GSF scale is to identify patients in 
SEAT situation (quick and worsening, functional state, comorbidity, nutritional 
state). Determination of the knowledge and expectations of the patient, family 
and of the professionals about the immediacy of death, opinion about palliative 
measures and limitation of the therapeutic effort, and of other additional 
parameters such as opportunistic infections, decubitus ulcers and superimposed 
crisis situation.570
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3
Some characteristics of advanced dementia in terminal stage are: cognitive 
impairment (MMSE < 6), no expectations of benefi t with the specifi c 
pharmacological treatment, GDS-FAST of 7, severe malnutrition (weight loss 
> 10% in previous 6 months, serum albumin of < 2.5 mg/dl), need for palliative 
measures and great impact on caregiving family.572,573,562,563,564,574
Recommendation
D
The term SEAT can be used in advanced degenerative dementia in terminal 
phase, which corresponds to stage GDS 7.
B
Evaluate the stage of SEAT using the Gold Standards Framework (GSF) 
instrument. The GSF is recommendable to fi nd out the expectations of the 
caregivers regarding the death of the patient, the need to establish palliative 
measures, the limitation of the therapeutic effort, and about the consumption of 
resources, complications and crisis situations.
C
Advanced dementia must be considered as terminal dementia if cognitive 
impairment is severe and there is severe dependence for the BADL, there is no 
possibility of therapeutic benefi t with the specifi c treatment, there is multiple 
comorbidity and a suitable nutritional status cannot be maintained.
14.2. Is it possible to determine, in people with advanced 
dementia at end-of-life stage, if their survival is going to 
be less than 6 months?
The prediction of survival in advanced and terminal dementia is a complicated but useful 
process to be able to establish the therapeutic strategy and therapeutic effort limits and to 
suitably inform the families.
The majority of scales to determine survival in terminal patients have been developed to be 
applied to patients with cancer.
Lacking simple and validated scales to predict survival in patients with 
dementia, some variables can be used that usually predict life expectancy of 
less than 6 months, such as: Severe cognitive impairments GDS-FAST 7c-
7d, severe disability with D on the Katz index or worse, defi cient nutritional 
state with a weight loss of > 10% during the previous 6 months and serum 
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Other data that predict a bad vital prognosis are: The presence of motor 
disorders, apathy, hallucinations, male sex, over 85 years of age and 




The most frequent causes of death in this period are pneumonia, other 




People with terminal dementia are included within the group of pathologies where patients 
must not be submitted to inadequate interventions, but must receive palliative measures that 
improve their comfort, decrease suffering and do not unnecessarily prolong life.575,583,584
Summary of evidence
2++
The variables that best predict survival of less than 6 months in people with 
terminal dementia are: Katz index of D or worse, GDS-FAST stage 7c-7d, 
defi cient nutritional state (weight loss of > 10% during the previous 6 months and 
serum albumin of < 2.5 mg/dl), recurrent infections and presence of decubitus 
ulcers.575,576,577
2++
Other signs of bad vital prognosis in advanced dementia are: presence of motor 
disorders, apathy, visual hallucinations, male sex, over 85 years of age and 
background of diabetes and cardiovascular disease.578,579,577,580,581
2++
The most frequent causes of death in terminal dementia are pneumonia, other 
infectious processes and malnutrition.572,582
Recommendation
B
To establish a life prognosis of less than 6 months in a person with advanced 
dementia, parameters with predictive power must be identifi ed, such as degree of 
cognitive impairment, degree of functional disability, presence of malnutrition 
and presence of systemic complications and comorbidity.
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14.3. When must palliative care be started on people with 
dementia?
The World Health Organisation (WHO) defi nes palliative care (PC) as “the approach that 
improves the quality of life of patients and their families facing the problem associated 
with life-threatening illness, through the prevention and relief of suffering by means of 
early identifi cation and impeccable assessment and treatment of pain and other problems, 
physical, psychosocial and spiritual”. They are non-curative, active, ordinary measures, based 
on scientifi c evidence and well-proven experiences, which pursue the comfort of the person 
affected and of the family environment, covering the needs that are generated and with the 
main objective of improving their quality of life.572
PC must be applied to all terminal and chronic diseases of clinical practice, 
including people with dementia.585,572,25,517,575,583
Expert opinion,
4
PC must be introduced as soon as possible when the fi rst unsolved needs 
or problems arise, and to prevent the appearance of undesirable predictable 
problems. It must be maintained and intensifi ed throughout the entire 
process; it is most needed in advanced stages when patients no longer 
respond to specifi c treatment and all interventions become palliative ones. 
Curative and palliative measures coincide in time. The proportion and transit 
towards exclusively PC management is gradual and personalised.585,517,586,564
PC in dementia must relieve physical and psychological suffering, provide 
the best possible quality of life and consider death as a natural process. 
It does not consist of accelerating or delaying the death process and must 
integrate psychosocial and spiritual aspects, supporting family and friends 




The need to receive PC is encoded according to the ICD as a secondary 
diagnosis, after the base disease, with the supplementary classifi cation 
codes of factors that have an infl uence on state of health and on the contact 
with the necessary services (ICD-9: V66.7; ICD-10: Z51.5).573
Expert opinion,
4
All health and social services professionals caring for people with dementia 
must be prepared, theoretically and practically, to offer PC. There are 
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Summary of evidence
4
There is a universal agreement to use PC in the management of people with 
dementia.585,572,25,517,575,583
3/4
The aim of PC is to relieve physical and psychological suffering, promote quality 
of life and consider death as a natural process. Psychosocial and spiritual aspects 
must be integrated, giving support to relatives throughout the entire process. 
They must be introduced after the diagnosis and be intensifi ed throughout the 
evolution587,571,575,585,517,586,564
4
Health and social services professionals caring for people with dementia must 
be prepared to offer PC.
Recommendation
D
Palliative care (PC) must be implemented in the management of people with 
dementia, and this must be introduced early on after carrying out the diagnosis 
and it must be prolonged and increased as the disease progresses.
D
The aim of PC is to relieve physical and psychological suffering, provide quality 
of life and consider death as a natural process. Psychosocial and spiritual aspects 
must be integrated, giving support to relatives.
D
Health and social service professionals must be prepared to offer PC to people 
affected by dementia.
14.4. Which are the most suitable health resources to care 
for people with dementia at end-of-life stage?
PC in people with advanced dementia can be offered in the different health 
services and areas, both at home and in hospital or in social health centres, 
with or without specifi c palliative care units.573,575,517
Expert opinion,
4
This care must be provided to all patients who need it and when they need 
it, quality care must be guaranteed and there must be coordination between 
the different healthcare levels for the process to be seamless.573,588,589,575
Expert opinion,
4
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The National Palliative Care Strategic Plan establishes an organised system 
to guarantee coordination between the different social health resources, 
promoting integrated actions. The Plan establishes that there must be 
healthcare continuity of the PC throughout the entire illness, once the care 
has been established, promoting the training of professional teams that care 
for these patients.573
The organisational model proposed contemplates:
Basic PC level (primary, general or palliative approach): This refers to the 
care that must be provided to all people and by all health professionals. The 
specifi c needs must be assessed and responded to, as well as knowing when 
patients must be referred to other services.
Specifi c PC level (secondary, specialised or advanced): This contemplates 
more complex interventions that require specialised procedures or 
techniques, or that require performing additional diagnostic tests or specifi c 





All people are entitled to receive PC when they need it, at any of the healthcare 
levels. The use of PC is probably benefi cial. 573,588,589,575
4
Healthcare continuity must be maintained when receiving palliative type 
measures.573,588,589,575
4
Coordination between the different healthcare levels in PC is desirable when 
caring for people in advanced and terminal stage of dementia, including the 
specifi c PC units when more complex needs have to be attended to.573
Recommendation
D
All people with advanced dementia must be provided with PC, whatever the 
healthcare level that is being applied.
D
Healthcare continuity must be maintained in PC when there is a change in the 
healthcare level of the person with advanced dementia.
D
Health organisations should foster training of all professionals to provide basic 
PC.
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D
Health organisations must guarantee accessibility to specialised PC when 
necessary.
D
Coordination between the different services and healthcare areas must be 
guaranteed, as well as continuity of palliative care.
14.5. How are the clinical manifestations and the needs 
of people with dementia and their caregivers identifi ed 
and managed in the advanced and terminal phase of the 
disease?
To identify and quantify the needs of people with advanced dementia in 
terminal stage and the needs of their caregivers, it is necessary to carry out 
an comprehensive, global and multidisciplinary initial evaluation, bearing 
in mind all the aspects that converge in this stage of the disease. The 
assessment system must be homogeneous and easy to apply, with validated 
and reliable, simple, fast, objective and standardised scales. A periodic 
control of all the variables must be carried out.590,591
Expert opinion, 
4
In general, the evidence about patients in terminal stage who receive PC comes from studies 
performed on cancer patients; research on non-oncological diseases must be improved.575 
The National Palliative Care Strategic Plan573 acknowledges the creation of specifi c PC 
programmes for invalidating and progressive degenerative neurological diseases, such as 
cerebrovascular disease, Parkinson's disease, multiple sclerosis, amyotrophic lateral sclerosis 
and dementia, as an improvement that must be carried out. Especially important is the need to 
have specifi c PC programmes in advanced and terminal dementia; this research area still has 
to be developed as dementia is one of the most important causes of death in elderly patients.592
In this question, some aspects about management in PC that may be important in patients 
with dementia will be commented on, such as the management of some BPSD (delirium, 
depression and anxiety), dysphasia and nutrition and hydration alterations, pain, fever and 
decubitus ulcers. Psychosocial type aspects, information to families and attention to spiritual 
aspects during the fi nal days and grief will also be commented on.
The authors have been inspired mainly by the CPG on Palliative Cures of the National Plan for 
the National Health System (2008)575 (http://www.guiasalud.es/GPC/GPC_428_ Paliativos_
Osteba_compl.pdf), where it is possible to fi nd comprehensive information about managing 
complications that appear in advanced and terminal stages of chronic diseases and that 
will not be commented on here (asthenia, anorexia, dyspnoea, coughing, mouth infections, 
nausea and vomits, diarrhoea, constipation, intestinal obstruction, ascites, hiccups, pruritus, 
haemorrhage, convulsions, metabolic disorders, etc.).
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Delirium
Delirium in patients with advanced and terminal dementia (GDS 6-7) is very diffi cult to 
diagnose, as their verbal communication ability is varied and reduced or non-existent, and the 
sudden onset of psychomotor agitation may be their only clinical expressiveness.575
In patients with some sort of verbal communication, delirium may be 
identifi ed via the Confusion Assessment Method (CAM), a validated and 
easy-to-use instrument, which assesses four items: Acute onset, fl uctuating 
course, lack of attention and disorganised thinking.593,594
Expert opinion,
4
When managing delirium the fi rst thing to do is to identify the triggering 
or precipitating cause which is often multifactorial (pain, drugs, fever, 
dehydration), and correct it.575,595
Expert opinion,
4
If the agitation persists, pharmacological treatment may be used. There are 
no RCT on the effectiveness of pharmacological treatment of delirium in 
terminal cancer patients or on non-cancer patients due to ethical reasons,575 
with the exception of a small randomised double-blind RCT with no placebo 
group in patients with AIDS at the end-of-life stage when haloperidol and 
chlorpromazine but not lorazepam, proved to be effective for delirium taken 






In clinical practice, benzodiazepines are also used, apart from haloperidol, in 
cases of delirium with great agitation (midazolam, lorazepam, clonazepam 







When there is no response to haloperidol, this is not tolerated or it is 
contraindicated, atypical antipsychotics can be used. We must remember 
that in the case of PDD and DLB, atypical antipsychotics may cause a 







The epidemiology of depression in patients with advanced neurodegenerative diseases is 
practically unknown.575 Depression and anxiety may be perceived in patients with advanced 
dementia who preserve some introspection capacity and are able to communicate (GDS-FAST 
6) and who are in a situation of terminal stage of life, due to a concomitant process,
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Depression in this stage is often underdiagnosed or confused with apathy, so 
it may deprive patients from treatment that would improve their quality of 
life. The possibility of hypoactive delirium must also be taken into account 
in the differential diagnosis. The clinical observation, the information 







In order to treat depression, its triggering factors must be identifi ed, 
applying non-pharmacological support interventions and using tricyclic 
antidepressants and SSRI, although their effectiveness has not been 
specifi cally determined in this stage of dementia.575
SR of RCT,
1+
Psychostimulants such as dextroamphetamine, methylphenidate modafi nil 
and pemoline may have a fast response and are well-tolerated. They can be 
useful above all when a fast onset of the antidepressant effect is required, 
or in cases with short life expectancy. Its effectiveness has only been 
demonstrated in cancer patients.575
Expert opinion,
4
Dysphagia. Malnutrition and dehydration
Dysphasia is frequent in advanced dementia; it appears independently from the aetiology 
and usually gets worse with the progression of the disease. It appears earlier on in VD and 
in dementia accompanied by motor symptoms. Apart from the actual dysphasia that causes 
direct damage to the neurological structures that control swallowing, the possibility of the oral 
intake diffi culty being due to swallowing-chewing apraxia must also be taken into account or 
if it is a question of rejecting the food.
There is little evidence about the management of dysphagia in PC. The 




General measures can be used aimed at favouring swallowing such as 
correct hydration, a soft diet adapted to the patient's preferences or the 
use of thickeners in liquid dysphasia. Postures that facilitate swallowing 






An improvement with SSRI has been described in some patients who 
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Dysphasia in advanced dementia is often complicated with hydration and 
nutrition problems, and it is a frequent cause of aspiration pneumonia, the 




Dehydration may be expressed by thirst, dryness of the mouth and state 
of confusion. Whenever possible rehydration will be carried out by oral 
route. If it is essential to provide liquids via parenteral route, the advantages 
and disadvantages must be assessed in this specifi c case, appropriately 
informing relatives so that they can take part in the decision. Hospital 




The effectiveness of endovenous and subcutaneous route (hypodermoclysis) 
is comparable, but hypodermoclysis is more comfortable and presents fewer 
complications. Subcutaneous route permits the continuous administration 
of electrolytes and saline solutions 24 hours, at a daily rate of 40-60 mL/








It must be taken into account that the hydration symptoms may persist 
despite an adequate replacement therapy, probably because the cause of the 




The use of extraordinary measures to maintain nutrition and hydration when 
the patient stops eating by mouth, such as the placement of a nasogastric 
probe (NGP) or permanent percutaneous gastrostoma (PPG), is one of the 
most diffi cult decisions to be taken by professionals and relatives.196,599,600 
Before taking any decision, the advance directive document, if any, or the so-
called replacement opinion (what the patient would have chosen according 
to his history of values) should be taken into account. The relatives should 




One Cochrane SR that included seven controlled observational studies, not 
fi nding any RCT, concluded that enteral nutrition by NGP or PPG in people 
with advanced dementia does not prevent aspiration pneumonia, does not 
improve the nutritional parameters, does not reduce the decubitus ulcers, 
does not improve infectious complications, does not improve the functional 
state or comfort or survival.600 On the other hand, NGP and PPG are not 
free from complications (micro-aspirations, pneumonia, gastrointestinal 





These techniques should only be used when the person preserves unacceptable 
BMI, there is no severe comorbidity associated with the dementia, and the 
opinion of professionals and caregivers is also favourable.
Expert opinion,
4
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Pain
Pain is present in many people with dementia but it is often not identifi ed 
and consequently not treated adequately. It is normal for patients with 





The presence of pain must always be suspected, investigated as routine and 




To evaluate pain in advanced dementia, behaviour scales, interviews with 
the caregivers or scales that have been specifi cally designed such as the 
PACSLAC (Pain Assessment Checklist for Seniors with Limited Ability to 
Communicate) and the DOLOPLUS-2 can be used.605 These scales are not 
validated in Spanish. They are based on observing the patient's behaviour in 




There are no RCT that support which is the best treatment of pain in advanced 
and terminal stage of dementia; however the use of the analgesic ladder of 
the WHO is advisable, where three levels of action are contemplated: A fi rst 
rung with non-opioid analgesics, a second with weak opioids and fi nally the 
administration of powerful opioids. Apart from classical analgesics, adjuvant 
drugs can also be used (tricyclic antidepressants, SSRI, anticomitial drugs, 
benzodiazepines, etc), although their use is based on expert opinion.606,605,575
Expert opinion,
4
There are also some non-pharmacological measures (massages, aromather-





An intercurrent infection may be suspected in cases of fever in advanced 
dementia. The most frequent are pneumonia and infection of the urinary 
tract. Pneumonia is a frequent cause of admission into acute treatment 




There is controversy about the use of antibiotics, as they do not seem to 
reduce mortality respect to patients treated exclusively with palliative 
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Hospital admission is not indicated, either, to treat it.610,611 Observational 
study,
2++
However, under certain circumstances, the use of antibiotics may benefi t the 





Skin problems are frequent in this stage of dementia, especially the 
appearance of decubitus lesions or pressure ulcers (PU). The origin is 
polyfactorial, including the characteristics of the actual skin (fragility, 
sensitivity) and systemic problems (nutrition, cardiovascular state, etc). 575
Expert opinion,
4
To prevent the appearance of PUs, there must be frequent position changes, 
maintaining the best possible state of nutrition, and adequate hydration and 
hygiene of the skin. The use of mechanical protections, pillows or special 





Psycho-emotional and psychosocial needs of people with advanced dementia and in
end-of-life stage
The psychosocial needs of people in advanced stage of dementia and end-
of-life may be diffi cult to identify, as there are serious communication 
diffi culties. Observing the reactions of the person and knowledge of previous 
characteristics may help us in this task. We can never forget that the person 
being studied may be aware of their problem and suffer psychologically 
because of this, and in these cases the professional support and support from 
their families may help them.
Expert opinion,
4
The assessment of the psychosocial aspects should be extensive, considering 
aspects related to the moment in life, the meaning and impact of the disease, 
coping style, impact on the perception of oneself, relationships with family 
and friends, sources of stress (economic diffi culties, family problems, etc), 
spiritual resources, economic circumstances, doctor-patient relationship 
and social resources network. (Social health centres, social workers, etc).
Expert opinion,
4
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Identifying and evaluating the psycho-emotional and psychosocial needs of people with 
advanced dementia and in end-of-life stage
Spiritual needs can be deduced from the behaviour or be specifi ed by the actual person affected, 
if possible, or by families and/or friends. Spirituality is a dimension that combines attitudes, 
beliefs, feelings and practices that go beyond what is strictly rational and material.617 When 
evaluating any person, this need must be taken into account. Basic communication techniques 
must be used, such as open-ended questions, active listening and silences, in order to obtain 
information. The patient's spiritual needs may vary throughout time.618
Spirituality has an impact on the general welfare of patients in PC and on 







There is no evidence to determine how spiritual care must be provided. 
Listening to the patients’ experiences is recommended as well as any 
questions that might arise; affi rm their humanity; protect their dignity, 
self-esteem and identity; and guarantee that spiritual support is offered as 
an integral part of their care. Spiritual support can be offered by relatives, 




Psychosocial support to the family and social needs
The needs and wishes of relatives providing care for people with advanced 
dementia and in end-of-life stage are: Have home aid, psychological support, 
informal support, support groups, information, training, economic aid, 
respite services and help for tiredness, anxiety and isolation. The priority 









Care of people with dementia and their families during the fi nal days of 
their lives
The care during the fi nal days of their lives must be exquisite, meticulous 
and caring. The suffering of both patient and family must be understood, 
offering them the best possible care and support. These are moments that 
leave deep marks, and if they do not feel comfortable or they feel that 
they are being neglected, negative feelings are going to be created that are 
diffi cult to erase.622
Expert opinion,
4
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It is important to attend to the special demands that arise in these moments of extreme fragility.623,624
Physical care:
• Revise the medication and suspend all treatments that are not essential.
• Make sure that the medication that may be necessary is available and prepare alternatives to 
oral route (subcutaneous or rectal).
• Suspend all unnecessary interventions and tests (analytical, checking vital signs, etc).
• Maintain the observation to control the symptoms as best possible.
Psychological aspects:
• Explore the patient's fears and wishes whenever possible. This is practically impossible in 
the majority of people with dementia in terminal stage.
• Allow patient to express their sadness and anxiety.
• Calm them down with respect to symptoms and ensure them that they will be offered all 
possible means to relieve their suffering.
• Evaluate religious and spiritual needs
Social or family aspects:
• Make sure that the family is aware of the state of imminent death of the patient.
• Use a clear language, without ambiguities: do not take for granted the knowledge of the 
dying process.
• Consider all the reasons for doubt and concern that might arise: Tiredness, fear of 
responsibilities, fear of not realising that death is imminent, feelings of blame due to 
moments of distraction or rest.
• Whenever possible provide a quiet atmosphere where patient can spend their fi nal days.
The factors that affect decision-making about death vary depending on the 
patient's needs, the resources available and the preferences expressed earlier 
on by the patient or the wishes of their families.
Expert opinion,
4
Needs related to death: Grief and losses
Human grief is a natural reaction to loss, especially the loss of a loved one. It is a totally 
personal and non-transferable experience, and it is an extremely stressful life event.625,626
The majority of people get over their loss and effectively cope with grief -normal grief-, and 
some even get stronger in adversity -resilience-; but sometimes circumstances make the process 
especially diffi cult -risk grief- and sometimes it becomes complicated-complicated grief.627,628
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The personality, personal history, experiences related to previous losses or the moments in life 
of the person are all decisive factors in the way they express their grief and in its subsequent 
evolution. There are people who are more susceptible to suffering health problems associated 
with grief and adapting to the loss.629,630
The evaluation of risk grief must be carried out on the primary caregiver, on 
relatives and closest friends; it must take into account: The characteristics 
of the disease, the care in end-of-life stage, the nature of the death, the 







Professional interventions (psychological advice, psychodynamic counsel-
ling therapies and cognitive-behavioural techniques) in normal grief are not 
effective and they may even be harmful; in risk grief they can achieve a slight 









The diagnosis of delirium in patients with dementia in GDS 6-7 stage is very 
diffi cult due to the patient's problems with verbal communication and gestures, 
but it may be suspected in the case of sudden onset intense agitation.575
4
The CAM scale can be used to assess dementia in patients who preserve some 
sort of effective verbal communication.593,594
4
The treatment of delirium in PC must start by identifying the cause (fever, pain, 
dehydration, drugs) and by its correction.575,595
1+
Haloperidol has proved to be effective and well tolerated in the management of 
delirium in patients with AIDS in terminal stages.575,596 Chlorpromazine has also 
proved effective, with less tolerability.
3/4
Benzodiazepines (midazolam, lorazepam, clonazepam and diazepam), can be 
used in delirium with marked agitation and based on short series of cases.564,575
3/4
When there is no response or good tolerability to haloperidol, atypical 




The clinical observation, the information provided by relatives, and some 
specifi c scales, are useful for the diagnosis.575
4 SSRI and tricyclic antidepressants (based on RCT) are effective.575
4
They are entitled to be suitably informed, respecting their right to confi dentiality, 
covering their basic needs, and preserving their social relationships
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4
When abuse is highly suspected, there is an ethical and legal obligation to protect 
the victim, activating legal resources. If there are physical injuries, a judicial 
report of injuries must be drawn up; if this is not the case, the Public Prosecutor 
will be notifi ed to adopt the measures established by law.
Dysphagia, malnutrition and dehydration
4
There is little evidence about the management of dysphagia in advanced dementia 
and fi nal stage. The treatment requires personalised evaluation to identify the 
cause and treat it.575
4
The diet must be adapted to the characteristics of the dysphagia. This must 
generally be soft and adapted to the person's tastes. Thickeners must be used if 
it is liquid dysphasia
2++
The use of NGP or PPG to maintain the intake and hydration in a person with 
advanced dementia is not supported by the evaluation of risk/benefi t.600
3
Providing liquids does not always improve dehydration symptoms, as it is often 
multifactorial.517,575
4
The decision to hydrate via parenteral route in the end-of-life stage must 
always be agreed upon with the relatives, evaluating the need for hospital 
admission.196,599,600
2++/3
The effectiveness of endovenous route and hypodermoclysis to provide liquids 
and treat dehydration is similar.575
2++/3




Pain is frequent in advanced dementia but it may go unnoticed and as a result 
un treated.601,602
4
Clinical observation, the opinions of the caregivers and specifi cally designed 
scales (PACSLAC and DOLOPLUS-2) must be used to evaluate pain in 
advanced dementia.605
4
The use of the WHO analgesic ladder is recommended to treat advanced and 
terminal dementia. Adjuvant drugs can be added to relieve and reduce adverse 
effects of classical analgesics.606,605,575
2+
Some non-pharmacological measures such as massages, aromatherapy and 
transcutaneous electrical nerve stimulation can also reduce pain.607
Fever
2++
Pneumonia is a frequent complication in people with advanced dementia and the 
main cause of mortality.608,572
1++/
2++
Antibiotics do not reduce mortality from pneumonia in people with advanced 
dementia, and they are a frequent cause of admission into acute treatment 
hospitals.609,610
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2++
Patients with severe dementia do not benefi t from being admitted into hospital 
to treat pneumonia.610,611
2++
Antibiotics may reduce discomfort caused by infected bronchial secretions in 
patients with advanced dementia.612,613
Pressure ulcers
4
PU are frequent in this stage. Many different factors intervene: Local or systemic 
cause.
2+
The prevention of PUs entails the association of different measures: Postural 
changes, local protection elements and the maintenance of a good nutritional 
and hydration state as well as skin hygiene.610,614,615,616
Psycho-emotional and psychosocial needs of people with advanced dementia and in
end-of-life stage
4
There are many different factors to evaluate in the psychological fi eld and emot 
ions in people affected by advanced dementia and at end-of-life stage.
4
It is diffi cult to identify the psychological and emotional needs of people with 
advanced dementia and at end-of-life stage, due to the problems involved in 
acknowledging their actual illness and with verbal communication and gestures
4
The assessment of the psychosocial aspects must be extensive and contemplate 
many different factors:
Identifying and evaluating the psycho-emotional and psychosocial needs of people with 
advanced dementia and at end-of-life stage
2+/3
Spirituality has an impact on the general welfare of people and on their quality 
of life.619
4
Spiritual support to people with dementia must not necessarily be offered by 
health professionals or by those responsible for religious services. The method 
to be followed in spiritual care is based on active listening.575




Relatives providing care for people with advanced dementia and at end-of-life 





There is no single intervention model for relatives of people with advanced 
dementia and at end-of-life stage, which is guaranteed with suffi cient scientifi c 
evidence.620,621
Care of people with dementia and their families during the fi nal days of their lives
4
The care during the fi nal days of the end-of-life stage must be extremely 
exquisite, meticulous and caring.622
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4
It is important to attend to the special demands that arise in these moments of 
extreme fragility (physical care, psychological, family and social aspects).623,624
4
The factors that affect decision-making about death vary depending on the 
patient's needs, the resources available and the preferences expressed by the 
patient or relatives.
Needs related to death: Grief and losses
2++/3/
4
The majority of people get over the loss of a loved one and effectively cope 
with grief. However, there are people who are more susceptible to suffering 
complicated grief and have problems in adapting to the loss.627,628
2+/3
The characteristics of the disease, the care received at the end-of-life stage, the 
nature of the death, the characteristics of the griever, and of the deceased, and 
interpersonal relations have an infl uence on risk grief.575,629
1+/2+
Psychological advice, psychodynamic counselling therapies and cognitive-
behavioural techniques in normal grief are not effective and they may even be 
harmful; in risk grief they can achieve a slight improvement, and in complicated 




Initial management of delirium must include the identifi cation and treatment 
of the triggering causes, as well as appropriate information for relatives and 
caregivers, and an evaluation of the need to use pharmacological treatment.
B
Haloperidol is the drug of choice for treating delirium in patients in terminal 
phase.
C
Benzodiazepines are effective in the management of delirium with marked 
agitation.
D
The use of haloperidol and atypical antipsychotics must be avoided in patients 
with PDD and DLB, due to the risk of extrapyramidal reactions.
Depression and anxiety
D
In people with advanced dementia at end-of-life stage due to a concomitant 
process, the diagnosis of depression must be based on the clinical observation, 
the information provided by relatives and, if possible, the use of specifi c scales.
B
If necessary, antidepressant drugs, such as SSRI and tricyclics may be used, 
bearing in mind the possibility of central anticholinergic effects.
D
Psychostimulants such as methylphenidate, dextroamphetamine, modafi lin and 
pemoline may have a fast response and are well-tolerated.
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Dysphagia, malnutrition and dehydration
D
Treatment of dysphagia requires individualised assessment of each case in order 
to identify and if possible, treat the cause.
D
The diet must be adapted to the clinical characteristics of the dysphagia. In the case 
of liquid dysphagia, thickeners may be effective. A soft diet that adapts as much 
as possible to the patient’s tastes is recommended. If the patient collaborates, 
the adoption of postures that facilitate swallowing with the supervision of the 
speech therapist is effective.
D Whenever possible, liquids must be administered orally.
D
The parenteral administration of liquids during the end-of-life phase must be 
carried out weighing up the advantages and disadvantages, and always after 
discussing it with relatives.
B
The use of a nasogastric probe or permanent percutaneous gastrostomy must be 
assessed individually and with caution in patients with advanced dementia, as 
there is evidence of a bad relationship between benefi t and risk.
Pain
C
The presence of pain must always be suspected in advanced dementia. This must 
be assessed through the patient’s behaviour, the observation of relatives and the 
appropriate scales such as PACSLAC and DOLOPLUS.
D
The use of the WHO analgesic ladder guideline is recommended for the 




It is recommendable not to treat pneumonia with antibiotics in a person with 
advanced dementia as it does not entail a benefi t.
B
Hospital admission is not recommendable to treat pneumonia in a person with 
advanced dementia.
B
Treatment with antibiotics is recommendable in people with advanced dementia 
who have breathing diffi culties due to super-infection of bronchial secretions.
Pressure ulcers
C
To prevent the appearance of pressure ulcers, there must be frequent changes in 
posture, using mechanical protections and maintaining a good state of nutrition, 
hydration and hygiene of the skin.
Psycho-emotional and psychosocial needs of people with advanced dementia and in
end-of-life stage
D
The psychosocial well-being of patients with life-threatening chronic diseases 
must be evaluated on a regular basis.
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D
The psychosocial assessment of patients in PC should include the following 
fi elds: Aspects related to the moment in life, the meaning and impact of the 
disease, coping style, impact on the perception of oneself, relationships, sources 
of stress, spiritual resources, economic circumstances, doctor-patient relationship 
and social resources network.
D
Health and social services professionals attending to them should offer them 
basic emotional support.
D
People with signifi cant levels of psychological suffering should receive 
specialised psychological help.
Identifying and evaluating the psycho-emotional and psychosocial needs of people with 
advanced dementia and in end-of-life stage
D
The team attending to people with dementia must bear in mind their beliefs and 
spiritual needs.
D
In the absence of appropriate evidence about what is the best way to provide 
spiritual support, offering this support as an integral part of the care is 
recommended, whatever the care context, and with an approach based on the 
principles of effective communication.
D
It is important to consider cultural differences with respect to spirituality, but 
this does not justify a lack of attention to these aspects in people who belong to 
different cultural or religious groups to our own.
Psychosocial support to the family. Evaluate the family and social needs
C
Caregivers must be offered the possibility of expressing their needs for support 
and information.
D
Identifying the most vulnerable or depressed caregivers is recommended in 
order to offer them intensive psychosocial support or specialised services.
Care of people with dementia and their families during the fi nal days of their lives
D
Appropriate care during the fi nal days of their lives should include:
• Informing the family and caregivers of the situation of approaching death 
and, in general, provide the necessary information that adapts to their needs.
• Explain and agree to the care plan with the patient, and whenever possible, 
with their families.
• Evaluate the medication the patient takes, suspending non-essential drugs, 
after explaining the reasons for this.
• Treat symptoms that produce suffering. The necessary drugs must be available 
if the patient is at home.
• Interrupting unnecessary or futile interventions or tests, according to the 
patient’s desires.
• Evaluate psychological, religious and spiritual needs of the patient, family 
and caregivers.
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• Provide care in a quiet atmosphere, respecting privacy and facilitating 
proximity with family and friends.
• Provide the channels and resources necessary both for hospitalisation and for 
home care.
Needs related to death: Grief and losses
B
Referral of patients with complicated grief to specialised services (psychology, 
psychiatry, etc.) is recommended for them to receive specifi c and structured care.
B
Regular monitoring is recommended in risk grief, with emotional support, 
individually evaluating the need for specifi c and structured psychotherapies.
B Formal or structured interventions are not recommended in normal grief.
D
In normal grief, providing information about the grief and about the available 
resources is recommended, as well as basic emotional support.
D
Professionals caring for patients at the end-of-life stage as well as their relatives, 
should have access to elementary training in grief, which will enable them to 
provide basic care to the grievers, understand and explore their needs, evaluate 
the risk factors, detect people with complicated grief and refer them to specialised 
service.
14.6. How can worsening due to the natural evolution of 
the illness be differentiated from worsening caused by a 
potentially reversible concomitant process?
People affected by dementia present a variable clinical course but a relatively predictable 
prognosis. Dementia passes through different stages, with well-defi ned characteristics and 
duration in AD, and more diffi cult to specify in other type of dementia such as DLB where the 
fl uctuating course is even a diagnostic criterion. In very advanced stages, the different types 
of dementia tend to become more homogeneous in their symptoms and functional disability.
If the deterioration course is too fast and unpredicted sudden changes appear 
in functional capacity, a concomitant process must be suspected, which 
has an infl uence on the clinical expression of dementia. In these cases it is 
essential to differentiate what corresponds to the natural history of dementia 
from what is a potentially reversible worsening due to comorbidity or an 
effect related to drugs.575
Expert opinion,
4
370 CLINICAL PRACTICE GUIDELINES IN THE SNS
Professionals must investigate the causes of the crisis and decide on the 
most appropriate measures to correct it and guarantee the comfort and 
quality of life of the person affected.
Expert opinion,
4
When this worsening appears, whatever the cause, there are a series of factors 
that must be evaluated when taking a therapeutic decision. The limitation of 
the therapeutic strategy is an important aspect to decide if the dementia has 
reached a very advanced stage: FAST of over 7c in AD; when the Barthel 
index is 0; if the progression is very fast from the onset; if the infections 
are serious, repeated and with no relevant benefi t with the treatment; if the 
dysphagia is problematic, with malnutrition and/or dehydration, and if there 
are refractory pressure ulcers.
Summary of evidence
4
If the deterioration course is too fast and unpredictable sudden changes appear 
in functional capacity, a concomitant process must be suspected, which has an 
infl uence on the clinical expression of dementia.575
4
In advanced dementia, considerable worsening may mean that a limitation of 
the therapeutic strategy has to be established following a multidisciplinary 
assessment of the case.
Recommendation
D
In a person with advanced dementia, the existence of a concomitant process 
must be suspected if the progression suddenly speeds up and above all if there 
are unpredictable changes.
D
When considerable worsening appears, regardless of the cause, a series of factors 
must be evaluated that may affect the therapeutic decision, always bearing in 
mind the values of the person and of the family.
D
It is recommendable to evaluate the possibility of therapeutic limitation if the 
dementia has reached a very advanced stage: FAST of over 7c in AD; when the 
Barthel index is 0; if the progression is very fast from the onset; if the infections 
are serious, repeated and with no relevant benefi t with the treatment; if the 
dysphagia is problematic, with malnutrition and/or dehydration, and if there are 
refractory pressure ulcers.
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14.7. What are the objectives of caring for people with 
dementia in terminal phase?
The objective of applying palliative measures in the care of people with 
dementia in terminal phase is to provide comfort, eliminate reasons for 
suffering and improve the quality of life as far as possible, using non-
aggressive measures. These measures may be applied at home, and other 






The application of palliative measures in the care of people with advanced and 
terminal dementia can be carried out at home or in hospital. Their objectives are 
to provide comfort, eliminate suffering and improve the quality of life.25,517,573
Recommendation
D
Whatever the location, it is recommendable for patients with advanced or 
terminal dementia to receive palliative measures to improve their comfort, 
suffering and quality of life, insofar as this is possible.
14.8. What extraordinary or greater measures should be 
questioned in the care of people with advanced dementia?
In advanced dementia and in terminal phase of life, extraordinary therapeutic measures that 
are not very benefi cial and may cause discomfort and adverse effects must be avoided.
The higher ranking measures considered are, cardiopulmonary resuscitation 
in the case of various cardiac arrest, artifi cial respiration in asphyxia or 
dialysis in the case of kidney failure, as they do not reduce mortality or 
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Cardiopulmonary resuscitation carried out outside the hospital is not 
effective and in the hospital it is not very effective either in this group 
of people, as the result obtained is three times worse than in people with 
intact cognition. In light of these results, its execution is not advisable as 
the efforts required are excessive when compared with the benefi ts; thus in 






In advanced dementia, if there is cardiac arrest, artifi cial respiration in asphyxia 
or dialysis in the case of kidney failure, do not reduce mortality or modify 
survival in this stage of dementia.633,634
2++
CPR in advanced dementia carried out outside hospitals is not effective. In 
hospital, it is three times less effective than in people with intact cognition.635,636
Recommendation
B
Cardiopulmonary resuscitation is not indicated in people with advanced 
dementia, as it is an extraordinary therapeutic measure that does not provide any 
signifi cant benefi t.
B
Neither artifi cial respiration nor dialysis are recommendable, either, in advanced 
dementia, because they provide no benefi t.
14.9. What therapeutic intermediate measures should be 
questioned in the care of people with advanced dementia?
In advanced dementia and at end-of-life stage, intermediate range therapeutic measures 
should not be carried out; however, this must be considered as a controversial topic and often 
the decision is diffi cult.638
Intravenous infusions to correct dehydration, the administration of 
antibiotics in the case of infection, artifi cial feeding by NGP or PPG due 
to dysphasia or rejection of food, hospitalisation as a health resource and 
the performance of unnecessary diagnostic tests, are considered to be 
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However, some of these measures may exceptionally be effective to relieve 
suffering or be the only alternative available. If this is the case, we will 
recommend internment in a health centre when care cannot be provided in 







In advanced dementia and at end-of-life stage, the evaluation of the effectiveness 
and safety advises against the use of intermediate range therapeutic measures 
(intravenous infusions, administration of antibiotics, artifi cial feeding, 
hospitalisation and execution of unnecessary diagnostic tests).639,640,584
2+
There are exceptional situations when intermediate range measures may be 
effective to relieve suffering or are the only available alternative.641
Recommendation
B
At the end-of-life phase of patients with advanced dementia, the use of 
intermediate range therapeutic measures (intravenous infusions, administration 
of antibiotics, artifi cial feeding, hospitalisation and execution of unnecessary 
diagnostic tests) is not recommended.
C
The use of intermediate range therapeutic measures should only be considered 
on those occasions when they can reduce suffering or they are the only available 
resource.
14.10. What information and aid must be provided to the 
families of people with terminal dementia?
In advanced stages of dementia and in the terminal phase of life, patients 
have already completely lost their capacity to understand and decide. 
Families need more information and support to continue assuming there 
task of caring and take decisions. Good communication may improve the 
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In this end stage a lot of care must be taken when giving bad news and 
improvisation is not acceptable. Some studies performed in PC context 
highlight the importance of the decision-making in the end of life stage 
being shared, and for the relationship between the health professionals and 








Families need more information and support to continue assuming the caring 
task, take decisions, adapt and get more involved.642
3/4
At this end stage of dementia a lot of care must be taken, not improvising when 
giving bad news.643,644
4
In many aspects, information is useful for the caregiver of a person with advanced 




It is recommendable to give information and support to caregivers of people 
with advanced dementia for them to continue assuming their work as caregivers, 
take decisions, adapt and engage more.
D
Informing and communicating bad news to the caregivers of people with dementia 
at the end-of-life stage requires adequate preparation of the professionals.
14.11. What legal regulations and ethical principles exist 
relating to communication with people with advanced 
dementia or with their families at the end-of-life stage?
Access to the truth is the right of all people, as everyone is entitled to 
decide, with support and with due counselling, about such important aspects 
as health/disease or life/death.643
Expert opinion,
4
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Sincere communication is an ethical imperative that entails respect for 
the wishes and values of the patients,642 it permits the organisation of care 
according to priorities and preferences, and facilitates decision-making. 
Special circumstances arise in people with advanced dementia, as they have 
lost their ability to understand and decide, and it will be their families that 
must be informed and assume decisions. The information must be true, 
understandable, adequate, and it must contemplate the purpose and nature 





People with advanced dementia have lost their ability to understand and decide, 
and it will be their families that must be informed and assume decisions.643,642
4
The information must be true, understandable, adequate, and it must contemplate 




The participation of patients and caregivers in decision-making at the end-of-life 
stage must be fostered.
D
If patients are not able to decide at this end-of-life stage, the advance directives 
expressed by them or their wishes included in the clinical record, or else the 
opinion of their legal representative and/or closest family, must be contemplated.
D
Informing the team of the decisions adopted at this end-of-life stage is 
recommended, recording the process in the clinical record.
D
If there are doubts during the decision-making process, consulting other expert 
professionals (other professionals, healthcare ethics committee, etc.) should be 
consulted.
14.12. In what cases is a post-mortem pathoneurological 
study recommended?
There are no publications that address the topic specifi cally. Given that for the majority of 
subtypes of dementia, the defi nite diagnosis requires a neuropathological study, it is normal 
practice in our media to foster this in those cases where a fi rm diagnosis in life has not been 
possible.
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Epidemiological surveillance systems recommend carrying out a post-
mortem neuropathological study due to public health reasons when a prion 
disease or other diseases of compulsory declaration are suspected and which 
were not properly diagnosed in life.
Expert opinion,
4
On the other hand, there are several neurological tissue banks in the national 
territory whose objective is to promote the study of neurological diseases 
through the collection, processing and storage of neuropathological tissue 
originating both from healthy donors and from people affected by different 
neurological diseases, and provide them on a non-profi t basis to independent 
researchers. The assignment of post-mortem neuropathological tissue to 
these banks is channelled through the donation by the actual individual or 





It is useful to carry out a pathological study of the brain in those cases where it 
has not been possible to reach a fi rm diagnosis in life.
4
When a prion disease is suspected, for public health reasons, it is compulsory for 
this to be declared, and confi rmation of the diagnosis is always recommended by 
an anatomopathological study.645
4
The study of neurological tissues in patients who have suffered dementia is 
useful in research into these diseases.646
Recommendation
D
It is recommended for the medical team attending to the patient at this end-of-
life phase to request the post-mortem neuropathological study to confi rm the 
diagnosis (above all in those cases where there is not an accurate diagnosis, or if 
a prion disease is suspected or any other disease of compulsory declaration) and 
foster the investigation.
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15. Diffusion, training and research in 
care of people with dementia 
Questions to be answered:
Dissemination
15.1. How must the topic of dementia be dealt with in the media in order to suitably inform the 
public, and which are the most appropriate media?
Training
15.2. What undergraduate dementia training must be given to health sciences and social services 
professionals?
15.3. What dementia training must be given in healthcare branches of vocational training?
15.4. What post-graduate dementia training must health professionals in general receive?
15.5. What post-graduate dementia training must health professionals engaged in the specifi c 
care of people with dementia receive?
Research
15.6. How important is research in the fi eld of dementia? 
15.7. What role must the different healthcare levels play in research on dementia?
Diffusion
15.1. How must the topic of dementias be dealt with in the 
media in order to suitably inform the public, and which are 
the most appropriate media?
In modern society, the general population and the health and social services 
professionals must be aware of the major social and health realities that 
affect them, such as normal ageing and pathological ageing, mainly when 
this is characterised by cognitive function impairment.
Expert opinion,
4
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The great prevalence of dementia means that this is practically a universal 
experience and that a large number of families live, for many years, with 
the people affected, or that they are aware of the problem indirectly through 
friends, neighbours, work colleagues, etc. The dissemination of knowledge 
on dementia through the media must be done adequately and in a way that 
is understandable for the different groups that make up society.647Currently 
the media references about people affected by dementia are routine,648 
therefore the subject must be dealt with normally and with the necessary 
sensitivity to prevent dramatising or stigmatising people who suffer the 
problem, always with due respect to the privacy and dignity of the person 
affected and of their environment.
All media are adequate to disseminate information about dementia. 
However, journalistic treatment in certain television or fi lm formats, (reports, 
documentaries, news, fi lms) that include cases about people affected, either 
fi ctitious or real, may have a very high impact on the population and be able 
to transmit values such as dignity and respect towards the affected people. 
Especially important is the diffusion about the disease when those affected 
are socially important people.193
Expert opinion,
4
One important aspect that the media must consider is their responsibility 
about disseminating certain technological and therapeutic advances 
that might awake false expectations in the population.647 It would be 
recommendable for the different media to have specialised informants about 
health matters who can advise them on the real scope of these scientifi c 
advances, contacting professional organisations that are competent in the 




The media must deal with the topic of dementia with normality, in a rigorous, 
respectful, sensitive and understandable manner.647,648
4
All media may be adequate to disseminate information about dementia. They 
should have specialised informants in health-related matters, to give advice 
about the real scope of scientifi c advances, and not awake false expectations in 
the population.193,647,648
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Recommendation
✔
Information about dementia through the media must be based on ethical 
principles and good practice.
✔
The existence of specialised journalism in health issues is recommendable. The 
media, the competent professional associations and family associations must 
collaborate in fostering good information about dementia.
Training
15.2. What undergraduate dementia training must be given 
to health sciences and social services professionals?
The great prevalence and incidence of the disease and its impact at personal, 
family, professional and social level, justifi es the general training received 
by all the health practitioners (physicians, nurses, psychologists, social 
workers, physiotherapists, occupational therapists, speech therapists, 
etc,) about the care of people with dementia, during their basic studies. 






Insuffi cient training is provided, in general, today, at the health sciences and social 
services faculties on such a frequent and impacting process as is dementia.649
Recommendation
✔
It is recommendable for health sciences university students to receive general 
dementia training, in aspects such as epidemiology, pathophysiology, clinical 
manifestations, diagnosis techniques, pharmacological and non-pharmacological 
treatment, on the needs of the patients and relatives, and resources available, as 
well as on associated ethical and legal aspects.
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15.3. What dementia training must be given in health 
branches of vocational training?
In general, there is a lack of appropriate training in dementia in the health 
branches of vocational training. Many of these professionals work very 
closely with patients and families, and they must respond adequately to 
needs and demands, and therefore they must receive general basic training, 
both theoretical and practical, on the effects of dementia related to cognitive 
aspects, BADL, BPSD and the appearance of physical disability, among 
other aspects.
Vocational training must foster the development of positive attitudes of 
respect and tolerance, which must be added to the theoretical and practical 
knowledge. The health personnel must carry out continuous ecological 
stimulation aimed at being able to maintain people’s capacities and thus 
delay the decline of the person affected. It is also advisable to know what 
social-health and social resources exist, as this will enable them to be better 
informants.
These include, most importantly, auxiliary nurses, geriatrics auxiliary 
nurses, social-health care (education for health, basic care, treatment 
administration, etc.), dietetics and nutrition technicians, (prepare and 
supervise diets), pharmacy assistants (technical support in complying with 
treatments), or emergency medical and transport technicians (containment 





There is a lack of appropriate training in the health branches of vocational 
training when preparing students in such an important topic as dementia.
Recommendation
✔
Health vocational training must guarantee the acquisition of theoretical and 
practical knowledge, as well as positive attitudes of respect and tolerance, to 
appropriately manage dementia.
✔
VT health personnel must be prepared to carry out continuous ecological 
stimulation aimed at maintaining the capacities of the individual affected by 
dementia at a maximum level, delaying the decline of the person affected and to 
give information about the management and resources in dementia.
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15.4. What post-graduate dementia training must health 
professionals in general receive?
Some experts have expressed that there is a lack of appropriate dementia 
training among PCT and that, therefore, it is essential to insist on the need for 




The PC professionals, as well as many of the professionals from the hospital 
area, frequently attend elderly people, among whom dementia is prevalent. 
All of them must increase the basic training received with adequate post-
graduate training, which must be periodically updated, and which must 
include ethical and legal aspects, to (right to die with dignity, last wishes 
documents, etc.) and care in advanced and terminal stages of the disease.
Expert opinion,
4
There are different medical, surgical specialities, or those that provide 
complementary inputs, contributing specifi cally to the diagnosis and 
treatment of people with dementia. According to the model of the Ministry 
of Health and Consumer Affairs of Spain, the subject matters referring to 
mild cognitive impairment and dementia,657,658,659,660 mental health, geriatric 





3 There is a lack of appropriate training dementia of PCT professionals.656
3/4
Health and social services professionals, whatever the healthcare level, are 
in repeated contact with people and families affected by dementia. There are 




All health and social services professionals must update their knowledge to be 
competent in the comprehensive management of dementia. Dementia must be 
addressed in an interdisciplinary fashion, providing care seamlessly from the 
moment it is detected until the end of life.
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15.5. What post-graduate dementia training must health 
professionals engaged in the specifi c care of people with 
dementia receive?
Post-graduate training, that is the training that all professionals must acquire after their basic 
training, is understood here as lifelong training and also as a guarantee for society of that its 
professionals are constantly updating their knowledge.
Lifelong training becomes especially important at a time when the changes 
in social values and the sustainability of the system are geared towards 




In Spain, neurology, geriatrics and psychiatry are the medical specialities 
that usually attend to people with dementia, at the specialised health care 
level. Contents related to dementia are contemplated extensively in their 
speciality curricula, placing emphasis, in each one of them, on those aspects 
that concern them.657,658, 659 660
Training plans
Neuropsychologists are professionals who have been trained to accurately 
assess cognitive functions; to this end they use psychometric tests that 
enable them to interpret and control the evolution of the process. They must 
also be capacitated to design and apply cognitive intervention therapeutic 
programmes. There is no national policy of consensus regarding the training 
programme for neuropsychology specialists. However, there are many 
different programmes that place emphasis on this topic, and which are the 




Nursing staff who are specialised in the care of people with dementia play 
a relevant role throughout the entire process: They accompany patients 
and their families, they encourage them with their advice and they carry 
out actions in order to maintain maximum autonomy of the person, paying 
special attention to the appearance of alarm signals of claudication or strain 
of the family, and, during the fi nal stretch of life, making sure they are 
comfortable and trying to reduce suffering.667,668,669,670,671,672
In nursing speciality training, the topic of dementia is addressed in the 
training plans of mental health, geriatric nursing and community nursing 
specialities.673,674,675
Training plans
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Social workers from specialised units must be especially prepared to 
correctly interpret any modifi cations in the family dynamics related to 
dementia and its continuous changes. These professionals, like the rest of 
the interdisciplinary team, must take part in discussing each case, in the 
team work and contact all the other health and social professionals at PC 
level, other social health resources and the associations of families.676,677
Training plans
The specifi c post-graduate dementia training for other health professionals 
who work with people with dementia, is not suffi ciently developed either, 
although there are proposals to improve it, as is the case of physiotherapy678 
or occupational therapy.679
Throughout the training, health and social services professionals must have 
been made aware of the repercussion of the disease on the caregivers and 
families, about the essential role that the associations of families play, and 





In Spain, neurology, geriatrics and psychiatry are the medical specialities that 
usually attend to people with dementia. Other specialities also collaborate in the 
diagnostic assessment and in the treatment.
Training 
plans
The National Teaching Commissions of the medical specialities of neurology, 
geriatrics and psychiatry, have drawn up a theoretical and practical programme 
related to dementia, which includes specifi c preparation for its diagnosis and 




Neuropsychology, nursing, social work, physiotherapists, occupational therapists 
and speech therapists, who are specifi cally trained to be competent in managing 
people with dementia, are required on the basic multidisciplinary team.662,663,669,679
Recommendation
✔
All health and social services professionals integrated into the specialised care 
of people with dementia must receive specifi c training that will cover aspects 
related to the diagnosis and treatment, needs and resources available, ethical and 
legal aspects, and the need for it to be managed in an interdisciplinary manner.
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Research
15.6. How important is research in the fi eld of dementia?
Dementia affects millions of people and their families. The majority of 
the cases are due to neurodegenerative diseases; AD is the most prevalent. 
We still do not have any curative or preventive treatments to avoid its 
devastating consequences. All of this justifi es the great effort that must be 
made in research, to adequately solve this.193
Dementia action 
plan Catalonia
Progress must continue to be made in diagnostic techniques, biological 
markers, neuro-imaging studies, et cetera.), which permit establishing a 
safe diagnosis or predicting which asymptomatic people or with MCI will 
develop dementia.
Research on dementia must be carried out with a multidisciplinary, 
interdisciplinary, global and multidimensional approach, contemplating 
basic, clinical and epidemiological aspects, new diagnosis techniques, 
treatment optimisation, cost effi ciency and also psychological and social 
aspects.
Research must be promoted and favoured by the Public administrations, 
the government bodies of the State and of the autonomous communities, 
and it must be coordinated with all other countries. Dementia is a universal 
problem. Exchanging knowledge and know-how, the speed and facilities 
provided by the media, enable us to advance in research, making the most 
of the synergies among the different teams.
The research lines and priorities must be framed within continuity and 
harmonisation projects, although they may vary depending on the context 
and strategies established in each territory and in each country. In general, 
research in dementia today should adapt to the lines indicated, at the Spanish 
level, in the National R&D&I Plan 2008-2010680 and at a European level by 









It is necessary to continue researching into the knowledge of diseases that 
accompany dementia.682,193
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4









The research lines and priorities must favour continuity, harmonisation and 
they may vary depending on the context and strategies established in each 
territory and in each country. Research in dementia should adapt to the National 
R&D&I Plan 2008-2010680 and at a European level to the 7th R&D framework 
Programme of the European Union.681
Recommendation
✔
The collaboration of everyone involved (health and social services professionals, 
patients and relatives) is important to make a joint effort in the study and research 
in dementia.
✔
Research in dementia must be promoted and fostered from the public 
administrations, the governing bodies of the State and of the autonomous 
communities; it must be coordinated with other countries and it must favour 
the exchange of knowledge between the different teams that work in the same 
research line in dementia.
15.7. What role must the different healthcare levels play in 
research on dementia?
PCT is the grassroots of our SNS and it is the health care level that is closest 
to the population. Its contribution to research in dementia may provide 
information about epidemiology, concomitant pathologies, risk factors, 
drug consumption, etc. Cognitive, behavioural or functional impairment 
are detected in PCT at the very earliest stages, which is a key factor to 
control the process and with respect to all the circumstances that surround 
it (changes, resource management, support to the family, etc.), assessment 
of the quality of life, advanced stages of the disease, etc. Likewise, the PCT 
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The SDC is the ideal framework to promote research on diagnosis, new 
pharmacological and non-pharmacological treatments, as well as to assess 




The SDC must promote the transfer of basic research to clinical research, 
through data or human biological sample banks and vice versa, collaborating 
with the basic research teams.683
Expert opinion,
4
The social health network, due to its characteristics, is the ideal framework to 
perform research on the needs of patients with dementia and their families; 
on pharmacological and non-pharmacological treatments, on the solution 
of crises provoked by severe behavioural alterations or disorders that are 
diffi cult management, quality of life studies and palliative care, etc.193
Dementia action 
plan Catalonia
One aspect to be taken into consideration is the need for training in research 








PCT may provide relevant information on the epidemiology of dementia, early 
detection, use and adherence to treatments, management and control; it can also 




SDC professionals must carry out research into the diagnostic validity, new 
techniques, clinical criteria, pharmacological and non-pharmacological 




The social health network may provide information to carry out research on 
dementia, regarding pharmacological and non-pharmacological treatments, the 
needs of patients and families, the management of severe behavioural disorders, 
care at end of life, etc.193
4
There is a need for training in research methodology at all healthcare levels and 
for all disciplines that intervene in the process22496}.
Recommendation
✔
It is recommendable for the three healthcare levels: PCT, SDCT and the social-
health network to participate in research on dementia; to this end, training in 
research methodology is required.
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16. Dissemination and implementation
CPGs are useful to improve the healthcare and results in patients. The great challenge today is 
to achieve the adherence of professionals. An implementation strategy, aimed at overcoming the 
existing barriers in the setting where it is going to be applied, is therefore essential.
The CPG is comprised of three versions for health professionals: full, abridged and quick. 
The fi rst two have information for patients. All the versions of the CPG are published in online 
version and can be accessed on the GuiaSalud and AIAQS websites. The abridged version and 
quick guideline are also published on hard support. The abridged version contains a CD-ROM 
with the full version of the guideline.
Dissemination and implementation strategy
For this CPG to reach the health professionals of the SNS, it will be disseminated through the 
GuíaSalud Catalogue (www.guiasalud.es). Also on the AIAQS website (www.aatrm.net).
Once the national dissemination plan has ended within the general framework of GuiaSalud, 
the guideline development group, together with the AIAQS, will perform those diffusion activi-
ties they consider appropriate.
Measuring the adherence or implementation of the CPG recommendations by monitoring 
and/or audita can improve its use. The AGREE instrument manual stresses the importance of pre-
paring indicators; item 21 on the applicability dimension deals with this aspect.13 Consequently, 
a CPG must offer a list of clear and quantifi able quality indicators or criteria, which are derived 
from the key recommendations included in the guideline. The most well-known classifi cation 
of indicators, and used in this guideline is the Donabedian classifi cation,684 which groups them 
into: Structure, process and results. To know and evaluate compliance with the recommendations 
considered to be most important, the assessment of some process variables and most important 
clinical results is proposed.
Indicator proposals
Table 12 contains a description of the 37 indicators proposed by the guideline development group, 
classifi ed according to the clinical area, type of indicator, dimension of the quality they address 
and the healthcare level where they may be applied (primary care, specialised care and social-
health care). It is important to bear in mind that the indicators are a proposal inspired by those 
drawn up by the Catalan Health Department (2006)685 and they are only an estimate. As they are 
quantitative measures, if obtained on a regular basis, they will permit the analysis of the evolution 
in time (monitoring).
388 CLINICAL PRACTICE GUIDELINES IN THE SNS
Table 12. Indicators proposed






Percentage of patients 
aged 65 and over with an 
adequate control of the vas-




Percentage of patients under 
the age of 65 with MCI or de-





Number of patients diag-
nosed with MCI and classi-





Number of patients with aeti-
ological clinical diagnosis of 






Number of patients with 
diagnosis of dementia and 





Number of patients with 
diagnosis of dementia on 
whom a thyroid function 






Number of patients with 
diagnosis of dementia with 
diagnostic neuroimaging test 






Number of patients with 
CSF study for diagnosis and 






Number of patients with 






Time elapsed between the 
fi rst signs of the cognitive or 
behavioural process, and its 





Number of patients diag-
nosed with MCI with con-






Number of patients diag-
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Table 12. Indicators proposed (continued)






Number of patients that satisfy 







Number of patients that satisfy 
diagnostic criteria for dementia 






Number of patients that satisfy 
diagnostic criteria for Parkin-






Number of patients that satisfy 
diagnostic criteria for fronto-






Number of patients that satisfy 








Number of patients diagnosed 
with mild or moderate Alzhei-
mer's disease who receive spe-








Number of patients diagnosed 
with mild or moderate dementia 
with Lewy bodies who receive 
specifi c pharmacological treat-







Number of patients diagnosed 
with mild or moderate Parkin-
son's disease dementia who re-
ceive specifi c pharmacological 







Number of patients with diag-
nosis of moderate or advanced 
Alzheimer's disease, who re-








Number of patients diagnosed 
with moderate or advanced de-
mentia with Lewy bodies who 
receive specifi c pharmacologi-
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Table 12. Indicators proposed (continued)








Number of patients treated with 
ACE inhibitors whose treatment 








Number of patients treated with 
memantine whose treatment 








Number of patients with 








Number of patients with mild 






Number of families who have 
participated in information 




Number of patients/families 
diagnosed with dementia who 




Number of people/families re-
ferred to the AFA
1/2
Control Process
Annual assessment by families 
of patients with dementia of the 
degree of satisfaction with:
• Information received
• Professional support
• Adaptation of health 
resources




Number of caregivers 
with assessment of risk of 
claudication
Adaptation 1/2
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Table 12. Indicators proposed (continued)






Existence of protocols on 








Number of patients with 
dementia controls in PCT, 
who have presented a crisis 
situation during the last year
Adaptation 1
Control Process
Time interval between the 
request for visit by PC 




Number of reports issued by 
the specialised dementia unit 
specifying:
• Diagnosis and stage
• Neuropsychological 
evaluation






Number of patients with 
dementia who receive palliative 
care
Adaptation 1/2/3
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Appendix 1. Clinical material
Appendix 1.1.     DSM –IV-TR criteria for the diagnosis of 
dementia (translated from APA, 2000)16
A. Presence of multiple cognitive defi cits manifested by:
(1) Memory impairment (impaired ability to learn new information or recall previously learned 
information), and
(2) One (or more) of the following cognitive disturbances:
(a) Aphasia (language impairment)
(b) Apraxia (loss of ability to execute motor activities despite an intact motor function)
(c) Agnosia (loss of ability to recognise or identify objects despite an intact sensory function)
(d) Defi ciency in executive functions (e.g., planning, organisation, sequencing, abstraction)
B. The cognitive defi cits of criteria (1) and (2) cause a signifi cant disturbance in social and oc-
cupational functioning and represent a signifi cant impairment with respect to the previous level.
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Appendix 1.2.     ICD-10 criteria for the diagnosis of 
dementia, adapted and summed up from the WHO, 199218
G1. Evidence of the following two:
(1) Memory impairment
(2) Impairment in other cognitive abilities with respect to the previous function level: 
Reasoning, planning, organisation and general processing or information.
G2. Preserved awareness of the environment during a period of time long enough to clearly 
demonstrate G1. When there are superimposed episodes of delirium, the diagnosis of dementia 
should be deferred.
G3. Impairment in emotional control or motivation, or a change in social behaviour, manifest as 




(4) Coarsening of social behaviour.
G4. For a confi dent clinical diagnosis, G1 should have been present for at least six months.
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Appendix 1.3.      Criteria for the diagnosis of dementia by 
the consultancy group of the neurology behaviour and 
dementia group of the SEN guideline, 2002,19 - abridged









II. These alterations must be:
a. Acquired, with impairment of the patient's previous capacities, confi rmed through a reli-
able informant or via successive assessments.
b. Objectifi ed in neuropsychological examination.
c. Persistent for weeks or months, and verifi ed in the patient with normal consciousness 
level.
III. The intensity of these alterations is suffi cient so as to interfere in the individual's normal 
activities, including occupational and social activities.
IV. The alterations are not accompanied by any disturbance of consciousness until terminal stag-
es, although intercurrent transient disturbances may occur.
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Appendix 1.4.     Classifi cation of the dementia is adapted 
from the SEN guideline, 20096,35
1. Degenerative dementias
1.a. Degenerative diseases where dementia is one of the main manifestations
Alzheimer’s Disease









Motor neuron disease 
2. Classifi cation of vascular dementia
2.a. Ischaemia multi-infarct dementia 
Strategic infarct dementia
Lacunar state
Subcortical arteriosclerotic leuko-encephalopathy (Binswanger’s disease) Inherited angiopathies
Hypertensive and arteriosclerotic angiopathy
Vasculitis
2.b. Hypoxic ischaemia
Diffuse anoxic-ischaemic or restricted encephalopathy due to selective vulnerability. Incomplete 
infarction of white matter
Borderline area infarction
2.c. Haemorrhagic
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3. Secondary dementia
Due to alteration of the CSF dynamic
Associated with neoplasia
With infectious origin
With endocrine-metabolic origin, defi cient or toxic. 
Due to demyelinating disease
Due to vasculitis and collagenosis
Due to trauma
Due to psychiatric disease
Others
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Appendix 1.5.     DSM-IV-TR criteria for AD summed up 
from Spanish Version, published by Masson, 200517
A.– The development of multiple cognitive defi cits manifested by:
A.1.– Memory impairment (impaired ability to learn new information or recall previ-
ously learned information), and 
A.2.– One or more of the following cognitive disturbances: a.- Aphasia; b.- Apraxia;
c.- Agnosia; d.- Disturbance in executive functioning.
B.– The above disturbances represent a decline from previous level of functioning and cause 
signifi cant diffi culties in social or occupational functioning.
C.– The course is characterised by gradual onset and continuing cognitive decline.
D.– The cognitive defi cits in criteria A.1 and A.2 are not due to any of the following:
D.1.– Other central nervous system conditions that cause progressive defi cits in memory 
and cognition (e.g., cerebrovascular disease, Parkinson’s disease, Huntington’s 
disease, subdural haematoma, normal-pressure hydrocephalus, brain tumour). 
D.2.– Systemic conditions that are known to cause dementia (e.g., hypothyroidism, vi-
tamin B
12
 or folic acid defi ciency, neurosyphilis, HIV infection).
D.3.– Substance-induced conditions.
E.– The defi cits do not occur exclusively during the course of a delirium.
F.– The disturbance is not better accounted for by any other psychiatric disorder that might jus-
tify the manifestations, such as major depression or schizophrenia.
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Appendix 1.6.     NINCDS/ADRDA Criteria for AD131, 
translated in the SEN guideline, 20096,44
Probable AD
• Dementia syndrome established by specifi c questionnaire and confi rmed by a neuropsy-
chological test.
• Defi cits in two or more areas of cognition.
• Progressive worsening of memory and other cognitive functions.
• No disturbance of consciousness.
• Onset between the ages of 40 and 90.
• Absence of systemic diseases or other brain diseases that could explain the symptoms in 
the patient.
Dementia is defi ned as a decline of memory and of other cognitive functions respect to the state 
of the patient prior to the onset of the disease.
The data that support the diagnosis, excluding other causes, include a progressive deterioration 
of specifi c functions such as language (aphasia), motor skills (apraxia) and of perception (ag-
nosia), impaired activities of daily living and behavioural disorders, family history of a similar 
disease, above all if documented neuropathologically, normality in routine studies of CSF, and 
specifi c changes in the EEG, cerebral atrophy data on CT, which increase if verifi ed serially.
Other data consistent with the diagnosis of probable AD, after exclusion of other causes, either 
are:
• Plateaux in clinical course.
• Associated symptoms, such as depression, insomnia, incontinence, delusions, hallucina-
tions, catastrophic verbal, emotional or physical outbursts, sexual disorders, weight loss, 
increased muscular tone, myoclonus or gait disorder, especially in the late stage, and epi-
leptic crises in advanced disease.
• Cranium CT normal for patient’s age.
The diagnosis is less probable if symptoms start in an acute manner, if there are focal neurologi-
cal fi ndings or if there are epileptic crises or gait disturbances in the early stage of the disease.
Possible AD
The diagnosis of possible AD is based upon the following:
• Dementia syndrome with no apparent cause, although there are variations in the onset, in 
the presentation or the clinical course with respect to typical AD.
• If there is another brain disorder or another systemic process suffi cient to produce demen-
tia, but not considered to be the cause of dementia.
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• If the patient has gradually progressive severe cognitive defi cit in the absence of other 
symptoms.
Certain AD
The patient must have satisfi ed in life the diagnostic criteria of probable AD and there must be 
pathological confi rm treat data obtained via brain biopsy or necropsy.
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Appendix 1.7.    Research criteria for AD proposed by 
Dubois et al., 2007133
Probable AD: A + one or more supporting feature B, C, D or E 
Core diagnostic criteria
A. Presence of an early and signifi cant episodic memory impairment that includes the following 
features:
1. Gradual and progressive change in memory function reported by patients or informants 
over more than 6 months.
2. Objective evidence of signifi cantly impaired episodic memory on neuropsychological as-
sessment: generally consisting of a deferred recall defi cit that does not signifi cantly im-
prove or does not normalise with cueing or recognition testing, after effective encoding of 
information has been previously assessed.
3. Episodic memory impairment may be isolated or associated with other cognitive changes at 
the onset of AD or as it advances.
Supporting features
B. Presence of medial temporal lobe atrophy:
• Volume loss of hippocampus, entorhinal cortex and amygdale evidence on MRI with quali-
tative ratings using visual scoring or quantitative volumetry of regions of interest (references 
to well-characterised population with age norms).
C. Abnormal cerebrospinal fl uid biomarkers:
• Low amyolid β1-42 concentrations, increased total tau or increased phospho-tau concentra-
tions or combinations of the three.
• Other well-validated markers to be discovered in the future.
D. Specifi c pattern on functional neuroimaging with PET:
• Reduced glucose metabolism in bilateral temporal parietal regions.
• Other well-validated ligands, including those that foreseeably will emerge such as Pittsburgh 
B or FDDNP




• Early appearance of the following symptoms: Gait disorders, convulsions, behavioural dis-
orders.
• Clinical features.
• Focal signs such as hemiparesis, sensory loss or campimetric defi cits.
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• Early extrapyramidal signs.





• Toxic and metabolic disorders that might require specifi c examinations
• FLAIR or T2 signal changes in MRI in medial temporal lobe consistent with infectious or 
vascular lesions.
Criteria for defi nite AD
AD is considered defi nite if the following are present:
• Clinical and histopathological evidence (cerebral biopsy or autopsy) of the disease, according 
to NIA-Reagan criteria for the post-mortem diagnosis of AD. Both must be present.
• Both clinical and genetic evidence (mutation in chromosomes 1, 14 or 21) of AD. Both must 
be present.
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Appendix 1.8.    Revised criteria for the clinical diagnosis 
of DLB (translated from McKeith et al., 2005)40
1. Central features
• Dementia defi ned as progressive cognitive decline of suffi cient magnitude to interfere with 
normal social or occupational function.
• Prominent or persistent memory impairment may not necessarily occur in the early stages, 
but it is usually evident with progression.
• Defi cits on tests of attention and frontal-subcortical skills and visuospatial ability may be 
especially prominent.
2. Core features (two are suffi cient to diagnose probable DLB, one for possible DLB)
• Fluctuating cognition with pronounced variations in attention and alertness.
• Recurrence of visual hallucinations which are typically well formed and detailed.
• Spontaneous motor features of parkinsonism.
3. Suggestive features (if there are one or more in the presence of one or more core features, a di-
agnosis of probable DLB can be made. In the absence of core features, one or more permits the 
diagnosis of possible DLB. Probable DLB cannot be diagnosed just with suggestive features)
• REM sleep behaviour disorder.
• Severe neuroleptic sensitivity.
• Low dopamine transporter uptake in basal ganglia demonstrated by SPECT or PET imag-
ing.
4. Supportive features (these are usually present, but diagnosis specifi city has not been shown)
• Repeated falls and syncope.
• Transient and unexplained loss of consciousness
• Important autonomic dysfunction (e.g., orthostatic hypotension, urine incontinence).
• Hallucinations in other modalities
• Systematised delusions
• Depression
• Relative preservation of medial temporal structures in CAT or neurological MRI.
• Generalised hypoperfusion in SPECT or perfusion scan with reduced occipital activity
• Hypo-uptake in SPECT of mycocardium with MIBG
• Prominent slow wave activity in EEG with temporal transient sharp waves.
5. The diagnosis of DLB is less likely:
• In the presence of cerebrovascular disease, evident as focal neurological signs or in neuro-
imaging.
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• In the presence of another systemic or neurological disease suffi cient to partly or totally ac-
count for the clinical picture.
• If the parkinsonism only appears for the fi rst time in an advanced dementia stage.
6. Temporal sequence of symptoms
DLB should be diagnosed when dementia occurs before or currently with parkinsonism (if it 
is present). The term Parkinson disease with dementia should be used to describe dementia that 
occurs in the context of well-established Parkinson's disease. In a practice setting the term that 
is most appropriate to the clinical situation should be used and generic terms such as Lewy body 
disease are often helpful. In research studies in which distinction needs to be made between DLB 
and PDD, the existing 1-year rule between the onset of dementia and parkinsonism continues 
to be recommended. Adopting other periods would simply confuse the compilation of data and 
comparison between studies. In other research contexts that include clinical pathological studies 
and clinical trials, both phenotypes can be considered together under categories such as Lewy 
body disease or alpha synucleinopathy.
CLINICAL PRACTICE GUIDELINE ON THE COMPREHENSIVE CARE 
OF PEOPLE WITH ALZHEIMER’S DISEASE AND OTHER DEMENTIAS 407 
Appendix 1.9.    Diagnostic criteria and features for 
dementia associated with Parkinson's disease, translation 
and adaptation of Emre et al., 200741 taken from the SEN 
CPG, 20096,48
I. Central or core features
Diagnosis of Parkinson's disease according to Queen Square Brain Bank criteria or others ac-
cepted in Spain. A dementia syndrome with insidious onset and slow progression, developing 
within the context of established PD, diagnosed by case history, clinical and mental examination, 
defi ned as:
 – Impairment in more than one cognitive domain.
 – Decline from premorbid level.
 – Intensity of defi cits suffi cient to impair daily living (social, occupational or personal care) 
regardless of the impairment ascribable to autonomic or motor symptoms.
II. Associated clinical features 
Cognitive features:
 – Impairment in attention. Impairment in spontaneous and focused attention. Poor perfor-
mance in attentional tasks; performance may fl uctuate during the day and from day to day.
 – Impaired executive functions. Impairment in tasks requiring initiation, planning, concept 
formation, rule fi nding, set shifting or set maintenance. - Impaired mental speed (bradyphre-
nia).
 – Impaired visuospatial functions. Impairment in tasks requiring visuospatial orientation, per-
ception or construction.
 – Impaired memory. Impairment of free recall memory or of recent events or in tasks requiring 
learning new material, memory usually improves with cueing. Better recognition than free 
recall.
 – Core language functions preserved for a long time. Word fi nding diffi culty or impaired com-
prehension of complex sentences may be present
Behavioural features:
 – Apathy: Decreased spontaneity; loss of motivation and interest.
 – Changes in personality and mood, including depressive features and anxiety.
 – Mostly visual hallucinations, usually complex, with visions of people, animals
 – Usually paranoid delusions, such as infi delity or phantom boarder (unwelcome guest living 
in the home).
 – Excessive daytime sleepiness.
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III. Features which do not exclude Parkinson's Disease Dementia, but make the diagnosis 
uncertain
 – Coexistence of any other abnormality which may by itself cause cognitive impairment, but 
judged not to be the cause of dementia (e.g., presence of relevant vascular disease in imag-
ing).
 – Time interval between the development of motor and cognitive symptoms not known.
IV. Features suggesting other conditions or diseases as cause of mental impairment, which 
make it impossible to reliably diagnose Parkinson's Disease Dementia
 – Cognitive or behavioural symptoms appearing solely in the context of other conditions, such as:
 – Acute confusion syndrome due to:
 – Systemic diseases or abnormalities
 – Drug intoxication
 – Major depression according to DSM-IV classifi cation.
 – Features compatible with NINDS-AIREN criteria for probable vascular dementia.
Probable Parkinson’s disease dementia 
A. Central or core features: Both must be present.
B. Associated clinical features:
 – Typical profi le of cognitive defi cits, including impairment of at least two or more of four 
cognitive domains (impaired attention that may fl uctuate, impaired executive functions, im-
paired visuospatial functions and impaired free recall memory that generally improves with 
clueing).
 – The presence of at least one behavioural symptom (apathy, depressive or anxious mood, 
hallucinations, delusions, excessive daytime sleepiness) support the diagnosis of probable 
Parkinson's disease dementia. The absence of behavioural symptoms however does not ex-
clude the diagnosis.
C. None of the features of group III.
D. None of the features of group IV.
Possible Parkinson’s disease dementia 
A. Central or core features: Both must be present.
B. Associated clinical features:
 – Atypical cognitive impairment profi le in one or more domains, such as prominent or recep-
tive type aphasia (fl uent), or pure storage failure amnesia (amnesia that does not improve 
with clueing or with recognition tasks) with reserved attention.
 – Behavioural symptoms may or may not be present.
C. One or more features of group III.
D. No feature from group IV.
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Appendix 1.10.    Criteria for the clinical diagnosis of 
FTLD, semantic dementia and progressive non-fl uent 
aphasia51 translated by the SEN guideline, 2009,6,52
Criteria for the clinical diagnosis of frontotemporal dementia
I. Central criteria:
A. Insidious onset and gradual progression
B. Early deterioration of social behaviour and interpersonal relations.
C. Early impairment of quantitative self-regulation capacity of personal behaviour
D. Early superfi ciality and emotional indifference
E. Early anosognosia
II. Manifestations that support the diagnosis:
A. Onset before the age of 65
B. Family unit of dementia or history of a similar disorder within the immediate family.
C. Behavioural disorder
1. Deterioration in personal care and hygiene
2. Lack of fl exibility and mental rigidity
3. Distract ability and lack of persistence
4. Hyperorality and dietary changes.
5. Stereotyped and perseverative behaviour
6. Utilisation behaviour
D. Speech and language impairment
1. Alteration in expressive facet:







1. Refl ection of cortical disinhibition
2. Urine incontinence
3. Akinesia, rigidity, tremors
4. Low and labile blood pressure
5. Bulbar palsy, muscular atrophy and weakness, fasciculation (neuron motor disorder)
F. Additional tests
1. Neuropsychological examination: Intense alteration during examination of the frontal func-
tions, in the absence of considerable memory, language and spatial perception disorder.
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2. Normal electroencephalogram in stages with obvious dementia
3. Brain neuroimaging tests (structural and/or functional): Abnormality of frontal and/or an-
terior temporal region
III. Aspects that exclude the diagnosis:
A. Clinical aspects
1. Sudden onset, acute intercurrent deterioration episodes
2. Previous head trauma close to the onset of the manifestations
3. Intense memory disorder during the initial stages of dementia
4. Spatial disorientation
5. Logoclonia and rapid loss of chain of thought
6. Myoclonia




1. Predominantly postrolandic location alterations in structural or functional neuroimaging 
tests, or multifocal brain lesions in computed tomography or magnetic resonance
2. Results in laboratory tests indicative of brain affectation of an infl ammatory or metabolic 
alteration, such as for example multiple sclerosis, syphilis, AIDS or herpetic encephalitis.
Criteria for the clinical diagnosis of semantic dementia
The semantic disorder (diffi culty to understand the meaning of words and/or identify objects) is 
the most outstanding alteration at the onset and during the entire disease. Other cognitive func-
tions, including autobiographic memory, remain intact or relatively preserved.
I. CENTRAL DIAGNOSTIC ASPECTS
A. Insidious onset and gradual progression
B. Language disorder characterised by:
1. Fluent spontaneous speech but progressively poor in content




C. Perception disorder characterised by:
1. Prosopagnosia: alteration of recognition of the identity of known faces and/or
2. Associative agnosia: alteration of recognition of the identity of objects
D. Copy of drawing and tests of element association based on perception data remain normal
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E. Normal repetition of isolated words
F. Normal reading and writing to dictation (of words that are read and written according to 
standard language rules)
II. ASPECTS THAT SUPPORT THE DIAGNOSIS
A. Aspects that support the diagnosis of frontotemporal degeneration
1. Onset before the age of 65
2. History of similar disorder in immediate family
3. Motor neurone disease (in a minority of patients), with bulbar palsy, muscular weakness 
and wasting and fasciculations.
B. Speech and language
1. Logorrhoea
2. Idiosyncratic use of words
3. Absence of phonemic paraphasia
4. Dyslexia and superfi cial dysgraphia (in irregular words of non-Spanish language whose 
pronunciation does not correspond to that of its syllables)
5. Arithmetic calculation not changed
C. Behaviour
1. Loss of interest and empathy (effective syntony) with other people
2. Decrease of interest in surroundings
3. Miserliness or greed
D. Physical signs
1. Absence or late appearance of cortical disinhibition refl exes
2. Akinesia, hypertonia, tremors
E Additional tests
1. Neuropsychology
a. Intensive semantic impairment, evidenced by defi ciencies in the understanding of 
words and in naming and/or recognising objects and faces
b. Phonology and syntaxes, elementary perceptive processing, spatial skills and episodic 
memory preserved
2. Normal electroencephalogram.
3. Brain neuroimaging (structural and/or functional): Abnormality (symmetric or are sym-
metric) that prevails in the anterior temporal region
III. ASPECTS THAT EXCLUDE THE DIAGNOSIS
A. From the case history and examination
1. Sudden onset and ictal events
2. Head trauma close to the onset of the manifestations
3. Intense early amnesia
4. Spatial disorientation
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a. Structural or functional defi ciency prevails in the retrorolandic region.
b. Multifocal lesions in computed tomography or magnetic resonance
2. Analytical laboratory tests discover signs of brain affectation due to infl ammatory or infec-
tious processes such as multiple sclerosis, syphilis, AIDS or herpetic encephalitis.
Criteria for the clinical diagnosis of progressive non-fl uent aphasia
Initially and throughout the evolution, the most prominent feature is diffi culty with expressive 
language, all other cognitive functions remaining relatively unimpaired or normal.
I. CENTRAL DIAGNOSTIC ASPECTS
A. Insidious onset and gradual progression
B. Spontaneous non-fl uent speech and at least one of the following alterations: Agrammatism, 
phenomic paraphasia, anomia.
II. ASPECTS THAT SUPPORT THE DIAGNOSIS
A. Aspects support the diagnosis of frontotemporal degeneration
1. Onset before the age of 65
2. History of similar disorder in immediate family
3. Motor neuron disease (in a minority of patients), with bulbar palsy, muscular weakness 
and wasting and fasciculations.
B. Speech and language
1. Stuttering or oral apraxia
2. Alteration in repeating ability
3. Alexia, agraphia
4. Understanding of normal words in initial stages
5. Mutism in advanced stage
C. Behaviour
1. Appropriate social behaviour in initial stages
2. Behavioural alteration similar to those observed in frontotemporal dementia, in advanced 
stages
D. Physical signs: late appearance of contralateral cortical disinhibition refl exes, akinesia, rigid-
ity and tremors
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E. Additional tests
a. Neuropsychology: Non-fl uent aphasia, in absence of intense amnesia and spatial percep-
tion disorder
b. Normal electroencephalogram Or slight are symmetric slowing down
c. Brain neuroimaging (structural and/or functional): Asymmetric abnormality that prevails 
in the dominant hemisphere, generally the left)
III. ASPECTS THAT EXCLUDE THE DIAGNOSIS
A. From the case history and examination
1. Sudden onset and ictal events
2. Head trauma close to the onset of the manifestations
3. Intense early amnesia
4. Spatial disorientation







a. Structural or functional defi ciency prevails in the retrorolandic region.
b. Multifocal lesions in computerised tomography or magnetic resonance
2. Analytical laboratory tests discover signs of brain affectation due to infl ammatory or in-
fectious processes such as multiple sclerosis, syphilis, AIDS or herpetic encephalitis.
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Appendix 1.11.    NINDS-AIREN Criteria for vascular 
dementia, adaptation and translation taken from the SEN 
CPG, 20096,46
I. Compulsory criteria for the diagnosis of probable vascular dementia:
1. Dementia: decline from a previous level of memory and two or more cognitive functions 
(orientation, attention, language, visuospatial function, executive functions, motor control, and 
praxis), severe enough to interfere with activities of daily living (regardless of how physical de-
fi ciencies interfere). Patients are excluded with disturbance of consciousness, acute confusional 
syndrome, psychosis, severe aphasia or major sensorimotor impairment that prevents the ade-
quate objectifi cation of neuropsychological alterations. Also excluded are patients with systemic 
disorders or other brain diseases (such as Alzheimer’ disease) that in and of themselves could 
account for the cognitive defi cits.
2. Cerebrovascular disease, defi ned by the presence of focal signs consistent with prior stroke, 
with or without history of prior stroke, and evidence of vascular lesion in neuroimaging tests – 
CT or MRI—(multiple large vessel infarct or single strategically placed infarct to produce cog-
nitive defi cit – angular gyrus, thalamus, basal forebrain, PCA or ACA territories -, or multiple 
basal ganglia and subcortical or periventricular white matter lesions, or combinations thereof). 
3. Relationship between sections 1 and 2 above, inferred by the presence of one or jore of the 
following:
– Onset of dementia within 3 month following a stroke
– Abrupt deterioration in cognitive function
– Fluctuating or stepwise progression of cognitive defi cits.
II. Feature consistent with probable vascular dementia:
a. Early presence of gait disturbance.
b. History of unsteadiness and frequent falls
c. Early appearance of increase of urinary frequency, urgency and other bladder control dis-
order not explained by urological disease.
d. Pseudobulbar palsy
e. Personality and mood change, abulia, depression, emotional incontinence, and other sub-
cortical defcits including psychomotor retardation and abnormal executive function.
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III. Features that make the diagnosis of vascular dementia uncertain or unlikely:
a. Early onset of memory defi cit and progressive worsening of memory and other cognitive 
function, in the absence of corresponding focal lesions on brain imaging.
b. Absence of focal neurological signs, other than cognitive disturbance
c. Absence of cerebrovascular lesions in CT or MRI.
IV. Criteria for possible vascular dementia:
Dementia (according to I.1), with focal neurological signs, in patients in whom brain imaging 
studies to confi rm CVD are missing, or in those that do not show a clear temporal relationship 
between dementia and stroke; also in patient with evidence of cerebrovascular disease, with sub-
tle onset or course different to that expected (prolonged plateaux or improvements).
V. Criteria for defi nite vascular dementia:
a. Clinical criteria for probable vascular dementia
b. Histopathological evidence of cerebrovascular disease obtained from biopsy or autopsy
c. Absence of neurofi brillary tangle and neuritic plaque exceeding those expected for age
d. Absence of other clinical or pathological disorder capable of explaining dementia
VI. Classifi cation of vascular dementia for research purposes:
 – Cortical vascular dementia 
 – Subcortical vascular dementia 
 – Binswanger’s disease
 – Thalamic dementia:
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Appendix 1.12.    Hachinski ischaemia scale to distinguish 









High Blood Pressure 1
History of stroke 2
Signs of atheroclerosis 1
Focal neurological sign 2
Focal neurological symptoms 2
A score of 4 or less supports an Alzheimer’s type dementia, and a score of 7 or more supports a 
diagnosis of multi-infarct dementia.
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Appendix 1.13.    SEN criteria for mild cognitive 
impairment (2009)6,65





This disturbance must be:
Acquired
Reported by the actual patient or by a reliable informant
Evolution of months or years
Objectifi ed in neuropsychological examination (performance < 1 or 1.5 DE respect to the 
group of the same age and study level) 
The cognitive disturbance interferes minimally or does not interfere with normal activities
There is no disorder of consciousness level, acute confusion state, focal neurobehavioural syn-
drome or dementia
418 CLINICAL PRACTICE GUIDELINES IN THE SNS
Appendix 1.14.    Global Deterioration Scale (GDS) and 
Functional Assessment Staging (FAST), correspondence 
in AD, adapted from the translation into Spanish by the 
behaviour and dementia study neurology study group 
(SEN guideline, 2002)19
GDS Stage FAST stage and clinical 
diagnosis
Characteristics
GDS 1. No cognitive 
disturbance
1. Normal adult No diffi culty either subjectively or objec-
tively
GDS 2. Very mild 
cognitive defi cit
2. Normal aged adult Complaints of memory loss. No defi cit is 
objectifi ed in clinical examination. Full 
knowledge and evaluation of symptoms.
GDS 3. Mild cognitive 
defi cit
3. Incipient AD First clear-cut defi cits
Manifestations in one or more of these areas:
• Getting lost in an unfamiliar location
• Evidence of poor working performance
• Incipient diffi culty to remember people’s 
names
• After reading, retains little material
• Forgets location, loses or misplaces valu-
able objects
• Little ability to remember new people 
they have met
• Decreased organisation capacity. 
Objective evidence of memory defi cit 
only observed with an intensive interview.
GDS 4. Moderate 
cognitive defi cit
4. Mild AD Decreased ability to perform complex tasks.
Clear-cut defi cit on careful clinical inter-
view:
• Decreased knowledge of current and re-
cent events
• Patients may exhibit some defi cit in re-
membering personal history
• Obvious concentration diffi culty on serial 
subtractions.
CLINICAL PRACTICE GUIDELINE ON THE COMPREHENSIVE CARE 
OF PEOPLE WITH ALZHEIMER’S DISEASE AND OTHER DEMENTIAS 419 
• Decreased capacity to travel, handle fi nanc-
es, etc.
Frequently, there are no defects in:
• Orientation in time and person.
• Recognition of familiar people and faces.
• Capacity to travel to familiar places. Denial 
is dominant defence mechanism
GDS 5. Moderately 
severe cognitive 
defi cit
5. Moderate AD The patient cannot survive for a long time 
without some assistance help. Requires help to 
choose clothing. Is unable to remember impor-
tant aspects of daily life (address, telephone, 
relatives’ names). Certain disorientation in time 
and space is frequent. Diffi culty to count down 
from 40 by 4s, or from 20 by 2s. They generally 
know their own name and their spouse’s and 
children’ names.
GDS 6. Severe 
cognitive defi cit
6. Moderate-severe AD Improperly put on clothing without assistance 
or prompting. They sometimes forget the name 
of their spouse on whom they are dependent to 
survive. They retain some data from the past. 
Time and space disorientation Diffi culty to 
count by 10s both backward and forward. They 
remember their name and differentiate family 
from strangers. Diurnal rhythm frequently dis-
turbed. Personality and emotional change occur 
(delusions, obsessive symptoms, anxiety, agita-
tion or aggressiveness and cognitive abulia).
6a Improperly put on clothing without assistance 
or prompting
6b Unable to bath themselves correctly
6c Unable to use the toilet
6d Urine incontinence
6e Faecal incontinence
GDS 7. Very severe 
cognitive defi cit
7. Severe AD Progressive loss of all verbal and motor skills. 
Neurological signs are often seen
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7a Unable to say more than half a dozen words
7b Only able to say one single intelligible
7c Unable to walk without assistance
7d Cannot sit up without assistance
7e Loss of ability to smile
7f Loss of ability to hold up head independently
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Appendix 2. Information for patients
What is dementia?
The World Health Organisation defi nes dementia as a "syndrome due to a disease of the brain, 
usually of a chronic or progressive nature, in which various disturbances of multiple higher corti-
cal functions, including memory, thinking, orientation, comprehension, calculation, learning ca-
pacity, language and judgement. Consciousness is not clouded. Impairments of cognitive function 
are accompanied by deterioration in emotional control, behaviour or motivation”.
These losses are greater than in normal ageing and with suffi cient entity to affect the daily 
activities that the person used to carry out.
If the cognitive problems start after the age of 65, it is considered that the dementia is late 
onset or senile. If it starts under the age of 65, it is considered that the dementia is early onset or 
presenile.
Is dementia frequent?
It affects 5% of people over the age of 65 and increases with age, until it affects 20% of people 
over the age of 80. The most frequent dementia is Alzheimer's disease, which represents 70% of 
the total of dementias. Other dementias that occur less frequently, are:: Vascular, dementia with 
Lewy bodies, frontotemporal degeneration and secondary dementias.
What are the symptoms of dementia?
The symptoms are mainly cognitive (memory, language, calculation skills and decision-making, 
etc), but behaviour disorders may also appear (indifference, depression, irritability, aggressive-
ness, improper behaviour, delusions, hallucinations,) functional disturbance (repercussion of 
work, on social and family life, loss of autonomy for hygiene and dressing), sleep, eating disor-
ders or urinary incontinence.
What is the natural course of dementia?
With the exception of dementia due to a cause that can be treated, as is the case of secondary de-
mentias, the course of the disease is unavoidably progressive. With time, patients lose independ-
ence, they are unable to care for themselves, get dressed, go to the toilet, eat or wash themselves 
and behavioural disturbances may also appear. The disease evolves in a way that there may be 
periods of stability and periods of fast deterioration.
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What are the risks factors of dementias?
Some factors slightly increase the risk of suffering dementia. The most outstanding are age, de-
pression, nicotine addiction, exposure to pesticides or low schooling level. For inherited cases, if 
any immediate relatives are affected, that is considered a risk.
On the other hand, physical exercise, intellectual activity and the moderate consumption of 
alcohol could act as benefi cial factors.
How is dementia diagnosed?
The diagnosis must be carried out by a physician based on the symptoms shown by the patient and 
what they are told by the informant. There must be a reliable informant, as, due to the nature of 
the disease, patients will not be able to inform well and will not be aware of all their symptoms.
Some tests help rule out other diseases that may simulate dementia or distinguish between 
different types of dementia.
Which tests must be performed to diagnose dementia?
The systematic tests that must be carried out to diagnose dementia are:
• Blood analysis.
• Cognitive tests: They permit establishing the patient’s degree of deterioration, distinguishing 
between dementias, mild cognitive impairment, depression and normality.
• Radiological tests (head scan or magnetic resonance).
In complex cases with uncertain diagnosis, other more complex tests may be required, which 
are normally carried out in specialised centres.
Is dementia inherited?
The majority of the cases of dementia are not inherited, although if there is a history in the family 
this may slightly increase the risk of suffering it in the future. Only a very small percentage of 
cases of dementia (one or two cases out of every thousand) is caused by alterations in the genes. 
These cases are inherited and are transmitted from parents to children with 50% probability of 
each child suffering from it.
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When must genetic studies be performed on patients with 
dementia?
Genetic studies must only be performed in cases of early onset Alzheimer's (< 65 years) with 
immediate family affected; in cases of frontotemporal lobar degeneration with immediate family 
affected or in cases of prion diseases, provided that the person affected or their relatives want to. 
In these cases, it is recommended for the patient and family to be referred to specialised 
centres in genetic counselling.
What treatments exist for dementias? 
Some secondary dementias have specifi c treatment depending on the course (surgery for hydro-
cephalia or tumours, corrections of endocrine and metabolic disorders, etc).
But the great majority of dementias are degenerative and currently there is no treatment that 
might curb its natural progression; however, there are some drugs that have proved to be effective 
in Alzheimer's disease, (donepezil, galantamine, rivastigmine, memantine) and some of them also 
in other degenerative diseases.
Other pharmacological treatments may be necessary at times to treat behavioural disorders 
(insomnia, delusions, hallucinations, aggressiveness, etc.).
Non-pharmacological treatments, especially cognitive intervention programmes may also 
provide benefi ts in some aspects, although the magnitude of this effect is moderate.
Other treatments, such as hormones, anti-infl ammatorie, piracetam, propentofylline, nimodi-
pine, selegiline, hydergine, idebenone, citicoline, ginkgo biloba, vitamins E or B, supplements of 
copper, ginseng, lecithin, omega-3 fatty acids, yok or the use of traditional medicine or medicinal 
herbs, vitamins, acupuncture, yokukansan have not shown a benefi cial effect in available studies.
What role does the caregiver occupy in the care of people 
with dementia?
Dementia is a disease that has a great impact on the patient's close environment, so the fi gure of 
caregiver is extremely important.
The care of a patient with dementia requires great dedication and it may sometimes involve 
leaving work, having less personal freedom, need for economic resources, etc. for the person car-
rying out this work. All of these aspects may produce anxiety, depression, stress and changes in 
the caregiver's health and they must be considered by the health team.
There are currently social resources that are managed through social work professionals, or 
community resources, mainly associations of families, that can provide help to care for patients at 
home or to plan and evaluate the use of external services (external caregiver, day centre, nursing 
home, law of dependence, etc).
 
424 CLINICAL PRACTICE GUIDELINES IN THE SNS
May the care of people with dementia have ethical and/or 
legal implications for their family or caregivers?
In the event of a case of dementia in the family, some ethical and legal aspects must be considered. 
The drafting of advance directives or living will, when people still preserve their capacity, must 
be questions to be taken into account. Also, aspects such as the evaluation of the capacity to drive 
vehicles or own fi rearms requires reconsideration. At other times, it is necessary to start a legal 
incapacitation process, or else take fi nancial decisions, etc, for which it is advisable to receive 
legal advice.
How can we contribute to research in dementia?
Given that the causes of the majority of the different types of dementia are unknown, research is 
essential to advance in the understanding of these diseases and in the development of future treat-
ments. To be able to do this, the collaboration of as many patients as possible is necessary, who 
may contribute in many different ways. These include:
• Participating in studies of new drugs (clinical trials). 
• Participating in non-pharmacological research studies. For example, just by way of blood 
extraction, it is possible to obtain a sample of DNA, which may help in numerous studies.
• Donating the brain: This permits, in the case of death, confi rming the diagnosis and having 
a biological sample of great value for research.
What is Alzheimer’s disease?
It is a neurodegenerative disease and the most frequent type of dementia, especially, although not 
exclusively, in the older population. The process usually starts with loss of memory and inability 
to retain new information. Patients repeat the same things and do not recognise their faults. Other 
faculties are then affected, (speech, reasoning, orientation, etc). In parallel, patients are going to 
lose autonomy; thus, in a fi rst stage, people require supervision for complex activities. As the 
disease progresses, they will require direct assistance for the most basic activities of daily living.
Furthermore, the majority of patients may present neuropsychiatric symptoms, such as indif-
ference, loss of control of emotions, depression or changes in appetite. As the disease progresses, 
hallucinations, delusions, agitation and aimless movements, such as erratic wandering, may ap-
pear.
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What is the cause of Alzheimer's disease?
The cause of Alzheimer's disease is unknown today. However, it is known that there are abnormal 
deposits of proteins (beta-amyloid and hyperphosephorylated tau) in the brain of patients with 
Alzheimer's, which alter the neuronal functioning, which leads to the death of the neurons af-
fected. The lesions initially concentrate in regions of the brain that are essential for memory and 
progressively spread through the cerebral cortex, affecting areas that control other functions.
There are cases, not many, when the disease is inherited and may affect patients under the 
age of 60, in whom genetic mutations that cause the disease have been found.
What is vascular dementia?
This is a type of dementia produced by the lack of blood irrigation in important areas for normal 
cognitive functioning. Vascular dementia is the second most frequent dementia after Alzheimer's 
disease, and represents 12% of dementias. It is normal for both types of dementia to co-exist, in-
teracting together and often it is impossible to distinguish the extent to which each one contributes 
to the patient’s clinical picture.
Are there different types of vascular dementia?
There are several types of vascular dementia, including:
• Multi-infarct dementia: Due to repeated infarctions of the large arteries in the brain cortex 
area. It is a sudden onset dementia with stepwise progression.
• Dementia due to single strategic infarct, that is, which produces one single lesion but in 
an area of the brain that is important for cognition.
• Subcortical vascular or small vessel dementia: Accumulation of infarcts or vascular le-
sions of the deep white matter of the brain due to disease of the small vessels. Normally 
it is caused by arteriosclerosis. Dementia caused in this case is progressive and there is 
usually slowness, gait disturbance and incontinence.
• Mixed dementia: This is a combination of several types of dementia. The most normal is 
the combination of Alzheimer's disease and vascular disease.
• Dementia due to haemorrhagic lesions.
What is the natural course of vascular dementia?
Generally, whether it is stepwise or continuous, the evolution is similar to the other types of de-
mentia, that is, a tendency towards progressive deterioration.
However, due to its variability, the evolution of vascular dementia is not very predictable. 
Certain stability is often observed for longer or shorter periods of time, although a new vascular 
event may cause a sudden decline of the cognitive function.
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How is vascular dementia diagnosed?
The diagnostic criteria are based on the presence of dementia, on a history of stroke, focal neuro-
logical signs and vascular lesions in neuroimaging. There must also be a correlation between the 
degree of vascular affectation and the clinical and neuropsychological data.
What treatment exists for vascular dementia?
Although infarcts are not reversible, the vascular risk factors must be treated (diabetes, high 
blood pressure, high cholesterol, etc) to reduce the risk of new lesions. Some drugs used to treat 
Alzheimer's disease may be used, although the clinical benefi t is small.
What is frontotemporal lobar degeneration or 
frontotemporal dementia?
Frontotemporal lobar degeneration is a rare neurodegenerative disease, but in patients under the 
age of 65 it is the second cause of degenerative dementia. Atrophy of the frontal and/or temporal 
lobes and of subcortical structures is observed in the brain, with abnormal protein deposits.
There are different clinical and neuropathological variants, but the frontal variant is the most 
frequent and represents more than half of the cases. In the frontal variant cases or frontotempo-
ral dementia, behavioural changes are the most prevalent at the start. In other cases, so-called 
semantic dementia and non-fl uent progressive aphasia, their ability to express themselves and/or 
understand are initially the prevailing disorders. Memory disorders, although they may appear, 
are not so important in the initial stages as in Alzheimer's disease.
What are the symptoms of frontotemporal lobar 
degeneration?
The early manifestations are behavioural disorders (disinhibition, violation of social norms, aban-
donment of personal care, lack of empathy, etc.) and/or of language, (loss of meaning of words 
or diffi culties to express themselves and/or articulate words) and less memory affectation. In 
advanced stages, all the cognitive functions are affected and motor complications also appear 
in some patients, either with similar symptoms to Parkinson's disease (parkinsonism) or with 
similar symptoms to amyotrophic lateral sclerosis (associated motoneuron disease). The patients’ 
symptoms and additional tests differentiate frontotemporal lobar degeneration from Alzheimer's 
disease in the majority of the cases, although in others the clinical evolution of both may be very 
similar, and there are cases when a certain diagnosis may only be established in the post-mortem 
study.
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What is the natural course of frontotemporal lobar 
degeneration?
Just like all other neurodegenerative diseases, the evolution of this dementia is progressive, in a 
similar way to Alzheimer's disease and the cognitive deterioration worsens and fi nally becomes 
global. However, it must be pointed out that the disease is very heterogeneous and its clinical 
course varies a great deal in different patients.
How is frontotemporal dementia diagnosed?
The diagnosis is carried out based on clinical criteria, due to the presence of certain symptoms 
and with the support of radiological tests and ruling out other processes. If there is a family 
background of the same disease, it may be a genetic case. In those cases, a genetic study may be 
performed if the patient and/or family are interested.
What treatment exists for frontotemporal lobar degeneration?
As in all other neurodegenerative diseases, there is no curative treatment. The drugs used to treat 
Alzheimer's disease do not offer any benefi t in frontotemporal lobe degeneration, and at times 
they make produce side effects.
What is dementia with Lewy bodies?
This is a neurodegenerative disease that produces typical lesions (Lewy bodies and neurites) in 
different regions of the nervous system.
What are the symptoms of dementia with Lewy bodies?
Other typical symptoms appear, apart from the dementia:
• Motor symptoms similar to those of Parkinson's disease: Tremors, rigidity, slowness, inex-
pressive face, small step gait with blockage, accelerations and hunched posture or lack of 
equilibrium.
• Fluctuations of consciousness level, where the patient is more sleepy or not very reactive, for 
hours or days, or is attentive and with a clearer mind.
• Visual hallucinations, with visions of people or animals, that appear spontaneously and not 
only as a result of the medication.
• Other symptoms: Abnormal functioning of the autonomous nervous system, which may pro-
duce low blood pressure when they get up, urine incontinence or erectile dysfunction, agitated 
dreams or intolerance to the drugs used to treat the agitation, aggressiveness and hallucina-
tions and delusions.
428 CLINICAL PRACTICE GUIDELINES IN THE SNS
Is Dementia with Lewy bodies frequent?
Dementia with Lewy bodies is less frequent than Alzheimer's disease, but it is the third most 
frequent after the latter and vascular dementia. It represents approximately 8% of all dementias.
What is Parkinson’s disease dementia?
This is dementia that appears in patients who previously had had Parkinson's disease. In people 
affected by the disease, it is normal to fi nd small cognitive defi cits, mainly mental slowness, 
memory problems and lack of attention, but some patients end up developing considerable cogni-
tive impairment, which may develop into dementia.
The brain lesions caused are similar to those of dementia with Lewy bodies.
Is Parkinson's disease dementia frequent?
Parkinson's disease dementia is very frequent in patients affected by this disease and it may affect 
up to 80% of them after eight years with the disease.
What is its natural course?
Like all neurodegenerative diseases, the evolution is progressive. The motor and cognitive symp-
toms worsen with the passing of time, as well as the patient's degree of dependence. Furthermore, 
the need to increase the number of drugs and the dose usually causes more side effects.
What is the cause of dementia with Lewy bodies and 
Parkinson’s disease dementia?
As in the majority of degenerative diseases, there is no known cause. A minority of the cases of 
Parkinson's disease have been associated with genetic mutations and families have been found 
where some members have Parkinson's disease and others have dementia with Lewy bodies, so 
genetics could play an important role, although in the majority of the cases, there is no past history 
in the family or genetic alterations.
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How is dementia with Lewy bodies diagnosed?
The diagnosis is clinical and is based on the presence of dementia, hallucinations parkinsonism, 
(slow movements, muscular rigidity, lack of stability, etc.), ruling out other diseases that may 
justify the symptoms. As in all dementias, the normal tests are blood analysis and neuroimaging 
tests, (scan or resonance) to rule out other diseases. If in doubt between Alzheimer's disease and 
dementia with Lewy bodies, especially when there is no clear parkinsonism, more complex neu-
roimaging tests must be carried out.
How is Parkinson's disease dementia diagnosed?
Parkinson's disease dementia is diagnosed when a patient already has a diagnosed Parkinson's 
disease via appropriate criteria, and presents cognitive impairment of suffi cient magnitude to 
be considered dementia. The fact that this impairment is not due to other diseases must be ruled 
out. Cognitive impairments may be diffi cult to evaluate when the patient is a very affected by 
Parkinson symptoms.
What treatment exists for dementia with Lewy bodies and 
Parkinson’s disease dementia?
As with Alzheimer's disease, these are degenerative dementias and currently there is no treatment 
that can curb its natural progression. Some of the drugs used in Alzheimer's disease may also 
slightly improve the cognitive, psychiatric (hallucinations) and functional symptoms in some 
patients.
Treatment of Parkinson symptoms presents a considerable limitation in the use of drugs, as 
anti-Parkinson drugs may produce or worsen the psychotic symptoms, such as delirium and hal-
lucinations, whilst the other medications used to treat the symptoms may worsen the Parkinson 
symptoms.
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Appendix 3. Glossary
Abuse: This refers to either a single or repeated act, or lack of appropriate measures, which 
occurs within any relationship where there are expectations of trust that causes harm or anguish 
in the elderly person.
ACE inhibitors: These are drugs whose action mechanism is the competitive and reversible 
inhibition of the cholinesterase enzyme (donepezil and galantine). Rivastigmine also inhibits the 
butyrylcholinesterase enzyme at a peripheral level.
Acute pain: Of sudden onset and short duration. 
ADAS-Cog: This is the cognitive part of the Alzheimer’s Disease Assessment Scale, which 
includes 11 individual tests: Spoken language ability (from 0 to 5), spoken language comprehen-
sion (from 0 to 5), ability to remember test instructions (from 0 to 5), word-fi nding diffi culty 
(from 0 to 5), commands (from 0 to 5), naming objects (from 0 to 5), constructive praxis (from 
0 to 5), ideational praxis (from 0 to 5), orientation (from 0 to 8), word recall (from 0 to 10), and 
word recognition (from 0 to 12). The score varies between 0 and 17; the high score indicates 
greatest impairment.
ADCS-ADL: alzheimer’s disease Cooperative Study - Activities of Daily Living. This was 
specifi cally designed to assess the functional ability over a wide severity range in patients with 
Alzheimer's disease. The 19-item ADCS-ADEsev19 has 54 points. The 23-item ADCS-ADL23 
has 78 points.
Advance directive document (ADD): Prior instructions document, which may include in-
dications that must be taken into account, in the medical area, when the time comes when one 
cannot express one's will, as well as appoint a representative who will become a valid interlocutor 
with the physician or medical team. It may be formalised in public document before notary or it 
may be private.
Advanced Activities of Daily Living (AADL): These are a series of especially complex 
and elaborate activities to control the physical medium and the social environment that allow 
individuals to develop a social role, maintain good mental health and good quality of life. They 
include: Work, gardening, DIY, hobbies, travelling, social participation, sports, etc.
Advanced dementia: Stage of dementia, whatever its aetiology, characterised by great dif-
fi culty to carry out basic activities of daily living, (getting dressed, having a bath and washing and 
use of the toilet). With a hierarchical loss of functions that sub-classifi es it into degrees of more 
severity. Mobility reduction and sphincter disturbances are common in the most advanced stage.
Agnosia: Recognition impairment that is due to sensory disorders or global cognitive defi -
cits, with prior knowledge of the object to be recognised.
Agony: State that precedes death in those diseases where life gradually fades away. It may 
last for hours or a few days and is characterised by the appearance of general physical impair-
ment, which may be quickly progressive, showing an increase in weakness, prostration and de-
crease of alertness, with a consequent increase in hours in bed, decreasing intake and alteration of 
vital signs, progressive tendency to low blood pressure, tachycardia and oliguria, with perception 
of imminent death by the patient, family and team of health professionals.
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Alzheimer’s disease: It is a degenerative type clinical-pathological entity that evolves pro-
gressively, which is clinically characterised by cognitive impairment and dementia and neuro-
pathologically by the presence of neurofi brillary tangles and neuritic plaques. It is the most fre-
quent type of dementia, representing up to 70% of the dementia cases. In the majority of cases, the 
presentation is sporadic, but there are cases associated with known autosomal dominant transmis-
sion mutations.
Anorexia: This is an eating disorder, which is characterised by a lack of normal appetite; it 
may be due to physiological causes, and which disappears when the cause disappears or else to 
psychological causes.
Aphasia: Loss of ability to produce and/or understand language. Language impairment due 
to brain lesion.
APOE: Glycoprotein involved in the transport of cholesterol and other lipids through the 
cell membranes in the brain. It occurs mainly in the glial cells and seems to be involved in cell 
growth and neuron regeneration.
Apolipoprotein E (ApoE): Glycoprotein involved in the transport of cholesterol and other 
lipids through the cell membranes in the brain. It occurs mainly in the glial cells and seems to be 
involved in cell growth and neuron regeneration. The ApoE Gene has three polymorphisms: ε3 
(the most frequent, present in 75% of the population), ε4 and ε2.
Apraxia: Disturbance of gesture (motor action with purpose) which is not explained by el-
ementary motor disorders (paresia, dystonia, tremors, etc) and with full knowledge of the action 
that is carried out.
Asthenia: Tiredness following minimal effort, decrease of functional capacity, weakness 
defi ned as an advanced feeling of inability to start any activity, decrease of the capacity of con-
centration, memory disturbance and emotional incontinence.
Barthel Index: It assesses 10 activities of daily living (ADL): Feeding, bathing, grooming, 
dressing, bowels, bladder, toilet use, transfers, walking on level surface, going up and down stairs. 
It is scored from 0 to 100 (90 for patients limited to wheelchair). The scores are not the same 
for each activity. Bladder and bowels must be evaluated with respect to the previous week. The 
global results are grouped together in four categories of dependence, in agreement with the score 
obtained: Independent (86 to 100), light dependence (60 to 85), moderate dependence (40 to 55), 
severe dependence (20 to 35), total dependence (0 to 19).
Basic Activities of Daily Living (BADL): These are a series of primary activities for people, 
aimed at their self-care and mobility, which provide them with elementary autonomy and inde-
pendence, enabling them to live without requiring continuous assistance from others; they include 
activities such as: Eating, sphincter control, using the toilet, getting dressed, getting washed, mov-
ing about, walking, etc
Before-after study: Study whereby the same group of people is assessed before and after an 
intervention or treatment.
Behavioural and psychological symptoms: These are symptoms of disturbed perception, 
thought, content, mood and behaviour that might appear in people with dementia, forming part of 
the expression of the disease.
Bias: This is an error that appears in the results of the study due to factors that depend on 
the collection, analysis, interpretation, publication or review of the data, and which might lead to 
incorrect conclusions or are systematically different to the truth about the objectives of a research.
Blind study: A study where some of those involved do not know which person is receiving 
one treatment or another, or placebo. The treatment is hidden to prevent the results of the research 
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being "infl uenced" by the placebo effect or by the bias of the observer. To correctly evaluate the 
blinding, it is necessary to know who in the study has been blinded (patients, researchers, health 
professionals, results and/or statistic awarders).
Cachesia: Picture of malnutrition and weight loss that may be associated with asthenia.
Caregiver: A person that provides unselfi sh and voluntary support to people affected, who 
either live with the patient or else devote part of their time (over 20 hours a week) to caring for 
the patients.
Case and control study: This is an observational epidemiological study, where the individu-
als are selected depending on whether they have (cases) or do not have (control) a certain disease, 
or in general a certain effect. Once the individuals have been selected for each group, it is studied 
whether they were exposed or not to a characteristic of interest, and the proportion of those ex-
posed in the case group is compared with the proportion of the control group.
Categorical scales: Qualitative descriptors are used, and the patient selects which is the 
most appropriate. Their advantage is the easy understanding thus favouring completion even in 
advanced stages of the disease. Its disadvantage is the limitation of the response options and the 
individual variability in the interpretation of the categories. The scores are: 1. Nothing; 2. Little; 
3. Quite a lot; 4. A lot.
CDR: Clinical dementia rating is a global evaluation scale of the degree of dementia that 
assesses six cognitive and functional areas: Memory, orientation, judgement and problem solving, 
community affairs, home and hobbies, and personal care. A total score is obtained by summing 
up the scores in each area and a composite score, where the evaluation of the state of the memory 
is fostered.
Cerebrovascular or vascular dementia: This is dementia secondary to one or several vas-
cular brain lesions, of any aetiology.
CGIC: The clinical global impression of change is a global classifi cation of all the domains 
of the current disease of the patient compared with the initial value. It is a seven-point scale, 
which goes from 1 (much better) to 7 (much worse): 4 indicates changes. The same professional 
carries out the assessments at both time points with contributions from family and caregivers.
Chronic pain: Lasts for more than 1 month.
CIBIC-plus: Change impression scale based on interviews with the physician, it provides a 
global assessment of the function in four areas: general, cognitive, behavioural and of the activi-
ties of daily living. All participants receive 4 points at the start of the study and the subsequent 
assessments on a scale from 1 to 7 points are associated with the initial value where 1 is notorious 
improvement, and 7 is considerable worsening. The information is obtained from the caregiver 
and from the patient. There are different versions.
Clinical Practice Guideline: Set of systematically developed instructions, directives, state-
ments or recommendations, whose purpose is to help professionals and patients take decisions 
about the most appropriate healthcare modality for specifi c clinical circumstances.
Clinical series: Also called case series, it is a type of study where the experience with a 
group of patients with a similar diagnosis, with no comparison group, is described.
Clinical Trial: Experimental study to evaluate the effi cacy and safety of a treatment or in-
tervention.
Cochrane library: Database on effectiveness produced by the Cochrane Collaboration, 
comprised among others, of original systematic reviews of this organisation.
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Cochrane review: Systematic Review carried out according to the Cochrane Collaboration 
methodology and published in the Cochrane Library.
Cohort study: This consists in monitoring one or more cohorts of individuals who present 
different degrees of exposure to a risk factor in whom the appearance of the illness or condition 
studied is measured.
Comorbidity: Presence of several added or associated diseases.
Confi dence Interval: This is the interval in which the real magnitude of the effect is found 
(never known exactly) with a pre-established degree of safety or confi dence. 95% confi dence in-
terval (or 95% confi dence limits) are often spoken of. This means that within that interval the real 
value would be found in 95% of the cases.
Confusion factor: This is a variable that distorts the measurement of the association be-
tween another two variables to be studied. The result of the presence of a confusion variable 
may be the observation of an effect when it really does not exist, or the exaggeration of a real 
association (positive confusion) or, on the contrary, the mitigation of a real association and even 
a reversal of the sense of a real association (negative confusion).
Consent (*): Expression of the free and conscious will, validly expressed by a capable per-
son, or by their authorised representative, preceded by adequate information.
Conservator: This is the person who is responsible for assisting, accompanying or advising 
the person under conservatorship to carry out those acts determined by a ruling. They may not, 
under any circumstances, replace the will of the person, as they do not represent them.
Conservatorship: It is a reduced scope guardianship, which is usually assigned in cases of 
partial modifi cation of capacity.
Contracture: This is defi ned as a 50% reduction or more of normal passive movement of 
the joint.
Delirium: Acute confusion state resulting from diffuse brain dysfunction. It is clinically 
characterised by the simultaneous disturbance of attention, perception, thought, memory, psycho-
motor behaviour, emotion and weak-sleep rhythm.
Delphi method: Qualitative research technique of consensus, aimed at comprehensive and 
dynamic explanation, and the analysis of certain phenomena with the purpose of generating ideas, 
sharing experiences and sensing tendencies for the future. It purports to analyse a reality, reaching 
agreements on the phenomena regarding which there is no conclusive information. It is especially 
useful when working with very subjective elements, when it is diffi cult to determine their intrinsic 
value. The method is applied by phases. The problem is formulated and a panel of trained experts 
is selected to contribute to the study with their knowledge and experience. The questions that will 
be submitted to study are determined and posed to the members of the panel. An anonymous ques-
tionnaire posed to the members of the panel in successive rounds until a consensus is reached. The 
study concludes with the preparation of a report containing the fi nal results of the survey.
Dementia: It is a clinical syndrome characterised by an acquired defi ciency in more than one 
cognitive domain, which represents a loss with respect to the previous level and which signifi -
cantly reduces functional autonomy. Dementia frequently appears with behavioural and psycho-
logical symptoms (BPSD), also called behavioural and emotional symptoms or neuropsychiatric 
symptoms. 
Dementia with Lewy bodies: Dementia with Lewy bodies is clinically characterised by 
the association of fl uctuating cognitive impairments, parkinsonism and psychotic symptoms, and 
pathologically by the presence of Lewy bodies and neurite in the brain cortex.
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Donepezil: Reversible central inhibitor of acetylcholinesterase. It is indicated for the symp-
tomatic treatment of mild and moderate AD.
Dyspnea: Subjective experience of breathing problems.
Early onset or pre-senile dementia: A picture of dementia is considered to be early onset or 
presenile by convention, when the fi rst symptoms appear before the age of 65.
Edmonton Symptom Assessment System: New symptoms or reasons for discomfort are 
analysed using visual analogical scales: Pain, dyspnoea, nausea, depression, anxiety, well-being, 
drowsiness, appetite, tirednes. Each scale has a 100 mm line. On the left of the line (0) with the 
term “absent” reference is made to the absence of the problem in question. On the right side, with 
the term “worst possible” (100) the maximum intensity of the symptom is expressed. The sum of 
the measurements on the different lines corresponding to the different symptoms, gives a global 
score which would be at least 0 and a maximum score of 900. Completion of the scale in people 
with dementia must be carried out by the caregiver and/or relative with proven and reliable ob-
servation capacity. Despite the extensive use of this instrument in Palliative Care units, there are 
no validation studies.
Effectiveness: Results of a diagnostic, preventive or therapeutic intervention when applied 
in normal practice, in non-experimental conditions. 
Effi cacy: Results of a diagnostic, preventive or therapeutic intervention when applied in 
experimental and/or controlled conditions, for example, in a clinical trial.
Estate/assets administrator: Person named to adequately look after the estate of people 
who have lost their capacity for self-management and who own a considerable fortune.
Evidence: Tests. Evidence-based Medicine: Medicine based on scientifi c tests.
Executive functioning: Capacity to think and plan, start, sequence, supervise and stop a 
complex behaviour.
Formal caregiver: A person, capacitated or not, who directly looks after the person affected, 
receiving a salary or pecuniary benefi ts for their work.
Frontotemporal lobar degeneration: It is a neurodegenerative disease that is clinically 
characterised by prominent behaviour and/or speech alterations, and pathologically by focal at-
rophy of the frontal and/or temporal lobes. Although it is not very frequent, it is the second cause 
of dementia in people under the age of 65, after Alzheimer's disease. It does not usually predomi-
nantly affect the memory or spatial skill.
Galantamine: Reversible central inhibitor of acetylcholinesterase. It is indicated for the 
symptomatic treatment of mild and moderate AD.«
GDS: Global deterioration scale is a scale that assesses the deterioration stages from normal-
ity (0) to the most advanced stage of dementia (7),
Genetic analysis (*): Procedure aimed at detecting the presence, absence or variants of one 
or several genetic material segments, which includes indirect tests to detect gene product or a 
specifi c metabolite that is indicative above all of a certain genetic change.
Genetic counselling (*): Procedure aimed at informing people about the possible conse-
quences for them or for their descendants of the results of a genetic analysis or screen and its 
advantages and risks, and where appropriate, to give them advice with respect to possible alterna-
tives derived from the analysis. It takes place both before and after a genetic test or screen and 
even in absence of these.
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Guardian: Person who is responsible for the care and attention of personal aspects, as well 
as the administration of their assets, of a person who has lost their self- government capacity due 
to illness.
Guardianship: Protection mechanism for people who have lost their self-government abil-
ity, subject to different control measures, such as the drawing up of an initial inventory, annual 
accountability, the need to obtain prior authorisation for certain acts of economic importance and 
the presentation of the fi nal statement of accounts when it ends.
Healthcare Levels: Different clinical care modalities that are provided to people depending 
on the type of care and the place where this care is provided.
Hyperorality: Oral or dietetic changes, binges, eating whims, excess tobacco and alcohol 
consumption, oral examination of objects.
Incidence: This is the number of new cases of an illness that are developed in a population 
during a certain period of time. It tells us the probability of a disease-free individual developing 
it in a certain period of time.
Informal caregiver: Person who provides unselfi sh and voluntary support to the person 
affected. In the majority of the cases they are direct family members (spouse, son/daughter, son-
in-law/mother-in-law, siblings, cousins, etc.) or very close friends.
Informed consent (*): This is a formal medical procedure whose objective is to apply the 
patient's principle of autonomy. Three requirements must exist at least, which are: Free will: 
Individuals must freely decide to submit themselves to a treatment or participate in a study with-
out there being persuasion, manipulation or coercion. Information: This must be understandable 
and must include the objective of the treatment or of the study, its procedure, benefi ts and poten-
tial risks, and the possibility of rejecting the treatment or study at any time after it starts, without 
this being able to harm them with respect to other treatments. Comprehension: This is the capacity 
that patients receiving the information have to understand.
Instrumental Activities of Daily Living (IADL): These are activities that allow people to 
adapt to their environment and maintain independence in the community. They depend, like the 
basic activities, on individuals’ state of health, but other elements intervene such as affective state, 
cognitive performance and aspects of the social environment. They include activities such as: 
Telephoning, shopping, cooking, looking after the house, using transport, managing medication, 
handling money, etc.
Irruptive pain: Moderate or severe intensity pain that appears over a chronic pain. It may 
start unexpectedly or predictably, (triggered by certain manoeuvres known by the patient and/or 
caregiver).
Judicial defender: Person appointed to cope with urgent situations if a guardian has still 
not been named or when important differences arise between guardian and the protected person.
Katz Index: This is a valid method to evaluate activities of daily living. It has good inter- 
and intra-observer reproducibility and with acceptable predictive capacity in the examination 
of functional capacity. It can be used by different members of the team, performing a structured 
examination of the patient's capacities.
Legal guardian: Physical persons and/or legal non-profi t person, whose objectives include 
the protection of people whose capacity to act has been modifi ed.
Legal incapacity: Ruling that recognises that a certain person, as a result of a disease they 
suffer, does not have the capacity to act or that this capacity to act is partially limited.
Living will: Advance directive document.
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Mechanical restraint: This is a medical action that pursues the physical restriction or con-
trol by means of any mechanism, material or equipment, tied to the body or very close to it, that 
patients may control or easily remove and which prevents them, or it is designed to prevent them, 
from moving freely and/or having normal access to their own bodies.
Memantine: It is a non-competitive NMDA (N-methyl D-Aspartate) receptor antagonist, 
which is reversibly linked to these receptors, blocking the entry of calcium and reducing the con-
centration of glutamate
Meta-analysis: This is a statistical technique that permits integrating the results from dif-
ferent studies (diagnostic test studies, clinical trials, cohort studies, etc.) in one single estimator, 
giving greater weight to the results of the larger studies.
Mixed pain: Coexistence of several of the pain producing mechanisms in one same person.
MMSE: Mini-mental State Examination is a test used for a short assessment of cognitive 
skills. The test poses questions about time and spatial orientation, mnesic abilities, calculation of 
series and attention, memory, spoken and written language, copy of a drawing. There is a Spanish 
version with 35 (Lobo, 1979), 30 (Lobo, 1999) items, and the Spanish version with standardised 
score according to age and schooling level.
Morbidity: Disease caused.
Mutual aid groups (MAG): Groups made up of caregivers of people affected by dementia, 
where they receive theoretic and practical training, as well as psychological support.
Neuropathic pain: Caused by direct lesion of nervous structures, either by direct tumour 
invasion, consequences of the treatment, or infections in a weakened patient (herpes zoster, etc.). 
Patients describe it as unpleasant, burning or stinging sensation or as a sensation of numbness, 
tingling, tightness, pruritus or pressure.
NICE: Institution that forms part of the NHS (British National Health Service). Its role is to 
provide physicians, patients and the public in at large with the best available evidence, mainly in 
the form of clinical guidelines.«
NNT/NNH: This is a measurement of the effi ciency of a treatment. It is the number of peo-
ple need to be treated (“number needed to treat" [NNT]) with a specifi c treatment to produce or 
prevent an additional episode. Likewise, it is defi ned as the number needed to harm (NNH) to 
assess undesirable effects.
Normal grief: Natural, normal and expected reaction -dependent upon the social cultural 
environment -, faced with having to adapt to the loss of a loved one, suffered by relatives and 
friends before, during and after death. Grief begins a long time before death, anticipatory grief; it 
increases dramatically around the moment of death (hours, days) acute grief; this continues after-
wards as early grief (weeks, months), intermediate grief (months, years) and late grief (years). It 
probably never ends, always leaving an indelible mark on the person, latent grief, which may be 
reactivated at any time.
NOSGER: Nurse’s Observational Scale for Geriatric Patients. An observational scale com-
pleted by nurses for geriatric patients. It contains 30 behaviour items, each one placed on a 5-point 
scale in agreement with the appearance frequency. The scores of the items are summed up as 
scores of daily living, self-care activities of daily living, mood, social behaviour and disturbing 
behaviour.
NPI: Neuropsychiatric inventory that assesses the frequency and severity of behavioural and 
neuropsychiatric symptoms in patients with dementia, based on an interview with the caregiver. 
It contains 12 items with a total score that goes from 0 to 144.
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Numerical scale: On a line divided into 0-10 intervals, patients indicate the problem inten-
sity. If it is not possible to indicate the line, they may verbally indicate the "number" that indicates 
the intensity of the problem. Score of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10.
Odds Ratio (OR): This is a measurement of the effi ciency of a treatment. If it is 1, the effect 
of the treatment is no different to the effect of the control. If the OR is greater or less than 1, the 
effect of the treatment is greater (or less) than the effect of the control. Take note that the effect 
that is being measured may be adverse (e.g. death, disability) or desirable (e.g. stop smoking).
Pain: Pain is defi ned by the Association for the Study of Pain (IASP) as "an unpleasant sen-
sory or emotional experience associated with actual or potential tissue damage".
Palliative care: Approach that improves the quality of life of patients and families who cope 
with problems associated with life-threatening illness, through the prevention and relief of suffer-
ing by means of early identifi cation and impeccable assessment and treatment of pain and other 
physical, psychosocial and spiritual problems.
Palliative care. Basic level: The aim is to assess the patients’ needs at different times or in 
different care areas, responding to these needs and knowing when to refer patients to other ser-
vices.
Palliative care. Specifi c level: They require specialised procedures or techniques. And their 
objectives are to provide care to patients with more complicated and intensive healthcare needs, 
perform additional diagnostic tests or very specifi c treatments that have to be carried out in the 
hospital, and attend to certain needs that do not need to be clinically complex, but are of a social 
or family nature.
Palliative care. Support team: They may intervene at home or in the hospital, with different 
patterns. They offer advice as well as specifi c or intermittent interventions, or they share respon-
sibility in direct care
Palliative care. Units: These are specialised PC units, requiring hospitalisation, attended by 
a competent interdisciplinary team.
Parkinson’s disease dementia: Parkinson’s disease dementia (PDD) is dementia that ap-
pears in the context of an established Parkinson’s disease, and which affects more than one cogni-
tive domain, mainly attention and executive and visuospatial function. For the operational diag-
nosis of PDD, it is considered that at least 1 year must have elapsed from the onset of parkinson-
ism and the appearance of dementia, unlike Lewy body dementia.
Partial incapacity: Capacity to act that is partially limited. 
Percentile: A value that divides a sorted set of statistical data in a way that a percent of these 
data is less than this value. One of the 99 points that divide the distribution into 100 parts of equal 
frequency.
Placebo: This is an inert intervention or substance that is used as control in clinical research. 
It is used to rule out cures due to unknown causes that would not be attributable to the therapy 
that is being researched.
Prevalence: It is the proportion of individuals of a population who present a disease or a 
characteristic at any time, or during a certain period of time. It tells us the likelihood of an indi-
vidual from a certain population having a disease at a time or during a certain period of time.
Primary caregiver: This is a person who comes from the patient's informal support system, 
who devotes the majority of their time, measured in number of hours/day, to their care.
Prior instructions document: Advance directive document.
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Psycho-educational programme: This is a resource that is used to provide information and 
training in skills to caregivers of people with dementia, so that they can carry out a better task of 
caring and also care for themselves better.
Psychomotor agitation: This is a behavioural disorder that is characterised by a signifi cant 
or inadequate increase of motor activity and that is accompanied by alterations of the emotional 
sphere.
Randomisation: Procedure whereby the selection of the sample or assignment to one treat-
ment or another, or to placebo, is done by random mechanisms.
Randomised clinical trial: Type of clinical trial where patients are assigned randomly, by 
chance, to the different treatments that are compared
Relative risk (RR): The quotient between the rate of events in the treatment and control 
groups. Its value follows the same interpretation as the OR.
Risk factor: This is any circumstance that increases the probabilitie of a person contracting 
a disease.
Rivastigmine: Reversible central inhibitor of acetylcholinesterase and butyrylcholinester-
ase. It is indicated for the symptomatic treatment of mild and moderate AD and for the Parkinson's 
disease dementia.
Safeguard: This means caring, attending, covering both the personal side and also the ad-
ministration of the assets that the person owns.
Self-government: This is the ability to sort out one’s own matters, the ability to tend to 
needs, reach objectives or satisfy desires. It has two dimensions: a) external dimension: Related 
or not to legal acts that have to do with third parties; b) internal dimension: Relative to one's own 
acts, such as self-care. The fi rst component of self-government is the capacity to act or capacity 
to take decisions, and the person must have suffi cient theoretic intelligence to be aware of the ele-
ments of the decision and of its consequences. Willingness is also required for the decision to be 
effective, and material means that make it possible or do not prevent it.
Self-guardianship: Any person, with suffi cient capacity to act, foreseeing the possibility of 
being declared incapable, appoints the person they wish as their guardian, and also adopts any 
provision referring to their personal care or the administration of their assets. Special power or 
preventive power: conferring powers in favour of a third party, who can represent them, through 
a written notarial document, establishing that it may continue to be used at the time in time when 
the person granting the power should become incapacitated.
SIGN: Scottish multidisciplinary agency that prepares evidence-based clinical practice 
guidelines as well as methodological documents on their design.
Somatic pain: This is produced by the stimulation of pain receptors in the deeper musculo-
skeletal and superfi cial skin structures.
Special power or preventive power: Confer powers in favour of a third person, who can 
represent them, through a written notarial document, establishing that it can continue to be used 
when the time comes that the person granting the power is incapacitated.
Statistical power: It is the capacity of a test to detect differences of a certain magnitude as 
statistically signifi cant among the groups compared.
Statistically signifi cant: In a study, if the probability of the differences in the effect found, 
when comparing two groups, is less than a previously defi ned signifi cance level, it is said that the 
differences are statistically signifi cant; that is, that it is very little probability of the differences 
observed between treatments or groups compared being due to chance. Normally a signifi cance 
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level of 5% is used, and they are usually presented as p < 0.05. However, it must be taken into 
account that a difference between treatments may be statistically signifi cant, but this does not 
always mean that the difference found is "clinically signifi cant" or relevant.
Strain of the caregiver: The strain of the caregiver is defi ned as the extent to which physical 
and emotional health, social life or the fi nancial situation of the caregiver, are negatively affected 
as a result of caring for the patient.
Systematic review (SR): This is a review where the evidence about a topic has been system-
atically identifi ed, assessed and summed up in agreement with predetermined criteria. It may or 
may not include the meta-analysis.
Tau protein: The tau are micro-tubular proteins that are abundant in neurons, and which 
are much less frequent outside the central nervous system. Their main function is to stabilise the 
axonal microtubules through the interaction with the tubulin.
Terminal stage of dementia: Short life prognosis, less than 2 years, characterised by severe 
cognitive impairment, highly pronounced incapacity and total dependence for basic activities of 
daily living, inability to speak and communicate; and the impossibility of benefi ting from spe-
cifi c treatments. As well as the presence of multiple comorbidity with severe, multifactorial and 
changing symptoms. Severe swallowing diffi culty or rejection that prevents the intake of food 
and liquids; weight loss of more than 10% in 6 months, and albumin levels of less than 2.5 mg/dl.
Total incapacity: Has no capacity to act.
Visceral pain: Caused by infi ltration, distension or compression of organs within the tho-
racic or abdominal cavity.
Visual analogical scales: They have been used to measure pain, but they are also of interest 
in assessing other subjective symptoms. They have the advantage of not being limiting and can 
be monitored visually. The main disadvantage is the diffi culty patients have in understanding the 
instructions for use, and the physical and cognitive problems for completion in advanced stages 
of the disease.
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Appendix 4. Abbreviations
AADL Advanced Activities of Daily Living
AAN American Academy of Neurology 




ADAS-Cog Alzheimer's Disease Assessment Scale - Cognitive
ADCS-ADL AD Cooperative Study - ADL Inventory
ADCS-ADL-Sev. Alzheimer's Disease Cooperative Study - Activities of Daily 
Living Scale
ADD Advance directive document.
ADDTC California Alzheimer's Disease Diagnostic and Treatment 
Centers
ADFACS AD Functional Assessment and Change Scale
ADL Activities of Daily Living
AES Apathy Evaluation Scale
AFA Association of families with Alzheimer's Disease
AIAQS: Agència d'Informació, Avaluació i Qualitat en Salut (be-
fore Agència d'Avaluació de Tecnologia i Recerca Mèdiques, 
AATRM)
ALS Amyotrophic lateral sclerosis
AMA American Medical Association
AMT Abbreviated Mental Test
APO-E Apolipoprotein E
APP Amyloid precursor protein
ASA Acetylsalicylic acid
B-A Beta-amyloid
BADL Basic Activities of Daily Living
BDS Barthel Index and Blessed Dementia Scale
BEHAVE AD Behavioural Pathology in Alzheimer's Disease Rating Scale
BMI Body mass index
BPRS Brief Psiquiatric Rating Scale
BPSD Behavioural and psychological symptoms of dementia
CAM Confusion Assessment Method
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CAMDEX Cambridge Mental Disorders of the Elderly Examination
CASE Caregiver Abuse Screen
CBD Corticobasal degeneration
CCB Calcium channel blockers
CCDTD Canadian Consensus Conference on the Diagnosis and 
Treatment of Dementia
CDR Clinical Dementia Rating
CEAFA Spanish Confederation of Associations of families with 
Alzheimer's Disease
CGIC-C Clinical Global Impression of Change Dementia Rating
CHMP2B Chromatin modifying protein 2B
Chol Cholesterol
CIBIC Clinician's Interview-Based Impression of Change
CIBIC-Plus Clinician's Interview-Based Impression of Change
CIDS Concord Informant Dementia Scale
CIWD Cognitive impairment without dementia
CJD Creutzfeldt-Jackob Disease 
CLOX 1&2 Executive Llock-Drawing Task 1 and 2
CMAI Cohen Mansfi eld Agitation Inventory
CPG Clinical Practice Guideline
CPR Cardiopulmonary resuscitation
CSDD Cornell Scale for Depression in Dementia
CSF Cerebrospinal fl uid.
CVA Cerebral vascular accident
DAD Disability Assessment in Dementia
DC Day Centre
DH Day Hospital
DLB Dementia with Lewy bodies
DM Diabetes Mellitus
DRS Dementia Rating Scale
DS Down Syndrome
DSM Diagnostic and Statistical Manual of Mental Disorders
DSM-IV Diagnostic and Statistical Manual of Mental Disorder, 5th edi-
tion,
DSM-IV-TR Diagnostic and Statistical Manual of Mental Disorder, 4th edi-
tion, Text revised
DUE Graduate nurses
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EADC European Alzheimer's Disease Consortium
EANA Elder Abuse Neglect Assessment
EASI Elder Abuse Suspicion Index
EAST Elder Abuse Screening Test
ECAQ Elderly Cognitive Assessment Questionnaire
EEG Electroencephalogram
EFNS European federation of neurological societies
E-IOA Expanded Indicators of Abuse
ELS End-of-life stage
EOFAD Early-onset familial Alzheimer's disease
ESAS Edmonton Symptom Assessment System
ESR Erythrocyte sedimentation rate
EXIT25 Executive Interview 25
FAST Functional Assessment Staging Tool
FDA Food and Drug Administration
FFI Fatal familial insomnia
FTLD Frontotemporal lobar degeneration
G&CP General and Community Practitioner
GAG Glycosaminoglycan
GBS Gottfries-Brane-Steen scale
GDS Global deterioration Scale.
GMS-AGECAT Geriatric Mental State
GPCOG General Practitioner Assessment of Cognition
GSF Gold Standard Framework
HAD Hamilton Anxiety Depression
HBP High Blood Pressure
HC Home Care
HD Huntington's Disease:
HIS Hachinski Ischaemia Scale
HIV Human immunodefi ciency virus
HR Hazard ratio
IADL Instrumental activities of daily living
IADL Instrumental Activities Daily Living
ICD-10 International Classifi cation of Diseases (10th version) of the 
World Health Organisation
INPEA International Network for the Prevention of Elder Abuse
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IOA Indicators of Abuse
IPA International Psychogeriatric Association
IQCODE Information Questionnaire on Cognitive Decline in the Elderly
IU International Units
LDLR Low-density lipoprotein receptor
LTE Limitation of therapeutic effort
LWB Lewy Bodies
MAG Mutual Aid Group
MAPT Microtubule-associated protein tau
MCI Mild cognitive impairment
MCT Mini-Cog Test (Lobo)
MHIS Modifi ed Hachinski Ischaemic Score
MIS Memory Impairment Screen
MMSE Minimental State Examination
MMSE - SEV Minimental for severe disease
MR Mechanical restraint
MRI Magnetic Resonance imaging
NGP Nasogastric probe
NICE National institute for health and clinical excellence
NINCDS/ADRDA National Institute of Neurological, communicative disor-
ders and Stroke-Alzheimer Disease and related Disorders 
Association Work Group
NINDS-AIREN National Institute of Neurological Disorders and Stroke/ 
Association Internationales pour la Recherche et 
l'Enseingement
NMDA N-methyl D-apartate
NOSGER Nurses Observation Scale for Geriatric patients
NPI NeuroPsychiatric Inventory
NPI-NH NeuroPsychiatric Inventory-Nursing Home
NRS Neurobehavioural Rating Scale
NSAID Non-Steroid Anti-infl ammatory Drugs
NTB Neurological Tissue Bank
OR Odds ratio
PC Palliative care
PCC Primary Care Centre
PCT Primary Care Team
PD Parkinson's disease
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PDD Parkinson's disease dementia
PDS Progressive Deterioration Scale
PENTIEN National Strategic Plan for the integral treatment of Neurological 
Disease
PET Positron emission tomography
PGRN Progranulin-associated protein gene
PSEN Presenilin
PSP Progressive supranuclear palsy
PU Pressure ulcers
RAGE Rating of Agressive Behaviour in the Elderly
RAVLT Rey auditory verbal learning test
RCT Randomised clinical trial
RDRS-2 Rapid Disability Rating Scale-2
REM Rapid Eye Movement sleep phase
RR Relative risk
SBP Systolic Blood Pressure
SBU Swedish Council on Health Technology Assessment
SCT Specialised Care Team
SCTD Specialised Care Team in Dementia
SDCT Specialised dementia care team
SEAT Advanced and terminal situation of chronic disease with lim-
ited prognosis
SEMFYC Spanish Society of Family and Community Medicine
SEN Spanish Neurology Society 
SHC Social-Health Care.
SIB Severe Impairment Battery
SIBL Severe Impairment Battery Language
SLE Systemic lupus erythematosus 
SNS Spanish National Health System
SPECT Single-photon emission computed tomography
SPMSQ Short Portable Mental State Questionnaire (Pfeiffer)
SR Systematic review of scientifi c evidence
SSRI Selective Serotonin Reuptake Inhibitors
T@M Memory impairment Test
TSH Thyroid stimulating hormone
USA United States of America
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VADAS Vascular Alzheimer's Disease Assessment Scale
V-ADAS-Cog Vascular Alzheimer's Disease Assessment Scale-Cognitive
VCP Valosin-containing protein gene
VD Vascular Dementia
WHO World Health Organisation
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Appendix 6. Methodological aspects
Bibliographic search strategies
Phase 1: Strategy to identify CPG and SRCT
Search by terms: dementia, frontotemporal AND (Lobar OR degeneration), vascular AND de-
mentia, Lewy AND bod*, alzheimer AND disease.
Search in the title, descriptors and/or key words fi elds, using the following terms:
#1 dementia OR (frontotempora AND (Lobar OR degeneration)) OR (vascular AND dementia) 
OR (lewy AND bod*) OR (alzheimer AND disease)
#2 practice guideline OR guideline OR consensus development conference OR recommend* OR 
consens* OR statement* OR (clinical AND protocol*) OR (medical AND protocol*)
#3 (systemat* AND review*) OR (systemat* AND overview*) OR (integrati* AND review*) OR 
(integrati* AND overview*) OR (quantitativ* AND review*) OR (quantitativ* AND overview*) 
OR (methodologic* AND review*) OR (methodologic* OR overview*) OR (manual AND 
search*) OR (collaborativ* AND review*) OR (collaborativ* AND overview*) OR (cochrane 
AND review) OR (Medline AND review) OR (Pubmed AND review) OR “hand searched” OR 
handsearch* OR “hand search” OR “hand searching” OR “pooled data” OR “review literature” 
OR meta-analy* OR metaanaly* OR meta analy* OR meta-analysis OR systematic OR (review 
AND random*) OR (review AND “clinical trials”)
#1 AND #2
#1 AND #3
Phase 2: Strategy to identify RCT
Search by terms: dementia, frontotemporal AND (Lobar OR degeneration), vascular AND de-
mentia, Lewy AND bod*, alzheimer AND disease.
Search in the title, descriptors and/or key words fi elds, using the following terms:
#1 dementia OR (frontotempora AND (Lobar OR degeneration)) OR (vascular AND dementia) 
OR (lewy AND bod*) OR (alzheimer AND disease)
#2 (random* OR trial* OR effi cacy OR effectiv* OR blind* OR placebo* OR cohort* OR multi-
cent* OR prospectiv* OR longitudinal OR follow*)fpt
#1 AND #2
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Main CPGs, consensus documents and positionings (recommendations) of scientifi c societies 
of use
1. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis 
of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of 





2. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, et al. Con¬sensus 
guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): 




3. Kessel H, Marín N, Maturana N. Primera Conferencia Nacional de Consenso sobre el Anciano 




4. Patterson CJ, Gauthier S, Bergman H, Cohen CA, Feightner JW, Feldman H, et al. The recog-
nition, assessment and management of dementing disorders: conclusions from the Canadian 




5. Canadian Guide to Clinical Preventive Health Care. Ottawa (Canada): Canadian Task Force 




6. Guideline for cognitive impairment: is this dementia? Symptoms to diagnosis. Edmonton, 
AB (Canada): Working group for Cognitive Impairment. Alberta Clinical Practice Guidelines 
Program; 2002 (revised 2004).148
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AGREE evaluation: Recommended with changes
Available at: http://topalbertadoctors.org/informed_practice/clinical_practice_guidelines/ 
complete%20set/Cognitive%20Impairment%20Symptoms%20to%20Diagnosis/ cognitive_
impairment_symptoms_to_diagnosis_guideline.pdf
7. Guide to assessing and counselling older drivers. Chicago, IL (US): American Medical 
Association (AMA); 2004.527




8. Chamorro García L. Guía de manejo de los transtornos mentales en atención primaria. 
Barcelona: Psiquiatria editores; 2004.412
Expert consensus





10. Feldman HH, Gauthier S, Chertkow H, Conn DK, Freedman M, Chris M. Progress in clinical 
neurosciences: Canadian guidelines for the development of antidementia therapies: a concep-




11. Management of patients with dementia. A national clinical guideline. Edinburgh, Scotland 
(United Kingdom): Scottish Intercollegiate Guidelines Network (SIGN); 2006. SIGN publi-
cation nº 86.129
AGREE evaluation: Recommended Available at:
http://www.sign.ac.uk/pdf/sign86.pdf
12. Chiu E, Chiu H. Dementia care in Asia-second consensus statement on quality services. Int 
Psychogeriatr. 2006;18(1):176.687
Expert consensus
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13. Guidelines for a Palliative approach in residential aged care. Canberra: The National 




14. Nutrition support in adults: oral nutrition support, enteral tube feeding and parenteral nutri-
tion. London (United Kingdom): National Institute for Clinical Excellence (NICE); February 
2006. GCG32.688
AGREE evaluation: Recommended Available at:
www.nice.org.uk/guidance/CG32
15. Dementia. The NICE-SCIE guideline on supporting people with dementia and their car-
egivers in health and social care. London (United Kingdom): National Collaborating Centre 
for Mental Health. Social Care Institute for Excellence. National Institute for Health and 
Clinical Excellence (NICE); 2007. National Clinical Practice Guideline Number 42.25
AGREE evaluation: recommended
Available at:
16. Dementia. Singapore: Ministry of Health; 2007. MOH Clinical Practice Guidelines. Informe 
Núm. 3/2007.140
AGREE evaluation: Recommended with changes
Available at: www.moh.gov.sg/mohcorp/uploadedFiles/Publications/Guidelines/Clinical_
Practice_ Guidelines/Dementia.pdf
17. Guideline for cognitive impairment-dementia-diagnosis to management. Edmonton, AB 
(Canada): Working group for Cognitive Impairment. Alberta Clinical Practice Guidelines 
Program; 2007.246
AGREE evaluation: Recommended with changes
Available at: www.albertadoctors.org/bcm/ama/ama-website.nsf/AllDocSearch/87256DB00 
0705C3F87256E05005534D5/$File/COGNITIVE_IMPAIRMENT_PART_2. 
PDF?OpenElement
18. Practice guideline for the treatment of patients with Alzheimer’s disease and other demen-
tias. Second edition. Arlington, VA (US): American Psychiatric Association(APA); 2007.42
AGREE evaluation: Recommended with changes
Available at: www.psychiatryonline.com/pracGuide/loadGuidelinePdf.
aspx?fi le=AlzPG101007
CLINICAL PRACTICE GUIDELINE ON THE COMPREHENSIVE CARE 
OF PEOPLE WITH ALZHEIMER’S DISEASE AND OTHER DEMENTIAS 455 
19. Arrieta Antón E, Fernández Pascual L, González Rodríguez V, Goñi Imizcoz M, Guerrero 
Díaz MT, López Merino P, et al. Guía de atención al paciente con demencia en atención pri-
maria. Valladolid: Gerencia Regional de Salud. Junta de Castilla y León; 2007.234
AGREE evaluation: Recommended with changes
Available at: www.salud.jcyl.es/sanidad/cm/profesionales/images?locale=es_
ES&textOnly=false& idMmedia=94952
20. Ayuso T, Ederra MJ, Manubens JM, Nuin MA, Vilar D, Zubicoa J. Abordaje de la demencia. 
Guía de actuación en la coordinación Atencion Primaria- Neurología. Pamplona: Servicio 
Navarro de Salud-Osasunbide; 2007.204
AGREE evaluation: Recommended with changes
Available at: http://www.navarra.es/NR/rdonlyres/90E6356A-73C3-4CA1-9291-
834501AA4324/0/ Guiaabordajedelademencia.pdf
21. Chertkow H. Alzheimer’s & Dementia: The journal of the alzheimer’s association. Alzheimers 
Dement. 2007;3(4).152
AGREE evaluation: Recommended with changes
22. Waldemar G, Dubois B, Emre M, Georges J, McKeith IG, Rossor M, et al. Recommendations 
for the diagnosis and management of Alzheimer’s disease and other disorders associated with 
dementia: EFNS guideline. Eur J Neurol. 2007;14(1):e1-26.5
AGREE evaluation: recommended
Available at: http://www.efns.org/fi leadmin/user_upload/guidline_papers/EFNS_guide-
line_2007_ management_of_disorders_associated_with_dementia.pdf
23. Guía de actuación compartida para el paciente con contención. Jaén: Subcomisión de cuida-
dos. Área de Salud Mental de Jaén. Junta de Andalucía; marzo 2007.556
Positioning (recommendations) of a scientifi c society
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25. Guideline for Alzheimer’s disease management. Assessing cognitive function. En: Evidence-
based geriatric nursing protocols for best practice. Delirium and acute problematic behavior 
in the long-term care setting. California (US): National Guideline Clearinghouse; 2008.235
AGREE evaluation: Recommended with changes Available at:
http://www.guideline.gov/content.aspx?id=12379
26. Guía de práctica clínica de la enfermedad de Alzheimer y otras demencias. Servicio Canario 
de la Salud. Gobierno de Canarias.202
Expert consensus
Available at: www2.gobiernodecanarias.org/sanidad/scs/content/5d1a6bd6-f9cc-11dd-9d99- 
e96480bea708/Alzheimer_1.pdf
27. Grupo de Trabajo de la Guía de Práctica Clínica sobre Cuidados Paliativos. Guía de Práctica 
Clínica sobre Cuidados Paliativos. Madrid: Plan Nacional para el SNS del MSC. Agencia 
de Evaluación de Tecnologías Sanitarias del País Vasco; 2008. CLINICAL PRACTICE 
GUIDELINES IN THE SNS: OSTEBA Nº 2006/08.575
AGREE evaluation: recommended
Available at: http://www9.euskadi.net/sanidad/osteba/datos/e_06_08_Cuidados_Paliat.pdf
28. Guía de recomendaciones clínicas. Demencia. Oviedo: Clínica Asturias; 2008.517
AGREE evaluation: Recommended with changes Available at:
www.princast.es/salud/pcais/pdfs/demencia.pdf
29. Molinuevo JL, Peña-Casanova J, Grupo de estudio de neurología de la conducta y demen-
cias. Guía ofi cial para la práctica clínica en demencias: conceptos, criterios y recomenda-
ciones. Barcelona: Sociedad Española de Neurología; 2009.6
AGREE evaluation: Recommended with changes Available:
http://www.imim.es/noticias/view.php?ID=121
This CPG updated the guideline of 2002.19
30. La atención sociosanitaria en España: perspectiva gerontológica y otros aspectos conexos. 
Recomendaciones del Defensor del Pueblo e informes de la Sociedad Española de Geriatría 
y Gerontología y de la Asociación Multidisciplinaria de Gerontología. [consultado 9 octubre 
2009]. Madrid: IMSERSO.187
Positioning (recommendations) of a scientifi c society
Available at: http://www.imsersomayores.csic.es/documentos/documentos/defensor-aten-
cion-01.pdf
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31. Antúnez C, Boada M, Alberca R, Bosch A, Berthier M, Alegret M. Documento Sitges 2009: 
Capacidad para tomar decisiones durante la evolución de una demencia: Refl exiones, dere-




This document updates the consensus of 2005.5
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